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Troponoid (or more commonly, tropone/tropolone) refers to a family of naturally 
occurring compounds with a unique seven-membered aromatic ring.  As with many secondary 
metabolites, many of the tropolones display a wide range of biological activity.  This activity 
includes: antibacterial/antifungal, insecticidal, phytotoxic, antimitotic, anti-diabetic, anti-
inflammatory, enzyme inhibition, anticancer, cytoprotective and reactive oxygenated species 
(ROS) scavenging.  Most of this broad-range activity is attributed to the tropolone moiety while 
side chains are seen as attributing to selectivity.  Therefore, tropolone may offer a unique 
scaffold to develop antiproliferatives since it can chelate metal ions, is relatively small and most 
likely promiscuous, likely resulting in several mechanisms of action to diminish the development 
of resistantance. 
 This work focuses on the synthesis of a more diverse library of α-tropolones and tropones 
with functional groups capable of chelation other than the native hydroxyl.  The library was used 
to assess structure activity relationship on the antiproliferative effects against cancer cell lines.  
Previous results with α-tropolones in the Anderson and Wright labs suggested selectivity towards 
hematological malignancies.  As a result, α-tropolones were assessed for antiproliferative effects 
against a panel of malignant hematological cell lines from T-cell, B-cell and myeloid lineage.  
From this panel, there appears to be selectivity towards cell lines of T-cell lineage.  The most 
susceptible cell line, Molt-4, was explored further to understand the mechanism through which 
α-tropolones exhibit antiproliferative properties. 
 Eric Ryan Falcone      University of Connecticut 2016 
 
Patients with hematological malignancies are at the highest risk of potentially deadly 
infections typically caused by gram-negative bacteria, with E. coli, K. pneumoniae, and P. 
aeruginosa being the most common and most lethal.  Since several natural tropolones have been 
found to be bacteriostatic and bactericidal against a broad range of bacteria and exhibit lead-like 
Gram-negative antibacterial activity, α-tropolones may be developed as antiproliferative agents 
effective against both hematological malignancies and bacterial infections.  The library of α-
tropolones was then screened for antiproliferative effects on Gram-negative bacteria.  Key potent 
tropolones were used to explore potential targets using an unbiased target identification 
approach.  These studies show that bacterial enolase is most likely the target through which 
tropolones exhibit antiproliferative properties against Gram-negative bacteria. 
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Chapter 1 
 
Inhibition of Metalloenzymes: Lessons from Clinically Used Inhibitors and Future 
Directions 
 
1.1 Introduction 
 
 A metalloprotein is any protein that incorporates a metal ion to stabilize protein structure, 
facilitate electron transport or catalyze chemical transformations.  Proteins in the latter group are 
more commonly referred to as metalloenzymes.  Over one third of all human proteins are 
metalloenzymes.1    Metalloenzymes incorporate a variety of metal ions in the active site that are 
essential to their function.2  While all metalloenzymes convert substrates into new entities, the 
majority do not utilize the metal ion for redox chemistry but rather as a means to activate the 
substrate or to stabilize anionic intermediates and transition states.3  One of the primary research 
objectives in metallobiochemistry over the past 50 years has been understanding how these metal 
ions promote function within the active site.4  From this work, it has been determined that 
ligands coordinate directly to the metal ion and this coordination appears to determine the 
electronic properties of the metal ion and enzyme activity.  Once coordinated, the metal ion 
generally withdraws electron density from ligand to polarize bonds and assist in enzyme 
turnover.3  Coordination occurs in one of three forms: syn-monodentate, anti-monodentate, or 
bidentate.  Syn-monodentate coordination is the most common and is typical of carboxylic acid 
coordination in both mono- and dinuclear metalloenzymes.  This type of coordination is mostly 
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observed because the most common amino acids in the active site of metalloenzymes are aspartic 
acid and glutamic acid.  Other common amino acids in the active site that stabilize the metal ion 
and assist in catalytic function are cysteine and histidine.3 
  Metalloenzymes are essential to a variety of biological functions including blood pH 
homeostasis, DNA transcription, gene regulation, matrix degradation and many others.5-7  
Therefore, it is not surprising that misregulation of metalloenzymes is associated with diseases 
including hypertension, inflammation and cancer.  Additionally, metalloenzymes have been 
linked to pathogenic bacterial and fungal infections, antibiotic resistance and viral infections.6-7  
As a result, inhibitors have been developed to target these clinically relevant metalloenzymes.  
These inhibitors all possess a metal binding group linked to a “backbone” structure thought to 
impart target selectivity.8  In this chapter select metalloenzymes and their small molecule 
inhibitors will be discussed.  It should be noted that this is only a partial list of targeted 
metalloenzymes and inhibitors developed for their inhibition. 
 
1.2 Clinical Inhibitors of Zinc Metalloenzymes 
 
 Zinc is essential for the growth and development of all forms of life and is the second 
most abundant metal in the human body.9  The first zinc metalloenzyme, carbonic anhydrase, 
was discovered in 1940 and served as the basis for metalloenzyme research.10  Currently more 
than 300 zinc metalloenzymes have been discovered with approximately 10% of the human 
proteome consisting of zinc metalloenzymes.11  Zinc is also the only metal ion found in all six 
enzymatic classes: oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases.9  
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Since zinc exists as Zn2+ in metalloenzymes, it has a filled d-orbital and therefore functions as a 
Lewis acid.  As a Lewis acid, zinc is neither “soft” nor “hard” and does not appear to exhibit a 
coordinating preference.  However, the most common binding geometry of zinc metalloenzymes 
is tetrahedral or trigonal bipyramidal.12  The active site of these zinc metalloenzymes typically 
coordinate zinc with histidine or cysteine but several have also been found to use aspartic acid, 
glutamic acid, tyrosine, asparagines and glutamine.9  Additionally, the active site of zinc 
metalloenzymes is unique in that it must contain at least one water molecule coordinated to zinc 
that is essential to catalytic activity.13  This water molecule may be ionized (as in the case of 
carbonic anhydrase), polarized to form a nucleophile (found in matrix metalloproteinases), or as 
an enzyme structure stabilizer that can be displaced by the binding ligand.9  Overall, the 
coordination of zinc in the active site controls acidity of the metal ion which imparts a slight 
preference towards metal chelating groups.  This feature may be exploited for the design of 
inhibitors against zinc metalloenzymes. 
 
1.2.1 Carbonic Anhydrase 
 Carbonic anhydrase (CA) is the oldest known class of zinc metalloenzymes.14  There are 
16 isoforms of mammalian CA which all catalyze the conversion of carbon dioxide and water 
into bicarbonate and protons.15  CA is essential for blood pH homeostasis, formation of 
cerebrospinal fluid and urine acidification.10  Misregulation of CA can lead to neurological 
disorders, glaucoma, epilepsy, ulcers, edema and cancer.10,15  For example, CA-IX is known to 
regulate pH of tumor cells and can promote tumor growth and survival.16  Due to its long history 
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in research and its medical importance, many CA inhibitors have been developed.  Clinically 
available CA inhibitors generally use sulfonamide as the metal binding group (Figure 1.1). 
 
Figure 1.1: Clinically Used Carbonic Anhydrase Inhibitors.  Metal chelating group(s) shown in 
red. 
 As depicted in Figure 1.1, all the clinically used inhibitors are sulfonamides.  
Sulfonamides are a class of metal binding groups that coordinate zinc in a monodentate fashion 
via a nitrogen atom.  A crystal structure of Azopt bound to human CA-II (Figure 1.2) depicts the 
coordination of zinc by the sulfonamide group of Azopt and three histidine residues (His 94, His 
96 and His 119).17  Although CA IX is linked to tumor growth and survival, inhibitors of CA-IX 
are not yet approved.  Several of the CA inhibitors used in the clinic are CA-II inhibitors (Azopt, 
Topamax and Trusopt), but most are not isozyme specific.  CA-II is the most active isozyme and 
is found primarily in red blood cells but also in other tissues.  Since CA inhibitors mostly act on 
CA-II, they are approved to treat glaucoma and epilepsy and may be used as diuretics and to treat 
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altitude sickness.18  Current research focuses on the development of CA inhibitors to treat 
hypoxic and metastatic tumors.19 
 
Figure 1.2:  Crystal structure (PDB: 4m2r)17 of Azopt (green) bound to CA-II (cyan).  The 
active site consists of three histidine residues (magenta) coordinated to Zn2+ (grey).  The 
sulfonamide (sulfur in yellow, nitrogen in blue and oxygen in red) of Azopt completes 
the coordination sphere of Zn2+ to inhibit enzyme activity. 
 
1.2.2 Angiotensin Converting Enzyme 
 Angiotensis converting enzyme (ACE) is critical for regulation of the rennin-angiotensin 
system which maintains blood pressure, electrolyte and fluid balance as well as blood volume.20  
It found in endothelial cells, epithelial and neuroepithelial cells, in the blood and other body 
fluids and as a membrane bound protein in the brain.  Another function of ACE is to cleave the 
C-terminal dipeptide of bradykinin to suppress its function.  Active bradykinin results in 
vasodilation through generating nitric oxide.21  As a result, ACE effectively controls 
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vasoconstriction and electrolyte retension which affect blood pressure.20  Therefore, ACE 
inhibitors are primarily designed to treat hypertension.  All of the ACE inhibitors are analogs of 
2-methylpropionyl-L-proline and typically coordinate zinc via a carboxylic acid which exists in 
pro-drug form for most of the inhibitors.  However, Monopril has a phosphinyl group and 
Capoten contains a thiol which coordinates the zinc.  Interestingly, all of the ACE inhibitors have 
a carboxylic acid as part of the proline scaffold, but this carboxylic acid only interacts with other 
residues within the hydrophilic active site of ACE. 
 
Figure 1.3: Clinically used ACE inhibitors.  Metal chelating group shown in red. 
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Figure 1.4: Crystal structure (PDB: 2c6n)22 of Zestril (green) bound to human somatic ACE 
(cyan). The active site consists of two histidine residues (magenta) and one glutamic acid residue 
(magenta) coordinated to Zn2+ (grey).  The carboxylic acid (oxygen in red and nitrogen in blue) 
of Zestril completes the coordination sphere of Zn2+ to inhibit enzyme activity. 
 
 Figure 1.4 depicts the somatic N domain of human ACE.  This domain appears to play an 
important role in the development of hypertension.22  While the N domain shares nearly 60% 
sequence homology with the C domain, it has distinct properties and function.  The active site of 
ACE consists of two histidine residues (His 361 and His 365) and one glutamic acid residue (Glu 
389) coordinated to Zn2+.  There are also several water molecules that assist in coordination, 
catalytic action and should be accounted for when designing inhibitors. 
 
1.2.3 Matrix Metalloproteinase  
8 
 
 Matrix metalloproteinases (MMPs) are a family of 24 extracellular zinc and calcium 
dependent endopeptidases.23  The primary function of MMPs is to degrade the extracellular 
matrix through proteolysis of components such as aggrecan, collagen, elastin, fibronectin, gelatin 
and laminin.24  Other functions associated with MMPs are cell movement, proliferation, wound 
healing, angiogenesis and apoptosis.  Perhaps most importantly, MMPs are linked to various 
disease states including arthritis, multiple sclerosis, periodontal disease, atherosclerosis, cardiac 
injury remodeling and cancer metastasis.  As enzymes involved in tumor migration, invasion and 
angiogenesis, MMPs are ideal targets for the treatment of cancer. 
 
Figure 1.5: MMP inhibitors used in clinical trials.  Metal chelating groups shown in red. 
 Over 50 MMP inhibitors have progressed into clinical trials, but most have failed to gain 
approval due to lack of isozyme and enzyme selectivity, poor pharmacokinetic profiles, poor oral 
bioavailability and in many cases a lack of efficacy in human trials.25  To date, the only MMP 
inhibitor to be approved is Periostat.26  Periostat is a tetracycline based molecule used to treat 
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periodontal disease.  While tetracyclines have several carbonyls and hydroxyls capable of 
coordinating zinc, it is unknown whether or not tetracyclines directly coordinate the zinc in 
MMP or exert some other inhibitory effect.  However, studies involving selectivity of small 
molecules with different metal binding groups towards MMP-1 indicate a clear preference of 
coordination with a hydroxymate (hydroxymate >> formyl hydroxylamine > thiol > phosphinate 
> α-aminoacrylate > carboxylate/sulfonamide/hydrazide).27   
 
Figure 1.6: Crystal structure (PDB: 1mmb)28 of Batimastat (green) bound to MMP-8 (cyan). The 
active site consists of three histidine residues (magenta) coordinated to Zn2+ (grey).  The 
hydroxamic acid (oxygen in red and nitrogen in blue) of Batimastat completes the coordination 
sphere of Zn2+ to inhibit enzyme activity.  
 
 The hydroxamate, Batimastat, exhibits a bidentate coordination of a zinc ion in MMP-8.  
MMP-8 has two zinc ions and two calcium ions, but Batimastat only appears to coordinate the 
more accessible zinc ion located in a solvent exposed pocket.  The zinc in this site is coordinated 
by three histidine residues (His 197, His 201 and His 207).  Batimastat exhibited significant 
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inhibitory activity and advanced to Phase III clinical trials but was abandoned due to poor oral 
bioavailability and inflammation of the inner wall of the abdomen when injected.29  Since 
hydroxamate based MMP inhibitors have all failed to pass Phase III clinical trials, it is apparent 
that newer MMP inhibitors should either utilize a different metal binding group or be designed 
with isozyme selectivity.  Isozyme selective inhibitors may be difficult due to high structure 
homology especially within sub-classes.  However, since the zinc of MMPs exhibits a preference 
towards hydroxamate inhibitors, hydroxamate mimetics of tissue inhibitors of metalloproteinases 
(TIMPs) might provide better selectivity.  There are four TIMPs that inhibit various MMPs with 
differential efficacy.23  Complexes of TIMPs and MMPs show inhibition in the subnanomolar 
range and may provide key insight towards inhibitor design.30 
 
1.2.4 Tumor Necrosis Factor-α Converting Enzyme 
 Tumor necrosis factor-α converting enzyme (TACE), also known as ADAM-17, is a 
proteinase which belongs to the same super-family metzincin as MMPs.31  TACE is membrane 
bound and proteolyzes the 26 kDa pro-TNF-α to the active 17 kDa form.  In addition to its 
essential role in TNF-α regulation, TACE is implicated in epidermal growth factor signaling, 
leukocyte rolling, cell adhesion, JAK-STAT signaling, platelet aggregation and activation and 
regulation of angiogenesis.32  As a result, TACE inhibitors could potentially treat rheumatoid 
arthritis, cancer, Alzheimer’s, cardiovascular disease, diabetes, Crohn’s disease and other 
autoimmune diseases. 
Since TACE is similar to MMP, initial TACE inhibitors were based on MMP inhibitors 
and utilized hydroxamates as the metal binding group.33  Interestingly, TACE and MMP share 
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the same catalytic site structure.31  As a result, two MMP inhibitors, Marimastat and Prinomastat, 
were tested in clinical trials as TACE inhibitors.  Similar to the MMP inhibitors, TACE 
inhibitors have failed to pass Phase III clinical trials due to poor oral bioavailability, 
musculoskeletal side effects, non-selective inhibition, liver toxicity, and/or poor efficacy in 
human clinical trials.  This is mostly due to the ability of TACE to proteolyze nearly 30 
membrane spanning proteins.32 
 
Figure 1.7: TACE inhibitors used in clinical trials.  Metal chelating groups shown in red. 
 
12 
 
 Several reviews of TACE inhibitors, their development and clinical trials have been 
published.31,32,35  From these reviews it is clear that many TACE inhibitors have been developed.  
Most are hydroxamate based and are both MMP and TACE inhibitors while others have been 
designed to be more selective.  The more selective inhibitors include sulfonamides, acetylinic 
tails, tryptophan, quinolines or macrocycles.  While these inhibitors do exhibit some selectivity, 
none appear to selectively inhibit TACE and not MMP.  As a result, the development of TACE 
inhibitors for diseases other than cancer has mostly been abandoned.  Newer TACE inhibitors in 
development use non-hydroxamate metal binding groups such as thiol, hydantoin or barbiturate, 
but have not moved into clinical trials. 
 
Figure 1.8: Crystal structure (PDB: 1zxc)34 of TMI-001 (green) to TACE (cyan) dimer. 
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Figure 1.9: Crystal structure (PDB: 1zxc)34 of TMI-001 (green) bound to TACE (cyan). The 
active site consists of three histidine residues (magenta) coordinated to Zn2+ (grey).  The 
hydroxamic acid (oxygen in red and nitrogen in blue) of TMI-001 completes the coordination 
sphere of Zn2+ to inhibit enzyme activity. 
 
As with MMPs, the TACE active site consists of three histidine residues (His 405, His 
409 and His 415) coordinated to a zinc ion.  The hydroxamate TACE inhibitors coordinate the 
zinc in a bidentate fashion and may form hydrogen bonds with water molecules in the active site.  
The more selective TACE inhibitors attempt to overcome the decrease in zinc affinity compared 
to the hydroxamates by increasing non-covalent interactions with other residues in the active site, 
especially Leu 348, Gly 349 and Glu 406, and the S1’ pocket.  The S1’ pocket is exploited by the 
tryptophan and quinoline based inhibitors. 
 
1.2.5 Histone Deacetylase 
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 Histone deacetylase (HDAC) is a class of enzymes which catalyze the deacetylation of 
lysine residues.  Although HDACs are known to deacetylate multiple substrates, the primary 
substrates appear to be histones.  Deacetylation of histone lysines causes the positive charge on 
the lysine to tightly associate with the negative charge of the phosphate backbone of DNA which 
results in tighter coiling of the DNA around the histone, repressing gene transcription.  There are 
18 isoforms of HDAC, but only 11 are zinc dependent.36  In addition to regulation of gene 
transcription, HDACs are linked to latent human immunodeficiency virus (HIV), cardiac 
hypertrophy and downregulation of apoptosis and other cellular proteins in cancer cells.10 
 As with most zinc metalloenzyme inhibitors, HDAC inhibitors typically use hydroxamate 
as the metal binding group.  Although several HDAC inhibitors have been approved for the 
treatment of select hematologic malignancies, these inhibitors suffer from lack of isoform 
selectivity, rapid renal clearance, multiple off target interactions and can be mutagenic.25,37  
Despite these drawbacks, HDAC inhibitors have the ability to cause hyperacetylation of cancer 
cells to induce cell cycle arrest and apoptosis.38  Newer HDAC inhibitors currently in clinical 
trials (see Figure 1.10) utilize benzamide to coordinate zinc in a bidentate fashion similar to the 
hydroxamate inhibitors.  Unlike the hydroxamate based inhibitors, the benzamide inhibitors 
exhibit isoform selectivity and generally target only class I HDACs.39  Romidepsin is a natural 
product that resembles a pro-drug since the reduction of the disulfide bond generates a thiol that 
coordinates zinc in the active site of HDAC.40 
 
15 
 
 
Figure 1.10: HDAC inhibitors approved for treatment of hematological malignancies 
(Belinostat, Panobinostat, Romidepsin and Vorinostat) and in clinical trials (Etinostat and 
Mocetinostat).37,41  Metal chelating groups shown in red. 
 
Figure 1.11: Crystal structure (PDB: 4lxz)42 of Vorinostat (green) bound to HDAC2 (cyan). The 
active site consists of one histidine residue and two aspartic acid residues (magenta) coordinated 
to Zn2+ (grey).  The hydroxamic acid (oxygen in red and nitrogen in blue) of Vorinostat 
completes the coordination sphere of Zn2+ to inhibit enzyme activity. 
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The HDAC active site consists of one histidine residue (His 183) and two aspartic acid 
residues (Asp 181 and Asp 269) coordinated to a zinc ion.  HDAC inhibitors coordinate the zinc 
in a bidentate fashion and may form hydrogen bonds with water molecules in the active site.  The 
more selective HDAC inhibitors exploit a deep hydrophobic foot pocket that extends away from 
the active site in class I HDACs.43  Although HDACs share significant homology of the active 
site, especially within sub-classes, better isoform selectivity may be attained through the design 
of “cap” groups which extend out of the active site to interact with surface residues.36 
 
1.2.6 Farnesyltransferase 
 Farnesyltrasferase (FTase) is a cytoplasmic protein which catalyzes the prenylation of the 
superfamily of Ras proteins.44  Post-translational modification and activation of Ras proteins by 
FTase requires the C-terminal recognition sequence CaaX, where “a” refers to any aliphatic 
amino acid and “X” is any amino acid.  After binding the Ras protein, FTase will transfer a 15 
carbon farnesyl unit from farnesyl pyrophosphate to the cysteine residue.45  Inhibition of Ras 
protein prenylation will prevent cytosolic export to the plasma membrane and subsequent 
pathway signaling.  Since mutated Ras genes are found in approximately 30% of all cancers, 
inhibition of FTase can inhibit tumor growth and improve survival when combined with standard 
chemotherapy.46  Additionally, FTase inhibitors may treat progeria, glaucoma, neurological 
diseases and are highly toxic to the malaria causing parasite Plasmodium falciparum.44 
 Because FTase catalyzes the transfer of a farnesyl group to a protein, FTase inhibitors are 
typically either farnesyl pyrophosphate analogs or peptidomimetics.45  The peptidomimetics bind 
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to the CaaX recognition site and coordinate zinc.  FTase activity requires binding of a CaaX 
protein, farnesyl pyrophosphate, Zn2+ and water.  By binding to the CaaX domain and 
coordinating zinc, these peptidomimetics effectively compete with the native protein substrates.  
Other key residues exploited by FTase inhibitors are the hydrophilic residues Lys 164, His 248, 
Arg 291 and Tyr 300.  These residues are essential to hydrogen bonding and proper orientation 
of farnesyl pyrophosphate for catalysis. 
 
Figure 1.12: Zinc coordinating Farnesyltransferase inhibitors in clinical trials.  Metal binding 
group shown in red. 
  
While FTase inhibitors are not currently approved, several are in late stage clinical trials.  
Zarnestra was originally investigated as a treatment for myelodysplastic syndromes, but failed to 
gain approval due to limited in vivo activity when used as a single agent.47  BMS-214662 is 
being investigated as a potent inhibitor of H-ras and K-ras for the treatment of acute leukemia 
and myelodysplastic syndromes.48  L-778123 was investigated both as a single agent as in 
combination with paclitaxel to treat head and neck cancer and non-small cell lung cancer but was 
abandoned due to adverse effects on heart rate.45  The common feature of these three inhibitors is 
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the monodentate coordination of zinc through an imidazole.  Other FTase inhibitors being 
investigated do not coordinate zinc and act as competitive inhibitors of farnesyl pyrophosphate 
binding. 
 
Figure 1.13: Crystal structure (PDB: 1sa4)49 of Zarnestra (green) bound to human 
farnesyltransferase (cyan). The active site consists of one histidine residue one aspartic acid 
residue and one cysteine residue (magenta) coordinated to Zn2+ (grey).  The imidazole (nitrogen 
in blue) of Zarnestra completes the coordination sphere of Zn2+ to inhibit enzyme activity. 
 
 The FTase active site consists of one aspartic acid residue (Asp 297), one cysteine 
residue (Cys 299) and one histidine residue (His 362) and coordinated to a zinc ion.  Since the 
active site is highly hydrophilic and contains multiple water molecules, FTase inhibitors 
typically form hydrogen bonds with water molecules in the active site.  Although the metal 
binding inhibitors in clinical trials utilize imidazole to coordinate zinc, thiol based 
peptidomimetic inhibitors have also been developed.  However, these inhibitors exhibit high 
levels of toxicity and have been abandoned.44  Future FTase inhibitors may benefit from being 
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designed as an analog of both farnesyl pyrophosphate and the CaaX peptide to increase 
solubility, bioavailability, membrane transportation and binding potency.44 
 
1.2.7 Leukotriene-A4 Hydrolase 
 Leukotriene-A4 hydrolase (LTA4H) is an enzyme that acts as both an aminopeptidase 
and epoxide hydrolase.50  LTA4H binds the epoxide leukotriene-A4 substrate and hydrolyzes it 
to the diol leukotriene-B4.  Leukotriene-B4 is pro-inflammatory as it activates neutrophils and 
signals the recruitment of eosinophils, macrophages, mast cells, T-cells, dendritic cells, smooth 
muscle cells and keratinocytes.51  Over production of leukotriene-B4 is associated with 
inflammatory bowel disease, rheumatoid arthritis, atherosclerosis, chronic obstructive pulmonary 
disease, asthma and cancer.51  Inhibitors of LTA4H have been designed to treat acute myelocytic 
leukemia, myocardial infarction and cystic fibrosis.50-53 
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Figure 1.14: LTA4H inhibitors that have proceeded to clinical trials. 
 
 Since the active site of LTA4H is structurally similar to ACE, one of the first inhibitors 
of LTA4H in clinical trials was the ACE inhibitor Captopril.  Both ACE and LTA4H belong to 
the MA family of metallopeptidases which seem to share a HEXXH sequence in the active site.54  
Because Captopril is a peptide mimetic, other peptide mimetic inhibitors were developed.  
However, one of the more potent peptide mimetics discovered, Bestatin, was isolated from 
Streptomyces olivoreticuli.55  The first crystal structure of LTA4H was solved bound to Bestatin.  
Here, Bestatin coordinates zinc in a bidentate fashion through the amide carbonyl and α-
hydroxyl.  Although hydroxamates are known to coordinate zinc in a bidentate fashion and 
hydroxamate LTA4H inhibitors have been developed, these hydroxamate inhibitors have no 
progressed to clinical trials most likely due to the clinical failures of other hydroxamate based 
21 
 
inhibitors.  However, two carboxylate based inhibitors, DG-051 and Acebilustat, have shown 
appreciable activity and have proceeded to Phase II clinical trials.51,53 
 
Figure 1.15: Crystal structure (PDB: 1hs6)56 of Bestatin (green) bound to human leukotriene A4 
hydrolase (cyan). The active site consists of two histidine residues and one glutamic acid residue 
(magenta) coordinated to Zn2+ (grey).  The amide carbonyl and α-hydroxyl (oxygen in red and 
nitrogen in blue) of Bestatin completes the coordination sphere of Zn2+ to inhibit enzyme 
activity. 
 
 The LTA4H active site consists of two histidine residues (His 295 and His 299) and one 
glutamic acid residue (Glu 318) coordinated to a zinc ion.  Several water molecules are also 
present in the active site, suggesting LTA4H inhibitors should be hydrophilic and may exhibit 
increased potency by forming hydrogen bonds with these water molecules.  Although several 
inhibitors have proceeded to clinical trials, none are currently approved as inhibitors of LTA4H.  
Captopril is currently only marketed as an ACE inhibitor, but is in Phase II clinical trials as a 
treatment for patients with non-small cell lung cancer who have previously been treated with 
radiation therapy.41  DG-051 does not appear to be in clinical trials and may have been 
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abandoned or potentially renamed due to financial issues with the company deCODE and 
subsequent new company Emerald BioStructures.  Bestatin is currently in Phase II clinical trials 
for both the treatment of lymphedema and pulmonary arterial hypertension.41  Acebilustat went 
to Phase II clinical trials in late 2015 but does not currently appear to be in any clinical trials.41  
Future inhibitors may benefit from the use of sulfonamides as the metal binding group as seen 
with the structurally similar enzyme ACE. 
 
1.2.8 Uridine Disphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine Deacetylase 
 Uridine disphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase 
(LpxC) is a critical enzyme in the cell wall synthesis of gram-negative bacteria.57  LpxC is a 
cytosolic amidase that catalyzes the first step of lipid A biosynthesis by deacetylating the amine 
of a 3-acyl-N-acetyl-glucoasmine moiety.58  Inhibition of LpxC prevents cell wall synthesis and 
inhibitors prove to be antibacterial.58  Since bacterial LpxC lacks a homologous mammalian 
protein, selective inhibitors without human toxicity may be developed.59 
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Figure 1.16: LpxC inhibitors in preclinical development.  Metal binding group shown in red. 
 
 Inhibitors of LpxC exhibit nanomolar activity against the enzyme and are generally lethal 
to Escherichia coli.60  Although most gram-negative bacteria share a homologous gene for LpxC, 
these inhibitors display a range of antibacterial activity in various gram-negative species.  CHIR-
090 for example exhibits low nanomolar potency against E. coli, Helicobacter pylori, Neisseria 
meningitidis and Pseudomonas aeruginosa but is weakly effective against Rhizobium 
leguminosarum.61  Despite possessing significant potency, it does not appear that LpxC 
inhibitors have been tested for toxicity.  However, in July 2015 Achaogen was awarded up to 
$4.5 million in funding over the next four years by the National Institute of Allergy and 
Infectious Diseases for the discovery and development of LpxC inhibitors.62  Achaogen received 
this award due to the success of their LpxC inhibitor ACHN-975 which has sub-nanomolar 
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activity and is bactericidal against P. aeruginosa, E. coli and Klebsiella pneumoniae.63  All of the 
current LpxC inhibitors are hydroxamates.  Although hydroxamates typically are problematic for 
mammalian targets, it is possible that highly selective hydroxamates for bacterial targets may not 
exhibit adverse effects in humans while maintaining potency and high zinc affinity in bacteria. 
 
Figure 1.17: Crystal structure (PDB: 3nzk)64 of CHIR-090 (green) bound to LpxC of Yersinia 
enterocolitica (cyan). The active site consists of two histidine residues and one aspartic acid 
residue (magenta) coordinated to Zn2+ (grey).  The hydroxamate (oxygen in red and nitrogen in 
blue) of CHIR-090 completes the coordination sphere of Zn2+ to inhibit enzyme activity. 
 
The LpxC active site consists of two histidine residues (His 79 and His 238) and one 
aspartic acid residue (Asp 242) coordinated to a zinc ion.  This active site sequence is distinct 
from other amidases (ie. ACE and LTA4H) since it does not adhere to the standard HEXXH, 
HXXE or HXXEH sequences.57 It may be possible that this unusual active site sequence could 
reduce off target effects if inhibitors are designed with high affinity.  Several water molecules are 
also present in the active site, suggesting LpxC inhibitors should be highly hydrophilic near the 
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zinc binding motif.  Additionally, there is a hydrophobic passage leading to the active site which 
binds the acyl chain of the natural substrate.  As depicted in Figure 1.17, CHIR-090 exploits this 
hydrophobic passage with the 4-phenylethynyl-benzyl-morpholine unit.  However, CHIR-090 
and the other LpxC inhibtors do not occupy the UDP-binding pocket, which may offer enhanced 
affinity and potency.60  Other studies indicate the zinc ion of LpxC exerts a metal binding group 
preference of: hydroxamate/phosphonate/thioacetoxyacetyl > thiolacetyl > phosphinate > 
carbonxylate/sulfonamide/hydrazide, suggesting the hydroxamate group may be replaced with 
either a phosphonate or thioacetyoxyacetyl group and maintain potency.58 
  
1.3 Clinical Inhibitors of Iron Metalloenzymes 
 
 Iron is the most abundant transition metal in the human body with approximately 0.5 
mg/mL found in whole blood samples.9,65  However, the majority of iron is sequestered by 
proteins such as ferritin, transferrins, hemosiderin and heme proteins.66  These iron sequestering 
proteins are typically cyto-protective since free iron(II) ions can react with hydrogen peroxide to 
generate reactive oxygen species.  Iron is present in the mitochondria, cytosol and nucleus and is 
required for most cellular processes.  As a key component of redox reactions, iron is critical for 
electron transfer, ribosome maturation, angiogenesis, respiration, DNA replication and repair and 
cell cycle control.67  Iron regulates the cell cycle by inhibiting cyclins and cyclin dependent 
kinases.  Chelation of iron prevents this activity and leads to cell cycle arrest in either the G1 or 
S phase.  Iron enzymes are involved in biosynthesis of hormones, metabolism of drugs, DNA 
repair and biosynthesis of antibiotics, making many of these enzymes key drug targets for 
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treatments of cancer, infection and neurodegenerative disorders.68  Iron is generally used to react 
with oxygen and three types of iron-oxygen active sites have been identified: heme containing 
iron coordinated to either cysteine, histidine or tyrosine, mononuclear iron coordinated by two 
histidines and a carboxylate, and dinuclear iron centers coordinated by two histidines and four 
carboxylates.69 
 
1.3.1 Hypoxia-Inducible Factor Prolyl Hydroxylase 
 Hypoxia-inducible factor (HIF) prolyl hydroxylases are iron and 2-oxoglutarate 
dependent dioxygenases.70  There are two known isoforms of this prolyl hydroxylase, PHD1 and 
PHD2.  Both catalyze the addition of a hydroxyl to proline 402 and proline 564 of HIF-α 
proteins.71  This hydroxylation serves as a recognition label for the von Hippel-Lindau protein 
which ubiquitinates HIF for proteasomal degradation.  Activated HIF binds to the hypoxia 
response element in the enhancer region of genes to transactivate vascular endothelial growth 
factor (VEGF) and erythropoietin.  This activations can lead to angiogenesis, erythropoiesis, 
apoptosis, cell proliferation and neuroprotection.70,72  Inhibition of PHD1 or PHD2 prevents the 
degradation of HIF-α and inhibitors can be used to treat anemia, ischemic disease, complications 
from diabetes and provide neuroprotection.71 
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Figure 1.18: Inhibitors of PHD2 in clinical trials.  Metal binding group shown in red. 
 
 HIF prolyl hydroxylase inhibitors in clinical trials are targeted against PHD2 and are used 
to treat anemia.  Fibrinogen, one of the pioneers in HIF prolyl hydroxylase inhibition, developed 
FG-2216 which may be used to treat anemia as a result of chronic kidney disease or as a result of 
cancer chemotherapy.  FG-2216 works by stabilizing and activating HIF through PHD2 
inhibition to induce erythropoietin.  The induction of erythropoietin increases the capacity of 
blood to transport oxygen and may increase red blood cell count.71  Following Fibrinogen’s lead, 
GlaxoSmithKline and Akebia Therapeutics Inc. have developed their own PHD2 inhibitors with 
a similar scaffold.  Both GSK-1278863 and AKB-6548 are being investigated for the treatment 
of anemia, with AKB-6548 specifically targeting anemia associated with chronic kidney disease.  
All three of these inhibitors coordinate iron in a bidentate fashion.  AKB-6548 and FG-2216 
coordinate iron using the nitrogen of the pyridine/isoquinoline ring and the β-carbonyl.  GSK-
1278863 uses a similar β-carbonyl but utilizes the carbonyl of a pyridone for iron coordination.  
Despite this difference, all three inhibitors form hydrogen bonds with Tyr 303, Tyr 329 and Arg 
383 as well as π-π stacking interactions with Tyr 310. 
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Figure 1.19: Crystal structure (PDB: 2hbt)73 of FG-2216 (green) bound to human HIF prolyl 
hydroxylase PHD2 (cyan). The active site consists of two histidine residues and one aspartic acid 
residue (magenta) coordinated to Fe2+ (orange).  The isoquinoline nitrogen and β-carbonyl 
(oxygen in red and nitrogen in blue) of FG-2216 complete the coordination sphere of Fe2+ to 
inhibit enzyme activity. 
 
 The PHD2 active site consists of two histidine residues (His 313 and His 374) and one 
aspartic acid residue (Asp 315) coordinated to a ferrous ion.  Several water molecules are also 
present in the active site, suggesting PHD2 inhibitors should be relatively hydrophilic.  
Additionally, there are hydrophobic pockets near the active site which have not been exploited 
by current inhibitors.71  PHD2 is part of a family of prolyl 4-hydroxylases, sometimes referred to 
as EGLN dioxygenases.72  It is unclear if PHD2 inhibitors also inhibit other members of this 
family, including collagen prolyl 4- hydroxylase, but future efforts should be made to avoid off 
target inhibition.  Additionally, the neuroprotective effects of HIF prolyl hydroxylase inhibition 
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have not yet been exploited by inhibitors in clinical trials and offer another area of potential for 
newer inhibitors. 
 
1.3.2 Peptide Deformylase 
 Peptide deformylase (PDF) catalyzes the removal of N-formyl from an N-terminal 
methionine during protein biosynthesis in bacteria.74  This transformation is a critical step in 
bacterial protein maturation.  Two types of PDF have been discovered.  Type 1 is found in all 
gram-negative bacteria and eukaryotes and some gram-positive bacteria.  Type 2 is found in 
gram-positive bacteria and mycoplasma.74  Although these two types may be found in gram-
positive bacteria, they share very low sequence homology.  For example, E. coli and S. aureus 
PDF only share 23% homology.75  This low homology makes PDF of gram-positive an ideal 
antibacterial target.  Additionally, PDF may serve as a target for some cancers and parasitic 
diseases such as malaria.74 
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Figure 1.20: Inhibitors of PDF based on Actinonin in clinical trials.  Metal binding group shown 
in red. 
 
 Actinonin, isolated from Streptomyces, is a PDF inhibitor and known antibiotic, but like 
most hydroxamates has poor bioavailability.74  As a result, actinonin has served as a general 
scaffold for the development of more potent PDF inhibitors.  While many PDF inhibitors with 
various scaffolds and metal binding groups have been synthesized, only four have proceeded to 
clinical trials.74,76  BB-2497 and BB-83698 were developed by a collaborative effort between 
British Biotech and Genesoft.  They have been investigated for the intravenous treatment of 
bacterial infections and have shown good efficacy and ideal pharmacokinetic properties for once-
daily dosing.77  Unfortunately, British Biotech was purchased by Vernalis and the clinical trials 
for these inhibitors were abandoned.74  GSK-1322322 is in Phase IIb trials and is being 
investigated as both an oral and intravenous treatment for acute bacterial infections and 
31 
 
community acquired pneumonia.41  LBM-415 was investigated as an oral treatment for 
respiratory tract infections but was discovered to possess unexpected safety issues due to an 
increase in methemoglobin and lower blood oxygen saturation.78 
 
Figure 1.21: Crystal structure (PDB: 3u04)79 of Actinonin (green) bound to PDF of Ehrlichia 
chaffeensis (cyan). The active site consists of two histidine residues and one cysteine residue 
(magenta) coordinated to Zn2+ (grey).  The hydroxamic acid (oxygen in red and nitrogen in blue) 
of Actinonin completes the coordination sphere of Zn2+ to inhibit enzyme activity. 
 
 Although the active site of PDF generally contains a ferrous ion coordinated by two 
histidine residues, one cysteine residue and two water molecules, the ferrous ion is highly 
unstable and readily oxidizes to the ferric form.  The ferric ion results in an inactive form of the 
enzyme and cannot be crystallized.74  Studies have shown that the ferrous ion can be replaced by 
either zinc or nickel and maintain activity and stability, which is why this crystal structure 
depicts zinc as the catalytic metal ion.  From this crystal structure and others, it has been 
determined that inhibitors of PDF must coordinate the ferrous ion as well as form a hydrogen 
bond with a nearby glutamic acid.  Additionally, inhibitors may gain better potency and 
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selectivity by exploiting three key pockets.  The S1 pocket is highly hydrophobic and conserved 
across species.  The S2 pocket is solvent exposed and is considered an open tunnel as residues 
are typically spaced too far for non-covalent interactions with ligands.  The S3 pocket is also 
solvent exposed but highly variable across species.  Therefore, inhibitors may benefit from being 
designed to interact with the S3 pocket to reduce toxicity and gain better potency.  Additionally, 
it has been determined that the most potent inhibitors of PDF possess either a hydroxamate or 
reverse hydroxamate metal binding group.  It is possible to replace the hydroxamate with either 
carboxylate or hydrazide, but these groups suffer from a loss in potency.  Substitution of 
hydroxamate with thiol results in greater loss of potency and substitution with phophonates 
appears to eliminate inhibitory activity.76 
 
1.3.3 5-Lipoxygenase 
 5-lipoxygenase (5-LOX) is a non-heme iron dioxygenase which catalyzes the lipid 
peroxidation of arachidonic acid to leukotriene A4.80-82  5-LOX is located in both the nucleus and 
cytosol, but upon activation translocates to the nuclear membrane.  This translocation allows it to 
interact with arachidonic acid to initiate the catalysis of several metabolites.  These metabolites 
may promote cell proliferation and stimulate angiogenesis through the induction of VEGF.82  5-
LOX has become a prime target of pharmaceutical and biotech industries due to its role in 
inflammation.83  Inhibition of 5-LOX has been found to attenuate inflammation after an ischemic 
event, serving as a neuroprotectant.  Additionally, 5-LOX appears to be involved in the 
progression of prostate, lung, colon and colorectal cancers. 
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Figure 1.22: 5-LOX inhibitors in clinical trials (Curcumin and Hyperforin) and approved for 
use. 
 
 Currently, two 5-LOX inhibitors are approved but only Zileuton is recognized as a 5-
LOX inhibitor.  Zileuton is marketed for the treatment of asthma.82  Minocycline is also 
approved by the FDA, but is used as a tetracycline antibiotic for the treatment of several gram-
positive and gram-negative infections.84  However, Minocycline is known to be both anti-
inflammatory and neuroprotective against ischemic events, Parkinson’s disease and Huntington’s 
disease.85  As a result, Minocycline is currently in clinical trials for the treatment of bipolar 
depression, Angelman syndrome, schizophrenia, autism, Huntington’s, Fragile X syndrome, 
rheumatoid arthritis, acute stroke recovery, the treatment of several cancers and other 
inflammation based diseases.41 Other 5-LOX inhibitors in clinical trials are curcumin and 
hyperforin.41  Curcumin inhibits 5-LOX with an IC50 = 8 µM and displays cytotoxicity against 
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colorectal cancer with a GI50 = 52 µM.  Although these values are significantly higher than 
typical chemotherapeutics, curcumin is in Phase II clinical trials as a treatment for pancreatic 
neoplasms.82  Hyperforin is isolated from St. John’s wort and has antidepressive, antibacterial 
and antiproliferative activity.86  Another important feature of hyperforin is that it activates 
pregnane X receptor to regulate expression of cytochrome P450 3A4 monooxygenase, a key 
enzyme in the oxidative metabolism of over 50% of all drugs.87  These important and potent 
activities has pushed hyperforin into Phase III clinical trials as a dietary supplement for the 
treatment of depression.41 
 
Figure 1.23: Crystal structure (PDB: 3v99)88 of the native ligand arachidonic acid (green) bound 
to 5-LOX (cyan). The active site consists of three histidine residues (magenta) coordinated to 
Fe2+ (orange). 
 
 Unfortunately, there is not a crystal structure of an inhibitor bound to 5-LOX.  However, 
from the crystal structure of 5-LOX bound to the native ligand arachidonic acid (Figure 1.23), it 
is clear three histidine residues (His 372, His 376 and His 530) coordinate the ferrous ion.  
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Although this is a similar coordination motif to carbonic anhydrase, the active site does not 
appear to be similar as the 5-LOX active site has a relatively large, mostly hydrophobic tunnel 
leading to the catalytic metal ion, whereas carbonic anhydrase active site is solvent exposed.  
This would suggest that 5-LOX inhibitors should be mostly long, hydrophobic molecules with a 
metal binding head group.  However, these inhibitors may benefit from having a hydrophilic 
“face” to interact with water molecules that line part of the tunnel. 
 
1.3.4 Cytochrome P450 
 Cytochrome P450 (CYP) is a superfamily of enzymes that catalyze the oxidation of 
native and xenobiotic chemicals.89  Primarily, the CYPs interact with a nitrogenous group on a 
chemical through a heme-coordinated iron to oxidize the nitrogen via glucuronidation or forming 
N-oxides.90  CYPs are found in all forms of life, with 57 CYP genes present in the human 
genome and CYP51A a key enzyme in the biosynthesis of the fungal cell wall.91-92  It is 
estimated that nearly 75% of all drugs are metabolized through oxidation by CYP 3A4, 2D6 and 
2C9, with CYP 3A4 being the most important and most abundant isoform in humans.92   
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Figure 1.24: Antifungal CYP inhibitors approved for clinical use.  Metal binding group shown 
in red. 
 
 While there are many FDA approved drugs that inhibit CYPs, only the imidazole and 
triazole based antifungal agents have been designed specifically to inhibit CYP.89,93  CYP51A, 
also known as 14α-sterol demethylase, is essential for ergosterol biosynthesis in fungi.  
Ergosterol is a critical component of the fungal cell membrane, and inhibition of ergosterol 
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synthesis compromises the integrity of the membrane.92  Since they are nitrogenous and 
lipophilic, the antifungal CYP inhibitors are themselves substrates for CYP oxidation by CYP 
3A4, 2C9 and 2C19.92  Inhibition by these antifungals is rapid, competitive and reversible.  
Interestingly, the triazoles show no inhibitory effect on CYP 1A2, 2D6 and 2E1, and 
posaconazole also does not inhibit CYP 2C8 or 2C9.94-95 
 
Figure 1.25: Crystal structure (PDB: 4wmz)96 of Fluconazole (green) bound to CYP51A of 
Saccharomyces cerevisiae (cyan). The active site consists of one cysteine residue (magenta) 
coordinated to the heme coordinated Fe2+ (orange).  The triazole (nitrogen in blue) of 
Fluconazole completes the coordination sphere of Fe2+ to inhibit enzyme activity. 
 
As with all CYPs, the active site of CYP51A contains a heme-coordinated ferrous ion 
that is also coordinated by a cysteine residue (Cys 470).  Due to the lipophilic nature of the heme 
ring, the active site is largely water-free.  However, there is a relatively hydrophilic region 
extending away from the heme.  This explains why the inhibitors are mostly lipophilic near the 
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triazole/imidazole ring but have mostly hydrophilic tails.  Unfortunately, the lipophilic nature of 
the antifungals results in poor water solubility.  Additionally, as CYP inhibitors, especially CYP 
3A4, they hinder the metabolism of other drugs such as benzodiazepines, anxiolytics, 
immunosuppressants, statins and warfarin.92  The reduced metabolism of these drugs can cause a 
highly toxic effect or a reduction in efficacy.  This stresses the need to explore derivatives of 
these antifungals for structure activity relationships to avoid inhibition of the key metabolic CYP 
enzymes as well as developing an understanding of the inhibition potential of their metabolites. 
 
 
1.4 Clinical Inhibitors of Magnesium Metalloenzymes 
 Magnesium is the most abundant divalent cation found in eukaryotic cells.97  Free 
magnesium is essential for the regulation of cell growth as it is an important regulatory cofactor 
for many enzymes, including: acetyl CoA synthetase, 5’-nucleotidase, phosphorylase kinase, 
phosphoribosyl pyrophosphate transferase, several ATPases, adenylate cyclase and enzymes in 
glycolytic pathways.98  Potentially due to its abundance, magnesium is one of the most versatile 
cofactors involved in both intracellular and extracellular processes.99  Additionally, magnesium 
is essential for the activation of enzymes involved in DNA replication.100  These enzymes 
typically coordinate the magnesium ion with aspartic acid as part of three structural motifs.  
RNA polymerase, DNA polymerase I and human immunodeficiency virus reverse transcriptase 
use the motif NADFDGD while telomerase and reverse transcriptase may use either YXDD or 
LXDD where X can be any amino acid.99  The magnesium ion in the active site of these enzymes 
is a “hard” ion and prefers binding “hard” ligands with low polarization potential.101-102  Oxygen 
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and nitrogen are the preferred atoms for magnesium binding, and all magnesium metalloenzymes 
in the Protein Data Bank are coordinated by at least one carboxylate in a monodentate fashion.100  
The coordination sphere of magnesium is octahedral and always includes at least one water 
molecule.  Unlike other metal ions in metalloenzymes, magnesium will not exchange a first shell 
water molecule for a protein ligand.92  Despite this characteristic, Mg2+ is not the preferred metal 
ion for these enzymes and may be displaced by Zn2+, Cu2+, Co2+, Ni2+, or Fe2+.  With the 
exception of Zn2+, these other metal ions may inhibit the enzyme.99 
 
1.4.1 Human Immunodeficiency Virus-Integrase 
 Human immunodeficiency virus (HIV) integrase is a 32 kDa enzyme that binds both viral 
and cellular DNA to catalyze the integration of the viral genome into the host DNA.103-104  The 
enzyme consists of three structurally and functionally distinct domains.  The N-terminal domain 
is a zinc finger region that is highly conserved in all retrovirus integrases and is implicated in 3’ 
processing and strand transfer.103  The C-terminal domain binds the host DNA and is critical for 
3’ processing and strand transfer.105  The catalytic domain contains the catalytic triad of aspartic 
acids and glutamic acid (DDE motif).106  This catalytic triad coordinates two metal ions.  While 
magnesium appears to be the preferred ion due to abundance, manganese may also be utilized.103 
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Figure 1.26: HIV integrase inhibitors approved for use (Raltegravir and Elvitegravir) and the 
first HIV integrase inhibitor to go into clinical trials (S-1360).  Metal binding groups shown in 
red. 
 Due to limited knowledge about HIV integrase in the early 1990s, initial attempts to 
develop inhibitors focused on topoisomerase inhibitors, dihydroxynaphthoquinone and caffeic 
acid phenethyl ester, to coordinate the zinc ion in the N-terminal domain.107  Although these 
compounds had some effect, true HIV integrase inhibitors were not determined until 1999.  High 
throughput screening identified diketo acids as potent inhibitors of HIV integrase.108  The first 
diketo acid to go into clinical trials was S-1360.109  Unfortunately, S-1360 failed to show 
efficacy in humans due to reduction of the carbon linked to the triazole.110  However, this led to 
the development of another molecule, Raltegravir, which was approved in 2007 and is capable of 
coordinating the two Mg2+ in a bis-bidentate fashion with a planar O-O-O structural motif.  
Raltegravir forms a 6-membered and 5-membered chelate ring.  Upon chelation, Raltegravir can 
move the fluorophenyl group to displace a 3’ adenine and tightly fit in the binding pocket.111  
Despite the potency of Raltegravir (IC50 = 40 nM), several resistant strains were discovered.  
These resistant mutants maintain the same structural motif coordinating the two Mg2+, 
suggesting that compounds with metal binding groups with higher affinity could be used to 
inhibit HIV integrase even in Raltegravir resistant strains.112  Eventually Elvitegravir (IC50 = 7 
nM) was developed and approved in 2012.  The increased potency of Elvitegravir may be due to 
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the formation of a 6-membered and a 4-membered chelate ring.112  Although HIV integrase 
inhibitors could be used as stand-alone treatments of HIV, combination therapy with an HIV 
protease inhibitor and an antiretroviral is the preferred treatment method.113 
 
Figure 1.27: Crystal structure (PDB: 3oya)114 of Raltegravir (green) bound to HIV integrase of 
Prototype Foamy Virus intrasome (cyan). The active site consists of two aspartic acid residues 
and one glutamic acid residue (magenta) coordinated to two Mg2+ (green).  The planar O-O-O 
motif of the dihydropyrimidine amide (oxygen in red and nitrogen in blue) of Raltegravir 
completes the coordination sphere of the two Mg2+ to inhibit enzyme activity. 
 
The HIV integrase active site consists of two aspartic acid residues (Asp 128 and Asp 
185) and one glutamic acid residue (Glu 221) coordinated to two magnesium ions.  Several water 
molecules complete the octahedral coordination sphere of each Mg2+.  Since the active site is 
highly hydrophilic and contains multiple water molecules, HIV integrase inhibitors are mostly 
hydrophilic and may form hydrogen bonds with water molecules in the active site.  Because 
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Mg2+ is a “hard” ion and prefers to coordinate with oxygen atoms, inhibitors should contain three 
planar oxygen atoms.  Additionally, inhibitors should be able to displace adenine and tightly bind 
in the DNA binding pocket to strongly inhibit HIV integrase as well as form π-π stacking 
interactions with Tyr 143.112  Other research has shown that Van der Waals interactions with Pro 
214 may also increase potency.111 
 
1.4.2 DNA Gyrase 
 DNA gyrase is a type IIA topoisomerase.  It is an ATP dependent enzyme that catalyzes 
the supercoiling of DNA in prokaryotes.115  DNA gyrase is also essential for DNA replication, 
transcription, repair, recombination, bacteriophage λ integrative recombination and 
decatenation.116-118  The enzyme is a tetramer consisting of two subunits, GyrA and GyrB.  GyrA 
forms a covalent bond with a 5’ phosphate of DNA to catalyze a double strand break.  GyrB 
hydrolyzes ATP for GyrA to ligate the DNA by forming a new phosphodiester bond.119  DNA 
gyrase is a popular target for antibiotics and may be a therapeutic target for antitumor agents.120  
Antibiotics that target DNA gyrase typically belong to one of two classes; quinolones which 
target GyrA and coumarins which target GyrB.  The antibiotics which target GyrB are 
competitive inhibitors of ATP, do not act by coordinating a metal ion and therefore will not be 
discussed further. 
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Figure 1.28: Fluoroquinolone inhibitors of DNA gyrase approved for use.  Metal binding group 
shown in red. 
 The quinolones, which have mostly been replaced by the more effective 
fluoroquinolones, are one of the most successful classes of antibiotics.121  Fluoroquinolones can 
be administered as front-line therapeutics for bacterial infections but are recommended for and 
often prescribed to treat multi-drug resistant infections.  These inhibitors act by stabilizing the 
cleaved DNA from the first step of the catalytic reaction.122  By stabilizing the GyrA-DNA 
complex, fluoroquinolones prevent DNA replication and transcription as well as the re-ligation 
of DNA after the double strand break, causing bacteriostasis.  At high enough concentrations, 
fluoroquinolones release the double strand broken DNA from GyrA.  Accumulation of the 
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broken DNA eventually leads to cell death.123  Public interest and demand for fluoroquinolones 
was drastically heightened in 2001 when Tom Brokaw announced on NBC Nightly News “in 
Cipro we trust”.  This statement was fueled by the terrorist attacks on September 11, 2001 and 
the subsequent anthrax scares.  During this time, Bayer and the United States government 
provided 60 tablets of Ciprofloxacin to military personel, first responders and anyone who may 
have been exposed to anthrax.  Medical providers would also prescribe ciprofloxacin to anyone 
who requested in, placing strains on production and most likely aiding the eventual bacterial 
resistance.124 
 
Figure 1.29: Crystal structure (PDB: 5btc)123 of Ciprofloxacin (magenta) bound to DNA gyrase 
of Mycobacterium tuberculosis (green). The active site of GyrA appears near the dimer interface 
and consists of the protein bound to DNA base pairs (blue-green, phosphate backbone in orange).  
A 3’ oxygen on DNA coordinates to Mg2+ (green) which is coordinated to DNA gyrase through a 
water network.  The two carbonyls of the quinolone motif (oxygen in red and nitrogen in blue) of 
Ciprofloxacin complete the coordination sphere of Mg2+ to stabilize the DNA-GyrA complex 
and prevent further catalysis. 
45 
 
 
 The necessity of a metal ion in the catalytic site has been debated since it has been 
proposed that intrinsic resistance of certain species to fluoroquinolones results from sequence 
variation which leads to a loss of metal ion to prevent drug interaction.125  However, Figure 1.29 
clearly indicates a metal ion forms a “bridge” between the GyrA-DNA complex and the 
fluoroquinolone through hydrogen bonds with several water molecules.  A similar “bridge” 
between the inhibitor to GyrA by a single water and Mg2+ is found in Staphylococcus aureus and 
Acinetobacter baumannii.123  Although Mg2+ is not directly coordinated by any residues of 
GyrA, S. aureus uses three acidic residues from GyrB to coordinate Mg2+ through a water 
network.  These three residues (Glu B435, Asp B508 and Asp B510) are conserved in 
topoisomerase and primase domains of bacteria.126  Additionally, a tyrosine residue (Tyr A123) 
was found to be essential for the catalytic activity of DNA gyrase in S. aureus, helping to cleave 
the phosphodiester bond of DNA once a 3’ oxygen has been coordinated to Mg2+ in GyrA.122  
Mycobacterium tuberculosis also has a catalytic tyrosine residue (Tyr 129) but only stabilizes 
Mg2+ with one residue (Asp 94) via a water molecule.  This lack of water mediated contacts to 
Mg2+ may explain the resistance of Mycobacterium to fluoroquinolones.123  Increased potency 
and selectivity towards Mycobacterium tuberculosis may be achieved through interactions with 
the nearby residues Arg 482, Thr 500 and Glu 501.  Although S. aureus also has a nearby 
arginine residue (Arg A122) it does not have a nearby threonine residue and the homologous 
glutamic acid residue participates in Mg2+ coordination.  Therefore, compounds that are designed 
towards inhibiting DNA gyrase of Mycobacterium tuberculosis may not inhibit that of S. aureus 
since there are structural differences in the coordination of Mg2+ and some differences in the 
residues surrounding the active site.  
46 
 
 
 
1.5 Clinical Inhibitors of Manganese Metalloenzymes 
 Manganese is the fourth most common metal ion cofactor and is found in approximately 
6% of enzymes.127  Similar to iron and copper, manganese is commonly found in redox 
processes which require electron transfer.99  Manganese is essential for enzymes that regulate 
development, energy metabolism, digestion, immune function, reproduction and antioxidant 
defense.128  Although protein binding characteristics of manganese are scarce, Mn2+ exhibits 
ligand affinity similar to Fe2+.99,129  This may be due to Mn2+ and Fe2+ having similar ionic radii, 
coordination preferences and free energy of solvation.129-130  It is known that Mn2+ and Fe2+ are 
maintained at similar concentrations in the cytosol and this maintenance utilizes a common 
transporter for cellular uptake.131  However, Mn2+ concentrations are elevated in chloroplasts, as 
a necessary component of photosystem II, and mitochondria.132  Additionally, Mn2+ may be 
replaced by Cu2+ or Zn2+ at high enough concentrations prior to protein folding.  Once a protein 
is folded properly, Mn2+ cannot be displaced by Cu2+ or Zn2+.133  It is unknown if Fe2+ is able to 
compete with Mn2+ due to key similarities. 
 
1.5.1 1-deoxy-D-xylulose 5-phosphate Reductoisomerase 
 1-deoxy-D-xylulose 4-phosphate reductoisomerase (DXR) catalyzes the conversion of 1-
deoxy-D-xylulose 5-phosphate into 2-C-methyl-D-erythritol 4-phosphate.134  DXR is required for 
the biosynthesis of isoprenoids through the non-mevalonate pathway in bacteria, protozoa, plants 
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and algae.135  The non-mevalonate pathway is not utilized by humans, suggesting the selective 
inhibition of DXR will not cause toxicity in humans.135  Although there is some debate about 
which metal ion is utilized for catalytic activity, DXR exhibits a high affinity for Co2+, Mn2+ and 
Mg2+ in descending order.   Similar affinity is displayed for both Co2+ and Mn2+, but DXR shows 
nearly 100-fold less affinity towards Mg2+.  While Mg2+ is more abundant than Mn2+ or Co2+, 
DXR displays the greatest kcat when Mn
2+ is in the active site.136-137  Additionally, Mn2+ allows 
the most ligand bond flexibility which better accommodates the transition state geometry.138  
Together, these results appear to indicate Mn2+ as the preferred metal ion for activity. 
 
Figure 1.30: Natural products that exhibit potent DXR inhibitory activity (Fosmidomycin is 
currently in clinical trials).  Metal binding group shown in red. 
 
 Currently there is only one DXR inhibitor in clinical trials, fosmidomycin, but another 
natural product exhibits greater DXR inhibition against Plasmodium falciparum.139  Both of 
these natural products are isolated from Streptomyces, with fosmidomycin isolated from S. 
lavendualae and FR900098 from S. rubellomurinus.140  Fosmidomycin is a slow, tight binding, 
competitive inhibitor with Ki values of 38-600 nM.
141  Despite this potency, fosmidomycin is not 
very permeable due to the polar, anionic phosphonate group.  Additionally, as with most 
hydroxamates, fosmidomycin displays poor bioavailability.135  Although it would appear that 
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fosmidomycin and FR900098 have two metal chelating groups, only the hydroxamate appears to 
coordinate Mn2+ while the phosphonate hydrogen bonds with several key residues in the active 
site. 
 
Figure 1.31: Crystal structure (PDB: 4ooe)142 of Fosmidomycin (green) bound to DXR of M. 
tuberculosis W203Y mutant (cyan). The active site consists of two glutamic acid residues and 
one aspartic acid residue (magenta) coordinated to Mn2+ (steel blue).  The hydroxamate (oxygen 
in red and nitrogen in blue) of Fosmidomycin completes the coordination sphere of Mn2+ to 
inhibit enzyme activity. 
 
In addition to the metal ion, DXR also requires NADPH for activity.  DXR is a 
homodimer with each unit divided into three domains.  The N-terminal domain binds NADPH, 
the central domain contains most of the active site residues as well as a flexibile “lid” region, and 
the C-terminal domain is comprised of mostly α-helices.143  The DXR active site consists of two 
glutamic acid residues (Glu 153 and Glu 222) and one aspartic acid residue (Asp 151) 
coordinated to Mn2+.  Several water molecules are also present in the active site and may be used 
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to complete an octahedral coordination sphere Mn2+ or a ligand may displace the water 
molecules to create a trigonal bipyramidal coordination sphere.144-145  Since the active site is 
highly hydrophilic and contains multiple water molecules, DXR inhibitors are mostly 
hydrophilic and form hydrogen bonds with hydrophilic residues in the active site.  Typically, the 
phosphonate forms hydrogen bonds with an asparagines, lysine, histidine and two serines.  
FR900098 may form Van der Waals interactions with a tryptophan residue on the flexible “lid” 
which may explain its increased potency.135  Due to the multiple interactions with the active site, 
the phosphonate group is essential to proper orientation and binding of the inhibitor.145  
Unfortunately synthetic inhibitors of DXR, with the exception of some sulfur contain isosteres of 
fosmidomycin, have not been able to produce greater potency.146  However, these inhibitors 
typically maintain the hydroxamate moiety and may benefit from the use of an alternative 
chelating moiety.  Additionally, an ester pro-drug form of the phosphonate as well as the 
addition of more lipid like moieties to interact with the “lid” region may increase the 
permeability and efficacy of synthetic inhibitors.135 
 
1.5.2 Arginase 
 Arginase is a binuclear metalloenzyme that hydrolyzes L-arginine to L-ornithine and 
urea.147  There are two isoforms of human arginase.  Arginase I is expressed in the liver and is 
the major isoform responsible for activity in the human body.148  Arginase II is mitochondrial 
and mostly expressed in the kidney and prostate.  L-arginine is also the only substrate of nitric 
oxide synthase (NOS), an enzyme critical for the production of nitric oxide (NO).149  NO 
promotes blood flow by regulating vasodilation and inhibiting platelet aggregation, regulates 
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hemostasis and leukocyte adhesion, exhibits anti-inflammatory effects, scavenges reactive 
oxygen species and contributes to vascular smooth muscle cell proliferation.149-150  Both arginase 
and NOS compete for L-arginine, with NOS having a much higher affinity but approximately 
1000-fold less activity than arginase.151  Consumption of L-arginine by arginase impairs the 
synthesis of NO and may contribute to asthma, cystic fibrosis, glomerular disease, psoriasis, 
arthritis, sickle cell disease, diabetes mellitus, hypertension, atherosclerosis, erectile dysfunction, 
ischemia reperfusion injury and aging.149, 152-157  Inhibition of arginase restores synthesis of NO 
and has been shown to protect patients with coronary artery disease from endothelial dysfunction 
resulting from ischemia reperfusion and reverses impairment of vasodilation.147, 149-150, 158 
 
Figure 1.32: Arginase inhibitors in pre-clinical [S-(2-boronoethyl)-L-cysteine] and clinical (N-
hydroxy-nor-L-arginine) development.  Metal binding group shown in red. 
 
 Arginase inhibitors being developed typically belong to one of two classes: boronic acid 
analogs and N-hydroxy-guanidinium analogs or L-arginine.149  The boronic acid analogs are able 
to be trigonal planar, which is the same molecular geometry of the guanidinium group of 
arginine.  This class of inhibitors acts through a nucleophilic attack of the boron atom by a 
hydroxide bridged to the metal ion.  The boronic acid analogs bind to the active site of arginase 
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approximately 50,000 times stronger than L-arginine, other amino acids, aldehyde based analogs 
and sulfonamide mimics.  S-(2-boronoethyl)-L-cysteine (BEC) is the most studied boronic acid 
analog and exhibits Ki = 0.4 µM against arginase I and Ki = 0.31 µM against arginase II.
159  BEC 
also enhances response to acetylcholine which restores vascular tone and normal blood flow in 
both high and low salt-treated animals.147  Additionally, BEC can enhance smooth muscle 
relaxation in human penile corpus cavernosum tissue and may be used to treat erectile 
dysfunction.148  Although BEC is has not progressed to clinical trials, it has severed as small 
molecule probe of arginase-NOS responses. 
 N-hydroxy-nor-L-arginine (nor-NOHA) is a hydroxylamine analog of L-arginine and 
binds in a similar fashion.  The N-hydroxy guanidinium side chain maintains the same trigonal 
planar geometry of the native ligand but the hydroxy group is able to displace the hydroxide ion 
which attacks the boron of BEC.160  However, due to the displacement of this hydroxide, nor-
NOHA is less specific than BEC against arginase I  (Ki = 0.5 µM) but more specific against 
arginase II (Ki = 50 nM).
161  nor-NOHA has recently completed Phase 2 clinical trials as a 
treatment for cutaneous microvascular endothelial function in patients with type 2 diabetes.41 
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Figure 1.33: Crystal structure (PDB: 3kv2)162 of N-hydroxy-nor-L-arginine (green) bound to 
human arginase I (cyan). The active site consists of four aspartic acid residues and two histidine 
residues (magenta) coordinated to two Mn2+ (steel blue).  The N-hydroxyl group (oxygen in red 
and nitrogen in blue) of N-hydroxy-nor-L-arginine completes the coordination sphere of Mn2+ to 
inhibit enzyme activity. 
 
The arginase active site of arginase I and II are nearly identical and consist of four 
aspartic acid residues (Asp 124, Asp 128, Asp 232 and Asp 234) and two histidine residues (His 
101 and His 126) coordinated to two Mn2+.  Several water molecules are also present in the 
active site and are used to complete an octahedral coordination sphere for each Mn2+.  The active 
site is relatively small and highly hydrophilic which is why most arginase inhibitors are an 
analog of L-arginine.  These inhibitors must mimic the trigonal planar geometry of L-arginine to 
properly fit in the active site and will benefit from interactions with at least three water 
molecules, Asp 128 and a nearby asparagine.  It may be possible to add functionalities to the 
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backbone of the inhibitor to form contacts with other water molecules and/or a nearby, non-
coordinating histidine and aspartic acid.  Structure based drug design efforts are currently being 
made with BEC as a scaffold to identify positions that are amenable to substitution to improve 
inhibitory activity.163-164  X-ray crystallography evidence suggests the α position of the amino 
acid moiety may be substituted with a two-carbon chain tertiary amine to be in close contact with 
the aforementioned non-coordinating aspartic acid residue (Asp 181 for arginase I and Asp 200 
for arginase II).165  Unfortunately, the nearly identical active site of arginase I and II makes it 
seemingly impossible to generate selective inhibitors.  However, tissue specific inhibitors could 
reduce universal arginase inhibition. 
 
1.6 Development of Inhibitors Towards A Copper Metalloenzyme 
 Copper is the second most abundant transition metal used in biology next to iron.166  It is 
also the third most used cell signal modulator after calcium and zinc.167  In addition to cell 
signaling regulation, copper also is an essential cofactor for numerous redox enzymes.168  These 
enzymes play critical roles in respiration, electron  transfer, mitochondrial aerobic metabolism, 
biosynthesis of neurotransmitters and neuropeptides, antioxidant action, iron uptake, 
pigmentation, photosynthesis, cross linking of collagen, wound healing, epigenetic modification, 
tissue integrity, synaptic function, metastasis and cell growth.167, 169-170  Despite being essential to 
these numerous biological processes, whole body copper concentrations are estimated to be 10-15 
M or less.132  However, copper exists in significantly higher concentrations in the blood (5-25 
µM)171 and neurons (100 µM).  The lower estimations of total body copper may be due to 95% 
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of copper being bound to proteins such as ceruloplasmin.172  Other areas of high copper content 
include the liver and the brain.173 
 Copper exists in two oxidized states, with Cu+ being more kinetically labile and favored 
in the cellular environment and Cu2+ being the primary extracellular state.170, 174  To be 
incorporated into proteins copper requires metallochaperones such as the ATPase Atx1 which 
incorporates two copper ions into tyrosinase.175  Since Cu+ is considered a “soft” acid it has a 
higher affinity towards “soft” bases such as thiols.176  Copper containing proteins can be 
subdivided based on ligands, spectroscopic features and functions as well as number of groups 
copper ions.177   Mononuclear copper proteins are divided into two classes: Type 1 and Type 2.  
Type 1 typically coordinate Cu+ via histidine, cysteine and sometimes methionine in a trigonal 
pyramidal or distorted tetrahedral geometry.  Type 2 coordinate Cu+ with histidine, aspartic acid 
and sometimes tyrosine in a distorted tetragonal geometry.  Dinuclear copper proteins are 
divided into two classes: Type 3 and CuA.  Type 3 coordinate Cu
+ with histidine and sometimes 
tyrosine in a tetragonal geometry while CuA resemble Type 1 copper proteins.  The last class of 
copper proteins, Cuz, is tetranuclear and coordinates copper with histidine and a sulfur ion.
178  
 
1.6.1 Tyrosinase 
 Tyrosinase is a dinuclear copper metalloenzyme that is a member of the oxidase 
superfamily.179  This enzyme can be found in bacteria, fungi, plants and animals.180-181  
Tyrosinase has two catalytic functions: the hydroxylation of monophenols and the oxidation of 
diphenols.181-182  These catalytic functions are directly related to the two copper ions and state of 
the active site.183  The active site can exist in three states: oxy-tyrosinase, deoxy-tyrosinase and 
55 
 
met-tyrosinase.  Oxy-tyrosinase is the state when molecular oxygen bridges the two copper ions.  
Here the copper ions are in the cupric (Cu2+) state.  The oxy-tyrosinase catalyzes the 
hydroxylation of a monophenol to a diphenol.  After the hydroxylation the enzyme is converted 
to the deoxy state.  Deoxy-tyrosinase is the reduced form of oxy-tyrosinase and therefore the 
copper ions are in the cuprous (Cu+) state.  Deoxy-tyrosinase can then bind molecular oxygen to 
regenerate the oxy state.  Oxy-tyrosinase can also oxidize a diphenol to a quinone.  After 
oxidation the enzyme is converted to the met state which resembles the oxy state but has a 
hydroxide bridge the two Cu2+ ions.  Met-tyrosinase can also oxidize a diphenol to a quinone.  
After oxidation, met-tyrosinase is converted to deoxy-tyrosinase.184 
 The most studied tyrosinase is mushroom tyrosinase because mushroom tyrosinase is 
cytosolic, can be purified and is commercially available while human tyrosinase is membrane 
bound and has yet to be purified.185  Tyrosinases primarily contribute to pigmentation as part of 
melanin biosynthesis.186  Inhibitors of tyrosinase are mostly used as cosmetic agents to treat 
hyperpigmentary disorders such as melasma, actinic and senile lentigines, ephelide and 
postinflammatory hyperpigmentation.187-188  Because tyrosinase in plants contributes to 
browning, tyrosinase inhibitors may also be used as food additives.189  Despite the seemingly 
trivial functions of tyrosinase inhibitors, inhibition of melanin biosynthesis may have more 
clinical relevance.  Fungi melanin has been linked to differentiation of reproductive organs and 
spore formation, virulence and tissue protection after injury.190-192  Neuromelanin in the human 
brain could contribute to dopamine toxicity which may be associated with neurodegenerative 
diseases such as Parkinson’s disease.193  Tyrosinase is critical to melanin biosynthesis since it is 
the rate limiting step.182-183  Therefore, inhibition of tyrosinase and subsequently the inhibition of 
melanin biosynthesis may lead to treatments of fungal infections and Parkinson’s disease. 
56 
 
 
Figure 1.34: Inhibitors of tyrosinase that have been used or tested as topical treatments of 
hyperpigmentation.  Metal binding group shown in red. 
 
 Currently, tyrosinase inhibitors are used for cosmetic purposes and as anti-browning food 
additives.184  These inhibitors include hydroxyquinone, arbutin, kojic acid and azelaic acid.  The 
“gold standard” of tyrosinase inhibitors is hydroxyquinone, which is used as a topical agent for 
skin whitening.188  However, hydroxyquinone can be a skin irritant and may be carcinogenic.194  
Although it is still commonly sold in over-the-counter topical creams in the USA, 
hydroxyquinone is now banned from cosmetics in Europe and is under investigation by the 
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FDA.188  Arbutin is considered to be safe, but is ineffective at the concentrations permitted in 
cosmetics.195  While kojic acid is also considered to be safe and is generally used as a positive 
control when assessing tyrosinase inhibitors, it does not appear to coordinate the copper in the 
active site of tyrosinase despite its known chelation ability.196  Azelaic acid is recommended as 
an alternative to hydroxyquinone and is used to treat melasma and post-inflammatory 
hyperpigmentation.197  However, azelaic acid also exhibits antibacterial and anti-inflammatory 
attributes that are most likely not associated with tyrosinase inhibition. 
 
Figure 1.35: Crystal structure (PDB: 3nq1)196 of kojic acid (cyan) bound to tyrosinase of 
Bacillus megaterium (green). The active site consists of two Cu2+  atoms (copper). 
  
Other compounds commonly used as positive controls for tyrosinase inhibition include L-
mimosine and tropolone.184  L-mimosine is a substrate analog of tyrosine, utilizing a 
hydroxypyridone motif instead of a phenol.  The 2-hydroxy-4-pyridone of L-mimosine is similar 
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to the alpha-hydroxy ketone of kojic acid and tropolone.  However, L-mimosine is not a selective 
inhibitor.  Reports indicate L-mimosine is capable of inhibiting DNA replication, causing cell 
cycle arrest in the G1 phase and inducing apoptosis through chelation of iron.198-199  As an iron 
chelator, L-mimosine has recently been linked to inhibition of PHD through coordination of Fe2+ 
in the active site.200  Tropolone is also known to strongly chelate metals, including Cu2+ of 
tyrosinase.  The alpha-hydroxy ketone of tropolone coordinates with at least one of the copper 
atoms in the active site of tyrosinase.  This alpha-hydroxy ketone motif is also found in 
flavanoids, such as quercetin, which also exhibit tyrosinase inhibitory activity.  Although 
quercetin exhibits the highest inhibition activity of the flavonoids, it is a relatively weak inhibitor 
with only 20% of the inhibitory activity of kojic acid.184  4-n-butylresorcinol is another motif 
found in some flavonoids and has been tested as a topical treatment to reduce the appearance of 
age spots.201-202  Not only is 4-n-butylresorcinol a more potent tyrosinase inhibitor, it also 
exhibits strong effects on reducing the pigmentation of age spots, melasma and other forms of 
hyperpigmentation.188 
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Figure 1.36: Crystal structure (PDB: 2y9x)203 of tropolone (green) bound to tyrosinase from 
Agaricus bisporus (cyan). The active site consists of six histidine residues (magenta) coordinated 
to two Cu2+ (copper).  The alpha-hydroxy ketone (oxygen in red) of tropolone completes the 
coordination sphere of Cu2+ to inhibit enzyme activity. 
 
 The active site of mushroom tyrosinase consists of six histidine residues (His 61, His 85, 
His 94, His 259, His 263 and His 296) coordinated to two Cu2+ atoms.  Several water molecules 
are also present in the active site (see Figure 1.35) and may be used in the coordination sphere 
for Cu2+.  The active site is solvent exposed but may be protected by a flexible loop region.  
Current inhibitors mimic either the monophenol or diphenol substrate and have the ability to 
coordinate Cu2+ in the active site.  Due to the small size and relatively simplistic features of these 
inhibitors, most are not selective towards tyrosinase and may elicit adverse side effects.  
Additionally, these inhibitors have been developed towards the inhibition of mushroom 
tyrosinase.  While mushroom tyrosinase exists as a cytosolic tetramer, human tyrosinase is a 
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highly glycosylated monomer which is membrane bound.184  In order to develop tyrosinase 
inhibitors capable of treating Parkinson’s more information about human tyrosinase is required.  
This includes kinetic activity and structural characterization of the enzyme.  It may also be 
possible that tyrosinase of melanocytes is different from tyrosinase in the brain and nervous 
system, which may further be used to develop selective inhibitors.204  Additionally, inhibitors of 
specific states of tyrosinase (ie. deoxy-tyrosinase) may provide greater selectivity and potency. 
 
1.7 Properties of Common Metal Binding Groups 
 Chelation is the bonding of ions to metal ions to form a ring-shaped complex and 
involves the formation of dipolar or coordinate bonds between an organic ligand and a metal 
atom.205  The organic ligand involved typically utilizes the atoms O, N, S and P to form the 
coordinate bonds.  These organic motifs are referred to as metal binding groups.  Metal binding 
groups can be optimized by size (number of atoms in ring-shaped complex), acidity, number of 
metal binding groups available, composition (types of atoms and monodentate or bidentate 
coordination) and relative geometry of coordinating atoms.3  The most common metal binding 
groups utilized by inhibitors are hydroxamates, carboxylates, phosphonates/phosphates, 
sulfonamides and thiols.206-207  Metalloenzyme inhibitors typically contain a moiety that mimics 
the natural substrate in addition to these metal binding groups to provide specificity.2  However, 
this may not be enough as many metalloenzymes utilize structurally similar substrates.3  To 
overcome this issue, one must take into account the local environment of the enzyme as it can 
play a significant role in the overall binding of the ligand and the metal.208  Additionally, binding 
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of the inhibitor leads to conformational changes in the active site geometry and these changes 
should mimic the natural conformational change of the enzyme bound to the native ligand.209   
While many clinical inhibitors of metalloenzymes aim to mimic the natural substrate and 
are designed to maximize interactions within the local environment, many of these inhibitors 
have poor pharmacokinetic properties, including low oral bioavailability and poor metabolic 
stability.3  Pro-drug forms have been able to overcome some of these limitations, but there is still 
a need to better understand how the chemical scaffold may affect the metal binding group and 
how the metal binding group affects both the metal and the metal-protein interaction.3  For 
example, most metalloenzymes are zinc based and show high affinity towards sulfur or nitrogen 
based ligands, but many zinc metalloenzyme inhibitors utilize carboxylic acid as the metal 
binding group.207  Although this is somewhat misleading since most hydroxamates fail clinical 
trials and many thiol based inhibitors exhibit poor side effects, this still expresses the need to 
develop inhibitors with metal binding groups designed for both the metal and the enzyme.  
Designing inhibitors that balance theses interactions may provide better selectivity and 
biocompatibility.3 
 
1.7.1 Hydroxamates 
 Hydroxamates are among the most commonly used metal binding groups due to their 
presence in natural products.  Among these natural products are bacterial siderophores.  
Siderophores are small molecules synthesized by bacteria in response to low levels of iron.  
Bacteria then utilize the siderophores to sequester iron.  The iron-siderophore complex can then 
be recognized by receptors on the cell wall and actively transported across the membrane to 
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release iron into the cytoplasm.210  While hydroxamates tend to favor chelation of Fe2+, Fe3+ or 
Cu2+, they exhibit good affinity towards first row transition metal ions as well as Mg2+.2-3  
Chelation of these metals is almost always in a bidentate fashion to form five membered chelate 
rings.  The only instances of monodentate binding of hydroxamates appear in the zinc 
metalloenzymes carbonic anhydrase and HDAC 4.3   
Although hydroxamates are easy to prepare and hydroxamate based inhibitors are 
typically highly potent in both in vitro and in vivo experiments, they have only had moderate 
success in clinical trials.3  One potential reason for their poor clinical success is that most 
hydroxamate inhibitors have been designed for zinc metalloenzymes.  However, hydroxamates 
exhibit 106-1011 fold greater affinity towards Fe3+ than Zn2+.33  This may explain their weak 
inhibitory activity towards carbonic anhydrases as well as their lack of selectivity towards many 
zinc metalloenzymes.24,211  Additionally, hydroxamates tend to have poor oral bioavailability, 
exhibit toxicity due to poor selectivity and have short metabolic half-lives.25  Hydroxamates can 
readily by hydrolyzed to hydroxylamine and carboxylic acid, are highly prone to glucuronidation 
and may be oxidized to an acyl nitroso group.3,212  Acyl nitroso formation may also lead to 
formation of reactive oxygen species and oxidative stress.212  All of these issues have lead 
researchers to explore non-hydroxamate and hydroxamate derivatives as potential metal binding 
groups in order to maintain high metal affinity while reducing metabolic problems. 
 
1.7.2 Carboxylates 
 The carboxylates aspartic acid and glutamic acid are the most commonly used natural 
metal binding groups in metalloenzymes to coordinate metal ions.3  While cysteine and histidine 
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residues are also very common in metalloenzyme metal coordinating motifs, carboxylates are 
more suitable towards the synthesis of inhibitors.  Not only are a wide variety of carboxylic acids 
commercially available but they can also be readily prepared through a number of well 
established synthetic methods.  In addition to being easily prepared, carboxylic acids are also 
easy to store and are relatively simple to handle.213  Carboxylic acids may coordinate metal ions 
in a monodentate or bidentate fashion.  The most common coordination is syn-monodentate, 
where both oxygen atoms are oriented towards the metal ion.  Anti-monodentate, where only one 
oxygen atom is oriented towards the metal ion, and bidentate coordination are possible but not 
very common.3  This is most likely due to the unfavorable angle and coordination ring formation 
of bidentate coordination and the resonance stability of the carboxylate which would suggest a 
preference for syn-monodentate coordination. 
 
Figure 1.37: Metal coordination modes of carboxylates. 
 Because carboxylates typically coordinate metals in a monodentate fashion their 
coordination bonds are generally weaker than those of hydroxamates.  As a result, carboxylates 
tend to coordinate divalent cationic metals.3  A survey of metalloenzymes in the Protein Data 
Bank (PDB) shows approximately 30% of ligands bound to Zn2+ are carboxylates.207  Despite the 
relatively weaker metal binding of carboxylates compared to hydroxamates, carboxylates exhibit 
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better bioavailability, are more metabolically stable, and may provide better mimetics for 
enzyme inhibition.214 
 
1.7.3 Phosphonates/Phosphates 
 Phosphonates and phosphates are generally used as zinc binding groups, with as many 
examples of phosphonate/phosphate zinc binding ligands found in the PDB as hydroxamate 
ligands.207  The first natural product inhibitor containing a phosphate was discovered in the 
1970s.  As a potent inhibitor of zinc dependent proteases, this phosphate based inhibitor led to 
the development of the ACE inhibitor Monopril.3  Other studies have shown the replacement of a 
cleavable peptide carbonyl with a phosphate will produce a competitive inhibitor.3  However, 
phosphate inhibitors are highly charged molecules which critically limits oral bioavailability as 
well as drastically increases renal clearance.215  Phosphonate inhibitors display moderate 
bioavailability, but similar to phosphate inhibitors suffer from rapid renal clearance.2  
 Despite the drawbacks of phosphonate/phosphate as a metal binding group, the 
phosphorus atom is known to conform to a tetrahedral geometry, making it an ideal and stable 
analog to tetrahedral intermediates formed by hydrolases.3  The tetrahedral geometry of 
phosphorus favors asymmetric monodentate coordination of metal ions over bidentate 
coordination.  Similar to carboxylates, the preference for monodentate over bidentate 
coordination reduces phosphorus based inhibitor potency 100-2000 fold compared to identical 
hydroxamate inhibitors.209  However, phosphonates are known to be tight binding chelators 
capable of binding divalent and trivalent metal ions.  Additionally, phosphonates are stable under 
harsh conditions, making them acceptable alternatives to hydroxamates.216 
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1.7.4 Sulfonamides/Sulfamides/Sulfamates 
 Sulfonamides, sulfamides and sulfamates are similar to 
phosphonates/phosphates/carboxylates in that they bind metals in a predominately monodentate 
fashion.207  However, sulfonamides, sulfamides and sulfamates are considered to be more 
desirable because they are more stable in water, are net neutral, and can enhance water solubility 
and bioavailability.215, 218  This class of metal binding groups show high affinity towards zinc and 
have been found to efficiently coordinate zinc in the active site of enzymes.211, 217-218  In fact, 
sulfonamides are the second most commonly found zinc binding ligands in the PDB.207  
Classically, sulfonamides, sulfamides and sulfamates have been used as inhibitors of carbonic 
anhydrases with low nanomolar potency.217-218  These carbonic anhydrase inhibitors can be 
primary sulfamides, primary sulfonamides and aromatic or heterocyclic sulfonamides and 
sulfamates.16, 217-218  Additionally, substituted sulfamides can inhibit proteases including: aspartic 
proteases (HIV-1 protease and γ-secretase), serine proteases (elastase, chymase, tryptase, 
thrombin, etc.) and metalloproteases (carboxypeptidase A and MMP).218  In HIV-1 protease, 
cyclic sulfamides are able to replace a catalytically active and essential water molecule and 
interact with a metal coordinating aspartic acid residue to enhance enzyme affinity and potency.  
Although this class of metal binding groups appears to be promiscuous, they display a much 
higher affinity towards carbonic anhydrases than MMPs despite identical zinc coordination 
motifs.219-220  This explains why most clinically tested and approved sulfonamides sulfamides 
and sulfamates are carbonic anhydrase inhibitors. 
 
1.7.5 Thiols 
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 Although thiols are used in both synthetic and biological coordination of metal ions, free 
thiols are known to have poor pharmacokinetic properties.  Most importantly, free thiols are 
known to form disulfide bonds with cysteine residues which lead to off-target protein binding 
and toxic side effects.3  However, thiol binds metal ions stronger than carboxylates and is 
considered to be a relatively potent zinc binding group.25  The strong zinc binding of thiol led to 
the discovery of Captopril.  While Captopril is the only FDA approved free thiol containing 
inhibitor, considerable efforts are being made to develop pro-drug formulated thiols.25  
Romidepsin, despite not being a synthetic inhibitor, is considered a pro-drug form since the 
disulfide bond can be reduced within the cellular environment to release a free thiol which has 
been found to coordinate zinc in HDAC.221  Thioacetate pro-drug forms have also been explored 
with ST7612AA1 advancing to pre-clinical studies against HDAC.222 
 
1.7.6 Other Metal Binding Groups 
 Since many of the classical metal binding groups have limitations in metal affinity, metal 
binding strength and pharmacokinetic properties, there has been increased focus on developing 
new metal binding groups.  Initial attempts at developing second generation metal binding 
groups focused on hydroxamate analogs.  These analogs include reverse hydroxamates, N-
substituted hydroxamic acids and N-hydroxyureas.  Each was developed with the aim of 
increasing stability and improving target specificity.3  The reverse hydroxamates are more stable 
than their respective hydroxamates with longer metabolic half lives due to lower susceptibility 
towards hydrolysis.3  However, similar to hydroxamates, the reverse hydroxamates can only be 
functionalized in one direction.  This limited functionalization potential is overcome by the N-
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substituted hydroxamates.  While the N-substituted hydroxamates offer the development of more 
specialized inhibitors which should increase selectivity, many exhibit a 10-fold decrease in 
potency towards the zinc metalloenyzme families MMP and ADAM.3  Despite this drawback, 
the N-substituted hydroxamates do not suffer from loss in potency towards PDF and several have 
been found to be potent inhibitors of LTA4H and fructose bisphosphate aldolase.3  N-
hydroxyureas, such as Zileuton, are similar to hydroxamates, but may be bifunctionalized similar 
to the N-substituted hydroxamates.3 
 
Figure 1.38: Hydroxamates and hydroxamate derivatives as metal binding groups. 
 Another major class of second generation metal binding groups consists of derivatives of 
carboxylates.  Although carboxylates are typically less potent than their respective 
hydroxamates, the carboxyaltes exhibit less pharmacokinetic liabilities.  The primary carboxylate 
derivatives being studied are alpha keto acids, alpha hydroxy acids and picolinic acids.  Each of 
these metal binding groups adds a donor atom alpha to the carboxylic acid which accomidates 
for the formation of a 5-membered chelate ring instead of the 4-membered chelate ring of 
carboxylates.3  The alpha keto acids are based on the biological compound α-ketoglutarate which 
is a key intermediate of the Krebs cycle and is a cofactor of iron dependent oxygenases.3  Alpha 
keto acids bind metals in a bidentate fashion, as evidenced by the crystal structure of N-
oxalylglycine bound to prolyl hydoxylase.223  Additionally, the alpha keto acids have an amide 
bond for resonance stabilization.3  Unfortunately, because α-ketoglutarate is used in many 
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metabolic cycles, it is possible that the alpha keto acids may metabolize too quickly.3  To avoid 
this, the alpha ketone may be converted to an alcohol to decrease susceptibility to nucleophilic 
attack.  These alpha hydoxy acids utilize the same donor atom as the alpha keto acids but have a 
different geometry due to the sp3 hybridized carbon.3  Picolinic acids are also bind metals such as 
zinc, manganese, copper, iron and molybdenum in a bidentate fashion.224  Since picolinic acid is 
a metbolite of tryptophan and a precursor of NAD+, it is a well studied functionality.224  
Inhibitors utilizing picolinic acid are primarily inhibitors of iron dependent oxygenases, but have 
also been found used as inhibitors of zinc β-metallolactamases.3 
 
Figure 1.39: Carboxylate and carboxylate derivatives as metal binding groups. 
 Thiol derivatives are also being developed as metal binding groups.  These derivatives 
attempt to harness the strong monodentate metal binding of the thiol sulfur atom while avoiding 
the promiscuity and toxic side effects associated with thiol.  One type of derivative focuses on 
replacing the oxygen of a carbonyl with sulfur.3  The most promising of these thiones is the 
dithiocarbamates.  Dithiocarbamates have a lower reduction potential and may be more 
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biocompatible compared to thiols and have the ability to bind metals in a bidentate fashion.  
Interestingly, some of these dithiocarbamates appear to function as immunosuppressants.225  
Another class of thiol derivatives being explored is beta mercaptoketone.  Beta mercaptoketones 
bind metals in a bidentate fashion to form a 5-membered chelate ring.3  While this may allow for 
the development of inhibitors with better potency and selectivity, beta mercaptoketones display a 
free thiol which may illicit similar toxic side effects of thiols due to off target binding.3 
 Other metal binding groups explored can be subdivided into monodentate chelators, 
bidentate chelators and tetrahedral intermediate mimics.  The monodentate metal binding groups 
include amines, alcohols, carbonyls, nitrogen containing heterocycles and oximes.  Although 
these groups all rely on nitrogen or oxygen atoms which are weaker chelators than sulfur, they 
typically present less pharmacokinetic liabilities.  The amine metal binding groups generally do 
not utilize primary amines, and in many cases utilize the amine in combination with another 
monodentate metal binding group.  However, terminal amines of peptide mimetics have been 
used as metal chelating groups.3  Similar to the amines, alcohols as metal chelating groups are 
generally not primary alcohols and many alcohol bearing inhibitors are phenols due to their 
known metal binding potential.226  The carbonyls may be part of ketones, amides, urea, or 
sulfoxides.207  Carbonyls of amides and ureas have better resonance while carbonyls of 
sulfoxides are polar.  Both of these properties can increase the metal binding strength of the 
oxygen.3  Another way to enhance the nucleophilicity of the carbonyl oxygen is to create an 
alpha nitromethyl ketone.227  The nitrogen containing heterocycle nitrogen atom functions as an 
imine to form a monodentate bond with the metal atom.  Potent examples of this class include 
triazole, imidazole, pyrazole, uridine, pyridine, hydantoin and barbiturate.3, 33, 207, 228  Although 
several of these functional groups are structurally related they appear to show some selectivity 
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towards isoforms or a certain class of TACE and MMP.3, 33  Oximes have been used to develop 
therapeutic agents capable of transferring acyl groups and are amenable to biotransformation as 
well as conjugation with both organic and inorganic molecules.229  Some furan oximes have 
already been developed which inhibit DNA, RNA and protein synthesis in lipoid leukemia cells 
while quinoline oximes have exhibited antitumor activity.230-232    Additionally, oximes form 
stable complexes with metals such as platinum, copper and manganese.233-234  While oximes are 
monodentate chelators, they may be used alpha to a carbonyl to create a bidentate chelator 
similar to a hydroxamate.229 
 
 
Figure 1.40: New monodentate metal binding groups being explored. 
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Bidentate metal binding groups being explored include benzamide, 3-hydroxypyridin-2-
thione, curcumin, bipyridine, pyrazolylpyridine, 8-hydroxyquinoline and bis-benzimidazoyl type 
functional groups.  Although benzamide itself is only a monodentate metal binding group, this 
bidentate metal binding group more accurately refers to N-(2-amino-phenyl)-benzamide.  
Benzamide as a metal binding group is not very common, but have been used to develop the 
potent HDAC inhibitors Entinostat and Mocetinostat.  The bidentate coordination involves the 
amine on the phenyl ring and the carbonyl of the benzamide to form a trigonal bipyramidal, 
seven-membered chelate ring.3  Despite aromatic amines not being very nucleophilic, metal 
coordination with the carbonyl may position the amine to enhance its anionic character.3  3-
hydroxypyridin-2-thione was selected as a novel heterocyclic bidentate metal binding group 
through a fragment based approach using reported zinc chelation and affinity as well as known 
ease of synthetic modification.235  Interestingly, this metal binding group is capable of selectively 
inhibiting HDAC 6 and 8 and does not exhibit inhibition of HDAC 1.  Modifications of 3-
hydroxypyridin-2-thione enhance selectivity and cause induction of apoptosis in several cancer 
cell lines.235  The bidentate coordination of this group involves the thione and the alpha 
hydroxyl; similar to the coordination exhibited by hydroxypyrones (ie. kojic acid) and 
hydroxypyridinones.  These heterocyclic bidentate metal binding groups are stronger chelators 
than their monodentate analogs and are more resistant to hydrolysis.236  Another anti-cancer, 
bidentate, metal binding group being explored is curcumin.  Curcumin is known to mediate 
multiple signaling pathways and was discovered to be capable of destabilizing the formation of 
β-amyloid fibrils associated with Alzheimer’s disease.237-239  Unfortunately curcumin exhibits 
poor water solubility which leads to poor bioavailability and suffers from rapid metabolism.240  
Due to these poor pharmacokinetic properties researchers have focused on developing 
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“supercurcumins” with a variety of formulations to improve solubility, stability and 
bioactivity.240  Metal chelation and metal complexes of curcumin have also been studied.  Iron-
curcumin complexes have displayed the highest potential to treat cancer while gallium 
complexes exhibit antiviral activity.241-242  Additionally, copper chelation appears to be involved 
in many of the anti-cancer properties associated with curcumin.243  While most metal binding 
group development has been focused on natural products, some have turned to metal binding 
groups commonly used in inorganic chemistry.3  These groups include 2,2’-bipyridine, 2-
pyrazolylpyridine and 8-hydroxyquinoline.  Interestingly, these metal binding groups have 
primarily been used as mimics of α-ketoglutarate.3  Bis-benzimidazoyl type groups are similar to 
the inorganic metal binding groups in that they utilize two known monodentate metal binding 
groups tethered together in a proper orientation to create a bidentate metal binding group.  
Benzimidazole is found in nature as part of N-ribosyl-dimethylbenzimidazole which coordinates 
cobalt in vitamin B12.
244  The bis-bezimidazoyl groups have been found to be potent inhibitors of 
viruses such as rhinovirus, poliovirus and coxsackievirus, target the minor groove of B-DNA, 
and be effective metal binding groups of Zn2+, Mn2+, Sc3+ and Hg2+ for the inhibition of trypsin 
and zinc-mediated serine proteases.245-248  
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Figure 1.41: New bidentate metal binding groups being explored. 
 Tetrahedral intermediate mimics may be mono- or bidentate metal binding groups, but 
form tetrahedral complexes when coordinated to a metal ion.  This class of metal binding groups 
includes silanediols, geminal diols and boronic acids.  Silanediols use silicon to generate a stable 
tetrahedral structure with two hydroxyls.  This tetrahedral structure is similar in size and shape to 
phosphates, but is less acidic.3  Typically they are used to make peptidomimetics by replacing a 
carbonyl in a peptide backbone.  Silanediol peptidomimetics are potent protease inhibitors.249  
Currently silanediols have been used as inhibitors of chymotrypsin, thermolysin, ACE and HIV 
protease.250-253  Geminal diols are similar to the silanediols but with a central carbon atom instead 
of a silicon atom.  As with the silanediols, geminal diols are similar to phosphates in that they 
bind metals in an asymmetric monodentate fashion and mimic the native tetrahedral intermediate 
catalyzed by the enzyme.  The geminal diols appear to best mimic the intermediates of 
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hydrolases.3  Boronic acids also mimic the tetrahedral intermediate of hydrolases and have been 
found to inhibit fatty acid amide hydrolase.254  Additionally, the boronic acids have been found 
to inhibit many enzymes which are involved in fundamental biological processes such as 
arginase, serine proteases and the proteasome.255-257  One potential drawback to boronic acids as 
a metal binding group is that the boron atom can covalently bind to serine.3 
 
Figure 1.42: New tetrahedral metal binding groups being explored. 
 Although there are many examples of known metal binding groups, little research has 
been done to determine how these groups influence selectivity or if weak metal binding groups 
can be enhanced by maximizing other interactions with the target protein.3  While newer metal 
binding groups are still being explored (ie. squaric acid, hydroxymethyl oxazoline and 1-
hydroxy-2-sulfanyl pyridinium), more information about the interplay between metal-ligand and 
protein-ligand interactions is essential.207, 258  Future research may benefit from combining both a 
synthetic and structural approach when exploring metal binding groups.3  Additionally, further 
investigation of the chemical space for new potential metal binding groups could lead to better 
selectivity and potency. 
 
1.8 Tropolone as a Metal Binding Group 
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 The tropolone motif is a unique cyclic structure which exhibits unusually high resonance 
energy, an unfavorable oxygen-oxygen distance making it an unusually strong acid and has the 
ability to form highly stable 5-membered chelate rings.259  Tropolone itself is soluble in both 
aqueous and organic solvents while tropolone-metal complexes are highly lipid soluble.260 
Natural tropolones have low molecular weight, ample sites for diversification and strong metal 
coordinating potential as seen with both zinc and iron.259-260  Additionally, tropolone is known to 
act as a bidentate metal binding group where the cyclic structure may rigidify the compound to 
enhance metal affinity relative to a hydroxamate, making tropolone a potential alternative to 
hydroxamate.261 
 One of the best studied and relatively simplistic natural tropolones, β-thujaplicin, is 
known to display a wide range of antiproliferative activity262-268 and is safely used in toothpaste, 
shampoo, cosmetics, hair tonic and as a food preservative in Japan and Russia.269-270 Most of this 
activity is likely due to or has been associated with metal chelation.  Research has determined β-
thujaplicin is capable of inhibiting many metalloenzymes, especially metalloproteases, with 
highest levels of activity exhibited against carboxypeptidase A.270  Other metalloprotease 
inhibited by β-thujaplicin include thermolysin and collagenase.  Interestingly, α-thujaplicin does 
not inhibit thermolysin or collagenase, suggesting various substitutions around the tropolone ring 
may increase selectivity towards a metal ion or be used to develop enzyme selectivity.271 
 A fragment based library approach to develop novel zinc binding groups determined 
tropolone displayed strong zinc binding potential.206  Subsequent studies with tropolone and β-
thujaplicin determined the tropolone motif showed greater potency against the two zinc 
metalloenzymes MMP3 and anthrax lethal factor than acetohydroxamic acid (a benchmark for 
hydroxamate comparison).261  The tropolone motif also displayed the strongest zinc binding 
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compared to the analogous cyclic, aromatic α-hydroxy ketones hydroxypyrone and 
hydroxypyridinone.  Another fragment based study determined β-thujaplicin binds to the zinc ion 
of CapF in S. aureus to alter the coordination sphere of zinc which destabilizes the enzyme.272  
Meanwhile, other studies have shown that β-thujaplicin can bind various heavy metal ions, most 
notably iron and zinc.273 
As an iron chelator, β-thujaplicin coordinates Fe3+ in a 1:1 ratio to generate an oxygen 
radical.274  Eventually this leads to release of a superoxide radical and Fe2+ which can undergo 
the Fenton reaction with hydrogen peroxide to form a hydroxyl radical.  This hydroxyl radical 
may be the cause of some of the antiproliferative effects associated with β-thujaplicin since a 
hydroxyl radical may attack membrane lipids, proteins and DNA molecules to exert 
antimicrobial and cytotoxic effects.274  Binding of β-thujaplicin to Fe3+ is also associated with 
DNA fragmentation and caspase-3 activation.264, 273  Interestingly, tropolone-iron complexes 
display high thermodynamic stability and a stronger binding constant than the transferrin-iron 
complex.260  This has led to the investigation for clinical use of tropolones as iron chelating 
agents.  Development of tropolones as gram-negative antibacterial agents is based on the 
hypothesis that tropolones can chelate iron to deprive bacteria of this essential growth factor.269  
It is known that small, lipophilic iron chelators inhibit protein and DNA synthesis in myeloid cell 
lines, which provides a reason to develop tropolones as anticancer agents.275  Additionally, β-
thujaplicin and related compounds were found to inhibit the iron metalloenzyme ribonucleotide 
reductase which is used in DNA synthesis.270 
Other biological effects of β-thujaplicin metal binding include the ability to extract Mg2+ 
from the inner mitochondrial compartment,262 stimulation of superoxide formation through 
copper binding274 and inhibition of the copper metalloenzymes dopamine β-oxygenase276 and 
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tyrosinase.277  While β-thujaplicin is known to exhibit a wide range of biological activities with 
multiple potential mechanisms of action, it is generally considered to be a powerful, lipophilic 
chelator of divalent metal cations.  Additionally, most of the biological activity of β-thujaplicin 
appears to be dependent on metal chelation.  This is exemplified by the lack of inhibitory activity 
of acetylated tropolone and β-thujaplicin methyl ether against metalloproteases271 and HDAC 
respectively.278  Although there has been some concern about the promiscuity of thujaplicins, α- 
β- and γ-thujaplicin display different activities and exhibit some enzyme selectivity.  For 
example, α-thujaplicin does not appear to inhibit human tyrosinase (>1000 µM) and is only 
moderately effective against mushroom tyrosinase (9.53 µM) while β-thujaplicin and γ-
thujaplicin are effective against human tyrosinase (8.98 µM and 1.15 µM respectively) but are 
much more potent towards mushroom tyrosinase (0.09 µM and 0.07 µM respectively).277  The 
thujaplicins and tropolone also display some metal binding preference with the highest affinity 
towards Fe3+, Fe2+ and Cu2+, moderate affinity towards Ni2+, Zn2+, Co2+ and Mn2+ and weaker 
affinity towards Mg2+ and Ca2+.259, 279-280  Despite the strong metal binding activity of tropolones, 
there have been few attempts to utilize this structure as a metal binding group in drug discovery, 
most likely due to limited synthetic accessibility as a result of its unusual aromatic structure. 
  
1.9 Conclusions 
 Metals such as calcium, magnesium, potassium, sodium, iron, zinc, cobalt and 
manganese are essential for most biological acitivity.  In many instances, these metal ions are 
crucial cofactors for enzymatic reactions.  A wide variety of metalloenzymes have been 
implicated in diseases such as bacterial infections, viral infections, immunological diseases, 
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neurological diseases and cancer. Targeting the catalytic metal ion of metalloenzymes offers the 
opportunity to develop new and selective therapeutics and has been a highly fruitful endeavor.  
Despite recent gains in understanding the function, structure and cellular localization of many 
metalloenzymes only a limited amount of the chemical space has been explored for metal 
binding groups.  Hydroxamates, carboxylates, phosphates/phosphonates, 
sulfonamides/sulfamides/sulfamates and thiols are the primary metal binding groups found in 
clinically used metalloenzyme inhibitors.  While each of these metal binding groups has inherent 
strengths and weakness, none have proven highly selective towards one metal.  This has stressed 
the need to further explore the chemical space for different metal binding groups which may 
offer better selectivity as well as better potency and pharmacokinetic properties.  Additionally, 
future research should also focus on understanding the interactions of the metal binding group 
with both the metal and the protein.  Meanwhile, natural metal binding groups with known 
chelating properties offer biologically relevant scaffolds which may be functionalized to provide 
enzyme selectivity.  One such natural metal binding group, tropolone, is a powerful chelating 
agent with attractive biological activity.  Tropolone offers ample sites for diversification where 
minor changes can drastically alter enzyme inhibitory activity.  Development and understanding 
of structural activity relationships of tropolone modifications may offer exciting new 
metalloenzyme inhibitors or an alternative metal binding motif for many hydroxamate inhibitors 
which have failed clinical trials. 
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Chapter 2 
 
Development of Lead-like Troponoids Based on the Natural Product α-Thujaplicin 
 
2.1 Background and Significance 
 
2.1.1 Discovery of Natural Troponoids 
 Troponoid refers to a family of naturally occurring compounds with a unique seven-
membered aromatic ring, commonly named tropone/tropolone.  While this core structure was not 
determined until the 1940s, the use of the troponoid colchicine dates back to antiquity.1  A 
metabolite of the autumn crocus (Colchicum autumnale), colchicine was first isolated in 1820 
and has typically been used to treat gout but was also reportedly prescribed as a treatment for a 
disease similarly described as cancer by the Roman emperor Nero’s military physician.2  
Colchicine has since been isolated from at least 37 different plants.  It is a tricyclic alkaloid with 
a trimethoxyphenyl as the A ring, a cycloheptane with an acetamide as the B ring and a 
methoxytropone C ring.  However, the structure of the C ring of colchicine was unknown until 
1945 when cyclohepta-2,4,6-trienone (tropone) was proposed as the C ring by Dewar.3   
Colchicine is known to bind to tubulin to inhibit microtubule polymerization and exhibits anti-
inflammatory properties.4  It is approved for the treatment of gout, a prophylactic for 
cardiovascular disease and familiar Mediterranean fever.5  Due to its long term use and early 
discovery, colchicine is one of the best studied tropolones with over 19,000 publications found 
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on PubMed spanning from 1908 to present.  This becomes even more evident when only 875 
results are returned by PubMed for the keyword tropolone. 
Eventhough colchicine was well studied, a relative expolsion of interest in tropolones 
began around 1932 with the isolation of puberulonic acid and puberulic acid by Harold 
Raistrick.6  Raistrick and coworkers isolated over 200 fungal metabolites and correctly identified 
the structures of many, but the structures for  puberulonic acid, puberulic acid and stipitatic acid, 
which he isolated in 1942, eluded him.1,7  What Raistrick could determine about the structure of 
these three metabolites was that each exhibited properties of aromatic hydroxy acids.  Again, it 
was Dewar’s 1945 proposal of the tropolone ring that solved the structure of stipitatic acid.8 
Nozoe independently proposed the same seven membered aromatic ring struture as 
Dewar in a presentation at the Formosa Branch of the Society of the Chemical Industry in 1941.  
Although this proposal involved the same tropolone moiety, Nozoe’s proposal was for the 
structure of a compound isolated from the heartwood of taiwanhinoki (Chamaecyparis 
taiwanesis) he termed hinokitiol.1  However, unlike Dewar’s proposal, Nozoe’s “tropolonoid” 
was met with skepticism and there exist no published accounts of this presentation.9  
Interestingly, Dewar was unaware of Nozoe’s work due to the lack of access to global scientific 
communications and the ongoing conflict of World War II.  In fact, Nozoe himself was unaware 
of Dewar’s proposal until 1948 because European and American publications were unavailable 
to Japan beginning in 1937.1  After learning of Dewar’s proposal, Nozoe finally published his 
findings in Japanese in 1949 with an English translation in 1950 and a subsequent publication on 
“compounds having a tropolone nucleus…as initially proposed by Dewar” in 1951.1,10 
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Figure 2.1: Images of the tropone and tropolone scaffold and early isolated natural troponoids. 
Since the tropolone ring was proposed by Dewar and Nozoe over 200 natural products 
have been found to possess this scaffold.  These natural products are mainly isolated from fungi 
and plants but can also be found in some bacteria and can range in complexity from tropolone 
itself to complex multicyclic systems such as pycnidione and pareirubrine A.1  As with many 
secondary metabolites, many of the tropolones display a wide range of biological activity.  Most 
of this activity is attributed to the tropolone moiety while side chains are seen as attributing to 
selectivity.11  The reason for activity being attributed to the tropolone moiety is because most 
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tropolones appear to have antimicrobial activity.12-13  It has been proposed that tropolone may 
offer a unique scaffold to develop novel antibiotics since it can chelate metal ions and most 
likely has several mechanisms of action to diminish the capability of microorganisms to become 
resistant.11,14-18 
 
2.1.2 Biological Activity of Natural Tropolones 
As mentioned, tropolones exhibited a variety of biological activity including: 
antibacterial, antifungal, insecticidal, phytotoxic, antimitotic, anti-diabetic, anti-inflammatory, 
enzyme inhibitory, anticancer, cytoprotective and reactive oxygenated species (ROS) 
scavenging.  Interestingly, the thujaplicins, especially hinokitiol, have been found to exhibit all 
of the biological activity mentioned with the exception of antimitotic activity; which has only 
been noted for one natural tropolone, colchicine.1  Tropolone itself is capable of expressing many 
of these biological activities.  As an antibacterial agent, tropolone produces bacteriostatic effects 
while the thujaplicins are both bacteriostatic and bactericidal against a broad spectrum of 
bacterial species.19  It is believed that tropolone’s antibacterial mechanism of action is exerted 
through effects on the cell wall and the plasma membrane.20  In addition to the thujaplicins, β-
dolabrin, 4-acetyltropolone, purpurogallin and black tea theaflavins have also demonstrated 
antibacterial/antifungal activity.  Both β-thujaplicin (hinokitiol) and β-dolabrin exhibit stronger 
antibacterial activity than gentamycin against Staphylococcus epidermidis while α-thujaplicin is 
more potent than gentamycin against Enterococcus faecalis.21-22  The thujaplicins, β-dolabrin, 4-
acetyltropolone and black tea theaflavins are active against both gram-positive and gram-
negative bacteria while purpurogallin has only been determined to be active against gram-
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positive.  However, purpurogallin shows strong antibacterial activity against methicillin resistant 
Staphylococcus aureus (MRSA) with a minimal inhibitory concentration (MIC) of 11.0 µg/mL.23  
Antibacterial/antifungal activity of these tropolones may be attributed to their ability to chelate 
metal as the addition of metal ions was found to reverse antifungal activity.24 
 
Figure 2.2: Structures of some natural tropolones that exhibit antimicrobial activity. 
Tropolone metal chelation appears to be an essential component to most natural tropolone 
activity.  Tropolone and hinokitiol exhibit phytotoxic activity through inhibition of ethylene 
production and inhibition of ACC oxidase.  Addition of Fe2+ to the in vitro experiments on ACC 
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oxidase activity eliminates the inhibitory effect of tropolone and hinokitiol.25  Pupurogallin and 
colchicine have also been found to inhibit ethylene production to inhibit peach seed growth but 
to a lesser extent than both tropolone and hinokitiol.26  Although the effects of pupurogallin and 
colchicine on ACC oxidase were not determined, ACC oxidase precedes ethylene production 
suggesting these tropolones share a similar plant growth inhibitory mechanism of action. 
Iron chelation of tropolones imparts activity against the iron metalloenzyme 12-
lipoxygenase and is linked to their apoptotic activity in teratocarcinoma F9 cells.  12-
lipoxygenase is related to inflammation, platelet homeostasis and thrombosis.  Humans have 
three isoforms of 12-lipoxygenase: epidermis, leukocyte and platelet.27  Hinokitiol has been 
found to inhibit both the leukocyte (IC50 50 µM) and platelet (IC50 0.1 µM) isoforms in a 
reversible manner with a 500-fold selectivity towards the platelet isoform.28  While there is not a 
crystal structure available to elucidate where hinokitiol binds to 12-lipoxygenase, an iron atom is 
a key component of the active site of 12-lipoxygenase.27  Since hinokitiol is known to chelate 
iron and addition of exogenous Fe2+ eliminates the activity of hinokitiol against ACC oxidase, it 
is likely hinokitiol chelates the active site iron of 12-lipoxygenase to inhibit its function.  A 
similar amelioration of hinokitiol activity with the addition of Fe2+ or Fe3+ was found in 
teratocarcinoma F9 cells.  When treated with hinokitiol, F9 cells would undergo apoptosis due to 
DNA fragmentation and caspase-3 activation.29  If the F9 cells were pre-incubated with non-
toxic concentrations of iron, hinokitiol could no longer induce DNA fragmentation or caspase-3 
activation.  However, a chelation complex of hinokitol and Zn2+ was determined to be 
significantly more cytotoxic in mouse melanoma B16BL6 cells than non-complexed hinokitiol.30  
Additionally, this (Zn2+)hinokitol complex causes DNA fragmentation in HeLa, Meth A and 
B16F1 cells but not in normal human fibroblast FS-4 cells. 
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Despite the strong evidence that tropolones preferentially bind iron and some biological 
activity can be reduced or eliminated by adding iron, zinc may have a greater effect on tropolone 
activity.  As exhibited by hinokitiol (Zn2+)tropolone complexes can have greater biological 
activity and tropolones have been found to chelate and inhibit several zinc metalloenzymes.  In 
addition to its anticancer activity (Zn2+)hinokitiol complex is an insulin-mimetic capable of 
improving hyperglycemia, tolerance to glucose and responsiveness to insulin.31  Although the 
mechanism is different, hinokitiol chelation of zinc in the active site inhibits carboxypeptidase 
A.21  α-Thujaplicin inhibits carboxypeptidase A (IC50 32.4 µM) but is less potent than hinokitiol 
(IC50 2.76 µM).
22  In a similar chelating mechanism, tropolone has shown potent inhibitory 
activity against matrix metalloproteinases (MMPs).  MMPs degrade connective tissues and 
deregulation of these enzymes is associated with cancer, arthritis, cardiovascular disease and 
inflammation. 
Iron and zinc are not the only metals associated with the biological activity of tropolones.  
Chelation of copper by tropolone inhibits polyphenol oxidase to prevent the darkening of fruits 
and other crops.32-33  Another copper metalloenzyme commonly associated with inhibition by 
tropolone is tyrosinase.  In 2011, Ismaya and coworkers determined the crystal structure of 
tropolone bound to mushroom tyrosinase and noticed that it formed a chelation complex with 
copper in the active site.34  Since then, tropolone has been used as a standard (IC50 400 nM) for 
inhibitory activity against mushroom tyrosinase.35  Hinokitiol, γ-thujaplicin and nootkatin have 
also shown potent inhibitory activity against tyrosinase.11  Additionally, copper chelation by 
hinokitiol inhibits the apoptotic effect of influenza viruses H1N1, H2N2 and H3N2.36  This work 
led to other research examining the potential of tropolones as antiviral inhibitors of Hepatitis C 
and human immunodeficiency virus (HIV).  While no natural tropolones were discovered to 
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inhibit Hepatitis C, tropolone derivatives have been developed to inhibit the helicase of this 
virus.37  Two dihydroxytropolones exhibited inhibitory activity against ribonuclease (RNase) H 
of HIV-1 reverse transcriptase.  These two tropolones, β-thujaplicinol and manicol, inhibit 
RNase H of HIV-1 and HIV-2 (IC50 0.2 µM and 1.5 µM respectively), but do not inhibit DNA 
polymerase activity, suggesting metal chelation activity of these two tropolones.38  Later it was 
discovered that β-thujaplicinol and manicol chelate Mg2+ in HIV integrase to prevent viral 
replication by disrupting the DNA strand transfer reaction.39 
Another important biological activity of tropolones is acting as scavengers of reactive 
oxygenated species (ROS).  Unlike most antioxidants that act as weak radical scavengers to 
prevent generation of ROS, the antioxidant activity of tropolones is most likely due to iron 
chelation.24  Contradictory to this notion, the (Fe2+)hinokitiol complex actually generates ROS 
which in turn causes DNA damage.40  This is similar to the effects seen with Fe3+ chelation of 
hinokitiol to cause single strand DNA breaks.  However, this effect was only observed for ratios 
less than 3:1 hinokitiol to iron.  Concentration ratios above 3:1 do not have toxic effects.41  
Adding to this confusion, tropolones elucidate protective effects in a dose dependent manner 
against hydrogen peroxide induced apoptosis in Jurkat cells.  This contradictory effect was 
attributed to tropolones forming redox-inactive iron complexes to provide protection against 
hydrogen peroxide.  However, formation of lipophilic tropolone-iron complexes can transport 
redox-active iron inside the cell membrane.41 
Although most tropolone bioactivity is thought to be directly related to metal chelation, 
the anticancer effects of tropolones are not as well understood.  Pareirubrine A, isolated from 
Cissampelos pareira, exhibits strong anti-leukemic activity.42  Miltipolone, isolated from Salvia 
miltiorrhiza, is active against a variety of cancer cell lines with GI50s of 0.9 - 6.0 µM but is 
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relatively nontoxic towards human umbilical vein endothelial cells with GI50 20 µM.
18  
Theaflavins have been found to inhibit the growth of prostate tumors implanted in athymic nude 
mice.43  Pycnidione exhibits strong anticancer effects against the lung cancer cell line A549 with 
a GI50 9.3 nM after 48 hours.  Additionally, pycnidione is able to decrease expression of cyclin 
D1, cyclin E and survivin to induce G1 arrest while activating caspases 8 and 3 and increasing 
PAI-1 (involved in tumor angiogenesis and invasion) and generation of ROS.44  Despite these 
promising features of these more complex tropolones, most anticancer research has been 
conducted with the structurally simpler thujaplicins, especially hinokitiol.  Hinokitiol has shown 
multiple anticancer effects across several cell lines.  In colon cancer cell lines HCT-116 and SW-
620 hinokitiol is growth inhibitory (GI50 4.5 µM and 4.4 µM respectively) through induction of 
S-phase cell cycle arrest.  It is also pro-apoptotic as hinokitiol induces caspases 3 and 9, 
increases expression of p21 and Bax, decreases expression of cyclins A and E, Cdk2 and Bcl-2.  
Hinokitol can also reduce tumor sizes of intradermally implanted HCT-116 and SW-620 in 
BALB/c-nude mice.45  In murine melanoma B16-F10 cells, hinokitiol inhibits MMP 1, 3 and 13 
and NFκB and suppresses phosphorylation of ERK 1/2, p38 and JNK to prevent cell migration 
and tumor growth in C57BL/6 mice.46  Hinokitiol also inhibits growth and DNA synthesis in 
FEM (human melanoma), PC-3 and LNCaP (prostate adinocarcinoma and carcinoma) cells.14,47  
Additionally, isoforms of hinokitiol have antiproliferative effects against the murine leukemic 
cell line P388.  α-Thujaplicin exhibits a GI50 3.8 µM after 24 hours incubation but exhibits less 
acute toxicity.48  After 48 hours at this same concentration, γ-thujaplicin inhibits P388 growth by 
85%.  At 3.8 µM α-Thujaplicin also inhibits 66% proliferation of the gastric carcinoma cell line 
KATO-III and 75% of Ehrlich’s ascites carcinoma.49   
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Figure 2.3: Structures of natural tropolones that exhibit anticancer activity. 
To summarize, naturally occurring troponoids exhibit a wide range of biological activity.  
This activity is likely a result of metal chelation.  Metal chelation by tropolones typically results 
in growth inhibition.  Tropolones can disrupt the bacterial cell wall and plasma membrane and 
cause cancer cell cycle arrest.  Additionally, tropolones inhibit various metalloenzymes including 
ACC oxidase, 12-lipoxygenase, carboxypeptidase A, MMP, tyrosinase and HIV integrase.  
While the activity of natural troponoids is promising, many lack the potency of typical natural 
products such as taxol and no true targets have been identified.  Development of synthetic 
troponoids offers the potential to increase activity and provide probes for target identification. 
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2.1.3 Synthesis of the Tropolone Core and the Thujaplicins 
After the tropolone structure was proposed by both Dewar and Nozoe several labs 
undertook efforts to synthesize this unusual molecule.  Most of the early efforts involved the 
direct oxidation of partially saturated seven-membered rings.  In 1950, Cook and coworkers 
discovered a route that involved the bromination and dehydrobromination of 1,2-
cycloheptadione (Scheme 2.1).50  Around this same time Doering and Knox reported an 
alternative route which involved the oxidation of cyclohepta-1,3,5-triene by potassium 
permanganate (Scheme 2.2).50  Interestingly, Doering and Knox also discovered that substitution 
on the 7 position of cyclohepta-1,3,5-triene followed by a reaction with potassium permanganate 
could lead to both β and γ substituted tropolones.  Unfortunately, both methods to achieve 
tropolone resulted in poor yields.  However, several key reactions were also developed which led 
to more efficient methods to synthesize tropolone based natural products and tropolone 
derivatives.50 
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Scheme 2.1: Cook and Coworkers Synthetic Route to Tropolone.  
 
 
Scheme 2.2: Doering and Knox Synthetic Route to Tropolone and Substituted Tropolones. 
 
 
 From Cook and coworkers’ synthetic route to tropolone, mono-, di- and tri-brominated 
tropolones were isolated from the reaction of 1,2-cycloheptadione with 2, 3 and 4 moles of 
bromine at 0°C in glacial acetic acid respectively.  They also discovered that the reaction of 2-
bromotropolone with diazomethane in ether resulted in the methyl ether 2-bromo-7-
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methoxytropone.51  The work by Doering and Knox also showed that reaction of tropolone with 
diazomethane resulted in the methyl ether.  They also discovered that reaction of the methyl 
ether with ammonia in methanol at 110°C for 6 days yielded 2-aminotropone.52  Hydrolysis of 2-
aminotropone with 6 N sodium hydroxide re-generated tropolone.  In this same work, Doering 
and Knox also discovered that 2-methoxytropone could be hydrolyzed by either 3 N 
hydrochloric acid (52% yield) or 2 N sodium hydroxide (73% yield) to give tropolone in decent 
yields.52 
 The initial work by Cook and coworkers and Doering and Knox paved the way towards 
the synthesis of natural tropolones, namely the thujaplicins.  While Cook and coworkers initially 
abandoned 1,2-cycloheptadione and brominated tropolone they were able to synthesize the 
thujaplicins from 4-isopropylcycloheptanone (β and γ) and 2-isopropylcycloheptanone (α).53  
Meanwhile, they also discovered that the reaction of tropolone in carbon tetrachloride with 0.5 
moles bromine at 4°C yielded 2-bromotropolone.54  Since palladium catalyzed coupling 
reactions were still decades away, the first tropolone derivatives typically required built in 
substitutions.  These built in substitutions are still being utilized today and the synthetic history 
of these tropolone derivatives from non-troponoid scaffolds is the subject of several reviews.50, 
55-57  However, in 1952 Doering and Mayer as well as Nozoe and coworkers developed a method 
to synthesize α-substituted tropolones using an organolithium reagent.  This reaction required the 
copper chelate of tropolone to produce the α-tropone intermediate.  The intermediate needed to 
be brominated then undergo acid catalyzed replacement of the bromide with hydroxyl to yield 
the α-substituted tropolone.58   
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Scheme 2.3: Synthesis of α-substituted tropolone from tropolone-copper chelate. 
 
Despite these synthetic advances, most tropolone synthesis attempted to generate the 
natural product and typically did not produce tropolone derivatives.  Tropolone derivatives that 
were developed generally were based on the more complex tropolones or hinokitiol.  In 1990 the 
first Suzuki coupled tropolone derivative from 2-bromo-7-methoxytropone was reported.59  
Similar to the synthetic procedures from 1952, conversion to the 2-aryltropolone required 
hydrolysis of the methyl ether with hydrobromic acid.  In 2013, the Wright lab reported a three 
step synthesis of α-substituted tropolones from the commercially available 2-chlorotropone.60  
This work involved a 2-aminotropone intermediate that was subsequently hydrolyzed similar to 
that reported by Doering and Knox. 
 
2.1.4 α-Tropolones as Lead-like Antiproliferative Agents 
 Most work involving α-tropolones has been on α-thujaplicin or other α-substituted natural 
tropolones.  While hinokitiol has been the primary focus of analyzing thujaplicin bioactivity, α-
129 
 
thujaplicin appears to be equally active.  Since the thujaplicins seem to be among the most active 
natural tropolones, work in the Anderson and Wright labs began with synthesizing simple 
analogs of both hinokitiol and α-thujaplicin.  Histone deacetylases (HDACs) were selected as a 
class of zinc metalloenzymes which tropolones could potentially inhibit through metal chelation.  
Screening HDACs 1-2, 4-6, and 8, tropolones were found to possess nanomolar potency in 
HDACs 2 and 8.  While most of the tropolones displayed similar activity, the key potent 
tropolone from this screen was β-phenyltropolone with IC50 0.06 nM and 1.47 nM in HDAC 2 
and 8 respectively.60 Following these exciting results, the tropolones were screened against a 
panel of cancer cell lines.  Although all the tropolones showed a preference towards 
hematological malignancies, the α-substituted tropolones generally exhibited the best activity.  
Here the key potent derivative was α-(4-methoxyphenyl)tropolone.60  When screened against 
normal human dermal fibroblasts (hDF), the tropolones did not exhibit cytotoxic effects, 
suggesting α-tropolones are lead-like antiproliferative agents. 
 
2.1.5 Project Objectives 
 Our goal was to create a more diverse library of α-tropolones to assess structure activity 
relationship against human leukemia cell lines.  Since previous results with a small, phenyl ring 
based library of α-tropolones suggest para-substitution on the phenyl ring may increase potency 
against HDAC, a series of α-phenyl tropolone analogs was desired.  As the scope of the project 
expanded to include testing for toxicity in nude mice, a series of α-tropolones with heterocyclic 
substitutions was desired to increase solubility and activity.  To exemplify the versatility of 
tropolone as a scaffold, reactions other than Suzuki-coupling reactions were also desired.  
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Additionally, since 2-aminotropones appear to be inactive, our goal was to explore the effect of 
other chelating group substitutions on tropone. 
 
2.2 Results and Discussion 
 
2.2.1 Synthesis of α-Tropolones from 2-chlorotropone 
 2-chlorotropone is a commercially available reagent that has proven amenable to the 
palladium-catalyzed Suzuki-coupling conditions to generate a series of α-aryltropones.60  
Following Suzuki-coupling, the addition of hydrazine to the 2-aryltropones yielded 2-amino-7-
aryltropones.  These aminotropones could then be hydrolyzed similar to the aminotropone 
synthesized by Doering and Knox to generate the desired α-tropolones in good yields (Scheme 
2.4). 
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Scheme 2.4:  Synthesis of α-tropolones from 2-chlorotropone. 
 
 
a RB(OH)2 ; 
b Yield of isolated products. 
 These results suggested that a large library of α-tropolones could easily be prepared from 
2-chlorotropone in three steps.  Based on this route, boronic acids with various other 
functionalities were purchased.  These boronic acids contained other heterocycles, various 
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substitutions on the phenyl ring and alkyl chains.  Some analogs still in development are listed in 
Table 2.1. 
Table 2.1:  α-Tropolones from 2-chlorotropone in development. 
 
a RB(OH)2; b Yield of isolated products. 
 
While it appears that this synthetic route is amenable to various substitutions, there are 
several limitations (Scheme 2.5).  First, addition of hydrazine to vinyl substitutions on 2-
chlorotropone resulted in a 1,10-conjugate addition of hydrazine resulting in a vinyl amine 
tropone.  This required hydrogenation of the olefin prior to reacting with hydrazine (see Chapter 
5 for synthesis of MO-1-OH, MO-2-OH and MO-7-OH).  Hydrazine also proved problematic 
towards a series of furan based derivatives and a substitution containing an aldehyde.  Here, 
hydrazine appeared to over react with these furan derivatives and the methoxy-benzaldehyde 
substitution and either resulted in no observable product or significantly lower product yields.  
The other major complication with this synthetic route is the hydrolysis of the aminotropone to 
the desired α-tropolone.  Although 2 N potassium hydroxide is less caustic than the 6 N sodium 
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hydroxide utilized by Doering and Knox, the reflux of the tropone in this ethanolic solution 
could affect functional groups on the desired substitution. 
Scheme 2.5:  Complications in α-tropolone synthesis from 2-chlorotropone. 
 
 
a RB(OH)2; b Yield of isolated products; *NMR shows impurities or over reacted material. 
134 
 
 Because some of these desired α-tropolones could not be prepared via the 2-
chlorotropone synthetic route, a new route was essential.  Suri and Nair reported that α-
tropolones could be synthesized from 2-bromo-7-methoxytropone.59  This synthetic route does 
not require hydrazine and could potentially avoid several of the issues from the 2-chlorotropone 
route.  
 
2.2.2 Synthesis of α-Tropolones from 2-bromo-7-methoxytropone 
 In 1990, Suri and Nair reported a synthetic route from the 2-bromo-7-methoxytropone 
originally synthesized by Cook and coworks as well as Doering and Knox.  Suri and Nair 
reported that this compound was amenable to the palladium-catalyzed Suzuki-coupling 
conditions to generate a series of α-aryltropolones.59  However, since diazomethane is explosive 
and typically requires generation in situ, a less hazardous route to the methoxytropone was 
desired.  In 1985, Bass and Gordon reported a simple route to tropolone ethers via reaction with 
potassium carbonate, an alkyl halide and dicyclohexyl-18-crown-6 in acetonitrile.61  The 
methoxytropone could then be brominated according to standard procedures.  Comparing the 
coupling results to those from the 2-chlorotropone route, the 2-bromo-7-methoxytropone route 
appears to be equally or slightly more amenable to the synthesis of the desired α-tropolones 
(Scheme 2.6). 
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Scheme 2.6: Synthesis of α-tropolones from 2-bromo-7-methoxytropone. 
 
 
a RB(OH)2; b Yield of isolated products after Suzuki-coupling 
 Deprotection of the methyl ether was carried out similar to the procedure used by 
Doering and Knox.  This acid hydrolysis of the methyl ether resulted in precipitation of the 
tropolone upon cooling.  The precipitate could be filtered and dried to yield the pure α-tropolone.  
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Unlike the 2-chlorotropone route, this method did not have adverse effects on the benzaldehyde 
substitution.  Additionally, benzoic acid methyl ester, nitro-benzene, bromo-benzene, aniline and 
benzodioxane substitutions were able to be synthesized by this method.  However, this acidic 
deprotection could not be used for the α-furan-tropolone as the furan could be hydrolyzed to the 
1,4-dicarbonyl derivative.  Acid deprotection of TMS-protected phenylacetylene 
methoxytropone also proved problematic as it resulted in hydrolysis of the alkyne to a ketone 
(compound EF-2-OH). 
 After consulting Greene’s Protective Groups in Organic Synthesis, a relatively mild ether 
deprotection method involving lithium chloride was selected.  This method developed by 
Bernard and coworkers involves the dealkylation of alkyl aryl ethers.62  Although Bernard and 
coworkers heated the dimethylformamide solution to 140°C, the temperature could be reduced 
for the tropolones to 120°C without sacrificing yields.  Additionally, this method reduced the 
time of deprotection from 6 hours to 2-3 hours. 
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Table 2.2: Synthesis of α-Tropolones from 2-bromo-7-methoxytropolone utilizing lithium 
chloride for dealkylation of methyl ether. 
 
a RB(OH)2; b Yield of isolated products. 
 
 It should be noted that some issues may arise from this process which result in lower 
yields.  First, based on NMR analysis, an impurity interpreted as a high molecular weight 
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hydrocarbon may be present after standard column chromatography.  Recrystallization from 
acidic water and methanol may be possible in most cases, but several products may be oils or 
amorphous solids.  In order to purify these compounds C-18 column chromatography may be 
used.  Elution from a C-18 column requires mixtures of water and organic solvents.  Here, the 
crude product was added to the column in 4:1 water:methanol and eluted with 50% methanol in 
water.  Although this method required longer evaporation times, all products purified via this 
technique were free of the high molecular weight hydrocarbon.  Another issue discovered was 
not all boronic acids may be coupled using the conditions depicted in Scheme 2.5.  For example, 
2-benzofuranboronic acid did not couple.  Typical coupling of 2-benzofuranboronic acid requires 
a solution of benzene/toluene and an aqueous solvent (ie. water or ethanol).  Using a solution of 
toluene and ethanol as reported resulted in minimal coupling.63  Interestingly, the methyl ether on 
the tropolone appeared to be replaced with ethyl ether.  Replacement of ethanol with methanol in 
the solution yielded the desired product (65%) with the methyl ether intact.  This reaction should 
be explored further to determine if a one-pot Suzuki-coupling and deprotection of 2-bromo-7-
methoxytropone with a boronic acid in toluene and water is possible. 
The dealkylation of the tropolone methyl ether appears to be amenable to the generation 
of a larger α-tropolone library despite some lower yields.  Via this method, α-tropolones 
presenting various heterocycles, alkynes, aldehydes and other functional groups are all able to be 
synthesized.  The next logical step in synthesizing the larger α-tropolone library was to 
synthesize more analogs with para-phenyl substitutions.  Although these para-phenyl analogs 
could be synthesized from the aniline, aldehyde, cyano-phenyl, phenol or alkyne tropolones, 
para-bromophenyl was selected to continue utilizing the same Suzuki-coupling conditions 
already being used.  The para-bromophenyl analog could also be used later for other coupling 
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reactions such as Sonogashira, Heck or Buchwald-Hartwig.  4-bromophenylboronic acid could 
be coupled to 2-bromo-7-methoxytropone using the same Suzuki-coupling conditions utilized for 
the other tropolone substitutions, but there appeared to be a significant impurity in the aromatic 
region based on NMR.  It was determined that this impurity was most likely a homo-coupled 
byproduct.  To avoid this problem, Suzuki-coupling of 4-bromophenylboronic acid was 
conducted according to a published method.64  While this appeared to reduce the impurity, it did 
not completely eliminate it.  After testing different equivalents of 4-bromophenylboronic acid, it 
was determined that the addition of 0.9 equivalents would result in a pure product based on 
NMR.  Now a series of para-α-phenyltropolones could be synthesized (Scheme 2.7). 
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Scheme 2.7:  Synthesis of para-α-phenyltropolones from 2-para-bromophenyl-7-
methoxytropone. 
 
 
a RB(OH)2; b Yield of isolated products. 
 After the successful synthesis of these para-α-phenyltropolones, select analogs were 
attempted directly from the non-protected para-bromophenyltropolone (BA-pBr-OH).  The 
normal Suzuki-coupling conditions could produce the desired para-α-phenyltropolones but 
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formed an inseparable mixture of both the coupled product and starting material.  Addition of 
more boronic acid did not overcome this obstacle.  Replacement of cesium carbonate with a 
weaker base, potassium acetate, and a stronger palladium catalyst also failed to yield product.  
Using a more reactive palladium catalyst and tricyclohexylphosphine to stabilize the transitional 
metal complex also failed.  Replacement of cesium carbonate with potassium fluoride was able 
to yield the desired product free of starting material.  However, this only proved successful for 
the coupling of 2-furanylboronic acid.  Excitingly, this reaction proved more successful than the 
2-step coupling/deprotect reaction with 2-para-bromophenyl-7-methoxytropone (overall yield 
72% vs 17%).  Future efforts should be made to successfully synthesize other tropolones from 
BA-pBr-OH. 
 
2.2.3 Synthesis of α-Tropolones Using Other Coupling Techniques After Suzuki-Coupling 
 In addition to Suzuki-coupling, BA-pBr-OH can be functionalized via other methods.  
Sonogashira-coupling to BA-pBr-OH was desired as the product could be used to introduce alkyl 
linker chains, branched analogs, triazoles via click-coupling, or as a probe for affinity 
purification by click-chemistry with biotin or a fluorescent tag.  To increase the coupling 
efficiency, potassium acetate was used as a base because acetate ions are thought to bind strongly 
to soluble palladium (II) and create complexes that are less prone to forming the inactive 
palladium black.65 
 
 
142 
 
Scheme 2.8: Sonogashira-coupling of alkynes to 2-para-bromophenyl-7-methoxytropone. 
 
 
 All three alkynes used were successfully coupled, with two in high yields.  It is unknown 
why 3-methyl-1-butyne did not couple as efficiently as the other two alkynes, but it may be 
possible that not enough copper iodide was in the reaction since a premixed stock of 10% copper 
iodide in bis(triphenylphosphine)palladium chloride was used as the catalyst.  Overall, these 
Sonogashira-coupling conditions should be useful to couple a variety of alkynes to 2-para-
bromophenyl-7-methoxytropone.  However, the lithium chloride dealkylation of the tropolone 
methyl ether resulted in a low yield for SG-PH-OH.  This may be because the product was 
precipitated after acidification, filtered and the filtrate which may have contained still soluble 
product was discarded.  It may be possible to avoid this problem by coupling directly to BA-pBr-
OH instead of the methyl ether. 
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As previously mentioned, there are several α-tropolones in this synthesized library that 
can be further functionalized through subsequent coupling reactions.  The amine on α-aniline-
tropolone (Am-NH2-OH) can be utilized in a variety of condensation reactions.  Since it has 
already been shown that γ-aminotropolone can be diacylated and selectively hydrolyzed to 
maintain the newly formed amide, this diacylation technique was explored.66 
Scheme 2.9: Synthesis of N-phenyl-amide α-tropolones. 
 
 
 The diacylation of Am-NH2-OH is successful and can be completed with different acyl 
chlorides.  Unfortunately, the diacylated intermediate tends to broadly diffuse on a column and is 
not easily purified.  Despite the inability to isolate the pure intermediate, the crude product can 
be washed with water and extracted with dichloromethane to remove DMAP and pyridine.  The 
resultant intermediate is easily dissolved in methanol and the ester hydrolyzed with base.  After 
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acidic work-up, the product can be purified by column chromatography and collected in good 
yields. 
  
2.2.4 Synthesis of Tropones with Alternative Chelating Moieties  
 Previous studies by the Anderson lab determined the aminotropone analogs of the α-
tropolones were inactive in cytotoxicity assays.  Because this lack of activity was not predicted 
due to the ability of the amine to act as a chelator with the tropone carbonyl, other potential 
chelating groups needed to be explored to determine if the hydroxyl is essential to the synthetic 
α-tropolones activity. It is known that thio-troponoids have biological activity67 and hydroxamic 
acids are commonly used as zinc chelators for histone deacetylase inhibition.68  Initial attempts 
to generate the thio-tropone through nucleophilic displacement of the methyl ether involved α-
phenyl-methoxytropone.  While it appeared as though some product was formed, the reaction 
was deemed unsuccessful.  Work by Kubo and coworkers discovered that bis-thioditropones 
could be synthesized through nucleophilic displacement of a tosyl group on the tropone.69  
Tosylation of α-phenyltropolone with p-toluenesulfonyl chloride was conducted similar to the 
diacylation of Am-NH2-OH to form the tosylated α-phenyltropone in good yields (88%).  The 
tosylated α-phenyltropone could then be reacted with either sodium hydrosulfide hydrate or 
sodium thiomethoxide in methanol at room temperature to form the thio-tropone and thioether-
tropone respectively. 
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Scheme 2.10:  Synthesis of thio-tropones. 
 
Exploitation of the reactivity of methoxytropones with amines to form aminotropones 
was attempted to achieve the hydroxylamino-tropone.70   Basic Buchwald-Hartwig conditions 
were used to couple o-(tert-butyldimethylsilyl)hydroxylamine and α-phenyl-methoxytropone to 
generate the hydroxylamino-tropone derivative.  Unfortunately, this reaction did not proceed as 
predicted.  However, refluxing o-(tert-butyldimethylsilyl)hydroxylamine with tosylated α-
phenyltropone yielded the hydroxylamino-tropone (18% yield).  Since this reaction undergoes 
the same nucleophilic substitution mechanism as the thio-derivatives, hydroxylamine 
hydrochloride salt was neutralized with triethylamine, dissolved in methanol and stirred with 
tosylated α-phenyltropone.  This reaction appeared to be slow at room temperature so the 
mixture was heated to 50°C and monitored by TLC.  Although this reaction also worked, an 
oxime may have formed resulting in a significantly lower yield of the hydroxylamino-tropone 
(7% yield). 
Scheme 2.11:  Synthesis of hydroxylamino-tropone. 
 
 Although it was determined that the aminotropones were biologically inactive in these 
assays, 2-amido-tropones may have different activity since they could potentially form 6 
membered chelate rings instead of the 5 membered chelate ring potentially formed by the 
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aminotropones.  To synthesize this derivative, the amino intermediate of the 2-chlorotropone 
synthetic route was acylated with acetyl chloride to form the simple acetamide-tropone. 
 
Scheme 2.12:  Synthesis of 2-amido-tropone. 
 
 Future synthetic work on these tropones with alternative chelating moieties should focus 
on increasing the yield of the hydroxylamino-tropone.  Additionally, synthesis of a carboxy-
tropone and phosphonate-tropone should be attempted. 
 
2.3 Conclusions 
 Synthesis of α-tropolones from commercially available 2-chlorotropone is an efficient but 
limited synthetic route.  A more versatile route towards the synthesis of new α-tropolones is 
based on elaboration of 2-bromo-7-methoxytropone that can be synthesized in bulk from 
commercially available tropolone.  Lithium chloride dealkylation of the methyl ether provides 
milder deprotection conditions for the methoxytropone compared to older methods involving 
reflux in strongly acidic solution.  Using this new method, a variety of α-tropolones have been 
successfully synthesized.  The coupling of 4-bromophenylboronic acid to 2-bromo-7-
methoxytropone creates a new scaffold for synthesis of α-phenyltropolones with variable 
substitutions in the para position.  Additionally, it has been shown that this coupled product can 
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be utilized in subsequent Suzuki and Sonogashira coupling reactions and the demethylated 
tropolone (BA-pBr-OH) has the potential to be used in a one step diversification reaction to 
generate new α-phenyltropolones with substitutions in the para position.  Other tropolones were 
synthesized through diacylation of α-anilino-tropolone followed by selective hydrolysis of the 
ether.  A thio-tropone, thioether-tropone and a hydroxylamino-tropone has also been synthesized 
from tosylated α-phenyltropone to investigate the necessity of the hydroxyl group for biological 
activity and/or formation of a 5 membered chelate ring. 
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Chapter 3 
 
Development of Synthetic α-Tropolonoids as Antiproliferatives Effective Against T-cell 
Acute Lymphoblastic Leukemia 
 
3.1 Background and Significance 
 
 Acute lymphoblastic leukemia (ALL) is a highly aggressive hematologic malignancy 
driven by aberrant proliferation of lymphoid precursor cells which primarily accumulate in bone 
marrow and blood but may spread to other tissues.1-3  While predisposition to ALL is considered 
uncommon, there is a greater occurrence in children.4  ALL is the most common childhood 
cancer worldwide with 4 to 5 children per 100,000 diagnosed each year and peak incidence 
between ages 2 and 5.5-6  Although 60% of ALL cases are 20 years old or younger, a second 
peak occurrence of ALL is found in patients older than 50.  Interestingly ALL accounts for 80% 
of all childhood leukemia but only 20% of adult leukemia.6 
 As the malignant hematopoietic cells expand in bone marrow, patients begin develop 
symptoms associated with ALL.  Typical symptoms include: weakness or fatigue usually 
associated with anemia, fever which may be caused by neutropenia or infection resulting from 
suppression of normal hematopoiesis, easy bruising and bleeding caused by thrombocytopenia, 
shortness of breath caused by a mass formed in the esophagus, trachea, thymus or lymph nodes, 
weight loss, bone or joint pain or swelling of the abdomen due to high white blood cell (WBC) 
count, swollen lymph nodes in the neck, armpit or groin, and headache, confusion and nausea as 
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a result of central nervous systems (CNS) involvement.3, 7  Because ALL may be of B- or T- 
progenitor cell origin, diagnosis requires extensive analysis.  Diagnosis involves flow cytometry 
to determine B- or T-cell lineage, morphology assessment and immunophenotyping to determine 
subtype, cytogenic analysis for common gene rearrangements and bone marrow biopsy to assess 
bone marrow involvement.3, 7  Subsequent diagnostic assessments may include complete blood 
count and well as a chemistry panel to screen for WBC count and potential involvement of other 
organs, careful screening for any active infection, and lumbar puncture for cytologic analysis of 
cerebrospinal fluid if CNS involvement is suspected.3, 7 
 Subtyping ALL is critical because each subtype exhibits different responses to therapy 
and is associated with a different prognosis.  Initial subtyping involves morphological 
assessment to determine L1, L2 or L3 morphology.  L1 morphology involves more mature 
lymphoblasts while L2 is more immature or mixed lineage.  L3 morphology is significantly less 
common and is referred to as Burkitt ALL.3  Burkitt ALL is of B-cell lineage and contains the 
translocation of MYC typically with IGH@.7  Cytogenic analysis of genetic rearrangements 
further subtypes ALL with L2 morphology.  One of the more common genetic rearrangements is 
the BCR-ABL1 fusion.8  Similar to chronic myelogenous leukemia (CML), this fusion results in 
the Philadelphia chromosome.  However, Ph+ ALL is characterized by a 190 kDa isoform of the 
Phildelphia chromosome while CML generally involves a 210 kDa isoform.3  Ph+ ALL is of B-
cell lineage and is associated with high risk and poor prognosis due to poor detection (unlike 
CML, Ph+ ALL may only be detected by fluorescence in situ hybridization or reverse-
transcriptase polymerase chain reaction), resistance to asparaginase and daunorubicin and 
toxicity from treatment with tyrosine kinase inhibitors.3-4, 9  Finally, flow cytometry and 
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immunophenotyping further subtype ALL and distinguish the more uncommon cellular subtype, 
T-cell ALL.3 
 
3.1.1 T-cell Acute Lymphoblastic Leukemia 
 Lymphoblasts of T-cell ALL are indistinguishable from B-cell ALL since they share 
many phenotypic features.  These lymphoblasts are generally small to medium in size with a thin 
nuclear membrane and little cytoplasmic space due to a high nuclear to cytoplasmic ratio.  
Vacuoles may be present within the cytoplasm, resembling more mature lymphocytes.  The 
nucleus may be round, irregular or convoluted in shape.  Inside the nucleus the chromatin is 
finely stippled and moderately condensed and nucleoli are not clearly visible.  One key feature 
which distinguishes T-cell ALL from B-cell ALL is the presence of more mitotic figures.  Other 
key differences involve cell markers.  Lymphoblasts of T-cell ALL typically are TdT and CD3 
positive.  CD3 is the only marker which is T-cell lineage specific.  However, CD3 alone is 
insufficient as a prognostic indicator.  Other markers which are variably expressed include 
CD1a, CD2, CD4, CD5, CD7 and CD8.  CD7 and cytoplasmic CD3 are often positive while 
CD4 and CD8 tend to be co-expressed.  Important precursor cell markers are CD99, CD34 and 
CD1a, with CD99 being the most useful indicator.  Interestingly, 19-32% of T-cell ALL cases 
express the myeloid antigens CD13 and CD33.  Although these indicators suggest myeloid cells 
or mixed lineage, standard T-cell ALL cannot be excluded from diagnosis.  Another useful cell 
marker is CD117 (c-kit) which is associated with aberrant expression of FLT3.  Adult cases often 
express CD25 and large transformed cells may express CD30.1 
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Historically T-cell ALL was treated as a single malignancy, but appreciable outcomes in 
patients receiving uniform treatment prompted extensive research on the molecular biology of 
the leukemia.  Based on immunophenotyping, T-cell ALL cases were originally stratified into 5 
subtypes: pro-T, pre-T, cortical, αβ mature and γδ mature.10  Pro-T cells express CD3 and CD7, 
may express CD34 but do not express CD2 or CD1a.  Pre-T cells are similar to pro-T but are 
CD2 positive.  Cortical T-cells express CD3, CD7, CD2 and CD1a, but do not express CD34.  
Mature T-cells are similar in expression to cortical, but do not express CD1a.  Additionally, pro- 
and pre-T are double negative for CD4 and CD8 while cortical are double positive and mature 
typically only express one.1  Due to the high similarity of pro- and pre-T and the similarity of 
both mature types, T-cell ALL is currently stratified into 3 subtypes: early, cortical and mature.11  
Typically patients diagnosed with early or mature T-cell ALL have worse prognostic outcomes 
than patients diagnosed with cortical T-cell ALL.11  Early T-cell ALL should not be confused 
with early T-cell precursor ALL (ETP-ALL) which has a distinct immunophenotype.4  ETP-ALL 
expresses the myeloid/stem cell markers CD13, CD33, CD34, CD117 and does not express 
CD1a or CD8 and may only weakly express CD5.  Additionally, ETP-ALL commonly has 
mutations in FLT3 and RAS; making ETP-ALL more closely resemble acute myeloid leukemia, 
but is differentiated due to expression of the T-cell marker CD3.4, 9 
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Figure 3.1: Representation of immunophenotypes of T-cell ALL as categorized by early, cortical 
or mature subtype. 
 
Therapeutic regimens for T-cell ALL may also differ due to cytogenic analysis.  Unlike 
assessment of morphology and immunophenotyping, cytogenic analysis cannot be used to 
subtype T-cell ALL since genetic abnormalities are highly heterogeneous, can be found across 
all subtypes and each abnormality infrequently occurs.10, 12  This is surprising considering 
approximately 50% of all cases have detectable genetic lesions.10  Due to the high heterogeneity 
of T-cell ALL genetic abnormalities, bone marrow samples must be tested to determine precise 
characteristics.13  Genetic abnormalities associated with T-cell ALL involve deregulation of 
growth, proliferation, chromatin remodeling, differentiation, self-renewal and the cell cycle as 
well as aberrant expression of transcription factors.7, 12  The hallmark of T-cell ALL is genetic 
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abnormalities in transcription factors of the basic helix loop helix, LIM-only domain, homeobox 
and MYC families as well as TAN-1.14  TAN-1 is a C-terminal domain of NOTCH1 and genetic 
alteration has been found to constitutively activate NOTCH1 in 50-70% of cases.15-18  Other 
common genetic abnormalities include deletion of CDKN2A (>70%) and impairment of 
PRC2.19-21  Some cases of T-cell ALL may also contain dysregulation of microRNA and 
chromosomal rearrangements often adjacent to promoter and enhancer elements of the T-cell 
receptor genes TRA@, TRB@, TRG@ and TRD@.1, 22-27  There are four main subgroups of 
chromosomal rearrangements: HOX11/TLX1, HOX11L2/TLX3, TAL or LMO genes and 
fusions involving CALM-AF10, MLL or SET-NUP214.28-30  Chromosomal rearrangements 
involving TAL or LMO genes or HOX11L2/TLX3 tend to be more common with incidences 
reported in 30% and 24% of cases respectively.29  The other rearrangements and fusions are 
more rare (4-8% of cases), with HOX11/TLX1 only reported in pediatric cases and unknown 
prognostic outcomes associated with MLL and SET-NUP214 fusions.28-30  As with all cases of 
T-cell ALL, ETP-ALL lacks consistent genetic abnormalities but tends to contain mutations 
involving regulators of hematopoietic development (58%), regulators of cytokine receptors and 
Ras signaling (67%), chromatin modification or epigenetic regulators (48%).9, 31  However, more 
than 60% of adult cases are associated with at least one mutation in DNMT3A, FLT3 or 
NOTCH1.32 
 
3.1.2 Therapies for T-ALL and Prognostic Outcomes 
 Acute lymphoblastic leukemia accounts for 80% of all childhood leukemia and 20% of 
adult.7  In the United States 6,590 new cases of acute lymphoblastic leukemia are estimated to 
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occur.3  T-cell ALL accounts for 15% of pediatric and 25% of adult cases and occurs more 
frequently in males.12, 21  ETP-ALL is more common in children and accounts for 12-15% of 
childhood T-cell ALL cases.33  Although ALL may occur at any age, 60% of cases happen under 
the age of 20 while 12% of cases occur in people over 65 with two peak incidents: between ages 
4 and 5 and over 50.7, 34  This makes the management of T-cell ALL highly complex given 
differences in biological features between children and adults as well as the high risk associated 
with peak incidence ages.13, 35  Other high risk features commonly associated with T-cell ALL 
include high leukocyte count, high tumor burden and central nervous system involvement.36  On 
average, the treatment of T-cell ALL lasts 1.5 to 3 years.3  The complexity of T-cell ALL 
diagnosis and treatment as well as the average length of treatment create a substantial economic 
burden.13 
 T- and B-cell ALL are initially treated the same and involve remission induction 
therapy.4, 6, 13  Remission induction therapy aims to cause disappearance of detectable leukemia 
(>5%) in both the bone marrow and other sites through the administration of high doses of 
multiple chemotherapeutics over a short period of time.37  Chemotherapeutics commonly used 
are vincristine, an anthracycline (ie. doxorubicin), and a corticosteroid.  This treatment regimen 
may also be supplemented with L-asparaginase.  Patients considered to be at high risk of relapse 
may also receive cyclophosphamide, methotrexate, 6-mercaptopurine, etoposide or cytarabine.37-
41  Vincristine is a standard front-line chemotherapeutic for both pediatric and adult T-cell ALL.4  
It works by binding tubulin of rapidly dividing cells, preventing the separation of chromosomes 
during metaphase and inducing apoptosis.42  Prolonged exposure leads to significant and 
sometimes irreversible peripheral neuropathy.4  Anthracyclines are DNA intercalating agents 
which prevent replication in rapidly proliferating cells and can cause DNA damage.43  As with 
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all anthracyclines, doxorubicin can lead to congestive heart failure depending on the cumulative 
dose.  It has been determined that doses exceeding 600 mg/m2 causes cardiotoxicity in 36% of 
patients.  Additionally, cardiotoxicity caused by doxorubicin results in 50% mortality.44  The 
corticosteroids given as part of remission induction therapy typically include either prednisone or 
dexamethasone.  While neither corticosteroid is considered to be toxic, they may cause 
depression and anxiety and long term exposure may cause osteoporosis, glaucoma and type 2 
diabetes.45  L-asparaginase prevents the conversion of L-asparagine to aspartic acid, depriving 
malignant hematological cells which are unable to synthesize asparagine leading to cell death.46  
It is not always prescribed to treat T-cell ALL because L-asparaginase is known to cause 
myelotoxicity and can significantly increase the chances of developing serious bacterial or viral 
infections.47  Remission induction therapy may also be accompanied by central nervous system 
(CNS) prophylaxis.  CNS prophylaxis may involve cranial radiation therapy with intrathecal 
injection of methotrexate, systemic administration of high doses of methotrexate and intrathecal 
injection of methotrexate or intrathecal injection of chemotherapeutics.3   
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Figure 3.2: Chemotherapeutics commonly used to treat both T- and B-cell ALL. 
Despite increased knowledge of subtype biology, genetic abnormalities and general 
toxicities of prescribed chemotherapeutics, treatment plans for T-cell ALL have not changed 
much over the past couple of decades and many chemotherapeutic combinations depend on 
oncology center preference.4, 21  Although complete remission is achieved in >90% of patients, 
these gains also come with significant life altering side-effects and higher risk of mortality due to 
chemotherapeutic toxicity.4, 48  Additionally, more than 50% of patients will relapse within 3 
years.41, 49  Therefore post remission therapy is critical.  Unfortunately, optimal post remission 
therapy is unknown and mainly consists of autologous or allogeneic bone marrow transplant 
(alloBMT).3  Typically only patients at high risk are recommended to undergo alloBMT after 
remission, but recent studies suggest patients with moderate risk benefit significantly more from 
alloBMT than patients at high risk.4   Unfortunately, alloBMT may result in 20-40% mortality 
due to graft-versus-host disease, veno-occlusive disease or liver and interstitial pneumonitis 
Vincristine Doxorubicin
Cyclophosphamide
Etoposide
CytarabineMethotrexate
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despite offering the lowest incidence of relapse.3  The low incidence of relapse associated with 
alloBMT is why most patients who do relapse typically undergo reinduction chemotherapy 
followed by alloBMT, especially since chemotherapy alone is highly unlikely to cure relapse 
cases.3 
Patients diagnosed with T-cell ALL generally have worse prognostic outcomes compared 
to B-cell ALL.50-53  The worse outcome is associated with a significant risk of relapse and low 
response to rescue therapy after relapse; with the subtype ETP-ALL linked to the greatest risk of 
relapse in addition to a high risk of remission therapy failure.21, 54  Failure to respond to 
remission therapy or rescue therapy after relapse is mainly due to chemoresistance.21  
Surprisingly, 60-80% of adults and greater than 90% of children will achieve complete 
remission, but more than 50% will relapse.3, 55  Despite decades of research, clinical care of T-
cell ALL has remained similar and strategies to achieve a second complete remission are 
severely lacking.  The majority of relapses occur within two years of first remission and results 
in 5-year survival rates of only 7-23%.  One factor which leads to relapse is minimal residual 
disease (MRD) located in the bone marrow.21  MRD is a significant prognostic tool since patients 
who are MRD positive after remission therapy are more suited for alloBM, are considered to be 
at higher risk of relapse and have a 5-year survival rate of 33% while MRD negative patients 
have an average 5-year survival rate of 75%.4  More than 90% of patients who are MRD positive 
after remission therapy relapse within 5 months and typically experience chemoresistance.56  
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Table 3.1: Trends in 5-year relative survival rates of select leukemia/lymphoma patients in the 
United States. 
 
 Not surprisingly, adults are predisposed to high risk features associated with increased 
chance of relapse and chemoresistance even during remission therapy.4  Predisposition to 
chemoresistance is thought to involve leukemic stem cells.  These stem cells exhibit asymmetric 
cell division, are capable of self-renewal and production of partially differentiated cells and are 
typically quiescent, making them relatively unsusceptible to chemotherapy.57  Chemoresistance, 
either initial or acquired after relapse, is the major barrier to achieving a second complete 
remission and improved survival rates.58  Unfortunately, the mechanism(s) through which T-cell 
ALL becomes chemoresistant is mostly unknown.14  Current therapeutic options after relapse 
include cytarabine, etoposide, clofarabine, nelarabine and may include clinical trials with γ-
secretase inhibitors.  The first line therapeutic option after relapse utilizes cytarabine and 
etoposide.  Cytarabine disrupts DNA synthesis, causing S phase cell cycle arrest.59  Side effects 
of cytarabine include leucopenia and thrombocytopenia, two disorders already associated with 
high risk T-cell ALL, and may cause cerebellar toxicity.  Etoposide is often used in combination 
with cytarabine or another chemotherapeutic and causes single strand breaks in DNA leading to 
apoptosis.60  Clofarabine is known to be active in relapse and refractory cases, but is a known 
Trends in 5-year relative survival rates (%) in the United States
Cancer type 1960-1963 1974-1976 1983-1985 1995-2001 2004-2010
Non-
Hodgkin’s 
lymphoma
31 47 54 60 72
Leukemia 14 34 41 48 60
Multiple 
myeloma
12 25 28 32 50
Acute
Lymphoblastic 
Leukemia
N/A 41 52 65 70
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hepatotoxin.4, 21  While clofarabine may be more active, it has primarily been used to treat 
children.61  Nelarabine, like clofarabine, is an analog of 6-mercaptopurine.  Despite being the 
best studied of the two, nelarabine is considered a third line option.4  Interestingly, nelarabine 
selectively accumulates in T-cells but is only prescribed for patients who are refractory to or 
have relapsed after treatment with at least two other chemotherapeutic regimens.6, 54, 62  γ-
Secretase inhibitors may be better options to the previously mentioned chemotherapeutics as they 
block a critical step in Notch activation, but are currently only in clinical trials and may result in 
gastrointestinal toxicity.4   
 
Figure 3.3: Late stage chemotherapeutic options to treat T-cell ALL. 
Despite the high risk of relapse, long term remission in children approaches 70-80% and 
is achieved in approximately 40% of adults.10  Overall cure rates are reported to be greater than 
90% in pediatric cases, 30-40% for adults under the age of 60 and 10% in patients older than 
60.4, 11  However, when these rates are stratified by risk group survival rates are not as promising 
as these numbers would suggest.  Pediatric cases are categorized into three risk groups: standard 
(40% of all cases), intermediate (45-50%) and high risk (10-15%).  Standard and intermediate 
risk groups fare the best with 90% and 70-80% survival rates respectively.  High risk pediatric 
cases do not have as successful long term survival rates, with only around 50% achieving long 
Clofarabine Nelarabine
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term survival.  Since adults are predisposed to high risk features, adult cases are only categorized 
into standard (20-25% of cases) and high risk (75-80%) subgroups.  Standard risk cases are 
associated with 60% long term survival while high risk cases only achieve 30% long term 
survival.7  There is an estimated 1,430 deaths that will be attributed to ALL in the United States 
in 2016.34  Together, the high risk of relapse, increased chemoresistance and poor prognostic 
outcomes for patients older than 25 or classified as high risk stresses the importance of continued 
research for better therapeutic options for T-cell ALL.3  This research should aim to better 
characterize genetic aberrations associated with T-cell ALL, minimizing toxic effects, improving 
cure rates and long term survival, and developing more options to induce a second remission and 
eradicate minimal residual disease.13 
Table 3.2: 40 year trends in leukemia death rates per 100,000 people for males and females. 
 
 
3.1.3 Strategies Toward Better Therapeutic Options 
 Current research focused on developing better therapeutic options to treat T-cell ALL is 
aimed toward inhibition of key genes/gene products or signaling pathways thought to be 
involved in pathogenesis and progression of the disease.  The majority of the aberrant genetic 
mutations associated with T-cell ALL can be categorized into four classes based on function: cell 
cycle, impairment of differentiation, self-renewal and proliferation and survival.7  CDKN2A and 
CDKN2B are the two genes commonly altered in T-cell ALL (65-70% of cases) and are linked 
Trends in cancer death rates per 100,000 of population
Leukemia 1971-1973 1980 1990 2000 2009-2013
Male 8.9 11.2 10.7 10.3 9.3
Female 5.3 6.5 6.2 5.9 5.2
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to cell cycle progression.54  Members of the CDKN2 family inhibit CDK4 and CDK6 to allow 
progression past the G1/S cell cycle checkpoint.  Alteration of CDKN2A/B are mostly deletions 
but may be point mutations or hypermethylation.63  Unlike most T-cell ALL mutations, deletions 
in CDKN2A/B tend to be homozygous.  These deletions occur in the tumor suppressor locus 
which contains the code for p14ARF and p16INK4a and promote uncontrolled cell cycle entry.7  
Loss of p14ARF leads to elevated levels of Mdm2 which inhibits transcriptional activation of 
p53.64  Additionally, aberrant BMI1 which interacts with MYC may also inhibit expression of 
CDKN2A/B expression.5 
 Impairment of differentiation typically involves MLL, LYL1, TAL1, TAL2, LMO1 
and/or LMO2.7  As previously mentioned, the MLL gene may form a fusion gene in 5% of T-cell 
ALL cases.  MLL1 is involved in hematopoietic differentiation and leukemogenesis.5  LYL1 is 
known to be important for normal angiogenesis, hematopoeisis and may from a translocation 
with the T-cell receptor beta locus on chromosome 7.10, 65  Aberrant expression of TAL1 is found 
in 60% of T-cell ALL cases and is associated with the regulation of stem cell development.  
When TAL1 or LYL1 are deregulated, LMO1 and LMO2 tend to become activated.  
Malignancies presenting these genetic abnormalities are associated with poor prognosis.  These 
malignancies frequently also have mutations in Ras, cytokine receptor pathways (ie. IL7R and 
JAK1), transcription factors and histone modifications.36   
 Gain of self-renewal capability in T-cell ALL is linked to activating mutations in 
NOTCH1.7  It has been determined that more than 60% of T-cell ALL cases have NOTCH1 
mutations.11  NOTCH1 encodes a heterodimeric cell membrane receptor that regulates T-cell 
development, signal transduction, proliferation, adhesion and apoptosis.10, 66  Activation results 
in changes in gene expression within the nucleus.67  Overexpression induces ectopic thymocyte 
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development and prevents other developmental options.14  Mutations in NOTCH1 are frequently 
accompanied by heterozygous mutations in FBXW7 (8-30% of cases).7  FBXW7 is a ubiquitin 
ligase which targets Notch1, cMYC, cyclin E and cJun for degradation.7, 10  Other genes which 
may be associated with aberrant NOTCH1 are JMJD3 and JAK1.  JMJD3 is a histone 
demethylase of H3K27 and is essential to the maintenance of NOTCH1 signaling.21  Gain of 
function mutation in JAK1 is found in 10-20% of adults with T-cell ALL.  This mutation may 
cooperate with constitutively activated NOTCH1 in the pathogenesis and progression of T-cell 
ALL and is associated with chemoresistance, increased risk of relapse and reduced overall 
survival.7 
 Constitutive activation of NOTCH1 may also cause increased phosphorylation and 
activation of the PI3K/AKT/mTOR pathway.7, 66  The PI3K/AKT/mTOR signaling pathway is 
highly active in 75-80% of T-cell ALL with mutations within the pathway discovered in 50% of 
these cases.11  Increased activity of PI3K/AKT/mTOR pathway is linked to chemoresistance and 
is involved in cell cycle progression, survival, translation, metabolism, and autophagy.11, 68   
Regulation of the pathway is highly complex with multiple feedback loops.  One feedback loop 
is the activation of mTORC1 by Akt which antagonizes mTORC2 which in turn reduces Akt 
activity.11  Activation of Akt leads to phosphorylation of multiple protein.  Phosphorylation by 
Akt activates Mdm2 and inactivates pro-apoptotic proteins including FOXO proteins, p21 and 
p27.  Akt also inactivates Bad, pro-caspase 9 and FasL.  Akt activates CREB, IKK to regulate 
expression of gene with anti-apoptotic activity.68  mTORC1 limits autophagy and promotes cell 
growth and proliferation.  Another function of mTORC1 is to phosphorylate and promote 
translation of 4E-BP1 which interacts with eIF4E to regulate mRNA translation.  mTORC2 also 
regulates proliferation through cytoskeleton regulation involving actin fibers, paxillin, RhoA, 
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Rac1 and PKCα.  While mutations in any of these genes could promote the pathogenesis of T-
cell ALL, the primary mutation appears in PTEN and rarely ever in PI3K or AKT.11  The 
mutation in PTEN is commonly a deletion which results in loss of function.  Interestingly, this 
appears to be a secondary event and may serve as a prognostic marker in the progression of T-
cell ALL.  Loss of PTEN function causes activation of the PI3K/AKT/mTOR pathway, enhances 
cell size, glucose uptake and proliferation which cumulatively causes a higher risk in failure of 
remission therapy.7 
 Activation of PI3K/AKT/mTOR is also controlled by the binding of IL-7 to IL7R.  This 
binding event is required for the function of PI3K-γ and -δ to promote thymocyte development 
and T-cell maturation.  Additionally, IL-7 binding activates Akt and mTORC1 which are critical 
for early and late phase T-cell development.  A mutation in IL7R-α results in constitutive 
activation of the PI3K/AKT/mTOR pathway as well as JAK1 and STAT5.14  IL-7 signaling also 
produces reactive oxygenated species critical for the proliferation and survival functions of 
PI3K/AKT/mTOR.11  Another function of IL-7 signaling is to promote expression of stem cell 
specific genes and inhibit T-cell transcription factors such as BCL11B.14  BCL11B is a member 
of the BCL family and is critical as a T-cell regulator in development, proliferation, 
differentiation and survival.69-70  It encodes a DNA binding protein essential for the maturation 
of T-cells from precursors to immature stages and more mature stages of development.10  
Overexpression of BCL11B has been found in T-cell ALL and may be important in 
leukemogenesis.69  BCL11B also regulates the transcriptional activation of EP300 which is 
important for cell growth, division, differentiation and tumor suppression.69, 71 
 In addition to IL-7 signaling and the PI3K/AKT/mTOR pathway, another major signaling 
pathway associated with proliferation and survival commonly mutated in T-cell ALL is p53.  
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Mutations in TP53 are found in up to 50% of adult cases and 2-10% of pediatric.63  However, 
these mutations are only discovered in 5% of initially diagnosed patients, making it much more 
common in relapse cases.7  This mutation is generally a point mutation in exons 5-8 and is 
associated with poor response to prednisone, high risk of treatment failure and poor clinical 
outcome.  The gene product of TP53 is p53 which acts as a checkpoint control for G1/S 
transition.  p53 is also important for senescence and apoptosis and has been found to inhibit 
Akt/mTOR as well as Notch signaling.63  Genes associated with p53 stabilization and activation, 
such as USP7 and ATM, may also be mutated in T-cell ALL.  USP7 stabilizes p53 and is 
implicated in transcriptional regulation, cell cycle progression and DNA damage response.21  The 
DNA damage response may be initiated by ATM.  ATM senses double strand breaks in DNA 
and signals multiple effector proteins for cell cycle arrest.72  These effector proteins include E2F, 
which can increase levels of p14ARF, and p53.63  Other DNA damage response signals from ATM 
include activation of signal transduction, cell cycle regulation, DNA repair, transcription and 
apoptosis.73  Activation of ATM may also occur due to elevated levels of both endogenous and 
induced oxidative DNA damage not associated with double strand breaks.74  If the DNA damage 
sensed by ATM is irreparable then ATM will phosphorylate and activate p53 triggering cell 
cycle arrest and apoptosis.72  Mutations in ATM are found in 2-17% of T-cell ALL cases and 
leads to constitutive activation.63  Constitutive activation of ATM and the DNA damage response 
is thought to lead to the emergence and selection of malignant cells with non-functional ATM 
and/or p53.72 
 Another action which may activate ATM is chromatin remodeling.  One reason for this 
hypothesis is that ATM phosphorylates of histone deacetylase (HDAC) 1.73  Maturation of T-
cells requires constant chromatin remodeling through DNA methylation and histone 
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modifications to allow for rapid gene expression.75  In addition to ATM, other common 
mutations in T-cell ALL can cause changes in chromatin structure.  As previously mentioned, 
BCL11B regulates the transcriptional activation of EP300.  EP300 and CREBBP have roles in 
hematopoiesis and acetylate histones as well as MYB, E2F1, TP53 and RB1.76-77  Loss of 
function mutations in CREBBP may result in chemoresistance.78  HDACs may also be 
implicated in primary T-cell ALL.  Somatic mutations in HDAC5 and HDAC7 have been 
discovered in 5% of pediatric cases and elevated expression or enhanced activity of HDACs are 
exhibited in T-cell ALL.21  While chromatin remodeling and epigenetic modification may be 
driving forces in the progression of T-cell ALL, enhancer sequences which recognize specific 
epigenetic modifications also contribute to the pathogenesis.  One super-enhancer sequence, 
BRD4, in particular recognizes acetylated H3K27 and singly methylated H3K4 and is associated 
with T-cell ALL oncogenes MYB, MYC, ERG, GFI1, CCND3, CDK6, TAL1 and NOTCH1.79 
 While all of the aforementioned genes/gene products or signaling pathways are 
considered to be therapeutic targets for the development of new anti-leukemic drugs, more 
research has focused on Notch, PI3K, mTOR, and HDAC inhibitors.  γ-Secretase inhibitors have 
been developed to block the Notch signaling pathway.  As mentioned previously, these inhibitors 
are occasionally prescribed as part of clinical trials for patients who have suffered a relapse after 
complete remission.  These inhibitors prevent the cleavage of and inhibit activation of Notch1.12  
Currently there are two γ-secretase in clinical trials for the treatment of hematologic 
malignancies: RO4929097 and LY3039478.80  The most well researched PI3K inhibitors are 
wortmannin and LY-294002.  Both of these are relatively potent (5 nM and 1.4 µM respectively) 
but non-selective inhibitors of PI3Ks.  They have also been found to inhibit other enzymes such 
as mTOR, MAPK, MLCK and BET.81  Additionally, wortmannin is known to exhibit a 
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detrimental effect on memory and can impair spatial learning abilities.  Because of their off 
target effects and detrimental side effects, these PI3K inhibitors are not being utilized.82  
However, two PI3K inhibitors are currently in clinical trials for various cancers: RP6530 and 
BKM120.80  Rapamycin, an mTOR inhibitor, is FDA approved but is currently in clinical trials 
as an anticancer therapeutic.  Rapamycin binds to FKBP12 which subsequently binds to 
mTORC1 to inhibit the mTOR pathway.83  Its derivative, everolimus, is also being investigated 
in clinical trials.80  HDAC inhibitors that have been FDA approved or are currently in clinical 
trials have been discussed in Chapter 1.  Briefly, there are 11 zinc-dependent or “classical” 
HDAC isoforms and 7 non-zinc-dependent isoforms called sirtuins.84  Most HDAC inhibitors 
have been developed to target the classical isoforms, but several have been developed to target 
sirtuins.85  There are other inhibitors being developed which target other factors associated with 
T-cell ALL but these targets are not as well studied and review of all inhibitors being developed 
is outside the scope of this chapter. 
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Figure 3.4: New anti-leukemic drugs in clinical trials. 
 
3.1.4 Tropolones as Anti-leukemic Agents 
 Naturally occurring tropolones are known to exhibit antiproliferative effects.86-88  The 
best studied tropolone, hinokitiol, has been found in inhibit DNA synthesis, induce cell cycle 
arrest and exhibit cytotoxic effects in the murine leukemia cell line P388.  Other naturally 
occurring tropolones related to hinokitiol (HKT) also display cytotoxic effects towards P388 
which may be associated with inhibition of the metalloenzyme ribonucleotide reductase.89  The 
structural isomer of hinokitiol, α-thujaplicin, displays similar potency against P388 as vincristine 
after 24 hours but with significantly lower acute toxicity.88  Tropolone itself inhibits the uptake 
γ-Secretase Inhibitors
RO4929097 LY3039478
mTOR Inhibitors
Rapamycin Everolimus
PI3K Inhibitors
Wortmannin LY-294002 RP6530 BKM120
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of leucine and thymidine in myeloid leukemia and causes oxidative damage similar to 
doxorubicin.90   
The Anderson and Wright labs synthesized and screened tropolone derivatives against 
two T-cell lymphocytes (Jurkat and HuT-78), a colon cancer cell line (HCT-116) and a 
pancreatic cancer cell line (BxPC-3).  Here the tropolones exhibited significant half maximal 
growth inhibition (GI50) of the T-cell lymphocytes.  This activity differed from that of vorinostat, 
a HDAC inhibitor, which displayed similar cytotoxic activity towards HuT-78 and HCT-116.  
The tropolones also did not appear to be toxic (GI50 >100 µM) towards primary human dermal 
fibroblasts while vorinostat gave a GI50 of 18.95 µM.
91 
Research in the Anderson and Wright labs determined the synthetic tropolones are 
inhibitory towards HDACs with significant selectivity towards HDAC2.91  It has been shown 
that HDAC2 inhibition is particularly exciting as a target of aggressive cancers including 
cutaneous T-cell lymphoma.92  Unlike most HDAC inhibitors, the tropolones did not inhibit 
HDAC6 or cause hyperacetylation of tubulin.  The tropolones also displayed different effects on 
p21 and caspase-8 activation from typical HDAC inhibitors.  However, the tropolones were able 
to enhance the expression of perforin similar to the HDAC inhibitor romidepsin.93  In a 
collaborative effort with the Giardina lab, the effect of the synthetic tropolones on differentiation 
regulators was compared to known epigenetic modifiers.  Tropolones were found to increase 
expression of Math1 without changing expression of Muc2.  This activity contrasts with that of 
HDAC inhibitors which increased expression of both Math1 and Muc2, but coincided with the 
activity displayed by sirtuin modulators.  Interestingly, both the tropolones and the sirtuin 
modulators increased expression of Fabp2 while HDAC inhibitors decreased Fabp2 expression.94  
These results suggest tropolones may exhibit antiproliferative effects through sirtuin modulation.  
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This may explain the selectivity towards the hematologic cancer cell lines as sirtuins appear to be 
involved in many of the processes which facilitate the pathogenesis of leukemia including 
PI3K/AKT signaling, RAS signaling, p53 activation, regulation of the Foxo family, EP300 and 
MYC. 95-96 
 
3.1.5 Project Objectives 
 Our goal was to screen a set of tropolone derivatives against sirtuins 1 and 2 to determine 
if previous anticancer effects exhibited by these tropolones could be attributed to sirtuin 
inhibition.  Because previous research with tropolone derivates displayed significant anticancer 
effects against hematologic malignancies, our other primary goal was to assess the activity of 
both the previously studied tropolones and the newly synthesized tropolones against a panel of 
leukemic cell lines.  These cell lines include T-cell, B-cell and myeloid malignancies to 
determine if tropolones exhibit lineage specific effects.  The most potent tropolones would also 
be assayed with peripheral blood monocytes to determine whether the cytotoxic effects against 
the leukemic cell lines were due to general toxicity. 
 
3.2 Results and Discussion 
 
3.2.1 α-Tropolones Modulate Sirtuin 1 and 2 
 Based on a screen of epigenetically active compounds on intestinal organoid cells derived 
from cancer-prone ApcMin/+ mice, synthetic tropolones exhibited activity profiles similar to 
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sirtuin modulators.94  To assess the potential of tropolones to modulate sirtuins, SIRT1 and 
SIRT2 activity was screened with 10 µM concentrations of 26 synthetic tropolones, two natural 
troponoids, three sirtuin inhibitors, a SIRT1 activator and a pan-HDAC inhibitor.  Activities 
were screened using the Direct Fluorescent Screening Assay Kits from Cayman Chemical 
Company.  Following the standard analysis procedures provided, % Inhibition was calculated as: 
% Inhibition =
Initial Activity - Sample
Initial Activity
x 100
 
 
 
Figure 3.5: % Inhibition of SIRT1 as determined by SIRT1 Direct Fluorescent Screening Assay 
Kit (n=3) with 10 µM of each compound.  Tenovin-6 was used as a positive control of 
SIRT1 inhibition.  Negative values indicate activation of SIRT1. 
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Figure 3.6: % Inhibition of SIRT2 as determined by SIRT2 Direct Fluorescent Screening Assay 
Kit (n=3) with 10 µM of each compound.  Tenovin-6 was used as a positive control of 
SIRT2 inhibition. Negative values indicate activation of SIRT2. 
  
The majority of the tropolones screened exhibit inhibitory activity against both SIRT1 
and SIRT2.  Interestingly, most of the tropolones appear to be more potent against SIRT1 than 
the sirtuin inhibitor Tenovin-6.  Tenovin-6 is one of the more potent sirtuin inhibitors developed 
and is known to inhibit SIRT1 (IC50 = 21 µM), SIRT2 (IC50 = 10 µM) and SIRT3 (IC50 = 67 
µM).97  Trans-resveratrol was included in the screen because it is reportedly a SIRT1 activator 
and does not activate SIRT2.98  Because most of the tropolones exhibit similar activity in SIRT1, 
it is difficult to determine any structure activity relationship.  Remarkably, the tropolones that 
exhibit the least inhibition activity against SIRT1 have substantial pharmaceutical liabilities.  EF-
1-OH has a benzaldehyde functional group which is a known Michael acceptor.  Michael 
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acceptors can be promiscuous and can form covalent bonds to inactivate enzymes which can lead 
to substantial toxicity.  BA-pCN-OH has a benzonitrile functional group.  The cyano group is 
readily hydrolyzed by acids to generate benzoic acid which can be moderately toxic and 
decomposition of benzonitrile can generate nitrogen oxides and hydrogen cyanide which is 
acutely toxic.99  Additionally, the two tropolones that slightly activate SIRT1 have a phenyl ring 
with a para-alkyl chain of four (MO-9-OH) or seven (BA-P7-OH) carbons.  Surprisingly, a 
similar compound with a two carbon alkyl chain (MO-10-OH) is among some of the more active 
inhibitors. 
 
Figure 3.7: Two reported sirutin modulators used as controls. 
In contrast to the moderate inhibitory activity of the tropolones towards SIRT1, the 
majority of the tropolones display weak inhibitory activity towards SIRT2.  Again, the similar 
activity exhibited makes it difficult to determine a structure activity relationship.  Interestingly, 
trans-resveratrol was determined to be an inhibitor of SIRT2 with 48% inhibition at 10 µM.  The 
inhibitory activity of trans-resveratrol against SIRT2 would explain why it does not activate 
SIRT2 at 200 µM and its structure could serve as a template to develop dual action SIRT1 
activators/SIRT2 inhibitors; however, these results necessitate more in-depth analysis of trans-
resveratrol sirtuin activity which is outside the scope of this project.  However, three of the 
tropolones and the natural tropolonoid, tropodithietic acid (TDA), appear to have IC50 values 
Tenovin-6 Trans-resveratrol
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around 10 µM or less.  Here the most potent tropolone has a phenol substituent.  The tropolones 
and Tenovin-6 were subsequently screened at five different concentrations: 1, 5, 10, 20 and 30 
µM; and IC50s were calculated from the inhibition activity curve. 
 
Figure 3.8: Non-linear regression analysis of log[inhibitor] versus normalized response. 
 
 The IC50 for Tenovin-6 was determined to be 8.4 µM which is similar to the estimated 
IC50 of 10 µM.
97  Next, the IC50s of BA-pOH-OH, BA-SM-OH and Am-Piv-OH were 
determined.  BA-pOH-OH proved to be nearly 2-times more potent than Tenovin-6 with IC50 = 
4.9 µM while Am-Piv-OH gave IC50 = 13.3 µM.  Unfortunately, an IC50 for BA-SM-OH could 
not be determined.  In the 10 µM screen, two of the three replicates for BA-SM-OH gave similar 
values while the third replicate was drastically different and omitted.  It may be possible that the 
outlier value was the true value which would explain why an IC50 could not be determined.  
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Although BA-pOH-OH and Am-Piv-OH are among the most potent known SIRT2 inhibitors and 
the tropolones in general may be among the most potent known SIRT1 inhibitors, the 
concentrations required to obtain an IC50 is significantly greater than the concentrations required 
for HDAC2 or HDAC8 inhibition by tropolones.  This would suggest the tropolones may exhibit 
similar epigenetic activity profiles to sirtuin modulators due to selective HDAC inhibition, 
independent of sirtuin activity.  It is also possible that the tropolones have a different mechanism 
than HDAC/sirtuin modulation that effects expression of certain genes including Math1, Muc2 
and Fabp2. 
 
3.2.2 α-Tropolones Exhibit Antiproliferative Selectivity Towards T-cell ALL 
 Since the initial series of tropolones developed in the Wright lab exhibited a growth 
inhibitory preference towards the hematological cell lines Jurkat and HuT-78 over the colon and 
pancreatic cancer cell lines HCT-116 and BxPC-3 respectively as well as other cancer cell lines 
not reported (colon: HT-29; lung: A549; brain: U-87 MG; breast: MCF-7), it was desired to 
explore any hematological lineage dependent preferences.  A panel of leukemic cell lines with T-
cell lineage (Jurkat, HuT-78 and Molt-4), B-cell lineage (Daudi and the murine cell line Ba/F3) 
or myeloid lineage (K562 and HL-60) were screened with the first generation α-substituted 
tropolones as well as the alkyl chain series of α-tropolones used in the organoid epigenetic 
controlled differentiation screen by the Giardina lab. 
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Table 3.3: GI50 values (µM) of first generation and alkyl α-tropolones against a panel of 
hematological cancer cells from T, B or myeloid lineage. 
 
 From this panel of hematological cancer cells there appears to be a preference towards 
cells of T-cell lineage.  While the GI50 values determined for HuT-78 are similar to those for B-
cell and myeloid lineage, it should be noted that HuT-78 is a cutaneous T-cell lymphoma 
whereas Jurkat and Molt-4 are T-cell ALL cell lines.  This data suggests tropolones are more 
potent towards T-cell ALL than the other malignancies tested including Daudi, a B-cell ALL cell 
line.  Interestingly, between the two T-cell ALL cell lines, the tropolones generally exhibit sub-
micromolar GI50 values in Molt-4 and micromolar values in Jurkat.  Vorinostat, which has been 
FDA approved to treat cutaneous T-cell lymphoma, was included as a positive control.  
T-cell B-cell Myeloid
Compound
Functional
Group
Jurkat HuT-78 Molt-4 Daudi Ba/F3 K562 HL-60
MO-OH-PH 3.33 5.17 0.59 5.77 6.65 8.25 2.79
MO-OH-SM 0.62 2.48 0.58 1.87 5.32 7.47 2.38
MO-OH-DM 0.75 3.62 0.52 3.36 7.22 7.35 3.22
MO-OH-TM 1.86 4.18 0.81 4.20 6.18 7.80 3.00
MO-OH-Nap 1.15 2.09 0.35 1.63 2.34 2.50 1.97
MO-1-OH NA 1.72 0.24 1.43 3.16 2.74 2.16
MO-2-OH 1.16 5.70 0.81 1.62 1.90 2.92 2.44
MO-7-OH 0.99 4.10 0.62 1.43 1.87 3.32 2.52
MO-9-OH 2.20 2.84 1.33 2.20 2.36 2.82 2.45
MO-10-OH 0.85 3.08 0.34 0.89 2.17 2.38 0.93
Vorinostat 0.51 1.58 0.26 0.49 0.39 1.30 0.16
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Vorinostat exhibited similar potency in most of these cell lines but was weaker against both 
HuT-78 and K562.  While it is unclear why vorinostat is less potent in these two cell lines, it is 
clear that the tropolones display significantly more selectivity, especially towards Molt-4 cells. 
 To determine if the selectivity towards T-cell malignancies and Molt-4 cells in particular 
was directly related to the tropolone pharmacophore or was associated with the α-substitution, a 
second generation of tropolones was tested on the same panel of cells.  This second generation 
was developed to determine the effects of various para-substitutions on the phenyl ring.  These 
substitutions aimed to create a range of hydrophobic/hydrophilic characteristics or to add 
functional groups which could be readily converted or used to attach other functional groups. 
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Table 3.4:  GI50 values (µM) of second generation α-tropolones against a panel of hematological 
cancer cells from T, B or myeloid lineage. 
 
 As with the first generation, the second generation of tropolones generally shows a 
preference towards Molt-4 cells.  Interestingly, the overall potency of the second generation 
tropolones is stronger than the first generation.  While this makes the selectivity towards T-cell 
T-cell B-cell Myeloid
Compound
Functional
Group
Jurkat HuT-78 Molt-4 Daudi Ba/F3 K562 HL-60
BA-P7-OH 1.93 1.74 1.44 1.45 0.41 6.29 1.67
BA-P8-OH 6.25 2.95 2.20 5.28 1.56 9.60 5.58
BA-pBr-OH 0.71 1.76 0.38 0.92 0.72 2.71 1.14
BA-PH-OH 1.07 2.02 0.80 1.56 1.71 2.47 1.95
BA-SM-OH 0.99 1.78 0.71 1.5 1.05 2.21 0.95
BA-DM-OH 1.66 2.15 0.88 1.45 1.67 2.62 2.24
BA-TM-OH 0.98 2.13 0.77 1.4 1.17 2.53 5.33
BA-Nap-OH 0.77 1.33 0.45 1.23 0.65 2.36 0.79
Am-NO2-OH 1.10 0.75 0.82 0.84 1.01 2.93 1.61
Am-NH2-OH 3.07 1.95 2.68 2.59 1.80 7.54 >10
HC-1-OH 0.92 0.71 0.52 0.83 0.55 7.57 0.98
EF-1-OH 2.18 0.97 0.98 1.00 0.45 5.57 2.86
EF-2-OH 2.76 2.03 2.58 2.31 0.81 >10 3.12
EF-3-OH 1.94 0.87 0.79 1.70 1.62 7.63 2.52
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malignancies weaker, it offers the ability to develop tropolones capable of treating multiple 
hematological malignancies.  Because the two generations of tropolones mainly rely on 
substitutions on a phenyl ring and primarily consist of para-substitutions, many of the tropolones 
exhibit similar potency.  This could potentially be attributed to the common α-phenyl-tropolone 
motif.  However, as with the sirtuin data, extending the para-alkyl chain beyond two carbons 
reduces potency.  The two other functional groups which reduce potency are a ketone and an 
amine.  This is somewhat confusing since a ketone is an electron withdrawing group and an 
amine is an electron donating group.  Additionally, most of the phenyl substitutions with electron 
withdrawing groups appear to have slightly better potency, but the same is true for the electron 
donating ether substitutions.  Based on these observations, it is clear that more diversity in 
functional groups and non-phenyl based substitutions needed to be explored to better understand 
any potential structure activity relationship. 
 Since the tropolones all appear to exhibit a preference towards Molt-4 cells, all newly 
synthesized tropolones were screened with Molt-4 to determine relative potency and any 
structure activity relationship.  The next series of tropolones analyzed can be divided into two 
categories: phenyl-substitutions and non-phenyl based compounds/natural troponoids. 
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Table 3.5: GI50 values (µM) of substituted phenyl α-tropolones against Molt-4 cells. 
 
 Based on these results, the most obvious trend is that meta-substitutions on the phenyl 
ring decrease potency.  Upon more critical analysis, it also appears as though functional groups 
that are strongly electron withdrawing or electron donating can decrease potency.  Although the 
nitrophenyl tropolone (Am-NO2-OH) is an exception to this statement, it is likely the aromatic 
nitro moiety causes acute toxicity due to formation of a nitroanion radial known to increase 
oxidative stress.100  Further exploration of functional groups is required to validate this notion.  
Other structural activity observations that can be made are that tropolones with higher 
Compound
Functional
Group
Molt-4 Compound
Functional
Group
Molt-4
MO-DMe-OH 0.39 ± 0.05 Am-Ac-OH >10
MO-11-OH 0.24 ± 0.05 Am-Piv-OH 1.00 ± 0.10
MO-pSMe-OH 0.16 ± 0.03 Am-P5-OH 1.02 ± 0.08
MO-pF-OH 0.47 ± 0.06 SG-TMS-OH 0.52 ± 0.03
MO-pCN-OH 7.33 ± 0.30 SG-PH-OH 0.28 ± 0.03
MO-pOH-OH 4.39 ± 0.26 EF-4-OH 4.45 ± 0.29
HC-5-OH 4.40 ± 0.29 BA-P5-OH 0.35 ± 0.08
HC-7-OH >10 BA-HC2-OH 0.34 ± 0.04
HC-10-OH 0.38 ± 0.03 Vorinostat 0.26
189 
 
hydrophobicity and aromaticity typically display higher potency and that adding a degree of 
unsaturation to the para-alkyl chain off the phenyl ring appears to increase potency of shorter 
alkyl chains (n >7).  Interestingly, the most potent tropolone has a para-thioether on the phenyl 
ring.  MO-pSMe-OH is structurally similar to MO-10-OH but is 2-times more potent.  It may be 
possible that other sulfur atom substitutions may increase potency and should be explored.  
Additionally, it would appear as though tropolone is amenable to substitutions incorporating 
peptidomimetics based on the moderate potency displayed by two of the amides: Am-Piv-OH 
and Am-P5-OH. 
Table 3.6: GI50 values (µM) of non-phenyl based α-tropolones and natural troponoids against 
Molt-4 cells. 
 
Compound
Functional
Group/Structure
Molt-4
MO-3-OH 1.06 ± 0.12
HC-2-OH 4.44 ± 0.37
HC-6-OH 1.01 ± 0.12
HC-12-OH 0.51 ± 0.09
Tropolone 9.04 ± 0.67
HKT 1.98 ± 0.31
TDA 2.00 ± 0.33
Vorinostat 0.26
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 The series of non-phenyl based substituted tropolones is rather limited due to synthetic 
problems associated with some of these groups (as discussed in Chapter 2).  While the furan 
group should contribute to the therapeutic index of tropolone, it is possible that it increases the 
solubility too much, making this tropolone unable to bind to its target.  Even though the furan is 
known to be the most reactive of the 5-membered heterocyclic compounds, the N-methylpyrrole 
and thiophene containing tropolones are more potent.101  While furan is generally the most 
reactive, pyrrole is more prone to electrophilic substitution.  Rate of electrophilic substitution for 
the three 5-membered heterocycles is: pyrrole>>furan>thiophene.102  These substitutions 
typically occur on the 2-position, α to the heteroatom.  However, the N-methylation of pyrrole 
destroys its aromatic character and alters its electrophilic substitution preference to the 3-
position, β to the heteroatom.  Together, these traits may help explain the differences in potency 
between HC-2-OH, HC-6-OH and HC-12-OH, the furan, N-methylpyrrole and 2-methyl-
thiophene respectively.  Being the most reactive and prone to acid hydrolysis, the furan (HC-2-
OH) may be quickly metabolized, therefore providing the least potency.  The N-methylpyrrole 
may lose potency due to loss of aromatic character, but the electrophilic substitution potential at 
the 3-position may help maintain potency.  This would need to be validated by α-pyrrole 
tropolone.  The 2-methyl-thiophene maintains aromaticity which may enhance potency and 
already has a substitution at the 2-position which may increase stability.  Synthesis of α-
thiophene tropolone and 3-substituted-thiophene α-tropolones could validate this notion. 
 Another structure activity relationship observed from this series is adding a degree of 
unsaturation to an alkyl chain conjugated to the tropolone decreases potency.  This is observed 
for the difference in Molt-4 potency between MO-2-OH (GI50 = 0.81 µM) and MO-3-OH (GI50 = 
0.99 µM), a pentyl and 1-pentenyl chain respectively.  While neither of these tropolones are 
191 
 
among the ten most potent, this may serve as caution against synthesis of alkyl chain linker 
substitutions possessing an alkene conjugated to the tropolone. 
 When comparing the α-synthetic tropolones to the natural troponoids, it is clear the α-
synthetic tropolones offer increased potency towards Molt-4.  Tropolone itself exhibits a GI50 of 
9.04 µM, but its native potency is significantly enhanced by simplistic substitutions on the ring 
such as the isopropyl of hinokitiol.  This effect has been observed in all biological studies with 
tropolone and hinokitiol and is not surprising that it remains consistent here.  However, TDA 
was expected to be highly potent and potentially toxic due to the disulfide that may be reduced to 
two thiols, but appears to be less potent than hinokitiol.  As discussed in Chapter 1, thiols may 
form disulfide bonds with cysteine residues which can lead to off-target protein binding and 
toxic side effects.  While it is unclear why TDA is less potent than expected, it is clear that again 
minor substitutions on the tropolone motif can significantly increase potency towards Molt-4 
cells. 
 One modification which TDA contains compared to tropolone is a carboxylic acid instead 
of a hydroxyl group.  To determine if the hydroxyl group promotes potency or if it may be 
substituted with another metal coordinating group, a series of alternative metal chelating 
troponoids based on α-phenyl tropolone were synthesized and screened with Molt-4 cells.  These 
alternative metal chelating groups included: amine, acetylamide, thiol, thiomethylether, 
hydroxylamine and methylether.  None of these substitutions exhibited growth inhibitory activity 
in Molt-4 cells up to 10 µM.  This would suggest that the hydroxyl group is critical for activity.  
It may be possible to replace the hydroxyl group with a carboxylic acid as with TDA to maintain 
activity, but this type of troponoid still needs to be synthesized and tested. 
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 Since many of the key potent tropolones are also highly hydrophobic, attempts to 
increase solubility were made to determine if low water solubility limited potential activity.  
Previously in the Anderson lab it was determined that the sodium salt of hinokitiol decreased 
activity in Jurkat cells so this salt formulation was avoided.  As discussed in Chapter 2, Zn2+ 
complexes of hinokitiol exhibit greater biological activity and may increase solubility.  A zinc 
complex of α-phenyl tropolone was synthesized and screened with Molt-4 cells.  The GI50 of the 
complex was determined to be 0.28 µM which is 2.1 times more potent than the zinc-free form 
(MO-OH-PH).  Although this would suggest that zinc complexes of tropolones will increase 
activity, 2 moles of α-phenyl tropolone make up the zinc complex and would account for 
doubling the apparent potency.  Since the zinc complex did not increase biological activity, a salt 
formulation involving L-arginine was explored.  L-arginine has been used to form an arginate 
salt of ibuprofen and has proven to increase absorption and increase the rate of effect while not 
effecting adverse event profiles.103  Arginate salts of hinokitiol, MO-pF-OH and HC-1-OH were 
prepared and screened with Molt-4 cells.  Although these salt formulations contained excess L-
arginine, comparable concentrations of L-arginine did not exhibit any effects.   
Table 3.7: GI50 values (µM) of α-tropolones and their respective arginate salts against Molt-4 
cells. 
 
Compound Molt-4 Compound Molt-4
HKT 1.98 ± 0.31 HKT-Arginate 3.82 ± 0.63
MO-pF-OH 0.47 ± 0.06 MO-pF-Arginate 0.55 ± 0.03
HC-1-OH 0.52 HC-1-Arginate 0.50 ± 0.06
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While the arginate salts of hinokitiol and MO-pF-OH suffered a slight decrease in potency, the 
arginate salt of HC-1-OH exhibited the same potency as the salt-free form.  Despite the slight 
decreases in potency, L-arginine increases the water solubility of the tropolone nearly 3-fold.  
This increased solubility may be critical for in vivo screening of tropolones in animal models.  It 
should also be noted that the excess of arginine in each arginate salt solution was determined 
based on NMR integration and may not be highly accurate.  This lack of accuracy could explain 
the perceived decrease in activity.  More accurate measurements of excess arginine will 
determine if this salt formulation effects in vitro activity. 
 
3.2.3 Elucidating the Activity of α-Tropolones in Molt-4 Cells 
Since the tropolones exhibited the greatest potency in the Molt-4 cell line, mRNA 
samples of untreated Molt-4 cells and Molt-4 cells treated with 1 µM MO-OH-Nap or HC-1-OH 
for 24 hours were collected and sent to Boston Children’s Hospital Molecular Genetics Core 
Facility.  There the samples were analyzed using an Illumina HumanHT-12 v4 Expression 
Beadchip.  The cubic spline data from the microarray was analyzed using the Stanford Tools 
plug-in for Excel.  This plug-in analyzes the data and determines fold changes in gene expression 
as well as estimating the false discovery rate by giving a q-value.  Based on literature 
precedence, a fold threshold was imposed at 1.5-fold, meaning only genes up or down regulated 
above 1.5-fold would be returned by the Stanford Tools plug-in.   In general, MO-OH-Nap gave 
lower q-values than HC-1-OH, but many of the “hits” were similar between the two treatments.  
With 47,323 genes/gene variants analyzed, 2740 were upregulated 1.5-fold and greater in both 
treatments and 1751 were downregulated.   
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Figure 3.9: Depiction of changes in gene expression as determined by microarray analysis of 
Molt-4 cells treated with MO-OH-Nap and HC-1-OH (A).  Genes with greater than 10-
fold upregulation found for both treatments as determined by Stanford Tools analysis of 
microarray data (B).  Genes with greater than 4.5-fold downregulation found for both 
treatments as determined by Stanford Tools analysis of microarray data (C). 
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After the Stanford Tools analysis, the “hits” were compared between the two treatments 
and an average fold change and standard deviation between the two treatment fold change values 
as well as an average q-value was calculated.  Typically “hits” with similar fold changes and low 
standard deviations also showed lower average q-values.  Only “hits” with similar fold changes, 
low standard deviations and reasonable q-values were investigated further, resulting in 1800 
upregulated and 898 downregulated gene/gene variants.  From here, each gene was searched in 
the KEGG Pathway Database and the NCBI Gene Database.  Based on these results, 562 
upregulated and 48 downregulated gene/gene variants were found to be of interest.  These genes 
were associated with MMP, inflammation, interleukins, HDAC, MAPK, Wnt, major 
histocompatibility complex, Ras, PI3K, BCL proteins, JAK/STAT, histones, NFkB, Notch, 
Fanconi anemia, Rho, mTOR, NK-cells, p53, cell-cycle, apoptosis, immune response, 
hematopoiesis, and T-cell development and signaling. 
Meanwhile, a collaboration with the Weimer lab suggested HDAC most likely was not a 
target due to poor increases in hyperacetylation as determined by Western blot analysis.  
However, the mTOR pathway appeared to be involved as well as p53 activation of apoptosis.  
Using this new information combined with results from the microarray, key genes of interest 
were determined to be involved with apoptosis, caspase induction, p53, the FOXO pathway and 
the PI3K/AKT/mTOR pathway.  Gene set enrichment analysis confirmed this by revealing MO-
OH-Nap and HC-1-OH decrease pathways related to protein expression and increase pathways 
related to DNA damage repair, cell cycle progression, immune cell signaling and cell adhesion 
and structure. 
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Table 3.8: Gene set enrichment analysis of microarray data from untreated Molt-4 cells versus 
cells treated for 24 hours with 1 µM MO-OH-Nap or HC-1-OH.  (GO = gene ontology; 
KEGG = Kyoto Encyclopedia of Genes and Genomes). 
GO-decreased by tropolone KEGG-decreased by tropolone 
Protein expression Protein expression 
TRANSLATION PROTEASOME 
 
RIBOSOME 
GO-increased by tropolone Metabolism 
DNA/cell cycle PORPHYRIN AND CHLOROPHYLL METABOLISM 
DNA INTEGRITY CHECKPOINT FRUCTOSE AND MANNOSE METABOLISM 
G1 S TRANSITION OF MITOTIC CELL CYCLE Signaling 
DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION CYTOKINE/CYTOKINE RECEPTOR INTERACTION 
MITOTIC CELL CYCLE CHECKPOINT 
 Immune function KEGG-increased by tropolone 
MYELOID CELL DIFFERENTIATION DNA/cell cycle 
T CELL ACTIVATION P53 SIGNALING PATHWAY 
REGULATION OF LYMPHOCYTE ACTIVATION Immune function 
Metabolism LEUKOCYTE TRANSENDOTHELIAL MIGRATION 
PEPTIDYL AMINO ACID MODIFICATION T CELL RECEPTOR SIGNALING PATHWAY 
GLYCOPROTEIN BIOSYNTHETIC PROCESS Structural 
CARBOHYDRATE BIOSYNTHETIC PROCESS ADHERENS JUNCTION 
Signaling GAP JUNCTION 
TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE  REGULATION OF ACTIN CYTOSKELETON 
   KINASE SIGNALING PATHWAY FOCAL ADHESION 
 
 Leading edge analysis of these pathways determined by gene set enrichment analysis 
confirmed that key genes of interest include: DNA damage response and cell cycle regulators 
(TP53, RB1, CDK6, BCL2 and CCNE2), phospholipid signaling (PIK3R3, PIK3R1, PIK3CB, 
PIK3CG, PTEN, PLCG1 and PDPK1), small GTPase signaling (NRAS, RHOA, Rock1, VAV3, 
RAC1, KRAS, GNAI3 and PAK2) and transcription factors (LEF1, E2F2 and CHUK).  
Interestingly, many of these genes are targets proposed for the development of better therapeutic 
options for T-cell ALL and are directly related to the microarray analysis and GO analysis genes 
of interest.  Within the DNA damage response and cell cycle regulators, TP53 may be the most 
relevant since TP53 codes the p53 protein which may be activated by ATM, regulates G1/S 
transition and signals cell cycle arrest and promotes apoptosis.  CDK6 is inhibited by the 
CDKN2 family of proteins and serves as a G1/S checkpoint while the BCL family is critical for 
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T-cell development, proliferation, differentiation and survival.  Phospholipid signaling involves 
the PI3K/AKT/mTOR pathway and regulates the FOXO family and RhoA which is involved in 
GTPase signaling. 
 Next, the microarray data was searched for genes of interest determined by leading edge 
analysis of pathways suggested by gene set enrichment analysis as well as promising therapeutic 
gene/gene product targets previously discussed. 
Table 3.9: Microarray results found for genes of interest. 
 
Although not every gene listed by leading edge analysis was determined to be a “hit”, the 
microarray data clearly indicates that DNA damage response and apoptosis may be the primary 
target of tropolones while the PI3K/AKT/mTOR pathway may be involved in the apoptotic 
activity of tropolones.  Furthermore, comparing the 151 probable cancer promoting mutated 
Gene
Average Fold
Change
Standard Deviation
Upregulated
AKT3 1.89 0.381
ATM 2.27 0.450
CDKN2B 7.18 0.929
EIF4E 4.83 0.001
FOXO3 2.48 0.514
FOXO6 2.51 0.098
HDAC7 2.93 0.980
IL7R 2.11 0.163
LYL1 1.85 0.183
MYCN 2.02 0.159
PIK3R1 1.87 0.138
Downregulated
BCL11B 4.78 0.807
BCL2 2.43 0.687
CREBBP 2.36 0.559
SIRT2 1.76 0.068
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genes in Molt-4 cells as listed in the NCI60 database to the microarray “hits” discovered 53 of 
these 151 genes were affected (see Appendix).  Again, these genes primarily belong to DNA 
damage response, apoptosis and the PI3K/AKT/mTOR pathway.  Additionally, several of these 
“hits” suggest tropolones may cause G1 arrest in Molt-4 cells.  Future studies should aim to 
elucidate cell cycle effects of tropolones on Molt-4 cells as well as validate the ability of 
tropolones to exert apoptotic activity through DNA damage response and the PI3K/AKT/mTOR 
pathway. 
 Since these results were found using Molt-4 cells, more information about the cell line 
may help with determining the validity of these “hits”.  Molt-4 cells are human T-lymphoblasts 
from a 19 year-old male patient with acute lymphoblastic leukemia.  This cell line is considered 
to be a suitable model for studying molecular mechanisms of apoptosis in T-lymphocytes. They 
express CD1, CD4, CD5 and CD7 and are therefore belong to the mature T-cell ALL subtype.104  
A key characteristic of this cell line is that Molt-4 cells overexpress nonfunctional, truncated 
p53.105  However, as with most mutations in T-cell ALL, the p53 mutation is heterozygous 
meaning Molt-4 cells can still express wild-type p53.  Additionally, the truncated p53 has been 
found to be capable of inducing apoptosis but with significantly lower efficiency.106  As a result, 
DNA damage can trigger signals that stabilize the wild-type p53 to induce G1 arrest and 
apoptosis.107  While the wild-type p53 can be stabilized and expressed, mutated p53 is 
upregulated in response to DNA damage and causes Molt-4 cells to only have partially 
functional DNA damage checkpoints.105  However, incubation exceeding 24 hours with DNA 
damaging agents leads to atypical apoptosis.  Atypical apoptosis displays features of both 
apoptosis and necrosis.107  The Wiemer lab has determined that the tropolone MO-OH-Nap is 
capable of increasing p53 expression and leads to an accumulation of nuclear p53.  Based on this 
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information, it would appear as though the tropolones may be DNA damaging agents capable of 
activating and stabilizing p53 in Molt-4 cells.  Apoptosis analysis after 24 hours of incubation 
was conducted by the Wiemer lab using Annexin V and propidium iodide.  This determined that 
tropolones display dose-dependent increases in early apoptotic and late apoptotic/necrotic cells, 
suggesting the tropolones cause atypical apoptosis.  Cell cycle analysis will need to be conducted 
to determine if incubation with tropolones also causes G1 arrest. 
 
3.2.4 Effects of α-Tropolones on Non-Tumorigenic Cell Lines 
 A previous report from the Anderson and Wright labs noted the first generation of α-
tropolones and the natural tropolone, hinokitiol, did not exhibit toxicity towards human dermal 
fibroblasts (hDF) up to 90 µM.  The Priestley lab determined these same α-tropolones and 
hinokitiol did not exhibit toxicity towards MCF-10A, an epithelial cell line derived from a 
mammary gland, up to 100 µM. 
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Table 3.10: GI50 values (µM) of first generation α-tropolones and hinokitiol against non-
tumorigenic cell lines. 
 
Because the tropolones generally exhibit cytotoxic activity at concentrations less than 10 µM, the 
second generation of tropolones were screened against hDF for 72 hours with a maximal 
concentration of 10 µM.  Again most of the tropolones did not exhibit any cytotoxicity towards 
hDF cells. 
 
 
 
 
 
Compound
Functional
Group
hDF MCF-10A
MO-OH-PH 96.46 >100
MO-OH-SM >100 >100
MO-OH-DM >100 >100
MO-OH-TM >100 >100
MO-OH-Nap 93.07 100
HKT >100 >500
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Table 3.11: GI50 values (µM) of second generation α-tropolones against hDF cells. 
 
Surprisingly, one of the more potent inhibitors of Molt-4, MO-1-OH, appears to be somewhat 
cytotoxic towards hDF with a GI50 of 8.81 µM.  While this is an approximately 37-fold 
difference in cytotoxicity, it creates some concern about the potential toxicity of this compound.  
However, it should be noted that MO-1-OH did not exhibit any cyotoxicity activity in MCF-10A 
nor the hepatocellular carcinoma cell line, HepG2, up to 100 µM and 500 µM respectively.  This 
may be due to the relative age of the DMSO stock solution since the hematological cells, MCF-
10A and HepG2 data was obtained early, but the hDF data was obtained after nearly two years of 
Compound
Functional
Group
hDF Compound Functional Group hDF
MO-1-OH 8.81 ± 2.53 BA-PH-OH >10
MO-2-OH >10 BA-SM-OH >10
MO-7-OH >10 BA-TM-OH >10
MO-9-OH >10 BA-Nap-OH >10
MO-10-OH >10 BA-P7-OH >10
EF-1-OH >10 BA-P8-OH >10
EF-2-OH >10 Am-NO2-OH >10
EF-3-OH >10 Am-NH2-OH >10
BA-pBr-OH >10 HC-1-OH >10
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use and may not be reliable due to potential degradation.  The stability of the tropolones in 
DMSO for long periods of time should be analyzed to determine if the cytotoxicity displayed 
towards hDF is due to degraded material. 
 Although the tropolones generally do not exhibit cytotoxic activity towards non-
tumorigenic cell lines and only displays limited cytotoxicity towards non-hematological cells, 
this is not enough to suggest that tropolones are selective towards malignant hematological cells.  
In order to suggest this selectivity, the tropolones must be screened against non-malignant 
hematological cells.  A suitable model to determine if tropolones are generally cytotoxic towards 
hematological cells or provide selectivity towards malignant hematological cells is healthy 
human peripheral blood monocytes (hPBMCs).  hPBMCs are any blood cell with a round 
nucleus (lymphocytes, monocytes, macrophages and dentritic cells) and are essential for immune 
responses such as cell-mediated cytotoxicity and inflammation.108-109  First, a potent tropolone 
from the first generation of synthetic α-tropolones and a more hydrophilic but still potent 
tropolone from the second generation were assayed with hPBMCs.  These two tropolone were 
selected for both their potency against Molt-4 and for their differences in solubility.  The 
differences in solubility may elucidate if solubility has a role in the activity of tropolones and if 
highly potent, selective and soluble analogs can be synthesized. 
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Table 3.12: GI50 values (µM) of two α-tropolones and a control (vorinostat) against hPBMCs 
and selectivity towards Molt-4 cells. 
 
The two α-tropolones tested show some cytotoxicity towards hPBMCs but this cytotoxicity is 
significantly less than that of vorinostat and their cytotoxicity towards Molt-4.  Interestingly, the 
more potent tropolone, MO-OH-Nap, is also more cytotoxic towards hPBMCs but displays 
slightly better selectivity than HC-1-OH.  This suggests that more soluble and more potent α-
tropolones may still be selective towards T-cell hematologic malignancies with minimal 
cytotoxicity towards healthy lymphocytes.  In terms of solubility, there does not appear to be a 
substantial difference in selectivity between relatively hydrophobic and hydrophilic α-
tropolones.   
 Because the hPBMC data for MO-OH-Nap and HC-1-OH was determined before the 
Molt-4 data for the compounds listed in Tables 3.5 and 3.6 was obtained, it is necessary to screen 
some of the most potent and more structurally diverse α-tropolones with hPBMCs.  Hinokitiol 
was also included in this screen to determine if the synthetic α-tropolones possessed better 
selectivity and potency towards Molt-4 cells. 
 
 
 
 
GI50 [µM] Selectivity
hPBMC Molt-4
MO-OH-Nap 4.89 0.35 14.0
HC-1-OH 6.13 0.52 11.8
Vorinostat 0.86 0.33 2.6
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Table 3.13: GI50 values (µM) of potent α-tropolones and hinokitiol against hPBMCs and 
selectivity towards Molt-4 cells. 
 
 Surprisingly, some of the most potent tropolones are highly selective towards Molt-4 
cells compared to hPBMCs and the natural tropolone, hinokitiol, is less selective than any of the 
synthetic α-tropolones.  This data also suggests that more hydrophobic tropolones may provide 
more selectivity towards malignant cells.  Additionally, the larger the substitution on tropolone 
appears to increase selectivity.  However, this does not explain why BA-pBr-OH, a 4-bromo-
phenyl, is more selective than MO-OH-Nap and HC-1-OH.  It is possible that MO-OH-Nap, 
while hydrophobic, is less selective due to its planar structure which may serve as a DNA 
intercalating agent.  While HC-1-OH should not be planar, it is somewhat similar to MO-OH-
Nap and displays DNA damaging characteristics.  Therefore, these newer α-tropolones should be 
screened to determine if they are also potential DNA damaging agents capable of triggering p53 
expression and apoptosis in order to rule out a different mechanism of action.  It should also be 
noted that the hPBMC GI50 values listed in Table 3.13 despite being in replicates are only from 
one biological screen and should be screened another two times in order to validate these 
numbers. 
GI50 [µM] Selectivity
hPBMC Molt-4
MO-pSMe-OH 4.84 0.16 30.25
MO-11-OH 5.64 0.24 23.50
SG-PH-OH 8.99 0.28 32.11
BA-HC2-OH 7.23 0.34 21.26
BA-P5-OH 6.93 0.37 18.73
BA-pBr-OH 5.65 0.38 14.87
HC-10-OH 13.10 0.38 34.47
HC-12-OH 6.23 0.51 12.22
SG-TMS-OH 8.50 0.52 16.35
HKT 11.09 1.88 5.90
205 
 
 
3.3 Conclusions 
 
 Tropolones are antiproliferative agents effective against hematological malignancies with 
selectivity towards T-cells.  As T-cell selective antiproliferative agents, tropolones are most 
effective against T-cell ALL.  Additionally, key potent tropolones are more selective towards 
malignant T-cells than hPBMCs which partially consist of healthy T-cells.  Although a variety of 
tropolones have been synthesized it is somewhat difficult to determine a structure activity 
relationship.  The more effective analogs typically are aromatic and mainly hydrophobic.  
Substitutions on the α-phenyl tropolone have determined that meta substitutions appear to 
decrease potency and strongly electron withdrawing and donating groups on the phenyl ring may 
decrease potency.  Additionally, incorporating sulfur atoms in the α-substitution may increase 
potency.  However, more structurally diverse analogs, as well as ortho-substituted phenyl rings 
and furan, pyrrole and thiophene analogs should be synthesized to better understand structure 
activity trends.  One trend that is apparent is that salt formulations may affect activity.  
Previously, it was determined that a sodium salt drastically decreased activity.  Here a zinc salt 
did not affect activity while arginate salts may have a slight effect on potency, but both increase 
solubility.  Another trend displayed by the tropolones is that larger, relatively hydrophobic 
substitutions appear to increase selectivity towards malignant T-cells (Molt-4) compared to 
healthy hPBMCs.  As seen from the study utilizing alternative chelating functional groups, the 
hydroxyl group appears to be essential to tropolone activity.  However, as seen with TDA, the 
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substitution of hydroxyl with a carboxylic acid may yield similar results.  Future attempts should 
be made to make a carboxylic acid substituted tropolone analog. 
 Based on reports by Anderson lab and the Giardina lab, tropolones appear to act as 
histone deacetylase modulators.  Although the Giardina lab determined tropolones do not exhibit 
gene expression profiles consistent with known HDAC inhibitors, they could not definitively 
determine if tropolones were sirtuin modulators.  Assays with Sirt1 and Sirt2 determined 
tropolones are capable of modulating sirtuin activity, mostly through inhibition.  However, the 
inhibitory activity of the tropolones is significantly less than the inhibitory activity previously 
reported against HDAC2 and HDAC8.  While this would suggest the tropolones display different 
gene expression profiles due to selective inhibition of HDACs, Western blot analysis of histone 
acetylation levels conducted in the Wiemer lab as well as microarray analysis suggests 
tropolones have a different mechanism of action.  From the microarray analysis it appears as 
though tropolones activate the apoptotic pathway most likely through DNA damage response and 
the PI3K/AKT/mTOR pathway.  Future studies will need to validate the action of tropolones on 
these pathways and should aim towards understanding this mechanism of action in order to 
develop more potent tropolones. 
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Chapter 4 
 
Development of Synthetic α-Tropolonoids as Antibiotics Effective Against Gram-negative 
Bacteria 
 
4.1 Background and Significance 
 
4.1.1 Characteristics of Gram-negative Bacteria 
 One of the most common techniques used to detect and classify bacteria is the Gram stain 
developed by Hans Christian Gram in 1884.1  This technique involves the staining of bacterial 
cultures with crystal violet dye followed by washing with alcohol.  Bacteria that retain the dye 
are considered Gram-positive while the unstained bacteria are considered Gram-negative.  Gram-
negative bacteria can subsequently be stained using safranin to develop a red or pink color.  
Although most forms of bacteria fit into these two categories, it should be noted that some 
bacteria can give false staining, such as Clostridia which stain as Gram-negative despite having 
characteristics of Gram-positive bacteria, or do not stain using this method, such as Mycoplasma 
spp. and spirochetes.2 
 Gram-negative bacteria do not retain the crystal violet dye after being washed with 
alcohol because the peptidoglycan layer for this type of bacteria is relatively thin compared to 
Gram-positive bacteria.3  While this relatively thin peptidoglycan layer is a clear characteristic of 
Gram-negative bacteria, the key differentiating feature of Gram-negative bacteria is the presence 
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of an outer membrane in addition to the typical cytoplasmic membrane.  The outer membrane is 
mostly comprised of lipopolysaccharide and phospholipids and is known to serve complex 
functions that control the response of the cell to the environment.4  One such function is to 
remove and stop transcription and translation of passive diffusion aqueous channels (porins) 
when exposed to certain antibiotics.5-6  Removal of porins is one of several methods Gram-
negative bacteria employ to develop resistance to antibiotics.  Other methods include: production 
of enzymes capable of degrading the antibiotic, mutations in the antibiotic binding site and up-
regulation of efflux pumps capable of removing antibiotics from the cell.6 As a result of these 
innate mechanisms of resistance, Gram-negative infections are becoming increasingly 
problematic.  In particular, the family Enterobacteriaceae is a leading cause of nosocomial 
infections, Pseudomonas aeruginosa is one of the most resistant forms of Gram-negative 
bacteria, and Acinetobacter can be found in virtually 100% of soil and water. 7 
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Figure 4.1: Diagram of Gram-negative bacteria cell wall. 
 
4.1.1.1 Enterobacteriaceae 
Enterobacteriaceae is a large family of rod shaped, facultatively anaerobic, Gram-
negative bacteria.8  This family can be subdivided into eight tribes: Escherichieae, 
Edwardsielleae, Salmonelleae, Citrobactereae, Klebsielleae, Proteeae, Yersineae, and Erwineae.  
Among these tribes are some of the most medically important species of bacteria as many are 
normally found in the gastrointestinal tract and can become pathogenic.  Members of this family 
account for nearly 80% of Gram-negative bacteria clinical isolates.  Approximately 75% of all 
urinary tract infections, two thirds of gastroenteritis cases and one third of all sepsis cases are 
caused by Enterobacteriaceae.7  Infections by Enterobacteriaceae are attributed to their fast 
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motility, fimbriae which bind tightly to host tissue, endotoxins and enterotoxins.8  Two of the 
most common species that cause nosocomial infections are Escherichia coli and Klebsiella 
pneumoniae. 
Escherichia coli (E. coli) is one of the most studied organisms and can be found 
worldwide.9-10  As a Gram-negative facultative anaerobe, it ferments lactose and possesses an 
outer membrane.  The outer membrane of E. coli contains several membrane proteins in addition 
to the typical lipopolysaccharide and phospholipids.  The membrane proteins are mainly the 
porins OmpC, OmpF and PhoE.  Because the porins are small in size, other transport proteins are 
necessary to provide essential nutrients including oligosaccharides, iron and vitamin B12.  While 
the outer membrane is an important protective barrier, the cytoplasmic membrane of E. coli 
contains over 20 proteins essential for growth and division.10  Approximately half of these 
cytoplasmic membrane proteins are able to bind beta lactams, making this membrane a primary 
target of antibiotics.  However, as with most microorganisms, the majority of biochemical 
processes necessary for growth take place in the cytoplasm.    
Although most strains of E. coli are considered non-pathogenic, it accounts for most 
common bacterial infections that result in urinary tract infections, bacteremia, and diarrhea as 
well as newborn cases of meningitis and clinical cases of pneumonia.7  While most infections are 
easily treated with co-trimoxazole (a dual folate synthesis inhibitor), nitrofurantoin (a bacterial 
DNA damaging agent), fluoroquinolones (bacterial topoisomerase II inhibitors) or in critical 
situations, cephalosporins (inhibitors of peptidoglycan synthesis), the number of antibiotic 
resistant strains has drastically risen since the beginning of the 21st century.11  In 2005, a study 
by the Bacteraemia Resistance Surveillance Programme determined that 16.6% of bacteraemia 
cases caused by E. coli were resistant to the fluoroquinolone ciprofloxacin.12  Additionally, there 
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has been a growing concern of β-lactam resistance since the 1980s due to mutational 
development of extended spectrum β-lactamases (ESBLs).  ESBL producing E. coli isolates 
found in the United Kingdom increased from 0% to 7.3% between 2001 and 2005 with as many 
as 50.9% harboring the ESBL CTX-M which confers resistance to cephalosporin.12  Another 
form of resistance common to Gram-negative bacteria is the use of efflux pumps to remove 
antibiotics that manage to pass through the cell wall.  E. coli utilize the AcrAB-TolC pump 
which is a member of the RND efflux pump family.  The RND pumps are multidrug efflux 
pumps that can export an array of structurally diverse molecules.5  Although increasingly 
resistant strains of E. coli are concerning, Klebsiella pneumoniae, a more frequently acquired 
hospital infection, has become poly-resistant and the discovery of resistant isolates has increased 
at faster rates. 
Klebsiella pneumoniae (K. pneumoniae) is a rod shaped, facultative anaerobe, capable of 
fermenting lactose, but unlike most Enterobacteriaceae is non-motile.7  It is the second most 
common cause of Gram-negative bloodstream infections and is associated with lobar pneumonia 
and urinary tract infections.  K. pneumoniae can be found worldwide as it is part of the normal 
flora of the mouth, skin and intestines.13   As part of the normal flora, K. pneumoniae is an 
opportunistic pathogen that can lead to high incidences of infection especially in patients 
undergoing chemotherapy.14  Other patients at risk of infection include: alcoholics, diabetics, and 
patients with chronic obstructive pulmonary disease.7  For these patients, mortality is high and 
treatments must be aggressive.  Typical treatments involve the use of multiple antibiotics with a 
preference for cephalosporin and aminoglycosides.  However, much like E. coli, K. pneumoniae 
has developed ESBLs.  The Bacteraemia Resistance Surveillance Programme determined that the 
incidence of ESBL containing isolates of K. pneumonia increased from 5.6% to 13.1% between 
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2001 and 2005.  Additionally, 81.5% of these isolates were resistant to cephalosporin.  Unlike E. 
coli, K. pneumoniae is often resistant to trimethoprim (a folate synthesis inhibitor) and 
fluoroquinolones.  Other forms of antibiotic resistance have also increased over the past 20 years, 
such as carbapenemases (KPC) and β-lactamases.  KPC isolates can now be found in most of the 
United States, France, Sweden, Norway, Scotland, Poland and regions throughout China and 
Latin America.6  The genetic material coding carbapenemases can also be transferred by K. 
pneumoniae to other Enterobacteriaceae.15  Another resistance mechanism K. pneumoniae has 
developed is the ability to reduce the number of porins in its outer membrane.16   
4.1.1.2 Pseudomonas aeruginosa 
Belonging to the family Pseudomonadaceae, Pseudomonas aeruginosa (P. aeruginosa) is 
a Gram-negative, rod shaped, aerobe.7  As an aerobe, it oxidizes aldose sugars, but not maltose.  
P. aeruginosa is found in soil, water, plants and animals and can tolerate a wide variety of 
physical conditions.  It can tolerate these various conditions because it can grow at both 37°C 
and 42°C, has flagella for motility and can use over 30 organic compounds for growth.  Moisture 
appears to be a critical factor for colonization as P. aeruginosa is typically found in the 
perineum, under arm and ear of humans and has been found on respiratory equipment, cleaning 
solutions, liquid based medicines, sinks, mops, food sources and processors as well as other 
sources of moisture in hospitals. 
Since P. aeruginosa is relatively ubiquitous in the hospital environment, it is not 
surprising that it is the fourth most frequently isolated pathogen and accounts for 10.1% of all 
nosocomial infections.7  While not always part of the normal human flora, P. aeruginosa  is an 
opportunistic pathogen capable of colonizing virtually any tissue, especially the skin of burn 
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victims, the lower respiratory tract of patients using ventilation, the lungs of cystic fibrosis 
patients, and the gastrointestinal tract of patients receiving chemotherapy.17   
P. aeruginosa infections are caused by the secretion of a wide variety of molecules and 
toxins.  A key virulence factor is the secretion of lipopolysaccharide that creates a protective 
barrier called a biofilm.  Biofilm formation creates a more favorable environment for bacteria 
because it traps nutrients and protects the cells from predation or other detriments.18-21  Cells 
embedded in the biofilm matrix closely resemble planktonic cells in the stationary growth phase.  
As such, biofilms are also characterized by a dramatic decrease in cell growth.22-24  This 
appearance of stationary growth behavior in biofilms helps further protect the cells from adverse 
environmental factors such as antibiotics.  In fact, biofilms can afford bacterial cells with 
anywhere from 100-1000 fold resistance to antibiotic treatments.25-27  Essentially, there is no 
major treatment of bacteria once they form biofilms.28-32  It is suspected that biofilms cause 
nearly 80% of all infections.26,33  Biofilm formation may also trigger virulence factors which can 
cause infectious diseases.34   
Other virulence factors produced by P. aeruginosa include three proteases: elastase, 
LasA and an alkaline protease.  Elastase is a zinc metalloenzyme that causes proteolysis of host 
proteins and has been linked to biofilm formation.35  LasA is known to cleave elastin, hydrolyze 
β-casein and lyse Staphylococci.7  The alkaline protease is not well studied, but some studies 
indicate it may cleave molecules of the immune system associated with signaling, inflammation 
and regulation.36  Two other important virulence factors include PrpL and exotoxin A.  PrpL is 
regulated by pyoverdine production and proteolyzes casein, lactoferrin, transferrin, elastase and 
decorin.37  The degradation of lactoferrin and transferrin increases the ability of siderophores 
such as pyoverdine to sequester iron and transport it into P. aeruginosa to be used for 
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metabolism.  Exotoxin A is the most toxic virulence factor and the most studied.38  Exerting an 
LD50 of 60-80 ng in a mouse,
39 exotoxin A causes the ADP-ribosylation of elongation factor 2 to 
inhibit host cell protein synthesis.40 
Treatment of P. aeruginosa infections is relatively controversial as antibiotics are often 
administered before diagnosis.7  Because P. aeruginosa is intrinsically resistant to many 
antibiotics due to low hydrophilic molecule permeability and has the ability to acquire genes 
from other bacteria encoding resistance, many antibiotics are ineffective.  P. aeruginosa 
produces β-lactamases, can make structural modifications to its outer membrane to increase 
resistance to imipenem and colistin, and has the RND type multi-drug efflux pump MexAB-
OprM that can export out quinolones, penicillines and cephalosporins and MexXY-OprM that 
exports out aminoglycosides.17  These multiple forms of intrinsic resistance necessitates the use 
of combinatorial treatment typically with an aminoglycoside with either penicillin or a third 
generation cephalosporin such as ceftazidime or cefoperzone.7  However, P. aeruginosa 
resistance to antibiotics continues to increase and it may only be a matter of time before a strain 
resistant to all conventional antibiotics is discovered. 
4.1.1.3 Acinetobacter 
The genus Acinetobacter was first identified in the 1900s and are colorless, non-motile, 
Gram-negative bacteria that grows on decaying organic matter.7  Interestingly, it is rod shaped 
during the exponential growth phase but spherical in the stationary phase.  In the stationary 
phase, Acinetobacter can retain crystal violet dye and are often confused for Gram-positive 
cocci.  Similar to Enterobacteriacea, Acinetobacter is capable of using a variety of organic 
sources for growth and is found in virtually all sources of soil and water.  Although optimal 
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growth is at 44°C, it has been found in pasteurized milk, frozen foods, hospital air, faucets, 
bedpans, washcloths, catheters, ventilators, reused needles and plasma protein fractions.7  While 
only present in approximately 25% of health populations, Acinetobacter is the most common 
Gram-negative organism found on the skin of hospital personnel.7 
The most commonly encountered nosocomial Acinetobacter species is A. baumannii.  
Similar to Enterobacteriacea and P. aeruginosa, A. baumannii is an opportunistic pathogen and 
causes a variety of diseases, including: pneumonia, septicemia, meningitis, urinary tract 
infections, endocarditis, and soft tissue infections in immunocompromised patients.41  A. 
baumannii also exhibits an assortment of intrinsic resistance mechanisms such as low 
permeability, reduction in the number of porins, employment of several RND efflux pumps, 
aminoglycoside modifying enzymes and β-lactamases.6-7  Multi-antibiotic resistance has been 
increasing at a drastic rate with resistance to three or more antibiotic classes found in 34.2% of 
all isolates found in the Asia-Pacific region.6  While the standard treatment used to include 
ampicillin, second generation cephalosporins, colistin, minocycline, carbenicllin and gentamicin, 
A. baumannii has now been found to be resistant to most of these antibiotics as well as 
cefotaxime, chloramphenicol, tobramycin and amikacin.7  Imipenem was seen as one of the few 
treatment options, but outbreaks of imipenem resistance have been documented.  Now the 
current choice of antibiotics is limited to carbapenems, polymixins and sulbactams.41 
4.1.2 Increased Risk of Infection in Cancer Patients 
 Many cancers and cancer treatments often leave patients immunocompromised and more 
susceptible to infections.  Patients with hematological malignancies are at the highest risk of 
potentially deadly infections because they are already considered immunocompromised and most 
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treatments alter the immune response.  In fact, while the survival rates of leukemia and 
lymphoma have improved to nearly 90%, infections account for the highest mortality rates.42  
This improvement in patient outcomes is mainly due to intense chemotherapy and newer 
treatment options such as stem cell transplantation, autologous stem cell reinfusion, granulocyte 
colony stimulating factors and broad spectrum antibiotics.43  Despite these improvements, the 
initial 2-3 weeks of acute leukemia is often a period of significant granulocytopenia, a drastic 
reduction of the innate immune system.7  During this time, approximately 50% of acute leukemia 
patients will develop a fever.2  Typically these patients are given broad spectrum antibiotics to 
combat any potential bacterial or fungal threat, as anywhere from 500-1000 different bacteria 
may inhabit the human body, mainly in the gastrointestinal tract.44  Infections during this time 
are typically caused by Gram-negative bacteria, with E. coli, K. pneumoniae, and P. aeruginosa 
being the most common and most lethal. 
While Gram-positive bacterial infections have become more frequent in the past several 
decades, Gram-negative bacteria are of particular concern due to inherent antibiotic resistance.  
The lipopolysaccharide component of the outer membrane is one of the primary resistance 
mechanisms of Gram-negative bacteria as it decreases the overall permeability of the cell.5  
Despite this extra layer of defense, antibiotics have been designed to overcome this permeability 
issue through utilization of porins within the outer membrane to pass into the peptidoglycan 
layer.  Antibiotics have been developed since the 1940s and have drastically reduced the severity 
of bacterial infections.45  However, this reliance on antibiotics has led to the rise of antibiotic 
resistant bacteria. Current antibiotics are designed to act on one of four main targets: cell wall 
synthesis, protein synthesis, DNA replication, or the integrity of the cell membrane.5  Antibiotics 
within the same class usually are based on the same pharmacophore and therefore are closely 
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related and commonly victim to the same mechanism of resistance.  This highlights the need to 
develop novel antibacterial agents that utilize structurally distinct pharmacophores, target 
unexploited essential components to bacterial growth, and/or act on several pathways to avoid 
resistance. 
4.1.3 Antibiotic Targets 
 Current Gram-negative antibiotics target well-studied processes and usually belong to 
one of 11 basic classes.  Aminoglycosides are active against most Gram-negative aerobic and 
facultative anaerobic bacteria.  They act by inhibiting protein synthesis by binding to the 30S 
ribosome.46  The β-lactam class of antibiotics includes penicillin derivatives, cephalosporins, 
monobactams and carbapenems.  All members of this class bind to penicillin binding proteins to 
inhibit cell wall synthesis.47  Glycopeptide antibiotics inhibit peptidoglycan synthesis by binding 
amino acids within the cell wall to prevent addition of new units of peptidoglycan.48  
Lincosamides bind 23S of the 50S subunit of the bacterial ribosome to dissociate peptidyl-tRNA 
from the ribosome.49  Similar to lincosamides, macrolide antibiotics cause dissociation of 
peptidyl-tRNA from the ribosome but bind the P site of the 50S subunit of the ribosome.49  
Nitrofurans are oxygen acceptors that inhibit cellular respiration and the biosynthesis of nucleic 
acids.50  Polymyxins bind lipopolysaccharide to disturb both the outer and inner membrane 
similar to a detergent.51  Ansamycins inhibit transcription through inhibition of bacterial RNA 
polymerase.52  Quinolones are topoisomerase II and IV inhibitors that cause DNA 
fragmentation.53  Sulfonamides are a class of competitive inhibitors of dihydrofolate reductase 
which prevents the synthesis of folate necessary to produce nucleic acids.54  The last major class 
of antibiotics effective against Gram-negative bacteria is tetracyclines.  Tetracyclines are similar 
to aminoglycosides as they also bind the 30S ribosomal subunit to prevent the binding of 
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aminoacyl-tRNA to inhibit protein synthesis.55  Despite this array of antibiotics, Gram-negative 
bacterial resistance has been increasing which stresses the need to develop new antibiotics, 
especially ones with different biological targets. 
Table 4.1: Resistance profiles (% susceptible) of Gram-negative bacteria against two classes of 
antibiotics. 
  Penicillins Cephalosporins 
  Ampicillin Amp/Sulbactam Piperacillin/tazobactam Cefazolin Cefepime Ceftazidime Ceftriaxone 
VCU 2014a 
      
  
E. coli 40 --- 96 86 95 --- 94 
Klebsiella 0 --- 91 92 95 --- 94 
P. aeruginosa   --- 90   90 ---   
Acinetobacter   ---     67 ---   
UCLA 2014 non-urine (RRUMC)b 
    
  
E. coli 39 45 91 72 82 81 82 
Klebsiella R 70 89 83 89 88 89 
P. aeruginosa R R 80 R 83 84 R 
Acinetobacter R 50 44 R 42 41   
UCLA 2014 non-urine (SMH-UCLA) inpatientb 
   
  
E. coli 43 50 94 78 87 87 87 
Klebsiella R 52 71 61 64 64 64 
P. aeruginosa R R 62 R 67 67 R 
MYSTIC 2008c 
     
  
E. coli --- --- 93.6 --- 94.5 92.6 89.3 
Klebsiella --- --- 85.6 --- 93 86.3 87.3 
P. aeruginosa --- --- 90.2 --- 86.6 85.6 8.9 
Acinetobacter --- --- 34.6 --- 31.5 31.5 11.8 
*R denotes intrinsic resistance 
aData from Virginia Commonwealth University (VCU) Department of Pathology – Microbiology/Immunology 
2014. 
bData from University of California Los Angeles (UCLA) Health System Antimicrobial Susceptibility Summary 
2014. 
cData from Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) 2008. 
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Table 4.2: Resistance profiles (% susceptible) of Gram-negative bacteria against four classes of 
antibiotics. 
  Carbapenems Aminoglycosides Fluoroquinolone Other 
  Ertapenem Imipenem Meropenem Amikacin Gentamicin Tobramycin Ciprofloxacin Levofloxacin TMP/SMX 
VCU 2014a 
        
  
E. coli --- --- 100 --- 91 --- 73 74 74 
Klebsiella --- --- 98 --- 96 --- 94 94 90 
P. aeruginosa --- --- 91 --- 94 --- 81 75   
Acinetobacter --- ---   --- 77 --- 60 64 72 
UCLA 2014 non-urine (RRUMC)b 
      
  
E. coli 99 99 99 99 83 84 63 --- 60 
Klebsiella 93 96 95 97 92 87 85 --- 80 
P. aeruginosa R 76 82 95 89 92 77 --- R 
Acinetobacter R 52 50 52 46 48 44 --- 46 
UCLA 2014 non-urine (SMH-UCLA) inpatientb 
     
  
E. coli 99 99 99 99 88 88 56 --- 60 
Klebsiella 73 77 82 82 80 64 66 --- 64 
P. aeruginosa R 54 99 99 86 88 51 --- R 
MYSTIC 2008c 
       
  
E. coli 98.2 98.6 98.6 --- --- 84.8 68.2 68 --- 
Klebsiella 93.5 94.5 94.2 --- --- 85.1 84.1 85.6 --- 
P. aeruginosa   79.5 85.4 --- --- 89.1 77 72.7 --- 
Acinetobacter   52 45.7 --- --- 59.1 32.3 33.9 --- 
*R denotes intrinsic resistance 
aData from Virginia Commonwealth University (VCU) Department of Pathology – Microbiology/Immunology 
2014. 
bData from University of California Los Angeles (UCLA) Health System Antimicrobial Susceptibility Summary 
2014. 
cData from Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) 2008. 
 
 While druggable targets effective against Gram-negative infections are still being 
discovered and validated, there is already a growing list of possible targets and agents effective 
against these targets.  One method being studied is the disruption and inhibition of a 
phenomenon called quorum sensing.  Quorum sensing typically causes a simultaneous 
phenotypic change in a community of the same bacteria.56-57  This synchronization of phenotypes 
allows bacteria to control certain behaviors that require a large population in order to function 
properly, such as swarming and biofilm formation.58  Quorum sensing inhibitors typically are not 
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bactericidal, but can be bacteriostatic and can prevent colonization, transfer of resistance genes 
and production of virulence factors.  Anti-virulence factor agents are also being developed for a 
variety of targets including proteases35 and adhesion proteins.59  Other Gram-negative targets 
with agents being developed include the essential metalloenzymes LpxC60-61, DXR62, peptide 
deformylase63 and enolase64. 
4.1.4 Natural Product Troponoids as Antibacterial Agents 
 The first troponoid, puberulonic acid, was isolated from Penicillium puberulum in 1932, 
but the first troponoid structure was not proposed until 1941.65  Since then more than 200 
troponoids have been isolated from various other fungi, bacteria and plants.  The most studied 
troponoids are the thujaplicins, specifically β-thujaplicin (hinokitiol, HKT).  As secondary 
metabolite natural products, thujaplicins have many widespread applications including 
antibacterial properties.  In 1938, it was discovered that HKT exhibits significant antibacterial 
activity against tubercle bacillus and other bacteria.66  Because HKT has poor water solubility, 
many early studies were focused on the unsubstituted thujaplicin, tropolone.  Tropolone itself has 
been found to be bacteriostatic and bactericidal against a broad range of bacteria.67 
 
 
 
 
 
 
238 
 
Table 4.3: Bacteriostatic Activity of Tropolone Against Gram-negative Bacteria.68 
Species Inoculum (CFU/mL) MIC (µM) 
Aeromonas hydrophila 
6.0 x 103 12 
6.0 x 107 100 
Chromobacter violaceum 
1.1 x 104 49 
1.1 x 108 100 
Escherichia coli 
8.0 x 103 410 
8.0 x 107 410 
Pseudomonas aeruginosa 
9.9 x 103 820 
9.9 x 107 820 
   
Table 4.4:  Bactericidal Activity of Thujaplicin Related Compounds.69 
 % Survival Rate 
Compound E. coli IFO 3301 (10 min) S. aureus IFO 12732 (10 min) 
Tropone 96 100 
Tropolone 65 43 
α-Thujaplicin 2 0 
Hinokitiol 2 22 
Hinokitiol sodium salt 1 5 
Hinokitiol-acetate 97 69 
β-Dolabrin 5 9 
 
Additionally, α and γ thujaplicin also exhibit antibacterial effects similar to HKT and tropolone. 
Table 4.5: Antibacterial Activity of Thujaplicins against Legionella species (Presented as MIC 
µg/mL).a 
Microorganism α-thujaplicinb β-thujaplicin γ-thujaplicin 4-acetyltropolone β-dolabrin 
L. pneumophila 
SG1 
12.5 6.25 50 3.1 6.25 
L. pneumophila 
SG3 
50 25 25 12.5 25 
aFrom Curr. Med. Chem. 2007, 14, 2597-2621. 
bFrom Biol. Pharm. Bull. 2004, 27(6), 899-902. 
 
 
As exemplified in the bactericidal work done by Morita and coworkers, the efficacy of 
troponoids appears to be directly related to the alpha hydroxy ketone moiety.  Removal of the 
hydroxyl group (tropone) or acetyl substitution eliminates the bactericidal activity.  Activity does 
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not appear to be affected based on α or β substitution or isopropyl versus isopropenyl; however, 
there is a significant difference between these versus unsubstituted tropolone.  In combination 
with the known chelation potential of tropolone,70 these results suggest that troponoid 
antibacterial activity is most likely due to metal chelation by the alpha hydroxy ketone.  It has 
been proposed that chelation of Mg2+ or Fe3+ may allow for more rapid passage through the outer 
membrane of Gram-negative bacteria where the ion can be dissociated, allowing the drug to pass 
through the cytoplasmic membrane.71  Additionally, the lead-like Gram-negative antibacterial 
activity of α, β and γ thujaplicin as well as β-dolabrin and 4-acetyltropolone suggests the 
tropolone chemotype offers a unique scaffold amenable to the development of new, potent and 
metalloprotein selective Gram-negative antibiotics. 
4.1.5 Project Objectives 
 Our goal was to assess the antibacterial activity of tropolone derivatives against Gram-
negative bacteria.  Because natural product tropolones are known to be biologically active 
against a variety of targets and are capable of chelating metal ions, the tropolones synthesized 
should offer antibacterial activity against Gram-negative bacteria.  The minimal inhibitory 
concentration of these tropolones against E. coli (ATCC 25922) and K. pneumoniae (ATCC 
10031) would be assessed first.  Tropolones exhibiting lead-like activity would subsequently be 
screened against P. aeruginosa and A. baumannii as well as clinical isolates of K. pneumoniae.  
Lipopolysaccharide and efflux pump knockout models of E. coli would then be screened to 
further elucidate the structural activity relationship of the tropolones and any permeability or 
efflux related problems associated with the tropolone chemotype or substitutions.  
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4.2 Results and Discussion 
 
4.2.1 Novel α-Tropolones are Active Against Gram-negative Bacteria 
 The original series of tropolones and aminotropone intermediates synthesized by Dr. 
Oblak, Dr. van Heyst and Mohamed Ammar,72-73 presenting either α or β substitution, were 
screened for activity against E. coli 25922 and K. pneumoniae 10031 using the minimal 
inhibitory concentration (MIC) assay.  Initial screening used E. coli and the maximum 
concentration of either 40 or 50 µg/mL.  Because K. pneumoniae is typically more robust than E. 
coli, the maximal concentration of 50 µg/mL was not adequate in most cases and needed to be 
increased to 125 µg/mL. 
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Table 4.6: MICs (µg/mL) of first generation Tropolones against E. coli 25922 and K. 
pneumoniae 10031. 
 
Compound R1 R2 MW 
E. coli 25922 
(µg/mL) 
K. pneumoniae 
10031 (µg/mL) 
Tropolone H H 122.12 > 40 > 50 
MO-OH-PH 
 
H 198.22 20 25 
MO-OH-DM 
 
H 258.27 > 40 100 
MO-OH-TM 
 
H 288.28 > 40 100 
MO-OH-Nap 
 
H 248.28 40 100 
HKT H 
 
164.2 25 31.25 
β-tert H 
 
178.23 > 50 125 
β-cyc H 
 
190.24 50 62.5 
β-PH H 
 
198.22 25 31.25 
β-SM H 
 
228.24 > 50 62.5 
HKT-OMe H 
 
178.23 > 50 > 500 
  
Based on these results, it appears as though there is minimal difference between α and β 
substituted tropolone activity.  Although there might be a slight preference for β versus α for K. 
pneumoniae, this is inconclusive due to the lack of diversity amongst the substitutions.  
However, it is clearly apparent that the alpha hydroxy ketone moiety is essential to antibiotic 
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activity since both the methyl ether form of hinokitiol (HKT-OMe) and the aminotropone 
intermediates (see Appendix) lack activity in E. coli up to 50 µg/mL and in K. pneumoniae up to 
500 µg/mL.  Here, the lead-like tropolone from the synthesized analogs is the α-phenyl tropolone 
(MO-OH-PH). 
Although not directly related to these antibacterial results, subsequent tropolones 
synthesized contained modifications on the α-phenyl substitution, alkyl chains, an alkyl chain 
connected to a cyclic carbon moiety or heterocyclic substitutions since heterocycles are known to 
display diverse biological activities.74 
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Table 4.7: MICs (µg/mL) of Key Potent Tropolones Against E. coli 25922 and K. pneumoniae 
10031. 
 
Compound R MW E. coli 25922 K. pneumoniae 10031 
MO-2-OH  192.25 20/10 10 
MO-10-OH 
 
226.27 20 10 
MO-pSMe-OH 
 
244.31 20 20 
BA-pBr-OH 
 
277.11 20 12.5 
BA-PH-OH 
 
274.31 20 12.5 
BA-HC2-OH 
 
264.28 20 20 
HC-2-OH 
 
188.18 20 10 
HC-6-OH 
 
201.22 40/20 40 
EF-3-OH 
 
256.25 40/20 20 
TDA* 
 
212.25 20 20 
*TDA is tropodithietic acid, a troponoid produced by Roseobacter gallaeciensis 
 While it was anticipated that low molecular weight ( < 400 Da), increased polarity and 
increased relative polar surface area would generate more potent tropolones, it is difficult to 
determine a trend in modifications to tropolone and Gram-negative MICs (for all tropolone MICs 
244 
 
see Appendix).  However, many of the key potent tropolones tend to possess a para substitution 
on the phenyl ring and several substitutions possess hydrogen bonding or chelation potential.  
Although molecular weight does not appear to be a factor with these tropolones, it appears as 
though there may be a fine line in developing more potent tropolones with a mix of hydphilic, 
aromatic and hydrophobic substitutions.  It should be noted that tropodithietic acid (TDA) was 
included as a natural troponoid possessing a carboxyl instead of a hydroxyl to determine if this 
type of substitution affected activity.  Interestingly, TDA appears to be one of the more potent 
troponoid analogs tested and may provide a scaffold on which to build more potent tropolones 
utilizing the carboxy-tropone chemotype; however, it should be noted that the dithietane may be 
reduced to the dithiol which may be responsible for the activity of TDA.  Other small molecules 
with either known metal chelating ability or possessing functional groups with metal chelation 
potential were also screened against K. pneumoniae 10031.  Surprisingly, vorinostat, catechol, 6-
aminocaproic acid and 3,4-dihydroxyphenylacetic acid did not show any effect up to 40 µg/mL.  
This suggests the tropolone scaffold is a more suitable metal chelation chemotype, tropolones are 
more permeable across the outer membrane than the three small molecules tested, tropolones are 
susceptible to efflux but vorinostat, catechol and 3,4-dihydroxyphenylacetic acid are, or 
tropolones interact with Gram-negative bacteria in a specific manner in which the other small 
molecules tested cannot to exhibit an antibacterial effect. 
 
4.2.2 α-Tropolone Display Activity Against Clinical Isolates of Klebsiella pneumoniae 
 Efficacy against E. coli 25922 and K. pneumoniae 10031 in the 20 µg/mL range is ideal 
for the development of more potent tropolones, but true lead-like drugs ideally should be 
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effective against both test strains and clinical isolates.  Two clinical isolates of K. pneumoniae, 
K. p. UCHC1 and K. p. UCHC3, were obtained from the University of Connecticut Health 
Center.  K. p. UCHC1 is resistant to trimethoprim (TMP) with an MIC greater than 20 µg/mL 
while K. p. UCHC3 is susceptible to TMP. 
Table 4.8: MICs (µg/mL) of Key Potent Tropolones Against Clinical Isolates of K. pneumoniae. 
 
Compound R K. p. 10031 K. p. UCHC1 K. p. UCHC3 
MO-OH-PH 
 
25 
40/20 20 
MO-2-OH  10 40 20 
MO-7-OH 
 
25 
40 20 
MO-10-OH 
 
10 
> 40 40 
MO-pSMe-OH 
 
20 
20 20 
BA-pBr-OH 
 
12.5 
20 20 
HC-1-OH 
 
20 
> 40 40 
HC-2-OH 
 
10 
20 20 
EF-2-OH 
 
10 
> 40 > 40 
EF-3-OH 
 
20 
> 40 > 40 
HKT  31.25 20 20 
TDA  20 20 20 
 
 Most of the tropolones show a slight loss of potency against the TMP susceptible K. 
pneumoniae clinical isolate, but several maintain sufficient MICs.   This indicates synthetic 
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tropolones may be developed as clinically useful Gram-negative antibiotics since they are not 
subjected to the same resistance mechanism utilized against TMP, a commonly prescribed, first-
line antibiotic for the treatment of urinary tract infections typically caused by Enterobacteriaceae.  
Not surprisingly, most of the tropolones lose efficacy against the TMP resistant clinical isolate of 
K. pneumoniae.  Although this isolate has not been fully characterized, this decrease in activity 
may indicate a decrease in the number of porins in the outer membrane to reduce permeability, 
an increase in multidrug efflux pumps or the mechanism of action of tropolones is similar to 
TMP.  However, several of the key potent tropolones maintain potency against this resistant 
isolate.  BA-pBr-OH and MO-pSMe-OH retain activity in both clinical isolates while MO-OH-
PH loses some potency against the TMP resistant isolate.  This seems to indicate that a para-
substitution on the phenyl ring may increase potency against more resistant isolates, but there 
appears to be a fine line in selection of functional groups as various alkyl chain lengths, acetyl 
group, and amide functionality all lose potency.  The furan of HC-2-OH may provide a key 
hydrogen bond acceptor or may covalently bind to a cysteine residue within the target. 
4.2.3 Activity of Tropolones Against Other Infectious Microbes  
 Since the tropolones exhibit lead-like potential against E. coli and K. pneumoniae it is 
prudent to screen them for activity against intrinsically more resistant Gram-negative bacteria 
such as P. aeruginosa and A. baumannii. 
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Table 4.9: MICs (µg/mL) of Key Potent Tropolones Against P. aeruginosa and A. baumannii. 
 
Compound R P. aeruginosa A. baumannii 
MO-OH-PH 
 
20 20 
MO-1-OH 
 
23 23 
MO-2-OH  38 19 
MO-10-OH 
 
45 23 
BA-pBr-OH 
 
28 14 
BA-PH-OH 
 
> 55 27 
EF-2-OH 
 
48 24 
EF-3-OH 
 
51 26 
HC-1-OH 
 
51 26 
HC-2-OH 
 
> 38 19 
HKT  > 164 11 
TDA  11 21 
 
 The MIC values listed in Table 4.9 were determined in the lab of a collaborator, Dr. 
Nigel Priestley, at the University of Montana.  These experiments were conducted based on the 
concentration of tropolone in µM and then converted to standard MIC values (µg/mL).  
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Although all the tropolones are relatively potent against A. baumannii, there appears to be a 
preference in potency against P. aeruginosa towards small, hydrophobic substitutions and a clear 
preference towards α-substitution since HKT is non-active.  Unlike the activity seen against 
clinical isolates of K. pneumoniae, HC-2-OH does not maintain similar activity to TDA in the 
more intrinsically resistant P. aeruginosa.  Interestingly, HC-2-OH is not one of the more potent 
tropolones in P. aeruginosa despite being one of the most potent analogs in all other Gram-
negative species examined.  This may indicate HC-2-OH and TDA exert activity through 
different mechanisms.  To validate this idea, tropolone analogs with carboxylic acids instead of 
hydroxyls should be synthesized and tested.  Additionally, it appears as though the more potent 
tropolone analogs against P. aeruginosa consist of small, hydrophobic substitutions. 
 It is known that cytoplasmic targeted Gram-negative antibiotics either enter the 
cytoplasmic membrane through passive transport through the outer membrane or via solute 
specific and/or self-promoted uptake.  Passive transport is the mechanism which cytoplasmic 
targeted antibiotics enter the Gram-positive cytoplasm.  To further understand the activity of 
tropolones against Gram-negative bacteria, the tropolones were screened by the Priestly lab 
against several Gram-positive bacteria and fungal species. 
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Table 4.10: MICs (µg/mL) of Key Potent Tropolones Against Gram-positive and Fungal 
Species. 
Compound S. aureus S. pyogenes B. anthracis E. faecalis C. albicans C. glabrata 
MO-OH-PH 39.643 19.822 19.822 19.822 39.643 19.822 
MO-1-OH 23.232 11.616 23.232 23.232 23.232 23.232 
MO-2-OH 19.212 19.212 19.212 19.212 19.212 19.212 
MO-10-OH 22.627 22.627 22.627 45.254 22.627 22.627 
BA-pBr-OH 13.856 13.856 138.557 27.711 13.856 13.856 
BA-PH-OH 27.431 27.431 27.431 6.858 54.863 27.431 
EF-2-OH 48.051 48.051 24.025 > 48.051 24.025 24.025 
EF-3-OH 51.251 51.251 25.625 > 51.251 25.625 25.625 
HC-1-OH 51.251 25.625 25.625 > 51.251 25.625 25.625 
HC-2-OH 37.636 18.818 18.818 37.636 18.818 18.818 
HKT 41.05 82.101 82.101 41.05 20.525 10.509 
TDA 5.306 21.225 21.225 10.612 21.225 10.612 
   
 While the activity of tropolones against Gram-positive and fungal species does not rule 
out the possibility of interacting with the cytoplasmic membrane to exhibit an antibiotic effect, it 
does rule out targeting the outer membrane of Gram-negative bacteria.  This data shows that α-
substituted tropolones are typically more effective against a range of Gram-positive bacteria 
compared to HKT.  However, there does not appear to be a trend in substitutions and activity for 
the α-tropolones.  The carbonyl substituted phenyl rings (EF-2-OH and EF-3-OH) lose 
significant potency against most of the species tested but maintain similar potency to other 
tropolones tested against Bacillus anthracis (B. anthracis).  Surprisingly, BA-pBr-OH, which is 
one of the more potent broad spectrum tropolones, loses 10-fold potency against B. anthracis.  
Due to the lack of trend in structural activity relationship and the perplexing loss of potency of 
BA-pBr-OH against B. anthracis, it is difficult to suggest a reason for tropolone potency or a 
potential mechanism of action. 
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All of the tropolones here are relatively potent against Candida albicans (C. albicans) 
and Candida glabrata (C. glabrata) including HKT.  Again, the relative consistent potency of 
the tropolones (~20 µg/mL) makes it difficult to suggest a reason for potency.  However, when 
taking into account the FDA approved antifungal agents, a potential mechanism of action could 
be explained.  The azole antifungals (ie. itraconazole, fluconazole, etc.) are inhibitors of the 
cytochrome P-450-dependent enzyme lanosterol and act by chelating Fe3+ in the active site.75  
Tropolones are known to bind Fe3+ and may act through a similar mechanism since bacteria also 
express essential cytochrome P-450 enzymes.76 Another class of antifungal agents, the 
echinocandins (ie. caspofungin, micafungin, etc.), inhibit 1,3-β-glucan synthase which 
synthesizes a critical polysaccharide (1,3-β-glucan) component of the fungal cell wall.77  1,3-β-
glucan is analogous to peptidoglycan, suggesting tropolones may disrupt cell wall synthesis in 
both bacteria and fungi. 
4.2.4 Using E. coli Knockout Models to Elucidate Potential Permeability and Efflux Issues 
 After testing the tropolones against a variety of bacterial and fungal species there does 
not appear to be any specific trend in substitutions and activity.  The best trend appears against 
P. aeruginosa where there is a preference towards small, hydrophobic substitutions.   The only 
other potential trend appears against the Enterobacteriaceae, E. coli and K. pneumoniae, where 
there is a fine line between tropolones with a mix of hydphilic, aromatic and hydrophobic 
substitutions and activity.  One reason for the lack of any strong structural activity relationship 
may be that the tropolones have limited permeability across the outer membrane or that the 
tropolones can be effluxed out of the cell at different rates to reduce overall efficacy.  To assess 
these possibilities the tropolones were screened against E. coli BW25113, which is homologous 
to 25922, and two knockout strains.  JW0451 comes from the Keio collection and is a knockout 
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model of E. coli BW25113 resulting in loss of acrB, a member of the RND efflux pump family 
and the major efflux pump in E. coli.78  NR698 is an E. coli mutant strain with altered LPS to 
increase permeability to small molecules.79 
Table 4.11: MICs of Tropolones Against E. coli and E. coli Knockouts. 
Compound BW25113 JW0451 NR698 Effect on Potency 
MO-OH-PH 20 > 40 40 None 
MO-9-OH 40 40 20 LPS 
BA-pBr-OH 20 20 10 LPS 
BA-DM-OH > 40 20 10 Efflux and LPS 
BA-P5-OH > 20 > 40 20/10 LPS 
EF-2-OH 20 20 20 None 
HC-1-OH 40 40 40 None 
HC-2-OH 20 20 20 None 
HC-10-OH > 40 40/20 10/5 Efflux and LPS 
BA-HC2-OH 20 20 20 None 
MO-pSMe-OH 20 20 10 LPS 
SG-TMS-OH > 20 > 40 5 LPS 
HKT 20 20 20 None 
 
 It is encouraging to note many of the tropolones are not affected by reduced permeability 
across the outer membrane or efflux pumps (for data on additional tropolones see Appendix).  
While several tropolones do experience permeability issues, they are mostly more hydrophobic 
than the other analogs.  Two tropolones, BA-DM-OH and HC-10-OH, appear to also be effected 
by efflux.  These two present very different substitutions and do not offer real insight into why 
they are subjected to efflux pumps since structurally similar tropolones such as BA-TM-OH is 
not.  Surprisingly, most of the tropolones with heterocyclic substitutions do not exhibit increased 
potency in NR698.  Again, these results suggest there is a fine line between tropolones with a 
mix of hydphilic, aromatic and hydrophobic substitutions and activity. 
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4.2.5 Exogenous Metal Effects on α-phenyl Tropolone Activity 
 From the broad spectrum activity exhibited against Gram-positive/negative bacteria and 
fungi it was proposed that one potential mechanism could be the ability to bind Fe3+ to inhibit 
essential cytochrome P-450 enzymes.  It was also proposed that tropolones have the potential to 
bind other metalloenzymes including the zinc metalloenzyme LpxC, magnesium metalloenzymes 
gyrase and polymerase, the manganese metalloenzyme DXR, or peptide deformylase, another 
iron metalloenzyme.  Based on this, it may be possible that addition of the preferred metal 
exogenously could eliminate tropolone activity.  To test this, solutions of the chloride salts of 
Fe3+, Zn2+, Mg2+, Mn2+, Ca2+ and Cu2+ were prepared and co-incubated with MO-OH-PH treated 
E. coli BW25113.  First, the metal ions and tropolone were serial diluted in a constant ratio 
(metal ion: 10 mM - 312 µM; tropolone: 80 µg/mL – 2.5 µg/mL).  Most of the metal ions tested 
had no effect on the MIC but may have precipitated in the 10 mM treated wells.  However, the 
wells treated with Fe3+ showed no antibacterial activity.  Because the 10 mM concentration of 
metal ions appeared to precipitate in the wells with 80 µg/mL tropolone it is possible that the 
excess concentration of metal caused precipitation.  To explore this possibility, the concentration 
of metal ion was held constant at 10 mM and tropolone was still serially diluted.  Again, most of 
metal ions had no effect on the MIC, except for Fe3+ and Cu2+.  Fe3+ treated wells showed no 
antibacterial activity while wells treated with Cu2+ showed drastically increased activity (MIC < 
2.5 µg/mL).  The enhanced antibacterial activity in the Cu2+ wells can easily be explained by the 
bactericidal effect Cu2+ at high enough concentrations.80  Previous work done in other labs has 
indicated that the ideal ratio of exogenous Fe3+ to tropolone for chelation and activity is 1:3.81  
MIC plates with the ratios of 3:1, 2:1 and 1:1 tropolone to Fe3+ were made to determine if these 
lower concentrations affected potency.  Although these lower concentrations (200-75 µM) did 
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not cause the precipitation seen with the higher concentrations, MO-OH-PH was still found to be 
inactive at double the MIC (40 µg/mL).  It should be noted that iron(III) chloride alone had no 
growth effect on E. coli.  Furthermore, Fe2+ also abolished the activity of MO-OH-PH while 20 
µM Fe3+ was determined to be the minimal concentration required to abolish activity at 40 
µg/mL (10:1 tropolone to iron). This may indicate that tropolones target an iron metalloenzyme. 
4.2.6 Elucidation of the Mechanism of Action of Tropolones as Antibacterial Agents 
 In order to probe the effects of tropolones on the morphology of the cell, Gram-stained 
preparations of E. coli treated with various compounds were imaged using confocal microscopy 
(see Figure 4.1).   Images of the untreated cells and cells treated with the negative control HKT-
OMe show little difference in morphology. However, images of cells treated with 20 µg/mL of 
HKT or BA-pBr-OH show that the cells become filamentous. These results are consistent with 
incomplete cell division and suggest that the tropolones may directly inhibit biosynthesis of the 
cell wall or inhibit targets critical to cell division.  
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Figure 4.2:  E. coli 25922 cells treated with a) DMSO, b) HKT-OMe as a negative control, c) 
HKT , d)  BA-pBr-OH. 
 
 A report on the antibacterial activity of tropolone did not find filamentous growth for any 
bacteria treated at sub-inhibitory concentrations.68  This would seem to indicate that substitutions 
on the tropolone ring may change the mechanism of action especially since this study also 
determined that tropolone expressed only 4% of the bactericidal activity of HKT.  Additionally, 
tropolone was found to lose activity in the presence of 20% sucrose.  The author suggests that the 
lack of filamentous growth means tropolone does not inhibit enzymes involved in cell wall 
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synthesis while the antagonistic activity of sucrose indicates tropolone acts on the cytoplasmic 
membrane.  To test this hypothesis, several concentrations of MO-OH-PH were co-incubated 
with 20, 10 or 5% sucrose or glucose in E. coli BW25113.  Neither sucrose nor glucose appeared 
to have any effect on the antibacterial activity of MO-OH-PH, suggesting the tropolone analogs 
may inhibit enzymes involved in cell wall synthesis. 
 Since many of the enzymes involved in cell wall synthesis are metalloenzymes, phenyl 
tropones with various substitutions of the hydroxyl group were tested to determine if the 
hydroxyl group was essential for activity or if activity could be enhanced by incorporation of 
other metal chelating functionalities.  
Table 4.12: Effects of Hydroxyl Substitution on E. coli MIC (µg/mL). 
 
Compound R E. coli BW25113 MIC 
MO-OH-PH -OH 20 
MO-NH2-PH -NH2 > 200 
MO-OMe-PH -OCH3 > 40 
MO-SH-PH -SH > 200 
MO-Am-PH 
 
> 40 
MO-SMe-PH -SCH3 > 40 
MO-NHOH-PH -N(OH)H > 40 
MO-H-PH -H > 40 
 
 The lack of activity in the tropones with metal chelating functional groups other than 
hydroxyl indicates metal chelation may not be part of the mechanism of action.  The protection 
of the hydroxyl as a methyl ether and the substitution of the hydroxyl with a hydrogen serve as 
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negative controls since the methyl ether should have minimal metal chelating potential and 
hydrogen cannot chelate metal.  Combining these results with those from the other metal 
chelating functional groups shows that the hydroxyl is essential for tropolone activity against 
Gram-negative bacteria.  However, it may be possible that the substitution of the hydroxyl with a 
carboxylic acid could yield similar results or increase potency as seen with TDA. 
Because true structure activity relationship of tropolone derivatives is not well 
understood, direct target identification approaches such as biotin affinity tags are not ideal.  
When small molecules exhibit biological activity but have unknown effects due to structurally 
diversity, indirect target identification techniques can be used.  Drug affinity responsive target 
stability (DARTS) is and indirect target identification technique developed by Huang and 
coworkers “for the initial identification of protein targets of small molecules”.82  DARTS uses 
the idea that the binding of a small molecule to a target protein will stabilize the protein and 
reduce the sensitivity of the protein to proteases.  Based on this principle, two tropolones (BA-
pBr-OH and HC-2-OH) were subjected to DARTS analysis.  Although the protocol developed by 
Huang and coworkers requires the incubation of whole cell lysates with the small molecule for 
30 minutes prior to thermolysin digestion, this protocol was developed for mammalian cells and 
not bacteria.  Due to this difference, it is not surprising that initial attempts were unsuccessful.  
To overcome this issue, the protocol was modified to a hybrid of Western Blot and DARTS 
analysis.  In short, tropolones were incubated with 4 mL of E. coli 25922 in a 6 well plate 
overnight before undergoing the standard DARTS protocol (see Chapter 5 for full protocol).  
Both BA-pBr-OH and HC-2-OH treatment expressed differential bands compared to the 
untreated (DMSO) lysates, indicating potential targets.  Figure 4.2 shows that although there are 
a couple of differential bands present on the gel, one band is clearly different and able to be 
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analyzed.  The band was excised from the gel and sent to the Keck MS & Proteomics Resource 
at Yale School of Medicine for LC-MS/MS protein identification.  With 83% coverage, the 
protein in the band was identified as enolase. 
 
Figure 4.3: Gel image of modified DARTS assay using E. coli 25922 treated with DMSO or 
HC-2-OH and lysed with thermolysin. 
 
 Enolase is a magnesium metalloenzyme that typically exists as a dimer which catalyzes 
the conversion of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP). 
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Figure 4.4: Catalytic mechanism of the conversion of 2-PG to PEP by enolase. 
The conversion of 2-PG to PEP is an essential step in the degradation of carbohydrates.83  
Although this catalytic activity is one of its primary functions, enolase has been implicated in 
several other important biological processes.  In E. coli, the enolase gene also contains CTP 
synthase which is essential for pyrimidine biosynthesis.83  There is an estimated 3131 dimers of 
enolase per cell in E. coli with approximately 1/10 of the total enolase sequestered in the RNA 
degradosome.84-85  The degradosome is comprised of RNase E, PNPase, RhlB and enolase and is 
located at the cell surface of bacteria and fungi and is part of the cytoskeletal structure of E. 
coli.83,86  As part of the degradosome, enolase stabilizes mRNA that encodes a transmembrane 
glucose transporter.87  Removal of enolase from the degradosome reduces the activity of RNase 
E nearly 10-fold.83  E. coli AT8 cells have abnormalities in RNase E which causes a defect in 
chromosome segregation and results in filamentous growth possibly due to a defect in 
attachment of the cytoplasmic membrane to the outer membrane.86  Additionally, enolase 
deficient E. coli exhibit interference in cell wall synthesis and repression of metabolic and 
transport enzymes that would normally remove growth inhibitors.88  Because tropolones are 
known metal chelators and E. coli treated with BA-pBr-OH exhibited filamentous growth, 
enolase is a plausible target.   
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To validate enolase as a target, the Enolase Activity Assay Kit (Sigma Aldrich) was 
purchased.  This kit uses a whole cell lysate and detects an intermediate of the conversion of 2-
PG to PEP.  The intermediate can react with a peroxidase substrate to give a fluorometric 
product that is proportional to the amount of enolase activity present.  After establishing a 
standard curve of peroxide generated indicating 100% enolase activity, peroxide curves of 
lysates of E. coli treated with MO-OH-PH, BA-pBr-OH or HC-2-OH were determined. 
 
Figure 4.5:  % Enolase activity in E. coli lysates as measured by fluorometric analysis of 
reaction with a peroxide substrate.  Peroxide generation of untreated lysate was normalized to 
100% activity.  Cells were treated with 1 mM, 0.1 mM or 0.001 mM of HC-2-OH, MO-OH-PH 
or BA-pBr-OH and peroxide generation was compared to untreated lysate and determined as % 
enolase activity.  BA-pBr-OH was not tested at 1 mM. 
 
 As seen in Figure 4.3, the tropolones tested had some effect on enolase activity, with HC-
2-OH having the most substantial effect with an IC50 potentially around 200 µM.  MO-OH-PH 
appears to have a slight effect while BA-pBr-OH did not exhibit any inhibitory effect on enolase.  
This may indicate that HC-2-OH acts via a different mechanism than the other tropolones and 
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this mechanism may involve enolase.  It should be noted that this assay does not utilize pure 
enolase enzyme and was developed to detect mammalian enolase activity.  Since E. coli enolase 
is known to have low cysteine content compared to mammalian enolases, this kit may not be 
ideal.89 
 As a result, E. coli enolase was expressed, purified, and assessed for activity.  The 
purified E. coli enolase exhibited activity similar to reported values and could be used to screen 
the inhibitory potential of the tropolones.  Because enolase is a metalloenzyme and tropolone is a 
metal chelator, initial inhibition assays included the some of the more potent tropolones and 
metal chelating small molecules. 
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Table 4.13: Initial Screening of Tropolones and Small Molecule Chelators (50 µM) with 
Purified Enolase. 
 
From this initial screen with the purified enolase it is clear that the tropolones exhibit more 
inhibitory activity than several small molecule chelators.  This suggests tropolones are relatively 
selective towards enolase and may be used to develop potent enolase inhibitors.  To assess the 
inhibitory potential of tropolones, several key potent, LPS limited and relatively non-potent 
synthetic α-tropolones were screened at 20 µM. 
 
Compound Structure % Enolase Activity % Inhibition
BA-pBr-OH 22 78
MO-OH-PH 30 70
MO-10-OH 47 53
Pyrazinecarboxylic
acid
69 31
Kojic acid 58 42
3-hydroxy-2-methyl-4-
pyrone
85 15
3,4-dihydroxyphenyl
acetic acid
84 16
Catechol 69 31
6-aminocaproic acid 71 29
Vorinostat 68 32
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Table 4.14: Evaluation of Key Potent Tropolone Inhibitory Activity on E. coli Enolase (20 µM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tropolone
Functional 
Group
% Inhibition
MIC in 
E. Coli 
(WT) µg/mL
BA-pBr-OH 70 20
MO-OH-PH 33 20
MO-10-OH 35 20
HC-2-OH 52 20
MO-2-OH 82 20/10
BA-PH-OH 58 20
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Table 4.15: Evaluation of LPS Limited Tropolone Inhibitory Activity on E. coli Enolase (20 
µM). 
 
 
 
 
 
 
 
 
 
 
 
Tropolone
Functional 
Group
% Inhibition
MIC in 
E. Coli 
(WT)
MIC in 
E. Coli JW0451
(LPS knockout)
HC-10-OH 31 >40 10/5
SG-PH-OH 30 >40 20
SG-TMS-OH 13 >40 5
BA-SM-OH 16 >40 20/10
BA-DM-OH 13 >40 10
BA-P5-OH 8 >40 20/10
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Table 4.16: Evaluation of Relatively Non-potent Tropolone Inhibitory Activity on E. coli 
Enolase (20 µM). 
 
 
 The enolase inhibition data mostly correlates with the E. coli MIC data as the most potent 
growth inhibitors are also the most potent enolase inhibitors.  Interestingly, the tropolones which 
display limited growth inhibition due to LPS are some of the least potent against enolase, 
exhibiting similar inhibitory activity as the relatively non-potent growth inhibitory tropolones.  It 
is unclear why these tropolones are weakly inhibitory towards enolase yet potent in the E. coli 
LPS knockout model.  However, enolase appears to be mainly a cell membrane associated 
protein in E.coli and the knockout model has an abnormal outer membrane, suggesting the LPS 
limited tropolones may act via a different mechanism.  While these tropolones are some of the 
larger analogs, the biphenyl tropolone, BA-PH-OH, is similar in size yet is potent in both the 
Tropolone
Functional 
Group
% Inhibition
MIC in 
E. Coli 
(WT)
MIC in 
E. Coli JW0451
(LPS knockout)
HC-5-OH 32 >40 >40
HC-7-OH 61 >40 40
BA-pCN-OH 20 >40 >40
MO-1-OH 35 >40 >40
MO-3-OH 28 40 40
Am-Ac-OH 7 >40 >40
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growth inhibition assay and enolase inhibition assay, suggesting size may not be a significant 
factor.  Surprisingly, HC-7-OH which is relatively non-potent in the growth inhibition assay is 
the third most potent analog tested.  Again, this is one of the larger analogs, suggesting size does 
not determine inhibition potential.  It is possible HC-7-OH is too polar to have an effect on the 
growth of E. coli even with a defective outer membrane but is a relatively potent enolase 
inhibitor. 
 Next, the three most potent tropolones were compared to a reported enolase inhibitor, 
ENOblock.64 
 
Figure 4.6: Structure of Reported Enolase Inhibitor, ENOblock. 
 
Table 4.17: Evaluation of Tropolone and ENOblock Inhibitory Activity on E. coli Enolase (10 
µM). 
 
Compound % Inhibition
ENOblock 30
BA-pBr-OH 51
MO-2-OH 48
HC-7-OH 37
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Here the tropolones were determined to be more potent than ENOblock.  ENOblock has been 
reported to potently inhibit mammalian enolase ENO3 (IC50 = 0.576 µM).  The relative lack of 
potency at 17-times the concentration against E. coli enolase suggests ENOblock is more 
selective towards mammalian enolase than bacterial enolase.  Since E. coli enolase only shares 
55% sequence identity with ENO3, it is not surprising that ENOblock is less effective.  
Additionally, the MIC of ENOblock in E. coli 25922 was determined to be 40 µg/mL, which is 
equal to the least effective tropolones.  This would suggest that the tropolones may be more 
selective towards Gram-negative bacteria enolase than mammalian enolase.  Gram-negative 
bacteria such as K. pneumoniae, P. aeruginosa and A. baumannii have 68-97% sequence identity 
compared to E. coli, which is greater than the sequence identity found for Gram-positive, fungal, 
mammalian and other animal enolase.   
 
Figure 4.7: Enolase Sequence Identity (%) Compared to E. coli. 
 Because the E. coli 25922 MIC and enolase inhibition data suggests tropolones may be 
selective towards Gram-negative bacteria enolase, yet some potent growth inhibitory tropolones 
(ie. MO-OH-PH) are relatively non-potent enolase inhibitors and vice versa (ie. HC-7-OH), it 
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was necessary to determine if enolase inhibition was a function of chelation due to the tropolone 
moiety or chelation independent and a function of the α-substitution.  To assess the activity of 
the tropolone moiety, the alternative chelator library of α-phenyl substituted tropones was 
screened with the enolase inhibition assay. 
Table 4.18: Evaluation of Alternative Chelating Groups on Tropolone Inhibitory Activity on E. 
coli Enolase (20 µM). 
Compound Functional Group % Inhibition 
MO-OH-PH Hydroxyl 33% 
MO-OMe-PH Ether 31% 
MO-HNOH-PH Hydroxylamine 40% 
MO-NH2-PH Amine 55% 
MO-SMe-PH Thioether 22% 
MO-SH-PH Thiol 24% 
MO-H-PH Hydrogen 54% 
MO-Am-PH Amide 51% 
 
Interestingly, some of the alternative chelating functionalities could increase enolase inhibition 
compared to the α-phenyl tropolone.  Based on this data, it would suggest that N>O>S in terms 
of chelating functionalities.  Somewhat surprisingly, the tropone (MO-H-PH) displays inhibitory 
activity against enolase comparable to the potent nitrogen containing tropones.  This suggests 
that the carbonyl of the tropone can form a monodentate coordination to the magnesium of 
enolase.  This carbonyl is very Lewis basic, making it sufficient for monodentate coordination 
and potential metalloenzyme inhibition.  Additionally, this data could offer alternative scaffolds 
for the development of enolase inhibitors.  While these alternative chelating functionalities are 
capable of inhibiting enolase, they did not inhibit bacterial growth, suggesting that the ionization 
in the tropolone scaffold may be critical for Gram-negative penetration. 
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4.3 Conclusions 
 
 Tropolones are antimicrobial agents effective against both Gram-positive and Gram-
negative bacteria as well as fungi.  As Gram-negative antibacterial agents, tropolones are 
effective against the most common pathogens: E. coli, K. pneumoniae, P. aeruginosa, and A. 
baumannii.  Additionally, key potent tropolones do not experience permeability or efflux issues 
and maintain potency in TMP resistant clinical isolates of K. pneumoniae.  Although a variety of 
tropolones have been synthesized, there is not a clear trend in structure activity relationship.  
While the more effective analogs typically have some aromaticity and small hydrophilic area, 
more analogs will need to be synthesized to better understand the structure activity relationship.  
As seen from the study utilizing alternative chelating functional groups, the hydroxyl group 
appears to be essential to tropolone growth inhibitory activity.  However, as seen with TDA, the 
substitution of hydroxyl with a carboxylic acid may yield similar results.  Future attempts should 
be made to make a carboxylic acid substituted tropolone analog. 
 Key potent tropolones cause filamentous growth of E. coli at sub-inhibitory 
concentrations.  Filamentous growth and the lack of an antagonistic effect by sucrose are 
indicative of inhibition of cell wall synthesis enzymes such as enolase.  Enolase was determined 
as a potential target by DARTS analysis, and has been validated through inhibition assays 
utilizing purified enolase from E. coli.  From the enolase inhibition assays it was determined that 
the carbonyl of the tropolone may cause monodentate coordination of the catalytic metal to 
inhibit enolase activity.  Here, the alternative chelating functional groups displayed the 
preference N>O>S suggesting bacterial growth inhibition may require ionization of the 
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tropolone, but enolase inhibition does not.  Further validation of enolase as the target for the 
antibacterial activity of tropolones should incorporate a labeled tropolone for pull-down assays.  
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Final Conclusions and Future Directions 
 Troponoids are an interesting class of natural products which offer a range of biological 
activity.  The tropolones are some of the best studied natural products from this class and the 
tropolone motif itself offers a scaffold that can be used to develop synthetic troponoids capable 
of eliciting an antiproliferative response.  Here, α-tropolone derivatives were readily synthesized 
from either 2-chlorotropone or tropolone, both of which are commercially available.  While the 
initial library of synthetic α-tropolones developed in the Wright lab has been expanded and 
incorporated more diverse functional groups, more synthetic work needs to be done in order to 
improve overall yield, potentially reduce synthetic steps required and to generate even more 
diverse functional groups.  Additionally, work should be done to make ortho substituted α-
phenyl tropolones as well as multi-substituted phenyl derivatives in order to assess structure 
activity relationships. 
 The α-tropolones synthesized for this work display a range of antiproliferative activity in 
both hematologic malignancies and Gram-negative bacteria.  Generally, derivatives with more 
aromatic character and more hydrophobicity exhibit more activity.  As antiproliferative agents 
for hematologic malignancies, synthetic α-tropolones appear to have some selectivity towards T-
cell leukemia and are most potent towards the T-cell ALL cell line Molt-4.  Additionally, the 
tropolones also exhibit a greater than 10-fold selectivity towards Molt-4 than healthy human 
peripheral blood monocytes, suggesting synthetic tropolones can be developed as 
antiproliferative agents of T-cell ALL without substantial risk of being generally toxic.  Since the 
Molt-4 line is derived from a patient in relapse, tropolones may be developed as third line 
chemotherapeutics similar to nelarabine.  While a comprehensive mechanism of action is still 
unknown, the activity of two of the more potent tropolones was assessed by microarray analysis.  
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These derivatives displayed activity involving cell cycle regulation, the apoptosis pathway, p53 
pathway and PI3K/AKT/mTOR pathway.  Some of the more interesting activity involved 
upregulation of ATM, CDKN2B, IL7R and PIK3R1 and downregulation of BCL11B and BCL2.  
Although these results need to be validated, Western blot analysis done by the Weimer lab 
suggests that caspase dependent regulation of p53 and activation of AKT/mTOR is most likely 
involved.  Future work should explore these effects on other cancer cell types as well as 
determine the selectivity of these new α-tropolones towards hematologic malignancies. 
 The antiproliferative activity exhibited against Gram-negative bacteria is lead-like with 
several compounds displaying minimal inhibition concentrations of ~10 µg/mL in strains most 
commonly involved in Gram-negative bacterial infection as well as clinical isolates of K. 
pneumoniae.  Several key potent tropolones elicited filamentous growth of E. coli consistent 
with inhibition of cell wall synthesis.  An unbiased target identification assay suggested 
tropolones inhibit enolase, which could explain both the antiproliferative activity as well as the 
filamentous growth.  While many of the tropolones exhibit lead-like inhibition activity towards 
enolase, the α-phenyl troponoids containing various metal chelating functional groups suggests 
that the hydroxyl group is unnecessary for inhibition.  This concept should be explored further 
through the synthesis of other troponoids.  Additionally, enolase needs to be crystallized with 
key potent tropolones in order to determine the binding domain.  Once the binding domain is 
determined, structure based drug design can be used to develop potentially more selective and 
more potent tropolones. 
 Overall, synthetic α-tropolones are lead-like antiproliferative agents useful against 
hematologic malignancies and Gram-negative bacteria.  Although the mechanism of action for 
the cancer antiproliferative activity is complex and not well defined at the present, the newer 
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tropolones have exhibited increased activity.  Interestingly, the key potent tropolones against 
Molt-4 is also one of the most potent analogs against bacterial enolase, E. coli and K. 
pneumoniae.  While it is unlikely that enolase is involved in the cancer antiproliferative activity 
due to a low percent identity between Gram-negative bacteria enolase and mammalian enolase, 
this dual antiproliferative activity may offer the ability to develop synthetic α-tropolones as 
antiproliferative chemotherapeutics for patients with T-cell ALL as well as Gram-negative 
infection preventative agents.  This dual action potential is important due to the high risk of 
mortality associated with Gram-negative infections in leukemic patents undergoing remission 
therapy and should be explored further. 
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Chapter 5 
 
Experimental Section 
 
5.1 Materials and Methods - Chemistry 
 
5.1.1 General Chemical Methods 
All reactions were carried out under an inert atmosphere of argon with dry solvents under 
anhydrous conditions unless otherwise stated.  Commercial grade solvents were used without 
further purification.  Tetrahydrofuran (THF) was used directly from a Baker cycle-tainer system.  
1,4-dioxane was used directly from a Sure Seal™ bottle from Sigma Aldrich.  N-N-
dimethylformamide (DMF) was used directly from an AcroSeal® bottle from Acros Organics.  
Reagents were purchased at the highest commercial quality and used without further purification 
unless otherwise stated.  Yields refer to chromatographically and spectroscopically (1H NMR) 
homogeneous materials.  Reactions were monitored by thin layer chromatography (TLC) carried 
out on Whatman silica 60 Å precoated plates using UV light as the visualizing agent and either a 
basic aqueous potassium permanganate (KMnO4) or a solution of ferric chloride (FeCl3) in 
methanol and water (1:1) and heated as developing agents.  Flash chromatography was 
performed using Baker silica gel (60 Å particle size).  NMR spectra were recorded on Bruker-
500 and 400 instruments and calibrated using residual undeuterated solvent as internal reference 
(ie. CHCl3 at δ 7.26 ppm 1H NMR, δ 77.0 ppm 13C NMR).  The following abbreviations were 
used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, h 
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= heptet.  IR spectra were recorded on either a Shimadzu FT-IR 8400 or Agilent Cary 630 FTIR 
Diamond ATR spectrometer.  Melting points (m.p.) are uncorrected and were recorded on Mel-
Temp digital melting point apparatus.  High resolution mass spectra (HRMS) were obtained from 
the University of Connecticut Spectral Facility by electrospray ionization of flight reflectron 
experiments. 
5.1.2 Synthetic Procedures 
General Procedure For Suzuki Couplings to 2-Chloro-2,4,6-cycloheptatrien-1-one:  2-Chloro-2,4,6-
cycloheptatrien-1-one (1.0 eq), boronic acid (1.5 eq) and cesium carbonate (3.0 eq) were added to 5:1 
dioxane/H2O (0.3 M) and the mixture was thoroughly degassed by bubbling argon through the solution 
(10 min).  Bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) was added and the mixture was again 
degassed with argon (5 min).  The homogenous solution was heated at 90°C for 16 h before being 
cooled to room temperature.  Water was added and the mixture was extracted with EtOAc (3x).  The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.  
Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the desired 2-substituted 
tropones. 
General Procedure for Reduction of C8-C9 Conjugated Olefin:  To a flame dried flask was added the 2-
substituted-7-methoxy tropone in MeOH (1.0 M).  To the solution was added 10% Pd/C (0.5 w/w) and 
the atmosphere of the flash was evacuated and backfilled with H2 (3 cycles).  The reaction mixture was 
stirred under an atmosphere of H2 (balloon) for 2 h before being filtered through a pad of celite, eluting 
with CH2Cl2.  The solvent was removed under vacuum and the residue was purified by flash 
chromatography (SiO2, EtOAc in hexanes) to provide the desired C8-C9 saturated tropone. 
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General Procedure For α-Amination of 2-substituted tropone:  To a solution of 2-substitued tropone 
(1.0 eq) in EtOH (0.2 M) was added 65% hydrazine monohydrate (25 eq).  The solution was allowed to 
stir at room temperature until all starting material was consumed as indicated by TLC.  The reaction was 
concentrated in vacuo and then taken up in EtOAc and washed with H2O (3x).  The organic layer was 
then washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.  Flash chromatography 
of the crude residue (SiO2, EtOAc in hexanes) provided the desired α-amino tropones. 
General Procedure For α-amino-2-substituted tropone Hydrolysis:  α-amino-2-substituted tropone (1.0 
eq) was dissolved in EtOH (0.2 M) to which was added 2N KOH (20 eq).  The reaction was heated to 90°C 
and stirred for 16 h.  The reaction was returned to room temperature and diluted with 15% NaOH.  The 
aqueous layer was washed with CH2Cl2 (3x) and then acidified to pH 2.0 and extracted with CH2Cl2 (3x).  
The organic layer was then washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
General Procedure for methyl-protection of 2-hydroxy-2,4,6-cycloheptatrien-1-one:  2-hydroxy-2,4,6-
cycloheptatrien-1-one (1.0 eq), potassium carbonate (3.0 eq) and dicyclohexano-18-crown-6 mixture of 
isomers (0.1 eq) were added to a two-neck flask with a reflux condenser attached and dissolved with 
acetonitrile (0.2 M).  The second neck was covered with a stopper and iodomethane was slowly added 
to the solution.  The solution was heated at 85°C for 16 h before being cooled to room temperature.  
The solution was filtered through a fritted vacuum funnel and the filtrate was taken up with 0.3 M 
potassium hydroxide.  Water was added and the mixture was extracted with CH2Cl2 (3x).  The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. 
General Procedure for Bromination of 2-methoxy-2,4,6-cycloheptatrien-1-one: 2-methoxy-2,4,6-
cycloheptatrien-1-one was dissolved with carbon tetrachloride (0.2 M) in a pressure vessel.  N-
bromosuccinimide (1.05 eq) was added and the mixture was heated at 80°C for 2 h before being cooled 
to room temperature.  The solution was filtered through a fritted vacuum funnel.  Water was added to 
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the filtrate and the mixture was extracted with CH2Cl2 (3x).  The combined organic layers were washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo.  Flash chromatography of the crude 
residue (SiO2, EtOAc in hexanes) provided the desired product. 
General Procedure for Iodination of 2-hydroxy-2,4,6-cycloheptatrien-1-one:  2-hydroxy-2,4,6-
cycloheptatrien-1-one, potassium carbonate (1.0 eq) and sodium methoxide (1.0 eq) were dissolved in 
methanol (0.3 M) in a two-neck round bottom flask with a reflux condenser attached.  A solid addition 
funnel was attached to the second neck.  Iodine (1.0 eq) was added to the solid addition funnel and was 
then slowly added to the refluxing solution.  Once the iodine was completely added, the solution was 
refluxed for 1 h before cooling to room temperature.  The solution was concentrated in vacuo and flash 
chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the desired product. 
General Procedure for Suzuki Couplings to 2-bromo-7-methoxy-2,4,6-cycloheptatrien-1-one:  2-bromo-
7-methoxy-2,4,6-cycloheptatrien-1-one (1.0 eq), boronic acid (1.5 eq) and cesium carbonate (3.0 eq) 
were added to 5:1 dioxane/H2O (0.3 M) and the mixture was thoroughly degassed by bubbling argon 
through the solution (10 min).  Bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) was added and 
the mixture was again degassed with argon (5 min).  The homogenous solution was heated at 90°C for 
16 h before being cooled to room temperature.  Water was added and the mixture was extracted with 
EtOAc (3x).  The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided 
the desired 2-substituted-7-methoxy tropones. 
General Procedure for Sonogashira Couplings to 2-(4-Bromo-phenyl)-7-methoxy-cyclohepta-2,4,6-
trienone:  2-(4-Bromo-phenyl)-7-methoxy-cyclohepta-2,4,6-trienone (1.0 eq), alkyne (3.0 eq) and 
potassium acetate (10.0 eq) were added to DMF (0.3 M) and the mixture was thoroughly degassed by 
bubbling argon through the solution (10 min).  Bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) 
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and copper (I) iodide (0.1 eq) was added and the mixture was again degassed with argon (5 min).  The 
homogenous solution was heated at 50°C for 16 h before being cooled to room temperature.  The 
reaction is then dried en vacuo using toluene as an azeotrope.  Residue is washed with saturated sodium 
bicarbonate and extracted with EtOAc (3x).  The combined organic layers are washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, 
EtOAc in hexanes) provided the desired product. 
General Procedure for Demethylation of 2-substituted-7-methoxy-2,4,6-cycloheptatrien-1-one with 
acid:  The 2-substituted-7-methoxy-2,4,6-cycloheptatrien-1-one was added to a 1:1 solution of 
methanol/HCl (0.3 M) and refluxed for 6 h before cooling to room temperature.  Generally the desired 
product would precipitate from the solution and was filtered and dried without further purification. 
General Procedure for Demethylation of 2-substituted-7-methoxy-2,4,6-cycloheptatrien-1-one with 
lithium chloride:  To a flame dried pressure vessel was added 2-substituted-7-methoxy tropone in DMF 
(0.6 M) followed by LiCl (3.0 eq).  The vessel was heated to 130°C for 3 h before cooling to room 
temperature.  The crude material was acidified to pH 2.0 and diluted with Et2O and brine.  The mixture 
was then extracted with Et2O (3x).  The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, EtOAc in 
hexanes) provided the desired α-substituted tropolone.  In most cases the tropolone contained an 
undesired impurity and required filtration through C18 silica gel, eluting with 50% MeOH/H2O. 
General Procedure for Suzuki Coupling to 2-(4-Bromo-phenyl)-7-hydroxy-2,4,6-cycloheptatrien-1-one: 
2-(4-bromo-phenyl)-7-hydroxy-2,4,6-cycloheptatrien-1-one (1.0 eq), boronic acid (1.5 eq) and potassium 
fluoride (3.0 eq) were added to 5:1 dioxane/H2O (0.3 M) and the mixture was thoroughly degassed by 
bubbling argon through the solution (10 min).  Bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) 
was added and the mixture was again degassed with argon (5 min).  The homogenous solution was 
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heated at 90°C for 16 h before being cooled to room temperature.  Water and a small amount 2 M HCl 
was added and the mixture was extracted with EtOAc (3x).  The combined organic layers were washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo.  Flash chromatography of the crude 
residue (SiO2, EtOAc in hexanes) provided the desired 2-substituted-7-hydroxy tropolone. 
General Procedure for Diacylation of 2-(4-amino-phenyl)-7-hydroxy-2,4,6-cycloheptatrien-1-one:  2-(4-
amino-phenyl)-7-hydroxy-2,4,6-cycloheptatrien-1-one, pyridine (2.0 eq) and 4-(dimethylamino)pyridine 
(0.1 eq) were dissolved in CH2Cl2 (0.2 M).  The solution was cooled to 4°C, acyl chloride (2.0 eq) was 
added and the solution was sealed and stirred for 2 h.  Water was added and the mixture was extracted 
with EtOAc (3x).  The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided 
the desired product. 
General Procedure for Ester Hydrolysis of Diacylated 2-(4-amino-phenyl)-7-hydroxy-2,4,6-
cycloheptatrien-1-one:  The diacylated 2-(4-amino-phenyl)-7-hydroxy-2,4,6-cycloheptatrien-1-one was 
dissolved in methanol (0.5 M).  A few drops of 3 M potassium hydroxide was added to the solution and 
stirred for 30 minutes.  2 M HCl was added and the mixture was extracted with EtOAc (3x).  The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.  
Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the desired product. 
General Procedure for Tosylation of 2-hydroxy-7-phenyl-2,4,6-cycloheptatrien-1-one: 2-hydroxy-7-
phenyl-2,4,6-cycloheptatrien-1-one and N-N-diisopropylethylamine (1.2 eq) were dissolved in 
acetonitrile (0.2 M).  Next, p-toluenesulfonyl chloride (1.1 eq) was added to the solution.  The vial was 
then sealed and stirred at room temperature for 2 h.  Water was added and the mixture was extracted 
with EtOAc (3x).  The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
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concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided 
the desired product. 
General Procedure for Thiol SN2 Reaction with Toluene-4-sulfonic acid 7-oxo-6-phenyl-cyclohepta-
1,3,5-trienyl ester: Toluene-4-sulfonic acid 7-oxo-6-phenyl-cyclohepta-1,3,5-trienyl ester and the 
desired thiol (1.9 eq) were dissolved in methanol (0.2 M) and stirred at room temperature for 2 h.  The 
solution was then concentrated in vacuo.  Flash chromatography of the crude residue (SiO2, EtOAc in 
hexanes) provided the desired product. 
General Procedure for O-(tert-Butyldimethylsilyl)hydroxylamine SN2 Reaction with Toluene-4-sulfonic 
acid 7-oxo-6-phenyl-cyclohepta-1,3,5-trienyl ester: Toluene-4-sulfonic acid 7-oxo-6-phenyl-cyclohepta-
1,3,5-trienyl ester and O-(tert-Butyldimethylsilyl)hydroxylamine (1.5 eq) were dissolved in dioxane (0.2 
M) and stirred at 100°C for 16 h.  The solution was then concentrated in vacuo.  Flash chromatography 
of the crude residue (SiO2, EtOAc in hexanes) provided the desired product. 
General Procedure for Formation of Zinc-Tropolone Complex:  Tropolone was added to a solution of 
1:1 EtOH/H2O (0.8 M).  Next, zinc acetate (0.5 eq) was added to the mixture and stirred for 2 h at reflux.  
The solution was then cooled to room temperature and the resulting zinc-bistropolone complex 
precipitated from solution and was collected on filter paper, dried and used without further purification. 
5.1.3 Tropolone Handling 
 Stock solutions of each tropolone (100 mM) were prepared in biology grade DMSO, 
sealed with parafilm and stored at -20°C.  Dilutions of 10 mM were prepared to be used for 
mammalian cell culture assays and enzyme assays.  Assays were designed such that cell cultures 
were not subjected to more than 2% DMSO by volume.  To avoid decomposition, samples were 
thawed at room temperature and stored as described immediately after use.  1HNMR and LC 
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traces show stored samples do not appear to deteriorate after an extended amount of time and use 
(~1 year).  
5.2 Materials and Methods - Biology 
 
5.2.1 Sirtuin 1 Enzyme Activity Assay 
 Sirtuin 1 enzyme activity was assessed using the SIRT1 Direct Fluorescent Screening 
Assay Kit from Cayman Chemical.  The kit was stored at -80°C until usage.  Reagents were 
thawed on ice and prepared according to supplied protocol.  Water used for dilutions was 
acquired from a Milli-Q Academic water purification system, filtered through a 0.22 µm 
sterilizing, low protein binding filter and autoclaved.  Compounds were tested in triplicate and 
diluted from 10 mM DMSO stock solutions with SIRT1 Direct Assay Buffer.  Tenovin-6, 
salermide and trans-resveratrol were from the Epigenetics Screening Library (96-Well) from 
Cayman Chemical.  Assay and calculations were performed according to the supplied protocol.  
The plate was read with a BioTek Synergy™ H1 hybrid reader using excitation at 350 nm and 
emission at 450 nm. 
 
5.2.2 Sirtuin 2 Enzyme Activity Assay 
Sirtuin 2 enzyme activity was assessed using the SIRT2 Direct Fluorescent Screening 
Assay Kit from Cayman Chemical.  The kit was stored at -80°C until usage.  Reagents were 
thawed on ice and prepared according to supplied protocol.  Water used for dilutions was 
acquired from a Milli-Q Academic water purification system, filtered through a 0.22 µm 
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sterilizing, low protein binding filter and autoclaved.  Compounds were tested in triplicate and 
diluted from 10 mM DMSO stock solutions with SIRT2 Direct Assay Buffer.  Tenovin-6, sirtinol 
and trans-resveratrol were from the Epigenetics Screening Library (96-Well) from Cayman 
Chemical.  Vorinostat (SAHA) was purchased from Sigma Aldrich and dissolved in DMSO to 
make a 10 mM stock solution.  Assay and calculations were performed according to the supplied 
protocol.  The plate was read with a BioTek Synergy™ H1 hybrid reader using excitation at 350 
nm and emission at 450 nm. 
5.2.3 Mammalian Cell Culturing 
 Mammalian cell cultures were prepared from cryogenically persevered samples.  Normal 
human adult dermal fibroblast (hDF) cells were generously provided by Dr. Theodore 
Rasmussen and grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies, 
cat. no. 11995-065) supplemented with 40% fetal bovine serum (FBS, Atlanta Biologies, cat. no. 
S11550) and 1% penicillin/streptomycin (Cellgro - Mediatech Inc. cat. no. 30-002-CI).  
Mammary gland, breast adenocarcinoma, derived from a metastatic site (MCF-7) were 
generously provided by Dr. Headley Freake and grown in DMEM supplemented with 10% FBS 
and 1% penicillin/streptomycin.  T-lymphoblast, acute lymphoblastic leukemia, derived from a 
patient in relapse (Molt-4) were generously provided by Dr. Andrew Wiemer and grown in 
RPMI-1640 supplemented with 10% FCS and 1% penicillin/streptomycin.  hPBMCs purified 
from human blood (purchased from Research Blood Components, Brighton, MA) and frozen in 
freezing media were generously provided by Dr. Andrew Wiemer.  The hPBMCs were thawed 
and resuspended in RPMI-1640 supplemented with 1x HEPES buffer, pyruvate, non-essential 
amino acids, 2-mercaptoethanol and 10% FBS and immediately used for the cell viability assay. 
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 Cryo-vials, stored in a liquid nitrogen phase storage container, are placed in a 37°C water 
bath for 3 to 4 minutes to thaw cryogenically preserved cells.  The thawed cells are then moved 
to a 15 mL conical tube and diluted with 10 mL of media and centrifuged at 125 x g for 5 
minutes at 4°C to pellet the cells and to remove DMSO in the cryogenic storage media.  After 
removing and discarding the supernatant, 3 mL of fresh media is used to resuspend the cell 
pellet.  The cell suspension is then added to a 25 mL T-flask with another 3 mL of media.  The 
T-flask is then placed in an incubator at 37°C with 5% carbon dioxide atmosphere. 
To preserve (pass) the unused adherent cells (MCF-7 and hDF) from a confluent culture 
the old media in the T-flask was discarded.  The flask is then washed with 6 mL of 0.25% trypsin 
to remove any residual media and discarded.  3 mL of trypsin was added to the flask and 
incubated for 5 minutes.  After incubation, the flask was viewed under a microscope to ensure 
the suspension of cells in the solution.  Next, 9 mL of DMEM was added to the flask to quench 
the trypsin.  100 µL of the culture is added to a 1.5 mL Eppendorf tube and combined with 400 
µL Trypan Blue and vortexed.  10 µL is then placed on a hemocytometer with a glass cover slide 
and counted.  Meanwhile, the remaining culture is transferred to a 15 mL conical tube and 
centrifuged at 125 x g for 5 minutes at 4°C.  After centrifuging, the supernatant is discarded and 
the cells are resuspended in fresh media and diluted to 3-5 x 105 cells/mL and 6 mL is added to a 
new T-75 flask.  If the cells are not confluent and the media has changed in color, the old media 
is discarded and fresh media is supplied without trypsinization.  MCF-7 media needs to be 
renewed 2-3 times per week while hDF media needs to be renewed 1-2 times per week.  
Cryogenic stocks can be made after the third passage for MCF-7 or the first passage for hDF.  
Stocks are prepared by combining 5 mL of cell culture at 1 x 106 cells/mL with 4 mL FBS and 1 
mL DMSO.  Approximately 2 mL is added to a cryo-vial.  The cryo-vial is placed in a freezer 
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box and stored at -20°C for 2 hours.  The freezer box is then moved to -80°C where it is stored 
overnight.  After this step the cryo-vial can be stored in a liquid nitrogen phase cell storage 
container for long term storage. 
To preserve (pass) the unused Molt-4 cells from a confluent culture the existing cells and 
media in the T-flask were counted and a dilution factor was determined to maintain the cell 
culture at 3-5 x 105 cells/mL.  Depending on the volume required to achieve this cell culture 
concentration and the age of the media, fresh media could be directly added, some of the existing 
culture could be discarded and fresh media added or some of the existing culture could be 
discarded while the remaining culture was centrifuged, old media removed and the cell pellet 
resuspended in fresh media. 
5.2.4 Mammalian Cell Viability Assay 
Cell viability assays with hDF and MCF-7 were performed using the Cell Titer 96 
Aqueous One Kit (Promega, Madison, WI).  100 µL of cells were seeded in 96 well plates 
(5x104 cells/mL).  The cells were then treated with various concentrations of tropolones or 
vorinostat and incubated at 37°C with 5% CO2 for 72 h.  Formazan content was determined by 
measuring the absorbance at 490 nm using Synergy H1 Multi-Mode plate reader (Biotek, 
Winooski, VT).  GI50 values were determined by non-linear regression analysis.  All experiments 
were repeated independently at least three times (n = 3). 
Cell viability assays with Molt-4 and hPBMCs were performed using the Quanti-Blue 
Cell Viability Assay Kit (BioAssay Systems, Hayward, CA).  100 µL of cells were seeded in 96 
well plates (105 cells/mL for Molt-4 and 106 cells/mL for hPBMCs).  The cells were then treated 
with various concentrations of the tropolones or vorinostat and incubated at 37°C with 5% CO2 
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for 72 h.  10 µL of the Quanti-Blue reagent was added into each well for the final 2 h of 
incubation and the plates were read by a Perkin-Elmer VICTOR X multilabel plate reader 
(excitation 550 nm, emission 600 nm).  GI50 values were determined by non-linear regression 
analysis.  All experiments were repeated independently at least three times (n = 3). 
5.2.5 Bacteria Culturing 
All reagents were purchased as bacteria culture tested from Fisher Scientific (Pittsburgh, PA) and 
used according to protocols described.  Stock cultures were prepared from overnight cultures by 
mixing 1 mL of culture (OD600 ~1) in a previously autoclaved cryogenic vial containing 200 μL 
of glycerol under sterile conditions. Long term stock cultures were stored at -78⁰C.  Luria-
Bertani (LB) agar was prepared using 25 g/L LB Broth, Miller (Fisher Scientific) and 15 g/L 
Agar, molecular genetics powder (Fisher Scientific) dissolved in water obtained from a Milli-Q 
Academic (Millipore, Billerica, MA), autoclaved and used under sterile conditions to form 
culture plates.  Iso-sensitest broth was prepared from Oxoid Iso-sensitest broth (Thermo 
Scientific, Waltham, MA) using 23.4 g/L dissolved in water obtained from a Milli-Q Academic 
and autoclaved.  Flat bottomed 96-well microtiter plates (Thermo Scientific) were used for 
susceptibility testing. Optical densities were measured with a Biospec-Mini DNA/RNA/Protein 
Analyzer (Shimadzu, Kyoto, Japan). 
5.2.6 Susceptibility Testing to Determine MIC Values Using Microdillution Method 
 All experiments were performed using Escherichia coli ATCC 25922 or Klebsiella 
pneumonia ATCC 10031 as the standard strain.  K. p. UCHC1 (a TMP resistant strain) and K. p. 
UCHC3 (a TMP susceptible strain) were used as clinical isolates.  Bacterial cultures were grown 
with aeration at 37°C in Iso-sensitest broth or from frozen glycerol stocks on Luria-Bertani (LB) 
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broth agar plates at 37°C.  Tropolones were synthesized as described previously.  Trimethoprim 
(TMP) was purchased from Sigma-Aldrich. 
 Minimum inhibition concentrations (MICs) were determined using the broth 
microdilution method according to CLSI standards, using a final inoculum of 5 x 105 CFU/mL.  
MIC was defined as the lowest concentration of antibiotic or inhibitor preventing visible growth 
after monitoring cell turbidity at an OD600 following an incubation period of 18 hours at 37°C. 
5.2.7 Efflux Pump Evaluation 
 To determine the effects of efflux pumps on the MICs of tropolones, Escherichia coli K-
12 strain BW25113, a well defined strain that has not been subjected to mutations, was used as 
the progenitor strain.  Escherichia coli JW0451, a single gene deletion variant of BW25113, has 
the gene coding a multidrug efflux pump subunit (acrB) deleted and therefore can be used to 
determine efflux effects. 
 MICs were determined using the broth microdilution method according to CLSI 
standards, using a final inoculum of 5 x 105 CFU/mL.  MIC was defined as the lowest 
concentration of antibiotic or inhibitor preventing visible growth after monitoring cell turbidity at 
an OD600 following an incubation period of 18 hours at 37°C. 
5.2.8 Lipopolysaccharide Permeability Evaluation 
 To determine the effects of lipopolysaccharide solubility being a limiting factor in Gram-
negative MICs, Escherichia coli K-12 strain BW25113 was used as the progenitor strain.  
Escherichia coli NR698 is a mutant strain that is defective in outer membrane 
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(lipopolysaccharide) biosynthesis and therefore is reported to impart increased outer membrane 
permeability to small molecules. 
 MICs were determined using the broth microdilution method according to CLSI 
standards, using a final inoculum of 5 x 105 CFU/mL.  MIC was defined as the lowest 
concentration of antibiotic or inhibitor preventing visible growth after monitoring cell turbidity at 
an OD600 following an incubation period of 18 hours at 37°C. 
5.2.9 Drug Affinity Responsive Target Stability (DARTS) Assay 
A cryogenically stored sample of E. coli 25922 was plated on a LB agar plate and 
incubated at 37°C overnight.  From the culture plate a single colony was picked using a sterile 
loop and added to 20 mL of LB media in a sterile 50 mL Falcon™ conical tube.  The tube was 
incubated at 37°C and shaken at 225 rpm in a New Brunswick Scientific C25KC incubator 
shaker overnight.  15 mL of culture was diluted with 10 mL of fresh LB media and OD600 was 
read on a Shimadzu BioSpec-mini.  4 mL of diluted culture was added to each well of a 6-well 
plate.  Appropriate amounts of either DMSO or tropolone were added to each well with less than 
4% DMSO in the final volume.  The 6-well plate was then incubated at 37°C overnight.  The 
resulting bacterial culture from each well was transferred to separate 1.5 mL Eppendorf tubes 
and centrifuged at 14,000 rpm for 3 minutes.  The supernatant was discarded and the process 
repeated until all culture had been pelleted.  Pellets were then washed with phosphate buffered 
saline and centrifuged at 14,000 rpm for 3 minutes.  Supernatant was discarded and the pellet 
was broken up by mechanical agitation.  Next, 200 µL of bacterial protein extraction reagent (B-
PER) with 2 µL of Halt Protease and Phosphatase Inhibitor Cocktail were added to lyse the cells.  
The lysate was placed on a rocker at 4°C for 45 minutes and then centrifuged at 14,000 rpm for 
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15 minutes.  After centrifuging, the supernatant was transferred to a new 1.5 mL Eppendorf tube 
and mixed with 200 µL of DARTS assay buffer and placed on ice.  DARTS assay buffer was 
previously prepared in an autoclaved 100 mL bottle by mixing Tris-HCl (50 mM), sodium 
chloride (50 mM) and calcium chloride (10 mM) in sterilized, filtered water.  The protein content 
in each tube was measured using the Bradford Assay and 1 µg of thermolysin (from Promega) 
was added for every 15 µg of protein reported.  Since the amount of thermolysin required was 
significantly less than 1 mg, 1 mM stock of thermolysin was prepared in sterilized, filtered water.  
The samples were then incubated at room temperature for 10 minutes.  Proteolysis by 
thermolysin was quenched by adding 0.5 M EDTA in a 1:10 volumetric ratio (20 µL).  Samples 
were stained with NuPAGE and run on a 4-12% Bis-Tris gel at 184 volts.  After cooling, the gel 
was stained with coomassie blue.  Gel images were recorded using a Nokia Lumia 920.  The 
differential band was excised from the gel using a sterile razor blade and sterile tweezers and 
placed in 500 µL of sterilized, filtered water in a sterile 1.5 mL Eppendorf tube.  The tube was 
sealed with parafilm and shipped via FedEx to the Keck MS & Proteomics Resource at Yale 
School of Medicine for LC-MS/MS protein identification. 
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Appendix A: Chemical Characterizations and Selected Spectra 
 
 
BA-pBr-OMe: yield: 88%.  Rf = 0.09 (1:1 EtOAc: Hexanes).  Mp =94.1-95.2 .  IR (KBr): ν: 3000, 2839, 1593, 
1576, 1496, 1356, 1269, 1221, 1161, 1070, 969, 819, 783, 742, 539.1HNMR (500 MHz, CDCl3): δ 7.53 (d, J 
= 8.5 Hz, 2H), 7.44 (d, J = 9.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.08 (t, J = 10.5 Hz, 1H), 6.90 (t, J = 10.0 Hz, 
1H), 6.77 (d, J = 9.5 Hz, 1H), 3.97 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 179.1, 166.2, 146.4, 140.3, 137.6, 
132.2, 131.3, 131.2, 127.0, 122.3, 112.2, 56.7.  HRMS (ESI) calcd for C14H11BrO2 [M+H]+: 291.0021; 
found:. 291.0034. 
 
 
BA-pBr-OH: yield: 82%.  Rf = 0.43 (1:1 EtOAc: Hexanes).  Mp = 125.7-126.6.  IR (KBr): ν: 3182, 1610, 1596, 
1556, 1475, 1418, 1395, 1358, 1298, 1238, 1213, 1180, 1105, 1073, 1002, 964, 938, 909, 884, 833, 819, 
807, 791, 732, 685, 631, 604, 571, 533, 510, 479, 440.1HNMR (500 MHz, CDCl3): δ 7.61 (d, J = 8.5 Hz, 2H), 
7.58 (d, J = 10.0 Hz, 1H), 7.44-7.42 (m, 4H), 7.12 (t, J = 9.5 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 172.0, 
170.6, 140.4, 138.9, 138.3, 137.2, 131.6, 131.1, 127.6, 122.8, 121.8.  HRMS (ESI) calcd for C13H9BrO2 
[M+H]+: 276.9864; found:. 276.9854. 
 
 
BA-Phe-OMe: yield: 80%.  Rf = 0.22 (1:1 EtOAc: Hexanes).  Mp = 159.7-161.0.  IR (KBr): ν: 3074, 3027, 
2967, 2838, 2135, 1590, 1574, 1466, 1354, 1268, 1216, 1170, 1091, 972, 834, 745, 697.  1HNMR (500 
MHz, CDCl3): δ7.66 (dd, J = 7.8, 3.1 Hz, 4H), 7.60 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 8.7 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 
7.38 (t, J = 7.3 Hz, 1H), 7.05 (t, J = 9.8 Hz, 1H), 6.91 (t, J = 9.6 Hz, 1H), 6.77 (d, J = 9.2 Hz, 1H), 3.97 (s, 3H).  13CNMR 
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(125 MHz, CDCl3): δ 179.4, 165.9, 147.1, 140.9, 140.8, 140.3, 137.3, 131.6, 129.8, 128.8, 127.3, 127.2, 
126.9, 126.8, 111.9, 56.5.  HRMS (ESI) calcd for C20H16O2 [M+H]+: 289.1229; found:. 289.1242. 
 
 
BA-Phe-OH: yield: 76%.  Rf = 0.39 (1:1 EtOAc: Hexanes).  Mp = 166.1-167.3.  IR (KBr): ν: 3136, 3024, 2918, 
1591, 1552, 1466, 1357, 1240, 1217, 1170, 764, 699.1HNMR (500 MHz, CDCl3): δ 9.91 (s, 1H), 7.74 (d, J = 
7.2 Hz, 2H), 7.72 – 7.68 (m, 3H), 7.66 (d, J = 8.3 Hz, 2H), 7.52 (t, J = 7.4 Hz, 2H), 7.49 – 7.40 (m, 3H), 7.16 
(t, J = 9.8 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 171.33, 170.46, 141.22, 140.68, 140.50, 138.80, 138.63, 
136.77, 129.77, 128.85, 127.54, 127.40, 127.20, 127.04, 121.87.  HRMS (ESI) calcd for C19H14O2 [M+H]+: 
275.1072; found:. 275.1062. 
 
 
BA-SM-OMe: yield: 72%.  Rf = 0.41 (EtOAc).  Mp = 160.1-161.3.  IR (KBr): ν: 3006, 2958, 2920, 2837, 1590, 
1576, 1496, 1250, 1217, 1084, 970, 824, 756. 1HNMR (500 MHz, CDCl3): δ 7.63 – 7.53 (m, 7H), 7.08 (t, J = 
10.1 Hz, 1H), 7.01 (d, J = 8.7 Hz, 2H), 6.94 (t, J = 10.2, 9.3 Hz, 1H), 6.79 (d, J = 9.6 Hz, 1H), 3.99 (s, 3H), 
3.88 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 166.01 , 159.41 , 147.32 , 139.77 , 137.46 , 132.26 , 131.68 , 
129.95 , 128.32 , 127.12 , 126.48 , 114.40 , 112.16 , 56.67 , 55.53.  HRMS (ESI) calcd for C21H18O3 [M+H]+: 
319.1334; found:. 319.1327. 
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BA-SM-OH: yield: 72%.  Rf = 0.24 (1:1 EtOAc: Hexanes).  Mp = 167.3-168.5.  IR (KBr): ν: 3156, 3034, 2960, 
2917, 2838, 1595, 1541, 1494, 1464, 1414, 1355, 1284, 1240, 1178, 1033, 911, 825. 1HNMR (500 MHz, 
CDCl3): δ 9.90 (s, 1H), 7.70 (d, J = 8.6 Hz, 3H), 7.63 (dd, J = 8.4, 2.0 Hz, 4H), 7.51 – 7.40 (m, 2H), 7.15 (t, J = 
9.5 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 3.92 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 171.27, 170.49, 159.40, 
140.84, 140.47, 138.64, 138.16, 136.69, 133.19, 129.74, 128.21, 127.37, 126.56, 121.92, 114.32, 55.39.  
HRMS (ESI) calcd for C20H16O3 [M+H]+: 305.1178; found:. 305.1177. 
 
 
BA-DM-OMe: yield: 98%.  Rf = 0.39 (EtOAc).  Mp = 155.2-157.8.  IR (KBr): ν: 3086, 2993, 2940, 2904, 
2832, 1578, 1549, 1491, 1461, 1270, 1221, 1209, 1178, 1013, 970, 843, 748.1HNMR (500 MHz, CD2Cl2): 
δ7.63 – 7.56 (m, 5H), 7.09 (t, J = 10.1 Hz, 1H), 7.01 (d, J = 3.0 Hz, 1H), 6.99 – 6.92 (m, 2H), 6.90 (dd, J = 
8.9, 3.0 Hz, 1H), 6.80 (d, J = 9.6 Hz, 1H), 4.01 (s, 3H), 3.86 (s, 2H), 3.82 (s, 3H).  13CNMR (125 MHz, CD2Cl2): 
δ 179.47 , 153.82 , 150.90 , 138.03 , 137.32 , 131.39 , 131.34 , 129.55 , 129.11 , 129.10 , 126.90 , 116.63 , 
113.38 , 112.75 , 111.86 , 99.99 , 56.51 , 56.38 , 55.8.  HRMS (ESI) calcd for C22H20O4 [M+H]+: 349.1440; 
found:. 349.1468. 
 
 
BA-DM-OH: yield: 72%.  Rf = 0.27 (1:1 EtOAc: Hexanes).  Mp = 144.9-145.8.  IR (KBr): ν: 3144, 3029, 3002, 
2953, 2829, 1615, 1548, 1472, 1452, 1364, 1244, 1231, 1206, 1175, 1052, 1024, 798, 718.1HNMR (500 
MHz, CDCl3): δ 9.94 (s, 1H), 7.74 – 7.66 (m, 3H), 7.63 (d, J = 7.6 Hz, 2H), 7.51 – 7.40 (m, 2H), 7.15 (t, J = 
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10.6 Hz, 1H), 7.02 (d, J = 3.1 Hz, 1H), 6.99 (d, J = 8.9 Hz, 1H), 6.93 (dd, J = 8.9, 3.1 Hz, 1H), 3.87 (s, 3H), 
3.83 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 171.24, 170.54, 153.84, 150.89, 140.63, 138.73, 138.47, 
136.71, 131.08, 129.36, 129.03, 127.39, 121.94, 116.69, 113.47, 112.72, 56.35, 55.85.  HRMS (ESI) calcd 
for C21H18O4 [M+H]+: 335.1283; found:. 335.1282. 
 
BA-TM-OMe: yield: 99%.  Rf = 0.42 (EtOAc).  Mp = 132.9-134.6.  IR (KBr): ν: 3317, 2928, 2837, 1589, 1572, 
1461, 1270, 1217, 1165, 1088, 1069, 998, 751.1HNMR (500 MHz, CDCl3): δ 7.60 – 7.55 (m, 5H), 7.13 (d, J 
= 8.6 Hz, 1H), 7.08 (t, J = 10.4 Hz, 1H), 6.95 (t, J = 10.6, 8.9 Hz, 1H), 6.80 (dd, J = 9.1, 3.2 Hz, 2H), 4.00 (s, 
3H), 3.98 (s, 3H), 3.95 (s, 3H), 3.76 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 179.61 , 165.97 , 153.35 , 151.65 
, 147.28 , 142.72 , 139.78 , 137.98 , 137.49 , 132.28 , 131.61 , 129.37 , 128.84 , 128.44 , 127.06 , 125.03 , 
112.10 , 107.73 , 61.23 , 61.17 , 56.65 , 56.23.  HRMS (ESI) calcd for C23H22O5 [M+H]+: 379.1546; found:. 
379.1535. 
 
 
BA-TM-OH: yield: 77%.  Rf = 0.23 (1:1 EtOAc: Hexanes).  Mp = 150.0-151.3.  IR (KBr): ν: 3111, 3005, 2978, 
2932, 2823, 1596, 1548, 1490, 1475, 1459, 1415, 1290, 1237, 1108, 1079, 1006, 756. 1HNMR (500 MHz, 
CDCl3): δ 9.91 (s, 1H), 7.73 (d, J = 10.1 Hz, 1H), 7.64 (q, J = 8.3, 6.6 Hz, 4H), 7.52 – 7.41 (m, 2H), 7.16 (dd, J 
= 12.1, 9.4 Hz, 2H), 6.82 (d, J = 8.7 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 3H), 3.79 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 171.5, 170.6, 153.5, 151.7, 142.8, 140.8, 139.0, 138.5, 138.3, 136.8, 129.3, 129.1, 128.3, 127.6, 
125.0, 122.0, 107.8, 61.3, 61.2, 56.3.  HRMS (ESI) calcd for C22H20O5 [M+H]+: 365.1389; found:. 365.1373. 
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BA-Nap-OMe: yield: 85%.  Rf = 0.48 (EtOAc).  IR (KBr): ν: 3036, 3005, 2940, 2834, 1570, 1492, 1267, 
1214, 1159, 1086, 972, 776. 1HNMR (500 MHz, CDCl3): δ 8.07 (d, J = 8.3 Hz 1H), 7.96 (d, J = 10.6 Hz, 1H), 
7.92 (d, J = 8.2 Hz, 1H), 7.69 – 7.65 (m, 2H), 7.64 (dd, J = 9.0, 1.0 Hz, 1H), 7.61 – 7.47 (m, 7H), 7.12 (t, J = 
10.2, 1H), 6.99 (t, J = 9.3, 10.2 Hz, 1H), 6.83 (d, J = 9.6 Hz, 1H), 4.03 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 
179.4, 165.9, 147.1, 140.3, 140.2, 139.9, 137.4, 133.8, 131.6, 129.7, 129.3, 128.5, 128.2, 127.6, 127.0, 
126.9, 126.1, 126.0, 125.7, 125.4, 111.9, 56.5.  HRMS (ESI) calcd for C24H18O2 [M+H]+: 339.1385; found:. 
339.1358. 
 
 
BA-Nap-OH: yield: 63%.  Rf = 0.31 (1:1 EtOAc: Hexanes).  Mp = 135.6-136.5.  IR (KBr): ν: 3152, 3042, 1610, 
1594, 1543, 1395, 1357, 1293, 1229, 800, 777, 741, 707. 1HNMR (500 MHz, CDCl3): δ 9.96 (s, 1H), 8.06 
(d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.78 (d, J = 10.1 Hz, 1H), 7.72 (d, J = 8.0 
Hz 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.61-7.44 (m, 6H), 7.19 (t, J = 9.8 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 
171.61, 170.32, 140.82, 140.70, 139.74, 138.96, 138.82, 136.79, 133.86, 131.56, 129.99, 129.28, 128.34, 
127.86, 127.46, 127.05, 126.14, 126.06, 125.87, 125.44, 121.66.  HRMS (ESI) calcd for C23H16O2 [M+H]+:  
325.1229; found:. 325.1251. 
 
 
BA-P5-OMe: yield: 95%.  Rf = 0.47 (EtOAc).  Mp = 104.8-106.0.  IR (KBr): ν: 3007, 2950, 2924, 2868, 2834, 
1587, 1563, 1490, 1465, 1277, 1220, 1164, 1088, 966, 755. 1HNMR (500 MHz, CDCl3): δ 7.49 – 7.43 (m, 
3H), 7.40 (d, J = 8.2 Hz, 2H), 7.03 (t, J = 10.6 Hz, 1H), 6.89 (t, J = 8.9 Hz, 1H), 6.75 (d, J = 9.6 Hz, 1H), 6.42 
(d, J = 15.9 Hz, 1H), 6.28 (dt, J = 15.8, 6.9 Hz, 1H), 3.95 (s, 3H), 2.22 (q, J = 7.1, 1.4 Hz, 2H), 1.52 (h, J = 7.4 
Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 165.91, 147.34, 139.84, 137.84, 137.32, 
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131.62, 131.59, 129.77, 129.72, 127.10, 125.70, 112.13, 56.63, 35.35, 22.71, 13.91.  HRMS (ESI) calcd for 
C19H20O2 [M+H]+: 281.1542; found:. 281.1563. 
 
 
BA-P5-OH: yield: 89%.  Rf = 0.44 (1:1 EtOAc: Hexanes).  1HNMR (500 MHz, CDCl3): δ 7.62 (d, J = 10.2 Hz, 
1H), 7.52 – 7.37 (m, 6H), 7.10 (t, J = 9.7 Hz, 1H), 6.45 (d, J = 15.8 Hz, 1H), 6.32 (dt, J = 15.7, 6.8 Hz, 1H), 
2.25 (q, J = 7.2 Hz, 2H), 1.54 (h, J = 7.4 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 
170.96, 170.65, 140.38, 138.50, 138.14, 136.62, 131.96, 129.48, 129.43, 127.31, 125.75, 122.14, 35.18, 
22.52, 13.73.  HRMS (ESI) calcd for C18H18O2 [M+H]+: 267.1385; found:. 267.1399. 
 
 
BA-P7-OMe: yield: 90%.  Rf = 0.62 (EtOAc).  Mp = 113.5-114.4.  IR (KBr): ν: 3008, 2952, 2921, 2846, 1587, 
1563, 1490, 1467, 1357, 1278, 1221, 1164, 1088, 968, 755. 1HNMR (500 MHz, CDCl3): δ 7.49 – 7.44 (m, 
3H), 7.38 (d, J = 8.3 Hz, 2H), 7.04 (t, J = 9.8 Hz, 1H), 6.90 (t, J = 9.8 Hz, 1H), 6.76 (d, J = 9.6 Hz, 1H), 6.42 (d, 
J = 15.8 Hz, 1H), 6.29 (dt, J = 15.6, 6.8 Hz, 1H), 3.98 (s, 3H), 2.24 (q, J = 14.3, 6.6 Hz, 2H), 1.51 (p, J = 7.7, 
2.5 Hz, 2H), 1.40 – 1.34 (m, 4H), 0.92 (t, J = 6.3 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 179.43, 165.77, 
147.24, 139.66, 137.72, 137.05, 131.76, 131.30, 129.56, 129.41, 126.88, 125.54, 111.83, 56.47, 33.10, 
31.46, 29.07, 22.59, 14.09.  HRMS (ESI) calcd for C21H24O2 [M+H]+: 309.1855; found:. 309.1865. 
 
 
BA-P7-OH: yield: 67%.  Rf = 0.49 (1:1 EtOAc: Hexanes).  Mp = 98.9-100.0.  IR (KBr): ν: 3148, 2950, 2920, 
2849, 1619, 1551, 1473, 1362, 1239, 1197, 792, 711. 1HNMR (500 MHz, CDCl3): 9.88 (s, 1H), 7.64 (d, J = 
10.2 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.49 – 7.44 (m, 3H), 7.41 (t, J = 10.3 Hz, 1H), 7.12 (t, J = 9.9 Hz, 1H), 
6.47 (d, J = 16.8 Hz, 1H), 6.35 (dt, J = 15.8, 6.8 Hz, 1H), 2.28 (q, J = 7.9, 6.5 Hz, 2H), 1.54 (p, J = 11.9, 7.2 
Hz, 2H), 1.43 – 1.34 (m, 4H), 0.96 (t, J = 6.5 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 170.99, 170.65, 140.39, 
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138.52, 138.14, 136.63, 132.25, 129.50, 129.25, 127.32, 125.76, 122.13, 33.11, 31.47, 29.05, 22.59, 
14.09.  HRMS (ESI) calcd for C20H22O2 [M+H]+: 295.1698; found:. 295.1705. 
 
 
BA-P8-OMe: yield: 87%.  Rf = 0.24 (1:1 EtOAc: Hexanes).  Mp = 117.2-118.4.  IR (KBr): ν: 3007, 2958, 
29020, 2850, 1587, 1564, 1491, 1278, 1221, 1164, 1088, 967, 755. 1HNMR (500 MHz, CDCl3): δ 7.47 (dd, 
J = 13.9, 5.6 Hz, 3H), 7.38 (d, J = 8.3 Hz, 2H), 7.04 (t, J = 10.7 Hz, 1H), 6.90 (t, J = 9.8 Hz, 1H), 6.75 (d, J = 
9.6 Hz, 1H), 6.42 (d, J = 13.9 Hz, 1H), 6.29 (dt, J = 15.8, 6.8 Hz, 1H), 3.97 (s, 3H), 2.24 (q, J = 8.3, 6.3 Hz, 
2H), 1.50 (p, J = 8.6, 5.6 Hz, 2H), 1.42 – 1.26 (m, 6H), 0.92 (t, J = 7.1 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 
179.57, 165.92, 147.37, 139.81, 137.87, 137.21, 131.91, 131.48, 129.71, 129.57, 127.04, 125.69, 112.01, 
56.62, 33.28, 31.93, 29.51, 29.08, 22.81, 14.28.  HRMS (ESI) calcd for C22H26O2 [M+H]+: 323.2011; found:. 
323.2022. 
 
 
BA-P8-OH: yield: 68%.  Rf = 0.70 (1:1 EtOAc: Hexanes).  Mp = 85.3-86.4 .  IR (KBr): ν: 3149, 3018, 2958, 
2918, 2850, 1618, 1595, 1553, 1474, 1364, 1275, 1243, 1216, 1197, 965, 787.1HNMR (500 MHz, CDCl3): δ 
9.90 (s, 1H), 7.63 (d, J = 10.0 Hz, 1H), 7.53 – 7.44 (m, 5H), 7.42 (t, J = 9.5 Hz, 1H), 7.12 (t, J = 9.9 Hz, 1H), 
6.47 (d, J = 15.8 Hz, 1H), 6.35 (dt, J = 15.7, 6.8 Hz, 1H), 2.32 – 2.25 (m, 2H), 1.57 – 1.49 (m, 2H), 1.43 – 
1.32 (m, 6H), 0.95 (t, J = 7.3 Hz, 3H).  13CNMR (125 MHz, CDCl3): δ 140.38 , 138.13 , 136.61 , 132.25 , 
129.49 , 129.25 , 127.30 , 125.76 , 122.12 , 33.14 , 31.77 , 29.33 , 28.92 , 22.66 , 14.12.  HRMS (ESI) calcd 
for C21H24O2 [M+H]+: 309.1855; found:. 309.1848. 
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BA-HC2-OMe: yield: % 51.  Rf = 0.49 (EtOAc).  Mp = 137.4-138.4.  IR (KBr): ν: 3127, 3024, 3006, 2924, 
2840, 1589, 1573, 1514, 1494, 1465, 1443, 1412, 1355, 1268, 1216, 1168, 1116, 1090, 1071, 1042, 1006, 
972.1HNMR (500 MHz, CDCl3): δ 7.74 (d, J = 7.4 Hz, 2H), 7.60 – 7.49 (m, 4H), 7.08 (dd, J = 54.5, 11.3 Hz, 
1H), 6.94 (t, J = 9.4 Hz, 1H), 6.79 (d, J = 9.7 Hz, 1H), 6.73 (d, J = 3.3 Hz, 1H), 6.52 (dd, J = 3.3, 1.8 Hz, 1H), 
3.99 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 179.34, 165.85, 153.86, 146.91, 142.20, 140.21, 137.41, 
137.19, 132.02, 131.57, 131.14, 131.09, 130.43, 129.81, 128.00, 126.88, 123.39, 111.88, 111.74, 105.36, 
56.51.  HRMS (ESI) calcd for C18H14O3 [M+H]+: 279.1021; found:. 279.1005. 
 
 
BA-HC2-OH: yield: % 72.  Rf = 0.87 (EtOAc).  Mp = 87.4-88.2.  IR (KBr): ν: 3150, 3069, 2763, 1617, 1549, 
1472, 1364, 1272, 1240, 1181, 1155, 1073, 1005, 901, 838, 824, 797, 756.1HNMR (500 MHz, CDCl3): δ 
7.80 (d, J = 9.2 Hz, 2H), 7.67 (t, J = 10.2 Hz, 1H), 7.65 – 7.58 (m, 2H), 7.55 (d, J = 1.7 Hz, 1H), 7.49 – 7.41 
(m, 3H), 7.14 (t, J = 9.4 Hz, 1H), 6.76 (d, J = 3.2 Hz, 1H), 6.55 (dd, J = 3.4, 1.8 Hz, 1H).  13CNMR (125 MHz, 
CDCl3): δ 171.24, 170.47, 153.63, 142.41, 140.38, 140.26, 138.69, 138.48, 137.02, 136.76, 131.46, 
130.98, 130.80, 129.76, 127.39, 123.61, 121.90, 121.61, 111.80, 105.66.  HRMS (ESI) calcd for C17H12O3 
[M+H]+: 265.1865; found:. 265.0835. 
 
 
 
 
SG-TMS-OMe: yield: 69%.  Rf = 0.15 (1:1 EtOAc: Hexanes).  Mp = 165.7-166.9.  IR (KBr): ν: 3008, 2957, 
2898, 2844, 2154, 1588, 1566, 1498, 1279, 1221, 838, 757. 1HNMR (500 MHz, CDCl3): δ 7.57 (d, J = 10.1 
Hz, 1H), 7.50 (d, J = 9.1 Hz, 2H), 7.44 (d, J = 6.4 Hz, 3H), 7.06 (t, J = 9.1 Hz, 1H), 6.90 (t, J = 10.7 Hz, 1H), 
6.76 (d, J = 10.1 Hz, 1H), 3.96 (s, 3H), 0.28 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 179.24, 166.10, 146.77, 
141.60, 137.54, 132.56, 132.03, 131.70, 130.08, 129.46, 126.96, 126.77, 122.81, 112.02, 105.27, 94.95, 
56.66, 0.18.  HRMS (ESI) calcd for C19H20O2Si [M+H]+: 309.1311; found:. 309.1317. 
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SG-TMS-OH: yield: 72%.  Rf = 0.55 (1:1 EtOAc: Hexanes).  Mp = 133.4-134.6.  IR (KBr): ν: 3159, 2960, 
2898, 2865, 2156, 1712, 1617, 1593, 1550, 1472, 1456, 1414, 1365, 1274, 1246, 1202, 1111, 1063, 1018, 
913. 1HNMR (500 MHz, CDCl3): δ 7.57 (t, J = 9.1 Hz, 3H), 7.49 (d, J = 6.3 Hz, 2H), 7.46 – 7.38 (m, 2H), 7.11 
(t, J = 10.4 Hz, 1H), 0.29 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 171.19, 170.44, 140.38, 139.93, 138.22, 
136.95, 131.79, 129.24, 127.35, 123.17, 121.77, 104.80, 95.23, 0.00.  HRMS (ESI) calcd for C18H18O2Si 
[M+H]+: 295.1154; found:. 295.1148. 
 
 
 
EF-1-OMe: yield: 99%.  Rf = 0.5 (EtOAc).  Mp = 127.0-128.3.  1HNMR (500 MHz, CDCl3): δ 9.98 (s, 1H), 7.94 
(s, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.07 
(t, J = 10.7 Hz, 1H), 6.89 (t, J = 10.7 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 192.34, 179.03, 166.32, 145.99, 142.38, 138.00, 136.43, 135.68, 132.73, 131.22, 128.97, 
128.79, 127.05, 112.43, 56.71.  HRMS (ESI) calcd for C15H12O3 [M+H]+: 241.0865; found:. 241.0857. 
 
 
EF-1-OH: yield: 54%.  Rf = 0.65 (EtOAc).  Mp = 134.0-134.4.  IR (KBr): ν: 3182, 2821, 2728, 1695, 1595, 
1555, 1474, 1417, 1358, 1302, 1282, 1209, 1149, 655.1HNMR (500 MHz, CDCl3): δ 10.10 (s, 1H), 9.87 (s, 
1H), 8.06 (s, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.66 (t, J = 7.8 Hz, 2H), 7.50 – 7.42 (m, 
2H), 7.15 (t, J = 10.5 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 192.12, 170.15, 140.59, 138.23, 137.42, 
136.70, 135.53, 130.79, 129.67, 127.66, 121.39.  HRMS (ESI) calcd for C14H10O3 [M+H]+: 227.0708; found:. 
227.0713. 
308 
 
 
 
EF-2-OH: yield: 44%.  Rf = 0.61 (EtOAc).  Mp = 154.1-155.5.  IR (KBr): ν: 3150, 3102, 3069, 2958, 2762, 
1714, 1617, 1549, 1473, 1365, 1271, 1241, 1218, 1179, 1155, 1073, 1006, 825, 798, 756.1HNMR (500 
MHz, CDCl3): δ 9.83 (s, 1H), 8.10 (d, J = 6.9 Hz, 2H), 7.66 (d, J = 6.9 Hz, 2H), 7.63 (d, J = 10.1 Hz, 1H), 7.50 
– 7.44 (m, 2H), 7.16 (t, J = 10.5 Hz, 1H), 2.70 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 197.63, 171.46, 170.32, 
144.65, 140.28, 138.10, 137.30, 136.66, 129.60, 128.30, 127.42, 121.55, 26.73.  HRMS (ESI) calcd for 
C15H12O3 [M+H]+: 241.0865; found:. 241.0829. 
 
 
EF-3-OMe: yield: 87%.  Rf = 0.44 (EtOAc).  Mp = 142.5-143.7.  IR (KBr): ν: 3106, 2965, 2762, 1716, 1618, 
1589, 1548, 1511, 1474, 1367, 1342, 1291, 1272, 1243, 1180, 1156, 1073, 1007, 839, 825, 799, 767, 
755.1HNMR (500 MHz, CDCl3): δ 8.02 (d, J = 8.4 Hz, 2H), 7.64 (ddd, J = 11.8, 5.4, 3.3 Hz, 1H), 7.50 (d, J = 
7.4 Hz, 2H), 7.45 – 7.39 (m, 2H), 7.05 (t, J = 10.1 Hz, 1H), 6.87 (t, J = 10.6 Hz, 1H), 6.75 (d, J = 9.6 Hz, 1H), 
3.92 (s, 3H), 3.88 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 179.07, 167.03, 166.24, 146.45, 146.22, 137.92, 
132.65, 132.24, 132.16, 129.57, 129.46, 129.40, 128.73, 128.64, 126.99, 112.27, 56.69, 52.25.  HRMS 
(ESI) calcd for C16H14O4 [M+H]+: 271.0970; found:. 271.0956. 
 
 
EF-3-OH: yield: 57%.  Rf = 0.74 (EtOAc).  Mp = 135.4-136.2.  IR (KBr): ν: 3235, 3149, 3068, 3013, 2959, 
2949, 2862, 2760, 1716, 1617, 1549, 1472, 1364, 1272, 1240, 1182, 1155, 1005, 825, 798, 767, 
755.1HNMR (500 MHz, CDCl3): δ 8.17 (d, J = 7.8 Hz, 2H), 7.63 (d, J = 7.9 Hz, 3H), 7.48 (s, 2H), 7.16 (s, 1H), 
4.00 (s, 3H).  13CNMR (125 MHz, Methanol-d4): δ 171.89, 170.29, 166.85, 145.29, 140.22, 138.97, 137.22, 
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129.36, 129.28, 129.16, 129.14, 128.90, 127.42, 121.25, 51.28.  HRMS (ESI) calcd for C15H12O4 [M+H]+: 
257.0814; found:. 257.0782. 
 
 
EF-4-OMe: yield: 99%.  Rf = 0.43 (EtOAc).  Mp = 90.1-91.3.  IR (KBr): ν: 3045, 2999, 2814, 2715, 1693, 
1612, 1570, 1494, 1462, 1436, 1410, 1380, 1355, 1275, 1216, 1179, 1151, 1095, 1078, 1015, 989.1HNMR 
(500 MHz, CDCl3): δ 10.08 (s, 1H), 8.02 (s, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.60 (t, J = 
7.6 Hz, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.16 (t, J = 10.2 Hz, 1H), 6.98 (t, J = 10.6 Hz, 1H), 6.84 (d, J = 9.7 Hz, 
1H), 4.02 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 192.21, 178.95, 166.25, 146.00, 142.20, 137.78, 136.38, 
135.57, 132.44, 131.06, 128.97, 128.65, 126.87, 112.12, 56.58.  HRMS (ESI) calcd for C15H12O3 [M+H]+: 
241.0965; found:. 241.0845. 
 
 
EF-4-OH: yield: 40%.  Rf = 0.64 (EtOAc).  Mp = 130.0-131.2.  IR (KBr): ν: 3179, 3052, 2921, 2818, 2802, 
2728, 1683, 1595, 1555, 1473, 1416, 1357, 1302, 1281, 1241, 1207, 1162, 1148, 1089, 734.1HNMR (500 
MHz, CDCl3): δ 10.09 (s, 1H), 8.05 (t, J = 1.8 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.65 
(t, J = 8.6 Hz, 2H), 7.49 – 7.41 (m, 2H), 7.15 (t, J = 10.4 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 192.14, 
172.02, 170.15, 141.03, 140.59, 138.22, 137.42, 136.69, 135.53, 130.79, 129.65, 129.11, 127.67, 121.40.  
HRMS (ESI) calcd for C14H10O3 [M+H]+: 227.0708; found:. 277.0714. 
 
 
Am-NO2-OMe: yield: 79%.  Rf = 0.50 (EtOAc).  IR (KBr): ν: 3169, 3105, 3067, 2976, 2925, 2874, 2848, 
2362, 1597, 1577, 1551, 1503, 1459, 1442, 1409, 1341, 1309, 1289, 1273, 1217, 1163, 1118, 1106, 1090, 
1063, 1045, 1014, 975.1HNMR (500 MHz, CDCl3): δ 8.32 – 8.27 (m, 2H), 7.70 – 7.64 (m, 2H), 7.50 (d, J = 
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8.9 Hz, 1H), 7.19 (t, J =  9.6 Hz, 1H), 6.98 (t, J = 10.6 Hz, 1H), 6.85 (d, J = 9.8 Hz, 1H), 4.03 (s, 3H).  13CNMR 
(125 MHz, CDCl3): δ166.46 , 147.96 , 145.22 , 137.93 , 133.13 , 130.40 , 126.69 , 123.27 , 112.12 , 56.65.  
HRMS (ESI) calcd for C14H11NO4 [M+H]+: 258.0766; found:. 258.0744. 
 
 
Am-NO2-OH: yield: 52%.  Rf = 0.67 (EtOAc).  Mp = 187.6-188.3.  IR (KBr): ν: 3248, 3151, 3106, 3070, 3012, 
2953, 2848, 2761, 1716, 1617, 1549, 1511, 1474, 1421, 1365, 1342, 1272, 1240, 1179, 1006, 799, 
747.1HNMR (500 MHz, CDCl3): δ 9.79 (s, 1H), 8.36 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 9.2 Hz, 2H), 7.63 (d, J = 
9.9 Hz, 1H), 7.52 – 7.48 (m, 2H), 7.22 – 7.15 (m, 1H).  13CNMR (125 MHz, CDCl3): δ 171.92 , 169.93 , 
146.47 , 140.19 , 137.75 , 137.45 , 130.40 , 127.46 , 123.50 , 121.00.  HRMS (ESI) calcd for C13H9NO4 
[M+H]+: 244.0610; found:. 244.0588. 
 
 
Am-NHBoc-OMe: yield: 84%.  Rf = 0.71 (EtOAc).  Mp = 194.9-196.2.  IR (KBr): ν: 3246, 3149, 3107, 3068, 
3046, 2970, 2761, 1709, 1589, 1548, 1512, 1473, 1364, 1321, 1271, 1241, 1218, 1174, 1155, 1050, 1006, 
838, 796, 757.1HNMR (500 MHz, CDCl3): δ 7.51 – 7.46 (m, 3H), 7.42 (d, J = 8.4 Hz, 2H), 7.06 (t, J = 10.1 Hz, 
1H), 6.96 – 6.89 (m, 1H), 6.78 (d, J = 9.6 Hz, 1H), 6.59 (s, 1H), 3.99 (s, 3H), 1.57 (s, 9H).  13CNMR (125 
MHz, CDCl3): δ 179.43, 165.74, 146.86, 138.17, 137.01, 135.84, 132.16, 132.09, 131.93, 131.17, 130.18, 
128.55, 128.46, 126.91, 117.94, 111.85, 56.46, 28.36, 24.89.  HRMS (ESI) calcd for C19H21NO4 [M+H]+: 
328.1549; found:. 328.1529. 
 
 
Am-NH2-OH: yield: 73%.  Rf = 0.68 (EtOAc).  Mp = 243.2-244.4.  IR (KBr): ν: 2979, 2782, 2726, 2650, 2578, 
2524, 2487, 1452, 1342, 1313, 1269, 1238, 1217, 1181, 1064, 792, 780, 710.1HNMR (500 MHz, DMSO-
d6): δ 7.66 – 7.56 (m, 3H), 7.50 – 7.42 (m, 3H), 7.35 (d, J = 10.1 Hz, 1H), 7.15 (t, J = 9.9 Hz, 1H).  13CNMR 
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(125 MHz, DMSO-d6): δ 172.87, 169.52, 140.20, 139.26, 137.09, 131.09, 127.72, 123.04, 120.93.  HRMS 
(ESI) calcd for C13H11NO2 [M+H]+: 214.0868; found:. 214.0870. 
 
 
Am-Piv-OH: yield: 64%.  Rf = 0.12 (1:1 EtOAc: Hexanes).  Mp = oil.  IR (KBr): ν: 3300, 3245, 3106, 3068, 
2953, 2926, 2893, 2841, 2761, 1713, 1588, 1572, 1505, 1460, 1310, 1288, 1270, 1238, 1213, 1175, 1062, 
749.1HNMR (500 MHz, CDCl3): δ 7.66 (d, J = 7.9 Hz, 2H), 7.62 (d, J = 10.2 Hz, 1H), 7.54 (d, J = 9.1 Hz, 2H), 
7.46 – 7.37 (m, 3H), 7.11 (t, J = 10.7 Hz, 1H), 1.37 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 171.16, 170.46, 
166.38, 148.14, 140.40, 138.22, 136.60, 130.09, 127.34, 121.94, 119.50, 117.72, 39.71, 27.65.  HRMS 
(ESI) calcd for C18H19NO3 [M+H]+: 298.1443; found:. 298.1474. 
 
 
Am-P5-OH: yield: 65%.  Rf = 0.13 (1:1 EtOAc: Hexanes).  Mp = 127.2-128.5.  IR (KBr): ν: 3296, 3178, 3079, 
2977, 2922, 2855, 2250, 1770, 1657, 1591, 1515, 1473, 1408, 1361, 1315, 1290, 1275, 1243, 1228, 1180, 
1117, 997.1HNMR (500 MHz, CDCl3): δ 9.85 (s, 1H), 7.63 (d, J = 9.4 Hz, 3H), 7.53 (d, J = 8.1 Hz, 2H), 7.49 – 
7.39 (m, 2H), 7.13 (t, J = 9.8 Hz, 1H), 5.93 (ddt, J = 16.6, 10.5, 6.0 Hz, 1H), 5.17 (d, J = 17.1 Hz, 1H), 5.10 
(d, J = 11.0 Hz, 1H), 2.54 (q, J = 4.3, 3.2 Hz, 4H).  13CNMR (125 MHz, CDCl3): δ 171.47, 170.65, 170.22, 
140.49, 138.59, 137.99, 136.83, 136.64, 135.58, 133.92, 130.08, 127.47, 121.74, 119.50, 116.01, 36.87, 
29.44.  HRMS (ESI) calcd for C18H17NO3 [M+H]+: 296.1287; found:. 296.1259. 
 
 
HC-1-OMe: yield: 95%.  Rf = 0.47 (EtOAc).  Mp = 117.2-118.4.  IR (KBr): ν: 2978, 2930, 2876, 2759, 1730, 
1588, 1571, 1503, 1456, 1420, 1354, 1304, 1268, 1246, 1211, 1173, 1156, 1126, 1086, 1063, 1047, 990, 
933, 916, 888, 862, 815, 740.1HNMR (500 MHz, CDCl3): δ 7.48 (d, J = 9.0 Hz, 1H), 7.11 – 7.00 (m, 3H), 
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6.94 – 6.87 (m, 2H), 6.77 (d, J = 9.6 Hz, 1H), 4.32 (s, 4H), 3.99 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 
179.46, 165.68, 146.77, 143.57, 142.17, 136.96, 134.53, 131.14, 126.81, 122.75, 118.53, 116.81, 111.83, 
64.53, 64.35, 56.48.  HRMS (ESI) calcd for C16H14O4 [M+H]+: 271.0970; found:. 271.0972. 
 
 
HC-1-OH: yield: 64%.  Rf = 0.42 (1:1 EtOAc: Hexanes).  Mp = 102.8-103.6. IR (KBr): ν: 3170, 2976, 2932, 
2874, 1590, 1578, 1551, 1504, 1470, 1423, 1409, 1356, 1299, 1288, 1250, 1231, 1194, 1158, 1127, 1063, 
1045, 1004, 924.1HNMR (500 MHz, CD2Cl2): δ 9.91 (s, 1H), 7.62 (d, J = 10.2 Hz, 1H), 7.47 – 7.38 (m, 2H), 
7.14 – 7.04 (m, 3H), 6.99 (d, J = 8.3 Hz, 1H), 4.34 (s, 4H). 13CNMR (125 MHz, CD2Cl2): δ. 170.92, 170.60, 
143.79, 143.22, 140.44, 136.58, 133.02, 127.29, 122.66, 122.20, 118.44, 117.13, 64.54, 64.38, 30.99.  
HRMS (ESI) calcd for C15H12O4 [M+H]+: 257.0814; found:. 257.0780. 
 
 
HC-2-OMe: yield: 84%.  Rf = 0.65 (EtOAc).  Mp = 96.8-97.7.  IR (KBr): ν: 3242, 3151, 3105, 3068, 2842, 
2761, 1714, 1617, 1549, 1474, 1366, 1271, 1242, 1216, 1180, 1154, 1073, 1017, 1006, 838, 825, 783, 
734.1HNMR (500 MHz, CDCl3): δ 8.25 (d, J = 9.2 Hz, 1H), 7.81 (d, J = 3.4 Hz, 1H), 7.56 (d, J = 1.7 Hz, 1H), 
7.14 – 7.01 (m, 2H), 6.84 (d, J = 9.3 Hz, 1H), 6.60 (dd, J = 3.5, 1.8 Hz, 1H), 4.02 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 176.63, 164.69, 150.97, 142.95, 134.57, 132.06, 131.12, 126.92, 115.80, 112.79, 112.05, 56.54.  
HRMS (ESI) calcd for C12H10O3 [M+H]+: 203.0708; found:. 203.0722. 
 
 
HC-2-OH: yield: 11%.  Rf = 0.56 (1:1 EtOAc: Hexanes). 1HNMR (500 MHz, CDCl3): δ 10.08 (s, 1H), 8.42 (d, J 
= 10.4 Hz, 1H), 7.82 (d, J = 3.4 Hz, 1H), 7.61 (s, 1H), 7.43 (d, J = 10.1 Hz, 1H), 7.35 (t, J = 10.0 Hz, 1H), 7.20 
(t, J = 10.1 Hz, 1H), 6.64 (dd, J = 3.5, 1.8 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 171.10, 167.70, 150.45, 
143.51, 135.92, 134.66, 127.54, 119.37, 116.48, 113.02.  HRMS (ESI) calcd for C11H8O3 [M+H]+: 189.0552; 
found: 189.0557. 
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HC-3-OMe: yield: 68%.  Rf = 0.08 (EtOAc).  Mp = oil.  IR (KBr): ν: 3443, 3026, 2965, 2927, 2838, 2769, 
2232, 1731, 1615, 1592, 1564, 1495, 1462, 1411, 1359, 1329, 1271, 1216, 1189, 1163, 1091, 1043, 1025, 
971.1HNMR (500 MHz, CD2Cl2): δ 8.64 (d, J = 6.3 Hz, 2H), 7.44 (d, J = 8.9 Hz, 1H), 7.39 (d, J = 6.3 Hz, 2H), 
7.13 (d, J = 10.7 Hz, 1H), 6.93 (d, J = 10.7 Hz, 1H), 6.79 (d, J = 11.0 Hz, 1H), 3.98 (s, 3H).  13CNMR (125 
MHz, CD2Cl2): δ 178.61, 166.48, 149.71, 144.79, 137.90, 133.19, 126.86, 124.23, 112.18, 56.76.  HRMS 
(ESI) calcd for C13H11NO2 [M+H]+: 214.0868; found:. 214.0898. 
 
 
BA-pCN-OMe: yield: 72%.  Rf = 0.47 (EtOAc).  Mp = 105.7-106.9.  IR (KBr): ν: 3056, 3012, 2971, 2941, 
2899, 2836, 2224, 1597, 1572, 1538, 1465, 1352, 1272, 1223, 1163, 1092, 972.1HNMR (500 MHz, CDCl3): 
δ 7.70 – 7.67 (m, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.9 Hz, 1H), 7.15 (t, J = 9.6 Hz, 1H), 6.94 (t, J = 
10.6 Hz, 1H), 6.81 (d, J = 9.7 Hz, 1H), 3.99 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 178.60, 166.37, 146.00, 
145.49, 137.86, 132.95, 132.12, 132.04, 131.92, 131.77, 130.18, 128.54, 128.45, 126.72, 118.87, 112.13, 
111.45, 56.61.  HRMS (ESI) calcd for C15H11NO2 [M+H]+: 238.0868; found:. 238.0857. 
 
BA-pCN-OH: yield: 24%.  Rf = 0.68 (EtOAc).  Mp = 144.1-145.2.  IR (KBr): ν: 3238, 3106, 3069, 2846, 2763, 
1714, 1618, 1510, 1460, 1368, 1321, 1271, 1237, 1178, 827, 799, 781, 769, 758.1HNMR (500 MHz, 
CD2Cl2): δ 7.79 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 9.6 Hz, 1H), 7.52 – 7.44 (m, 2H), 7.17 
(ddd, J = 9.9, 8.4, 2.5 Hz, 1H).  13CNMR (125 MHz, DMSO-d6): δ 172.91, 169.60, 145.93, 140.18, 138.86, 
137.57, 132.32, 130.83, 127.71, 120.79, 119.26, 110.82.  HRMS (ESI) calcd for C14H9NO2 [M+H]+: 
224.0712; found:. 224.0711. 
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BA-pOH-OH: yield: 84%.  Rf = 0.79 (EtOAc).  Mp = 178.1-179.0.  IR (KBr): ν: 3248, 3108, 3068, 2924, 2762, 
1720, 1618, 1587, 1545, 1511, 1433, 1370, 1338, 1291, 1272, 1239, 1175, 1156, 1104, 1072, 838, 825, 
800, 780, 767.1HNMR (500 MHz, Methanol-d4): δ 7.66 (d, J = 10.2 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.36 (d, J 
= 8.3 Hz, 2H), 7.16 (t, J = 9.4 Hz, 1H), 6.85 (d, J = 8.3 Hz, 2H), 5.48 (s, 1H).  13CNMR (125 MHz, Methanol-
d4): δ 173.07, 171.71, 158.92, 142.01, 141.43, 137.84, 132.73, 131.99, 129.11, 123.32, 116.10, 54.95.  
HRMS (ESI) calcd for C13H10O3 [M+H]+: 215.0708; found:. 215.0709. 
 
MO-DMe-OMe: yield: 87%.  Rf = 0.47 (EtOAc).  IR (KBr): ν: 3339, 3033, 3007, 2918, 2855, 2728, 1734, 
1595, 1574, 1492, 1458, 1403, 1379, 1352, 1310, 1273, 1242, 1213, 1184, 1150, 1098, 1033, 995.1HNMR 
(500 MHz, CDCl3): δ 7.45 (d, J = 8.9 Hz, 1H), 7.10 (s, 2H), 7.05 – 6.99 (m, 2H), 6.87 (t, J = 10.6 Hz, 1H), 6.74 
(d, J = 9.6 Hz, 1H), 3.95 (s, 3H), 2.36 (s, 6H).  13CNMR (125 MHz, CDCl3): δ 179.83, 165.86, 148.05, 141.47, 
137.62, 137.26, 131.48, 129.75, 127.19, 127.01, 111.98, 56.60, 21.51.  HRMS (ESI) calcd for C16H16O2 
[M+H]+: 241.1229; found:. 241.1224. 
 
MO-DMe-OH: yield: 70%.  Rf = 0.5 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3157, 3034, 2916, 2858, 1614, 1599, 
1548, 1474, 1456, 1364, 1314, 1256, 1214, 1093, 987.1HNMR (500 MHz, CDCl3): δ 7.61 (d, J = 10.2 Hz, 
1H), 7.48 – 7.40 (m, 2H), 7.17 – 7.08 (m, 4H), 2.42 (s, 6H).  13CNMR (125 MHz, CDCl3): δ 170.93, 170.74, 
140.58, 139.80, 138.87, 137.84, 136.71, 129.96, 127.23, 126.89, 122.45, 21.39.  HRMS (ESI) calcd for 
C15H14O2 [M+H]+: 227.1072; found:. 227.1073. 
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MO-3-OH: yield: 31%.  Rf = 0.59 (1:1 EtOAc: Hexanes).  Mp = oil.  1HNMR (500 MHz, CD2Cl2): δ7.76 (d, J = 
10.3 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.08 – 7.00 (m, 2H), 6.51 (dt, J = 15.3, 6.9 Hz, 1H), 2.32 (q, J = 7.2, 1.5 
Hz, 2H), 1.58 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H).  13CNMR (125 MHz, CD2Cl2): δ170.71 , 169.16 , 157.19 , 
137.46 , 136.00 , 135.75 , 127.80 , 127.23 , 121.73 , 35.75 , 22.38 , 13.77.  HRMS (ESI) calcd for C12H14O2 
[M+H]+: 190.2384; found: 191.1049. 
 
HC-4-OMe: yield: 65%.  Rf = 0.29 (1:1 EtOAc: Hexanes).  Mp = 151.2-152.1.  IR (KBr): ν: 2925, 2853, 2367, 
1973, 1734, 1597, 1573, 1537, 1467, 1412, 1364, 1276, 1221, 1191, 1165, 1151, 1142, 1107, 1082, 1017, 
981.1HNMR (500 MHz, CD2Cl2): δ 8.49 (d, J = 9.3 Hz, 1H), 8.21 (s, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.52 (d, J = 
8.2 Hz, 1H), 7.39 – 7.34 (m, 1H), 7.29 (dd, J = 14.9, 7.4 Hz, 1H), 7.15 (dt, J = 32.2, 10.1 Hz, 2H), 6.86 (d, J = 
9.4 Hz, 1H), 4.04 (s, 3H). 13CNMR (125 MHz, CD2Cl2): δ164.78 , 154.29 , 134.13 , 133.94 , 132.42 , 129.72 , 
126.83 , 125.60 , 123.01 , 122.24 , 112.05 , 111.95 , 110.75 , 56.67.  HRMS (ESI) calcd for C16H12O3 
[M+H]+: 253.0865; found:. 253.0843. 
 
 
Am-Boc-H:  yield: 99%.  Rf = 0.34 (1:1 EtOAc: Hexanes).  Mp = 175.8-176.4.  IR (KBr): ν: 3257, 3176, 3094, 
3044, 3002, 2984, 2964, 2927, 1715, 1624, 1597, 1547, 1530, 1501, 1466, 1450, 1414, 1387, 1363, 1317, 
1260, 1237, 1153, 1125, 1049, 1028, 1017, 901.1HNMR (500 MHz, CDCl3): δ 7.52 (d, J = 8.5 Hz, 2H), 7.43 
(d, J = 8.4 Hz, 2H), 7.40 (d, J = 9.1 Hz, 1H), 7.24 – 7.13 (m, 2H), 7.07 (t, J = 9.6 Hz, 1H), 6.99 (ddt, J = 10.9, 
7.5, 1.2 Hz, 1H), 6.66 (s, 1H), 1.57 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 186.59, 152.61, 151.84, 142.09, 
138.75, 135.97, 135.13, 134.41, 133.71, 132.88, 130.05, 117.95, 28.36.  HRMS (ESI) calcd for C18H19NO3 
[M+H]+: 298.1443; found:. 298.1430. 
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Am-Boc-NH2: yield: 71%.  Rf = 0.39 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3420, 3243, 3112, 2981, 2937, 
2358, 2121, 2017, 1963, 1702, 1587, 1511, 1429, 1345, 1229, 1158, 1056, 833.1HNMR (500 MHz, CDCl3): 
δ 7.55 (d, J = 9.6 Hz, 1H), 7.49 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.16 (t, J = 10.8 Hz, 1H), 6.95 (d, 
J = 9.9 Hz, 1H), 6.82 (t, J = 9.8 Hz, 1H), 6.57 (s, 1H), 6.08 (s, 2H), 1.58 (s, 9H).  HRMS (ESI) calcd for 
C18H20N2O3 [M+H]+: 313.1552; found:. 313.1574. 
 
 
 
HC-5-H:  yield: 97%.  Rf = 0.59 (1:1 EtOAc: Hexanes).  Mp = 115.7-116.8.  IR (KBr): ν: 3206, 3084, 3061, 
2976, 2902, 2789, 1628, 1570, 1498, 1485, 1461, 1389, 1334, 1295, 1253, 1236, 1102, 1032, 925.1HNMR 
(500 MHz, CDCl3): δ 7.38 (d, J = 8.8 Hz, 1H), 7.22 – 7.12 (m, 2H), 7.10 – 6.96 (m, 4H), 6.88 (d, J = 8.0 Hz, 
1H), 6.02 (s, 2H).  13CNMR (125 MHz, CDCl3): δ 186.50, 151.93, 147.97, 147.32, 142.01, 136.04, 135.16, 
133.84, 133.60, 133.03, 123.21, 109.98, 109.93, 108.13, 101.24.  HRMS (ESI) calcd for C14H10O3 [M+H]+: 
227.0708; found:. 227.0720. 
 
HC-5-NH2:  yield: 86%.  Rf = 0.33 (1:1 EtOAc: Hexanes).  Mp = 133.4-134.6.  IR (KBr): ν: 3402, 3241, 3182, 
3143, 3111, 3011, 2923, 2879, 2852, 2777, 1605, 1500, 1486, 1458, 1429, 1348, 1282, 1228, 1197, 1092, 
1034, 930.1HNMR (500 MHz, CDCl3): δ 7.54 (d, J = 9.7 Hz, 1H), 7.17 (t, J = 10.1 Hz, 1H), 7.07 (d, J = 1.7 Hz, 
1H), 6.98 – 6.93 (m, 2H), 6.90 (d, J = 8.0 Hz, 1H), 6.81 (t, J = 9.2 Hz, 1H), 6.11 (s, 2H), 6.02 (s, 2H).  13CNMR 
(125 MHz, CDCl3): δ 174.47, 147.14, 146.97, 138.49, 136.31, 135.13, 123.10, 123.03, 112.52, 110.37, 
110.00, 108.03, 101.02.  HRMS (ESI) calcd for C14H11NO3 [M+H]+: 242.0817; found:. 242.0804. 
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HC-5-OH:  yield: 99%.  Rf = 0.30 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 2892, 2711, 2643, 2547, 2484, 2064, 
1944, 1714, 1615, 1587, 1570, 1548, 1435, 1387, 1286, 1230, 1187, 1092, 1034, 933.1HNMR (500 MHz, 
CDCl3): δ9.81 (s, 1H), 7.63 (dd, J = 10.2, 1.0 Hz, 1H), 7.48 – 7.38 (m, 2H), 7.14 – 7.08 (m, 2H), 7.02 (dd, J = 
8.0, 1.8 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H).  13CNMR (125 MHz, CDCl3): δ 170.30, 147.72, 
147.46, 140.43, 138.62, 136.60, 133.68, 127.27, 123.16, 121.88, 110.01, 108.28, 101.30.  HRMS (ESI) 
calcd for C14H10O4 [M+H]+: 243.0657; found:. 243.0666. 
 
 
HC-6-H:  yield: 67%.  Rf = 0.40 (1:1 EtOAc: Hexanes).  Mp = 80.0-81.4.  IR (KBr): ν: 3116, 3094, 3052, 2979, 
2925, 2880, 2361, 1623, 1563, 1510, 1460, 1405, 1379, 1364, 1309, 1275, 1251, 1237, 1217, 1180, 1091, 
1054, 1012, 950.1HNMR (500 MHz, CDCl3): δ 7.46 (d, J = 8.8 Hz, 1H), 7.20 – 7.16 (m, 2H), 7.06 (t, J = 11.0 
Hz, 1H), 7.02 – 6.96 (m, 1H), 6.79 (t, J = 4.5 Hz, 1H), 6.38 (dd, J = 3.6, 1.8 Hz, 1H), 6.22 (dd, J = 3.7, 2.6 Hz, 
1H), 3.57 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 186.26, 144.92, 141.31, 137.27, 135.33, 133.64, 133.04, 
125.11, 112.55, 108.13, 35.51.  HRMS (ESI) calcd for C12H11NO [M+H]+: 186.0919; found:. 186.0938. 
 
 
HC-6-NH2:  yield: 67%.  Rf = 0.71 (EtOAc).  Mp = 183.5-184.7.  IR (KBr): ν: 3391, 3374, 3243, 3119, 1611, 
1517, 1482, 1449, 1421, 1402, 1330, 1304, 1237, 1190, 1087, 1038, 917.1HNMR (500 MHz, CD2Cl2): δ 
7.92 (dd, J = 9.8, 1.3 Hz, 1H), 7.60 (td, J = 10.0, 1.2 Hz, 1H), 7.46 (d, J = 11.4 Hz, 1H), 7.20 – 7.01 (m, 2H), 
6.55 – 6.37 (m, 2H), 4.86 (d, J = 5.4 Hz, 2H), 3.74 (s, 3H).  13CNMR (125 MHz, CD2Cl2): δ 175.69, 160.74, 
142.32, 138.49, 137.38, 135.14, 124.63, 124.18, 115.47, 111.14, 109.11, 36.22.  HRMS (ESI) calcd for 
C12H12N2O [M+H]+: 201.1028; found:. 201.1040. 
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HC-6-OH:  yield: 99%.  Rf = 0.34 (EtOAc).  Mp = 69.8-71.0.  IR (KBr): ν: 3197, 2898, 2711, 2642, 1944, 
1713, 1606, 1589, 1550, 1483, 1452, 1430, 1415, 1367, 1287, 1088, 1034, 934.1HNMR (500 MHz, CDCl3): 
δ 7.68 (d, J = 10.2, 1.0 Hz, 1H), 7.49 – 7.39 (m, 2H), 7.10 (t, J = 10.5 Hz, 1H), 6.84 (t, J = 2.2 Hz, 1H), 6.35 – 
6.25 (m, 2H), 3.56 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 171.20, 169.75, 141.43, 136.82, 132.50, 131.19, 
127.08, 124.44, 121.94, 111.11, 108.22, 35.29.  HRMS (ESI) calcd for C12H11NO2 [M+H]+: 202.0868; 
found:. 202.0878. 
 
 
HC-7-H:  yield: 74%.  Rf = 0.05 (1:1 EtOAc: Hexanes).  Mp = oil.  1HNMR (500 MHz, CDCl3): δ 7.70 – 7.65 
(m, 1H), 7.60 – 7.45 (m, 3H), 7.42 (ddd, J = 8.4, 5.6, 1.3 Hz, 1H), 7.24 – 7.17 (m, 1H), 7.13 – 7.02 (m, 1H), 
3.86 – 3.60 (m, 8H).  13CNMR (125 MHz, CDCl3): δ 186.21, 170.13, 151.46, 142.59, 140.78, 140.05, 
136.91, 136.14, 135.57, 134.95, 133.81, 133.75, 130.65, 129.18, 128.55, 128.45, 128.18, 127.23, 126.24, 
125.90, 66.91.  HRMS (ESI) calcd for C18H17NO3 [M+H]+: 296.1287; found:. 296.1299. 
 
HC-7-NH2:  yield: 52%.  Rf = 0.29  (EtOAc).  IR (KBr): ν: 3408, 3277, 3190, 3051, 2962, 2918, 2852, 1592, 
1517, 1455, 1428, 1342, 1300, 1268, 1238, 1208, 1110, 1067, 1022, 949.1HNMR (500 MHz, CDCl3): δ7.59 
(dt, J = 10.0, 1.9 Hz, 2H), 7.55 – 7.47 (m, 2H), 7.43 (dt, J = 7.6, 1.5 Hz, 1H), 7.19 (t, J = 10.0, 1.1 Hz, 1H), 
6.96 (d, J = 10.0 Hz, 1H), 6.81 (t, J = 9.8 Hz, 1H), 6.31 (s, 2H), 3.75 (m, 8H).  13CNMR (125 MHz, CDCl3): 
δ174.08 , 158.22 , 142.66 , 140.84 , 138.72 , 135.85 , 134.77 , 131.18 , 128.57 , 128.20 , 126.11 , 123.08 , 
112.72 , 66.98.  HRMS (ESI) calcd for C18H18N2O3 [M+H]+: 311.1396; found:. 311.1379. 
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HC-7-OH:  yield: 63%.  Rf = 0.16 (EtOAc).  Mp = 224.7-225.8.  IR (KBr): ν: 2961, 2812, 2651, 2540, 1673, 
1594, 1546, 1472, 1416, 1381, 1356, 1311, 1282, 1247, 1190, 1175, 1120, 1090, 998, 936.1HNMR (500 
MHz, DMSO-d6): δ 12.98 (s, 1H), 8.06 (d, J = 1.8 Hz, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.74 (d, J = 7.3 Hz, 1H), 
7.67 (d, J = 9.8 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.47 (t, J = 10.1 Hz, 1H), 7.36 (d, J = 10.3 Hz, 1H), 7.16 (t, J 
= 9.9 Hz, 1H), 3.35 (s, 8H).  13CNMR (125 MHz, DMSO-d6): δ 172.85, 169.61, 167.59, 141.20, 140.26, 
139.29, 137.15, 134.16, 130.99, 130.65, 129.09, 128.81, 127.78, 120.99.  HRMS (ESI) calcd for C18H17NO4 
[M+H]+: 311.3319; found:. 311.3307. 
 
 
MO-pF-H:  yield: 99%.  Rf = 0.47 (1:1 EtOAc: Hexanes).  Mp = 69.6-70.4.  IR (KBr): ν: 3033, 2967, 2924, 
2862, 1628, 1558, 1519, 1503, 1451, 1416, 1383, 1266, 1233, 1216, 1197, 1161, 1097, 981.1HNMR (500 
MHz, CDCl3): δ 7.54 – 7.49 (m, 2H), 7.36 (d, J = 8.6 Hz, 1H), 7.23 – 7.15 (m, 2H), 7.15 – 7.08 (m, 2H), 7.07 
– 6.97 (m, 2H).  13CNMR (125 MHz, CDCl3): δ 186.29, 163.82, 161.85, 151.32, 142.33, 136.45, 135.87, 
135.84, 135.33, 133.61, 133.41, 131.13, 131.06, 115.12, 114.95.  HRMS (ESI) calcd for C13H9FO [M+H]+: 
201.0716; found:. 201.0745. 
 
 
MO-pF-NH2:  yield: 81%.  Rf = 0.81 (EtOAc).  Mp = 200.7-202.0.  IR (KBr): ν: 3427, 3271, 3149, 1595, 1498, 
1449, 1429, 1400, 1347, 1268, 1215, 1154, 1091, 1011, 912.1HNMR (500 MHz, CDCl3): δ 7.57 – 7.46 (m, 
3H), 7.17 (dt, J = 25.4, 9.4 Hz, 3H), 6.97 (d, J = 9.9 Hz, 1H), 6.83 (t, J = 9.8 Hz, 1H), 6.13 (s, 2H).  13CNMR 
(125 MHz, CDCl3): δ 174.35, 163.15, 157.78, 141.24, 138.60, 135.42, 131.26, 131.20, 123.15, 114.92, 
114.75, 112.56.  HRMS (ESI) calcd for C13H10FNO [M+H]+: 216.0825; found:. 216.0845. 
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MO-pF-OH:  yield: 92%.  Rf = 0.59 (EtOAc).  Mp = 134.1-135.0.  IR (KBr): ν: 2536, 2214, 1896, 1603, 1541, 
1507, 1489, 1459, 1422, 1384, 1363, 1294, 1279, 1243, 1227, 1191, 1166, 1103, 914.1HNMR (500 MHz, 
CDCl3): δ7.62 (d, J = 10.1 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.50 – 7.40 (m, 2H), 7.19 (t, J = 8.7 Hz, 2H), 7.14 (t, J = 9.7 Hz, 
1H).  13CNMR (125 MHz, CDCl3): δ 171.50, 170.24, 140.46, 138.17, 136.83, 135.75, 131.18, 131.12, 
127.36, 121.65, 115.36, 115.19.  HRMS (ESI) calcd for C13H9FO2 [M+H]+: 217.0665; found:. 217.0669. 
 
 
HC-8-H:  yield: 99%.  Rf = 0.13 (1:1 EtOAc: Hexanes).  Mp = 59.8-61.0.  IR (KBr): ν: 3163, 3014, 2925, 2852, 
1624, 1570, 1537, 1500, 1460, 1436, 1408, 1393, 1378, 1274, 1226, 1188, 1159, 1118, 1063, 1024, 
981.1HNMR (500 MHz, CDCl3): δ 8.48 (s, 1H), 7.88 (s, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.17 – 7.10 (m, 2H), 
7.07 (t, J = 10.0 Hz, 1H), 6.94 (ddd, J = 10.0, 7.0, 2.0 Hz, 1H), 3.92 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 
185.11, 143.50, 140.39, 138.84, 134.94, 133.74, 132.83, 132.19, 132.09, 132.01, 131.92, 131.71, 119.66, 
39.08.  HRMS (ESI) calcd for C11H10N2O [M+H]+: 187.0871; found:. 187.0899. 
 
 
HC-8-NH2:  yield: 57%.  Rf = 0.38 (EtOAc).  Mp = 143.6-144.8.  IR (KBr): ν: 3383, 3274, 3154, 3053, 2957, 
2923, 2852, 1627, 1594, 1569, 1515, 1475, 1434, 1410, 1369, 1298, 1236, 1171, 1117, 1058, 991.1HNMR 
(500 MHz, CDCl3): δ 8.55 (s, 1H), 7.95 (s, 1H), 7.91 (d, J = 10.0 Hz, 1H), 7.14 (t, J = 9.9 Hz, 1H), 6.97 (d, J = 
10.0 Hz, 1H), 6.85 (t, J = 9.9 Hz, 1H), 6.17 (s, 2H), 3.99 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 173.00, 
156.44, 138.81, 134.74, 134.39, 133.12, 132.20, 132.06, 123.38, 121.74, 113.33, 39.03.  HRMS (ESI) calcd 
for C11H11N3O [M+H]+: 202.0980; found:. 202.0999. 
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HC-9-H:  yield: 75%.  Rf = 0.34 (1:1 EtOAc: Hexanes).  1HNMR (500 MHz, CDCl3): δ 7.28 – 7.24 (m, 1H), 
7.23 – 7.20 (m, 1H), 7.10 – 7.05 (m, 2H), 2.39 (s, 3H), 2.22 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 166.96, 
143.19, 141.78, 137.88, 135.64, 134.44, 133.24, 115.76, 12.02, 10.95.  HRMS (ESI) calcd for C12H11NO2 
[M+H]+: 202.0868; found:. 202.0892. 
 
 
HC-9-NH2:  yield: 63%.  Rf = 0.65 (EtOAc).  Mp = 210.0-211.1.  IR (KBr): ν: 3403, 3236, 3179, 3113, 3018, 
2927, 2851, 1609, 1513, 1450, 1409, 1366, 1332, 1279, 1238, 1211, 1119, 1049, 1034, 971.1HNMR (500 
MHz, CDCl3): δ 7.36 (d, J = 9.6 Hz, 1H), 7.24 (t, J = 10.1 Hz, 1H), 6.99 (d, J = 10.1 Hz, 1H), 6.80 (t, J = 10.2 
Hz, 1H), 6.29 (s, 2H), 2.35 (s, 3H), 2.20 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 173.82, 165.83, 159.83, 
157.11, 139.26, 136.44, 132.13, 132.05, 131.06, 128.60, 128.51, 122.54, 117.47, 112.59, 11.80, 10.95.  
HRMS (ESI) calcd for C12H12N2O2 [M+H]+: 217.0977; found:. 217.0982. 
 
 
Am-DMe-H:  yield: 73%.  Rf = 0.43 (1:1 EtOAc: Hexanes).  Mp = 136.8-138.1.  IR (KBr): ν: 3116, 3064, 
2994, 2949, 2920, 2878, 2852, 2800, 1624, 1599, 1563, 1523, 1502, 1479, 1460, 1444, 1350, 1326, 1291, 
1260, 1226, 1209, 1193, 1164, 1120, 1062, 976.1HNMR (500 MHz, CDCl3): δ 7.59 – 7.53 (m, 2H), 7.41 (d, J 
= 9.1 Hz, 1H), 7.18 (d, J = 12.0 Hz, 1H), 7.12 (ddd, J = 12.0, 7.7, 1.2 Hz, 1H), 7.05 (t, J = 9.9 Hz, 1H), 6.92 
(dd, J = 10.8, 7.8 Hz, 1H), 6.80 – 6.75 (m, 2H), 3.04 (s, 6H).  13CNMR (125 MHz, CDCl3): δ 186.90, 152.22, 
150.80, 141.28, 135.57, 134.83, 134.62, 133.74, 131.70, 131.48, 130.45, 127.41, 111.72, 40.36.  HRMS 
(ESI) calcd for C15H15NO [M+H]+: 226.1232; found:. 226.1251. 
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Am-DMe-NH2:  yield: 86%.  Rf = 0.69 (EtOAc).  Mp = 190.0-191.2.  IR (KBr): ν: 3403, 3230, 3140, 3036, 
2877, 2838, 2796, 1602, 1511, 1446, 1427, 1355, 1317, 1272, 1238, 1227, 1192, 1162, 1119, 1061, 1031, 
1004, 947.1HNMR (500 MHz, CDCl3): δ 7.58 (d, J = 9.7 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 7.10 (t, J = 10.0 Hz, 
1H), 6.91 (d, J = 10.6 Hz, 1H), 6.85 – 6.76 (m, 3H), 6.10 (s, 2H), 3.03 (s, 6H).  13CNMR (125 MHz, CDCl3): δ 
174.71, 157.28, 150.04, 142.44, 137.99, 134.11, 130.54, 123.22, 112.60, 112.02, 40.62.  HRMS (ESI) calcd 
for C15H16N2O [M+H]+: 241.1341; found:. 241.1363. 
 
 
HC-10-H:  yield: 99%.  Rf = 0.59 (1:1 EtOAc: Hexanes).  Mp = 115.1-116.2.  IR (KBr): ν: 3051, 3028, 2922, 
2257, 1627, 1568, 1449, 1385, 1266, 1185, 840.1HNMR (500 MHz, CDCl3): δ 8.01 (ddd, J = 7.8, 4.0, 1.2 
Hz, 2H), 7.64 (d, J = 8.5 Hz, 1H), 7.60 – 7.55 (m, 2H), 7.50 – 7.42 (m, 2H), 7.38 (t, J = 7.5 Hz, 1H), 7.31 (d, J 
= 12.1 Hz, 1H), 7.23 (ddd, J = 12.1, 7.6, 1.5 Hz, 1H), 7.14 – 7.03 (m, 2H).  13CNMR (125 MHz, CDCl3): δ 
186.04, 156.07, 153.24, 148.26, 142.09, 137.61, 135.30, 134.08, 133.58, 128.17, 127.20, 124.79, 124.61, 
124.24, 122.80, 122.75, 120.84, 120.65, 111.87.  HRMS (ESI) calcd for C19H12O2 [M+H]+: 273.0916; found:. 
273.0925. 
 
 
HC-10-NH2:  yield: 82%.  Rf = 0.77 (EtOAc).  Mp = 218.3-219.2.  IR (KBr): ν: 3413, 3240, 3181, 3142, 3053, 
1599, 1518, 1469, 1448, 1435, 1408, 1349, 1315, 1279, 1259, 1234, 1188, 1115, 1055, 847.1HNMR (500 
MHz, CDCl3): δ 8.00 (t, J = 7.7 Hz, 2H), 7.74 (d, J = 9.5 Hz, 1H), 7.54 (d, J = 7.9 Hz, 2H), 7.45 (td, J = 7.4, 2.6 
Hz, 2H), 7.37 (t, J = 7.5 Hz, 1H), 7.27 (t, J = 10.1 Hz, 1H), 7.01 (d, J = 10.0 Hz, 1H), 6.88 (t, J = 9.8 Hz, 1H), 
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6.20 (s, 2H).  13CNMR (125 MHz, CDCl3): δ 174.13, 157.51, 156.10, 153.74, 139.30, 137.54, 136.11, 
128.35, 126.91, 124.49, 124.39, 122.88, 122.61, 122.57, 120.55, 119.93, 112.43, 111.86.  HRMS (ESI) 
calcd for C19H13NO2 [M+H]+: 288.1025; found:. 288.1042. 
 
 
HC-10-OH:  yield: 91%.  Rf = 0.64 (EtOAc).  Mp = 53.8-55.0.  IR (KBr): ν: 3051, 3028, 2922, 2852, 2538, 
2359, 1923, 1627, 1568, 1449, 1386, 1266, 1185, 1117, 804.1HNMR (500 MHz, CDCl3): δ 8.05 (ddd, J = 
12.0, 7.7, 1.3 Hz, 2H), 7.82 (d, J = 10.0 Hz, 1H), 7.59 – 7.47 (m, 6H), 7.40 (t, J = 7.5 Hz, 1H), 7.19 (ddd, J = 
10.4, 6.6, 4.0 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 170.81, 170.80, 156.11, 153.32, 141.05, 137.56, 
133.64, 132.17, 128.43, 128.00, 127.33, 127.16, 124.74, 124.19, 122.88, 122.75, 122.42, 120.85, 120.72, 
111.83.  HRMS (ESI) calcd for C19H12O3 [M+H]+: 289.0865; found:. 289.0863. 
 
 
MO-pSMe-H:  yield: 76%.  Rf = 0.43 (1:1 EtOAc: Hexanes).  Mp = 93.0-94.1.  IR (KBr): ν: 3092, 3060, 3037, 
3019, 2975, 2920, 1729, 1627, 1563, 1514, 1486, 1464, 1431, 1406, 1379, 1319, 1265, 1234, 1189, 1091, 
1014, 970.1HNMR (500 MHz, CDCl3): δ 7.48 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.9 Hz, 1H), 7.30 (d, J = 8.3 Hz, 
2H), 7.21 – 7.12 (m, 2H), 7.05 (t, J = 10.7 Hz, 1H), 7.01 – 6.95 (m, 1H), 2.53 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 186.42, 151.77, 142.13, 139.32, 136.54, 136.08, 135.22, 133.67, 133.15, 129.63, 125.95, 15.64. 
HRMS (ESI) calcd for C14H12OS [M+H]+: 229.0687; found:. 229.0668. 
 
 
MO-pSMe-NH2:  yield: 76%.  Rf = 0.37 (1:1 EtOAc: Hexanes).  Mp = 112.4-114.0.  IR (KBr): ν: 3397, 3236, 
3183, 3147, 2914, 1650, 1588, 1516, 1491, 1428, 1397, 1341, 1316, 1299, 1269, 1238, 1189, 1113, 1089, 
1013, 967.1HNMR (500 MHz, CDCl3): δ 7.54 (d, J = 9.6 Hz, 1H), 7.47 (d, J = 9.5 Hz, 2H), 7.37 – 7.32 (m, 
2H), 7.17 (t, J = 10.0 Hz, 1H), 6.93 (d, J = 10.0 Hz, 1H), 6.82 (t, J = 9.8 Hz, 1H), 6.17 (s, 2H), 2.55 (s, 3H).  
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13CNMR (125 MHz, CDCl3): δ 174.34, 157.78, 141.57, 139.28, 138.42, 137.58, 135.27, 130.01, 126.29, 
123.13, 112.60, 16.00.  HRMS (ESI) calcd for C14H13NOS [M+H]+: 244.0796; found:. 244.0788. 
 
 
MO-pSMe-OH:  yield: 79%.  Rf = 0.61 (EtOAc).  Mp = 122.0-123.4.  IR (KBr): ν: 3139, 2919, 1619, 1592, 
1555, 1547, 1470, 1433, 1397, 1362, 1319, 1300, 1274, 1262, 1241, 1216, 1200, 1190, 1112, 1094, 1059, 
1014, 972.1HNMR (500 MHz, CDCl3): δ 7.63 (d, J = 10.2 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.49 – 7.41 (m, 
2H), 7.38 (d, J = 8.8 Hz, 2H), 7.13 (ddd, J = 10.1, 9.4, 1.4 Hz, 1H), 2.58 (s, 3H).  13CNMR (125 MHz, CDCl3): 
δ 171.28, 170.35, 140.34, 139.14, 138.43, 136.66, 136.44, 129.75, 127.38, 126.11, 121.83, 15.66.  HRMS 
(ESI) calcd for C14H12O2S [M+H]+: 245.0636; found:. 245.0623. 
 
 
HC-11-H:  yield: 69%.  Rf = 0.27 (EtOAc).  Mp = 174.9-176.0.  IR (KBr): ν: 3024, 2975, 2361, 2336, 1672, 
1628, 1557, 1518, 1465, 1433, 1413, 1398, 1352, 1271, 1238, 1190, 1167, 1114, 1046, 979.1HNMR (500 
MHz, CDCl3): δ 9.24 (s, 1H), 8.93 (s, 2H), 7.43 – 7.39 (m, 1H), 7.26 (dd, J = 3.8, 1.6 Hz, 2H), 7.13 (tt, J = 4.0, 
1.7 Hz, 2H).  13CNMR (125 MHz, CDCl3): δ 185.28, 158.11, 156.73, 145.91, 142.89, 137.13, 136.01, 
134.92, 133.56, 133.48, 109.99.  HRMS (ESI) calcd for C11H8N2O [M+H]+: 185.0715; found:. 185.0719. 
 
 
HC-12-H:  yield: 97%.  Rf = 0.57 (1:1 EtOAc: Hexanes).  Mp = 66.4-67.5.  IR (KBr): ν: 3076, 3060, 3009, 
2962, 2912, 2852, 2362, 1754, 1618, 1563, 1490, 1461, 1439, 1391, 1379, 1326, 1286, 1235, 1208, 1161, 
1060, 1033, 877.1HNMR (500 MHz, CDCl3): δ 7.86 (d, J = 9.5 Hz, 1H), 7.56 (d, J = 3.9 Hz, 1H), 7.26 – 7.14 
(m, 2H), 7.12 (t, J = 10.0 Hz, 1H), 6.99 (t, J = 10.6 Hz, 1H), 6.83 (d, J = 3.8 Hz, 1H), 2.56 (s, 3H).  13CNMR 
(125 MHz, CDCl3): δ 184.12, 146.52, 143.98, 139.99, 136.82, 135.16, 133.52, 132.34, 131.32, 128.43, 
125.27, 15.44.  HRMS (ESI) calcd for C12H10OS [M+H]+: 203.0531; found:. 203.0563. 
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HC-12-NH2:  yield: 34%.  Rf = 0.56 (1:1 EtOAc: Hexanes).  Mp = 101.8-103.0.  IR (KBr): ν: 3445, 3399, 
3281, 3178, 3143, 3065, 2922, 2853, 1735, 1595, 1561, 1505, 1425, 1376, 1353, 1311, 1266, 1239, 1216, 
1164, 1107, 1063, 1006, 976.1HNMR (500 MHz, CDCl3): δ 8.14 (d, J = 10.2 Hz, 1H), 7.52 (d, J = 3.8 Hz, 1H), 
7.18 (t, J = 9.9 Hz, 1H), 6.99 (d, J = 10.1 Hz, 1H), 6.91 – 6.82 (m, 2H), 6.19 (s, 2H), 2.59 (s, 3H).  13CNMR 
(125 MHz, CDCl3): δ 171.81, 156.64, 143.58, 139.38, 134.76, 134.27, 134.11, 126.37, 124.31, 123.24, 
113.87, 15.25.  HRMS (ESI) calcd for C12H11NOS [M+H]+: 218.0640; found:. 218.0654. 
 
 
MO-11-H:  yield: 94%.  Rf = 0.67 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3031, 2952, 2902, 2864, 2714, 1693, 
1626, 1564, 1518, 1505, 1461, 1435, 1405, 1383, 1360, 1257, 1229, 1200, 1123, 1110, 1095, 1053, 1016, 
979.1HNMR (500 MHz, CDCl3): δ 7.49 (q, J = 8.5 Hz, 4H), 7.42 (d, J = 8.8 Hz, 1H), 7.22 (d, J = 12.0 Hz, 1H), 
7.19 – 7.13 (m, 1H), 7.08 (t, J = 9.8 Hz, 1H), 6.99 (dd, J = 10.9, 7.6 Hz, 1H), 1.39 (s, 9H).  13CNMR (125 
MHz, CDCl3): δ 186.66, 152.41, 151.53, 142.18, 136.96, 136.15, 135.07, 133.69, 132.91, 128.88, 125.13, 
34.68, 31.32.  HRMS (ESI) calcd for C17H18O [M+H]+: 239.1436; found:. 239.1419. 
 
 
MO-11-NH2:  yield: 87%.  Rf = 0.80 (EtOAc).  IR (KBr): ν: 3396, 3229, 3138, 2949, 2901, 2863, 2715, 1693, 
1602, 1591, 1503, 1460, 1434, 1342, 1309, 1271, 1232, 1179, 1119, 1097, 1016, 986.1HNMR (500 MHz, 
CDCl3): δ 7.58 (d, J = 9.7 Hz, 1H), 7.48 (d, J = 1.3 Hz, 4H), 7.16 (t, J = 10.0 Hz, 1H), 6.94 (d, J = 10.0 Hz, 1H), 
6.82 (t, J = 9.8 Hz, 1H), 6.12 (s, 2H), 1.40 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 174.55, 157.66, 150.20, 
142.30, 139.34, 138.58, 134.97, 129.16, 124.92, 123.18, 112.45, 34.60, 31.40.  HRMS (ESI) calcd for 
C17H19NO [M+H]+: 254.1500; found:. 254.1508. 
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MO-11-OH:  yield: 52%.  Rf = 0.5 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3169, 2962, 2902, 2867, 1714, 1615, 
1592, 1550, 1475, 1455, 1435, 1416, 1360, 1236, 1202, 1110, 1065, 1022, 996.1HNMR (500 MHz, CDCl3): 
δ7.66 (d, J = 10.1 Hz, 1H), 7.53 (s, 4H), 7.49 – 7.38 (m, 2H), 7.12 (t, J = 9.7 Hz, 1H), 1.42 (s, 9H).  13CNMR (125 
MHz, CDCl3): δ171.11 , 170.59 , 151.35 , 140.64 , 138.77 , 136.87 , 136.59 , 129.02 , 127.38 , 125.26 , 122.07 , 
34.72 , 31.36.  HRMS (ESI) calcd for C17H18O2 [M+H]+: 255.1385; found:. 255.1386. 
 
 
MO-NHOH-PH:  yield: 18%.  Rf = 0.79 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3418, 2923, 2851, 2356, 1731, 
1611, 1490, 1456, 1413, 1377, 1288, 1253, 1224, 1178, 1097, 1073, 1026, 996.1HNMR (500 MHz, CDCl3): 
δ 10.16 (s, 1H), 8.34 (s, 1H), 7.64 (d, J = 7.5 Hz, 2H), 7.49 (dd, J = 89.2, 7.7 Hz, 3H), 7.43 – 7.39 (m, 2H), 
7.24 (dd, J = 7.7, 1.7 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 154.46, 153.32, 137.74, 
132.58, 130.27, 129.78, 129.39, 128.15, 127.25, 119.77, 116.69.  HRMS (ESI) calcd for C13H11NO2 [M+H]+: 
214.0868; found:. 214.0879. 
 
 
MO-SH-PH:  yield: 59%.  Rf = 0.68 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3089, 3052, 3034, 3017, 2963, 2922, 
2852, 2008, 1960, 1581, 1546, 1479, 1439, 1390, 1352, 1315, 1285, 1255, 1220, 1193, 1115, 1092, 1076, 
1031, 1012, 987.1HNMR (500 MHz, CDCl3): δ 10.06 (s, 1H), 8.61 (d, J = 10.4 Hz, 1H), 7.56 – 7.45 (m, 6H), 
7.32 – 7.27 (m, 1H), 7.22 (t, J = 9.9 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 180.40, 172.11, 142.00, 140.90, 
140.56, 136.44, 132.81, 131.88, 129.09, 128.39, 128.35.  HRMS (ESI) calcd for C13H10OS [M+H]+: 
215.0531; found:. 215.0504. 
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HC-9-OMe:  yield: 87%.  Rf = 0.3 (EtOAc).  IR (KBr): ν: 3417, 3055, 2966, 2925, 2839, 1591, 1573, 1503, 
1464, 1437, 1417, 1357, 1274, 1215, 1167, 1118, 1095, 968.1HNMR (500 MHz, CDCl3): δ 7.37 (d, J = 9.0 
Hz, 1H), 7.18 (t, J = 10.2 Hz, 1H), 6.94 (t, J = 9.1 Hz, 1H), 6.85 (d, J = 9.7 Hz, 1H), 4.02 (s, 3H), 2.36 (s, 3H), 
2.20 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 178.06, 166.43, 165.43, 159.56, 138.71, 137.46, 132.90, 
132.15, 132.07, 131.93, 128.55, 128.46, 126.45, 116.65, 112.14, 56.58, 11.97, 11.00.  HRMS (ESI) calcd 
for C13H13NO3 [M+H]+: 232.0974; found:. 232.0984. 
 
 
HC-13-H:  yield: 99%.  Rf = 0.18 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3020, 3005, 2957, 2362, 1580, 1557, 
1460, 1394, 1377, 1324, 1303, 1280, 1257, 1239, 1224, 1199, 1080, 1005, 936.1HNMR (500 MHz, CDCl3): 
δ  8.22 (s, 1H), 7.37 – 7.32 (m, 1H), 7.22 – 7.13 (m, 2H), 7.07 – 7.00 (m, 2H), 4.06 (s, 3H), 4.00 (s, 3H).  
13CNMR (125 MHz, CDCl3): δ 185.67, 168.08, 165.20, 158.04, 146.35, 141.34, 136.85, 135.35, 134.08, 
133.32, 132.14, 132.06, 131.94, 128.55, 128.46, 115.67, 54.92, 54.22.  HRMS (ESI) calcd for C13H12N2O3 
[M+H]+: 245.0926; found:. 245.0900. 
 
 
HC-13-NH2:  yield: 58%.  Rf = 0.29 (EtOAc).  IR (KBr): ν: 3374, 3264, 3164, 2987, 2953, 2927, 2359, 1612, 
1594, 1556, 1469, 1454, 1397, 1380, 1359, 1312, 1291, 1253, 1238, 1207, 1132, 1082, 1035, 1008, 
974.1HNMR (500 MHz, CDCl3): δ 8.18 (s, 1H), 7.41 (d, J = 9.6 Hz, 1H), 7.18 (t, J = 10.1 Hz, 1H), 6.95 (d, J = 
10.0 Hz, 1H), 6.76 (t, J = 9.8 Hz, 1H), 6.39 (s, 2H), 4.04 (s, 3H), 3.96 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 
173.87, 168.52, 164.75, 157.81, 157.15, 138.77, 136.39, 134.50, 132.11, 132.03, 128.62, 128.52, 122.47, 
117.57, 112.60, 60.40, 54.80, 54.10.  HRMS (ESI) calcd for C13H13N3O3 [M+H]+: 260.1035; found:. 
260.1049. 
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SG-PH-OMe:  yield: 99%.  Rf = 0.46 (EtOAc).  1HNMR (500 MHz, CDCl3): δ 7.63 – 7.56 (m, 4H), 7.52 (dd, J = 
8.7, 5.6 Hz, 3H), 7.42 – 7.37 (m, 3H), 7.11 (t, J = 8.7 Hz, 1H), 6.95 (t, J = 8.6 Hz, 1H), 6.80 (d, J = 9.7 Hz, 
1H), 4.01 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 179.17, 165.98, 146.71, 141.21, 137.37, 131.83, 131.66, 
131.23, 131.16, 131.08, 129.45, 128.35, 128.26, 126.82, 123.35, 122.86, 111.87, 89.46, 56.53.  HRMS 
(ESI) calcd for C22H16O2 [M+H]+: 313.1229; found:. 313.1225. 
 
 
SG-PH-OH:  yield: 35%.  Rf = 0.5 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3175, 3109, 3052, 3032, 3008, 2915, 
2887, 2830, 2358, 1981, 1701, 1594, 1550, 1509, 1474, 1441, 1416, 1357, 1298, 1271, 1238, 1216, 1178, 
1158, 1107, 1069, 1004, 974.1HNMR (500 MHz, CDCl3): δ 9.86 (s, 1H), 7.70 – 7.62 (m, 3H), 7.62 – 7.55 (m, 
4H), 7.52 – 7.43 (m, 2H), 7.43 – 7.37 (m, 3H), 7.15 (t, J = 8.1 Hz, 1H).  13CNMR (125 MHz, CDCl3): δ 173.68, 
170.40, 147.03, 140.39, 139.72, 138.34, 136.93, 131.69, 131.45, 129.39, 128.39, 127.38, 123.36, 123.21, 
121.73, 90.3, 89.19.  HRMS (ESI) calcd for C21H14O2 [M+H]+: 299.1072; found:. 299.1081. 
 
 
EF-5-H:  yield 71%.  Rf = 0.34 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3060, 3018, 3000, 2959, 2842, 2751, 
2362, 1679, 1624, 1602, 1572, 1513, 1497, 1461, 1442, 1423, 1390, 1379, 1275, 1259, 1244, 1230, 1205, 
1187, 1168, 1115, 1023, 1007, 951.1HNMR (500 MHz, CDCl3): δ 10.49 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.88 
(dd, J = 8.7, 2.5 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.21 – 7.13 (m, 2H), 7.07 (d, J = 9.4 Hz, 2H), 7.00 (t, J = 8.5 
Hz, 1H), 3.99 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 189.35, 186.24, 161.95, 150.72, 142.22, 137.13, 
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136.24, 135.43, 133.69, 133.45, 132.42, 129.39, 124.59, 111.31, 55.92.  HRMS (ESI) calcd for C15H12O3 
[M+H]+: 241.0865; found: 241.0874. 
 
 
HC-12-OMe:  yield 59%.  Rf = 0.54 (EtOAc).  IR (KBr): ν: 3049, 2997, 2967, 2917, 2854, 2836, 1722, 1584, 
1551, 1466, 1444, 1408, 1379, 1361, 1323, 1267, 1232, 1217, 1199, 1165, 1086, 1051, 1017, 973.1HNMR 
(500 MHz, CDCl3): δ 7.99 (d, J = 9.4 Hz, 1H), 7.52 (d, J = 3.8 Hz, 1H), 7.07 (t, J = 10.0 Hz, 1H), 6.97 (t, J = 
10.0 Hz, 1H), 6.88 – 6.79 (m, 2H), 3.99 (s, 3H), 2.56 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 177.10, 164.52, 
145.16, 138.98, 138.10, 132.79, 130.74, 127.46, 126.77, 124.80, 112.75, 56.58, 15.39.  HRMS (ESI) calcd 
for C13H12O2S [M+H]+: 233.0636; found: 233.0663. 
 
 
HC-12-OH:  yield 27%.  Rf = 0.29 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3182, 3166, 3143, 2910, 2359, 2342, 
1596, 1584, 1539, 1508, 1478, 1443, 1418, 1364, 1293, 1270, 1241, 1220, 1166, 1117, 1068, 1028, 1004, 
950.1HNMR (500 MHz, CDCl3): δ 9.88 (s, 1H), 8.23 (dd, J = 10.3, 0.8 Hz, 1H), 7.68 (d, J = 3.8 Hz, 1H), 7.46 
(d, J = 10.0 Hz, 1H), 7.36 (t, J = 10.0 Hz, 1H), 7.17 (t, J = 10.1 Hz, 1H), 6.89 (d, J = 3.5 Hz, 1H), 2.61 (s, 3H).    
HRMS (ESI) calcd for C12H10O2S [M+H]+: 219.0480; found: 219.0474. 
 
 
Am-Ac-OH:  yield 76%.  Rf = 0.61(1:1 EtOAc: Hexanes).  IR (KBr): ν: 3280, 3064, 2926, 2852, 2359, 1689, 
1594, 1549, 1496, 1478, 1454, 1437, 1395, 1346, 1276, 1224, 1202, 1176, 1072, 1023, 987.1HNMR (500 
MHz, CDCl3): δ 9.70 (s, 1H), 9.11 (d, J = 9.9 Hz, 1H), 7.64 (d, J = 9.1, 1.1 Hz, 1H), 7.48 (d, J = 4.4 Hz, 4H), 
7.43 (h, J = 4.4 Hz, 1H), 7.32 (t, J = 10.5 Hz, 1H), 7.14 (t, J = 9.8 Hz, 1H), 2.31 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 177.47, 170.15, 147.88, 147.54, 141.06, 139.20, 134.99, 130.02, 129.16, 128.16, 128.11, 
121.30, 25.75.  HRMS (ESI) calcd for C15H13NO3 [M+H]+: 256.0974; found:. 256.0966. 
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MO-Am-PH:  yield 76%.  Rf = 0.61 (1:1 EtOAc: Hexanes).   IR (KBr): ν: 3499, 3278, 3243, 3007, 2962, 2953, 
2924, 2852, 2358, 1687, 1540, 1497, 1473, 1456, 1438, 1396, 1377, 1347, 1274, 1240, 1226, 1198, 1182, 
1110, 1083, 1019, 965.1HNMR (500 MHz, CDCl3): δ9.70 (s, 1H), 9.16 – 9.05 (m, 1H), 7.64 (dd, J = 9.2, 1.1 Hz, 
1H), 7.48 (d, J = 4.4 Hz, 4H), 7.35 – 7.27 (m, 1H), 7.14 (dd, J = 10.3, 9.2 Hz, 1H), 2.31 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ147.86 , 147.54 , 141.06 , 139.18 , 134.97 , 130.00 , 129.17 , 128.15 , 128.10 , 121.27 , 25.75.  HRMS 
(ESI) calcd for C15H13NO2 [M+H]+: 240.1025; found: 240.1042. 
 
 
MO-OTs-PH:  yield 88%.  Rf = 0.71 (1:1 EtOAc: Hexanes).  1HNMR (500 MHz, CDCl3): δ 7.97 (d, J = 8.8 Hz, 
2H), 7.51 (d, J = 9.2 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.40 (dt, J = 6.0, 2.5 Hz, 3H), 7.38 – 7.33 (m, 4H), 7.17 
(t, J = 9.7 Hz, 1H), 6.99 (t, J = 10.6 Hz, 1H), 2.47 (s, 3H).  13CNMR (125 MHz, CDCl3): δ 178.42, 154.77, 
151.89, 145.43, 139.76, 136.70, 133.85, 133.21, 129.66, 129.44, 129.41, 129.02, 128.76, 128.68, 128.13, 
21.74.  HRMS (ESI) calcd for C20H16O4S [M+H]+: 353.0848; found: 353.0857. 
 
 
MO-SMe-PH:  yield 98%.  Rf = 0.61 (1:1 EtOAc: Hexanes).  IR (KBr): ν: 3078, 3046, 2953, 2917, 2851, 
2358, 1603, 1578, 1546, 1489, 1475, 1458, 1438, 1420, 1396, 1353, 1316, 1271, 1253, 1200, 1153, 1098, 
1071, 1028, 1014, 950.1HNMR (500 MHz, CDCl3): δ 7.50 (t, J = 9.9 Hz, 3H), 7.44 (t, J = 7.6, 6.7 Hz, 2H), 
7.40 (d, J = 7.6 Hz, 1H), 7.13 – 7.05 (m, 2H), 7.00 (t, J = 9.3 Hz, 1H), 2.42 (s, 3H).  13CNMR (125 MHz, 
CDCl3): δ 181.71, 161.15, 144.94, 140.82, 137.23, 131.31, 129.53, 128.89, 128.04, 127.97, 126.54, 15.95.  
HRMS (ESI) calcd for C14H12OS [M+H]+: 229.0687; found: 229.0714. 
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SG-EtOH-OMe:  yield 94%.  Rf = 0.23 (EtOAc).  IR (KBr): ν: 3395, 2924, 1710, 1677, 1589, 1557, 1491, 
1463, 1438, 1407, 1355, 1326, 1271, 1216, 1160, 1111, 1089, 1043, 1014, 972.1HNMR (500 MHz, CDCl3): 
δ 7.50 – 7.43 (m, 5H), 7.09 (t, J = 10.1 Hz, 1H), 6.93 (t, J = 11.2 Hz, 1H), 6.79 (d, J = 9.6 Hz, 1H), 3.99 (s, 
3H), 3.85 (t, J = 6.3 Hz, 2H), 2.74 (t, J = 6.9 Hz, 2H).  13CNMR (125 MHz, CDCl3): δ 179.16, 165.95, 146.74, 
140.88, 137.41, 131.84, 131.28, 129.34, 126.86, 122.97, 111.94, 87.06, 82.43, 61.19, 56.50, 23.94.  
HRMS (ESI) calcd for C18H16O3 [M+H]+: 281.1178; found: 281.1194. 
 
 
SG-iPr-OMe:  yield 46%.  Rf = 0.49 (EtOAc).  1HNMR (500 MHz, CDCl3): δ 7.48 – 7.43 (m, 4H), 7.07 (t, J = 
10.5, 9.6 Hz, 1H), 6.92 (t, J = 10.1 Hz, 1H), 6.77 (d, J = 9.6 Hz, 1H), 3.98 (s, 3H), 1.31 (d, J = 6.9 Hz, 6H).  
13CNMR (125 MHz, CDCl3): δ 179.20, 165.88, 162.60, 146.84, 140.38, 137.28, 135.23, 135.18, 131.66, 
131.13, 130.24, 129.24, 127.65, 126.83, 123.67, 111.86, 96.46, 79.74, 56.48, 36.51, 23.06, 21.21.  HRMS 
(ESI) calcd for C19H18O2 [M+H]+: 279.1385; found: 2789.14041. 
 
 
PIV-tropolone: yield 86%.  1HNMR (500 MHz, CDCl3): δ 7.21 (d, J = 10.8 Hz, 2H), 7.14 (t, J = 10.4 Hz, 2H), 
7.06 (t, J = 9.7 Hz, 1H), 1.41 (s, 9H).  13CNMR (125 MHz, CDCl3): δ 175.86, 137.80, 133.94, 133.16, 123.97, 
39.20, 27.25, 27.09.  HRMS (ESI) calcd for C12H14O3: 207.1021; found: 207.1044. 
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O
O
 
MO-1-unsat-OMe: yield 94%.  Rf = 0.26 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 2925, 2918, 2849, 
1632, 1610, 1595, 1570, 1488, 1466, 1448, 1364, 1270, 1249, 1217, 1178, 1043, 969, 750.  1HNMR (500 
MHz, CDCl3): δ 7.54 (d, J = 9.2 Hz , 1H), 6.96-6.93 (m, 2H), 6.80 (t, J = 19.7, 9.7, 10 Hz, 1H), 6.68 (d, J = 9.7 
Hz, 1H), 6.24 (dd, J = 16, 7.2, 7.2 Hz, 1H), 3.88 (s, 3H), 2.17-2.13 (m, 1H), 1.79-1.62 (m, 5H), 1.32-1.11 (m, 
5H).  13CNMR (126 MHz, CDCl3): δ 178.8, 164.0, 143.9, 141.3, 132.3, 130.6, 126.8, 126.6, 112.1, 56.2, 
41.6, 32.6, 25.8.  HRMS (ESI) calcd for C16H20O2 [M+H]+: 245.1542; found: 245.1533. 
O
O
 
MO-1-OMe: yield: 86%. Rf = 0.27 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 3053, 2945, 2842, 2662, 
1738, 1575, 1568, 1556, 1504, 1455, 1372, 1128, 1062, 1055, 1042, 1037, 837, 798, 748.  1HNMR (500 
MHz, CDCl3): δ 7.37 (d, J= 8.9 Hz, 1H), 6.99 (t, J = 20.2, 10.5, 9.8 Hz, 1H), 6.82 (t, J = 19.5, 9.5, 10.0 Hz, 
1H), 6.74 (d, J = 9.7 Hz, 1H), 3.92 (s, 3H), 2.79-2.76 (m, 2H), 1.81-1.62 (m, 5H), 1.48-1.44 (m, 2H), 1.36-
1.11 (m, 4H), 0.99-0.91 (m, 2H).  13CNMR (126 MHz, CDCl3): δ 179.2, 163.4, 150.5, 135.2, 130.3, 126.8, 
111.7, 55.9, 37.5, 36.5, 33.6, 26.4, 26.0.  HRMS (ESI) calcd for C16H22O2 [M+H]+: 247.1698; found: 
247.1696. 
HO
O
 
MO-1-OH: yield: 76%. Rf = 0.54 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 3204, 2919, 2901, 2848, 
1599, 1547, 1537, 1475, 1418, 1380, 1229, 1205, 1125, 996, 731. 1HNMR (500 MHz, CD2Cl2): δ 9.65 (bs, 
1H), 7.47 (d, J = 9.9 Hz, 1H), 7.32-7.25 (m, 2H), 7.00-6.96 (m, 1H), 2.84-2.80 (m, 2H), 1.80 (d, J = 13.6 Hz, 
2H), 1.72-1.64 (m, 3H), 1.50-1.46 (m, 2H), 1.36-1.13 (m, 5H), 1.00-0.92 (m, 2H).  13CNMR (126 MHz, 
CD2Cl2): δ 172.7, 168.9, 142.6, 139.9, 136.2, 127.9, 121.7, 38.4, 37.5, 33.8, 33.3, 27.3, 26.9.  HRMS (ESI) 
calcd for C15H20O2 [M+H]+: 233.1541; found: 233.1550. 
 
O
O
 
MO-2-unsat-OMe: yield: 88%. Rf = 0.25 (1:1 EtOAc: Hexanes). Mp = N/A.  IR (KBr): ν: 2958, 2929, 2870, 
1633, 1610, 1590, 1570, 1560, 1489, 1465, 1438, 1364, 1270, 1250, 1218, 1177, 1057, 1039, 969, 782, 
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750, 671.  1HNMR (500 MHz, CDCl3): δ 7.40 (d, J = 9.1 Hz, 1H), 6.84-6.79 (m, 2H), 6.68 (t, J = 19.7, 9.7, 10 
Hz, 1H), 6.58 (d, J = 9.7 Hz, 1H), 6.22-6.16 (m, 1H), 3.74 (s, 3H), 2.05 (q, J= 23.1, 7.3, 7.4, 8.4 Hz, 2H), 1.33 
(h, J = 36.9, 7.4, 7.4, 7.4, 7.4, 7.4 Hz, 2H), 0.77 (t, J = 14.8, 7.4, 7.4 Hz, 3H).  13CNMR (126 MHz, CDCl3): δ 
178.3, 163.7, 143.2, 135.2, 132.2, 130.5, 128.8, 126.5, 111.9, 55.9, 35.1, 21.9, 13.3.  HRMS (ESI) calcd for 
C13H16O2 [M+H]+: 205.1229; found: 205.1247. 
O
O
 
MO-2-OMe: yield 84%.  Rf = 0.26 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 2954, 2923, 2869, 2855, 
1595, 1567, 1556, 1496, 1466, 1463, 1446, 1435, 1413, 1375, 1270, 1254, 1218, 1175, 1114, 1045, 1022, 
795, 748.  1HNMR (500 MHz, CDCl3): δ 7.34 (d, J =8.9 Hz, 1H), 6.96 (t, J = 20.3, 10.6, 9.8 Hz, 1H), 6.79 (t, J 
= 19.6, 10.5, 9.1 Hz, 1H), 6.70 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.75-2.72 (m, 2H), 1.56 (m, 2H), 1.32 (m, 
4H), 0.86 (m, 3H).  13CNMR (126 MHz, CDCl3): δ 179.5, 163.7, 150.3, 135.6, 130.5, 127.0, 111.9, 56.2, 
36.3, 31.8, 28.7, 22.4, 13.9.  HRMS (ESI) calcd for C13H18O2 [M+H]+: 207.1385; found: 207.1410. 
HO
O
 
MO-2-OH: yield: 75%.  Rf = 0.6 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 3172, 3161, 3153, 3140, 
2957, 2927, 2924, 2869, 2857, 1616, 1601, 1549, 1488, 1477, 1468, 1422, 1381, 1293, 1240, 1232, 850, 
799, 743, 718, 696.  1HNMR (500 MHz, CD2Cl2): δ 9.60 (bs, 1H), 7.46 (d, J = 9.9 Hz, 1H), 7.31-7.24 (m, 2H), 
6.96 (t, J = 18.7, 9.0, 9.7 Hz, 1H), 2.80 (t, J = 15.5, 7.6, 7.9 Hz, 2H), 1.61 (m, 2H), 1.35 (m, 4H), 0.89 (m, 
3H).  13CNMR (126 MHz, CDCl3): δ 172.9, 169.1, 142.1, 139.9, 136.2, 127.7, 121.8, 35.9, 32.4, 29.4, 23.1, 
14.4.  HRMS (ESI) calcd for C12H16O2 [M+H]+: 193.1229; found: 193.1249. 
O
O
 
MO-7-unsat-OMe: yield: 85%.  Rf = 0.28 (1:1 EtOAc: Hexanes).  Mp = 77.4-79.0.  IR (KBr): ν: 3057, 3024, 
3005, 2964, 2936, 2897, 2835, 1632, 1587, 1564, 1489, 1466, 1452, 1438, 1409, 1364, 1272, 1247, 1217, 
1175, 1154, 1059, 1042, 1030, 971, 937, 819, 799, 751, 700, 674.  1HNMR (500 MHz, CDCl3): δ 7.46 (d, J = 
9.0 Hz, 1H), 7.24-7.12 (m, 5H), 7.03 (d, J = 15.7 Hz, 1H), 6.89 (t, J = 20.0, 9.95, 10.1 Hz,  1H), 6.42-6.36 (m, 
1H), 6.63 (d, J = 9.7 Hz, 1H), 6.42-6.36 (m, 1H), 3.82 (s, 3H), 3.51 (d, J = 6.9 Hz, 2H).  13CNMR (126 MHz, 
CDCl3): δ 178.3, 163.9, 142.8, 139.4, 133.3, 132.6, 130.9, 129.9, 128.2, 128.1, 126.5, 125.8, 111.9, 55.9, 
39.4.  HRMS (ESI) calcd for C17H16O2 [M+H]+: 253.1229; found: 253.1258. 
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MO-7-OMe: yield: 82%.  Rf = 0.29 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 3024, 2929, 2913, 2853, 
1594, 1574, 1497, 1466, 1453, 1374, 1271, 1219, 1177, 751, 700.  1HNMR (500 MHz, CDCl3): δ 733 (d, J = 
8.9 Hz, 1H), 7.28-7.14 (m, 5H), 6.97 (t, J = 20.3, 10.6, 9.7 Hz, 1H), 6.79 (t, J = 19.6, 9.6, 10.0 Hz, 1H), 6.71 
(d, J = 9.6 Hz, 1H), 3.92 (s, 3H), 2.82 (t, J = 15.4, 7.6, 7.8 Hz 2H), 2.70 (t, J = 15.5, 7.6, 7.9 Hz, 2H), 1.96-
1.90 (m, 2H).  13CNMR (126 MHz, CDCl3): δ 179.4, 163.8, 149.7, 142.1, 135.7, 130.7, 128.3, 128.2, 126.9, 
125.6, 56.2, 36.1, 35.7, 30.5.  HRMS (ESI) calcd for C17H18O2 [M+H]+: 255.1385; found: 255.1406. 
HO
O
 
MO-7-OH: yield: 73%.  Rf = 0.35 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 3026, 2927, 2923, 2857, 
1616, 1600, 1550, 1473, 1459, 1453, 1424, 1382, 1293, 1263, 1247, 1233, 1214, 738, 699.  1HNMR (500 
MHz, CD2Cl2): δ 7.47 (d, J = 9.8 Hz, 1H), 7.34-7.17 (m, 7H), 6.98 (t, J = 20.6, 9.9, 10.7 Hz, 1H), 2.88 (t, J = 
15.5, 7.6, 7.9 Hz, 2H), 2.72 (t, J = 15.4, 7.6, 7.8 Hz, 2H), 1.99-1.93 (m, 2H).  13CNMR (126 MHz, CD2Cl2): δ 
173.0, 168.7, 142.8, 141.8, 140.0, 136.4, 129.0, 128.8, 127.9, 126.3, 121.5, 36.3, 35.7, 31.2.  HRMS (ESI) 
calcd for C16H16O2 [M+H]+: 241.1229; found: 241.1253. 
O
 
MO-10-H: yield: 97%.  Rf = 0.29 (25% EtOAc in Hexanes).  Mp = N/A.  IR (KBr): ν: 3024, 2964, 2931, 2873, 
1638, 1575, 1464, 1384, 1261, 833, 791, 690.  1HNMR (500 MHz, CDCl3): δ 7.45 (d, J = 15.0 Hz, 2H), 7.38 
(dd, J = 10.0, 1.0, 1.0 Hz, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 12.0 Hz, 1H), 7.13 (ddd, J = 21.0, 9.0, 
9.0, 1.5, 1.5, 1.5, 1.5 Hz, 1H), 7.05 (t, J = 19.5, 10.5, 9.0 Hz, 1H), 6.96 (dd, J = 18.5, 7.5, 8.0 Hz, 1H), 2.71 
(q, 23.0, 8.0, 7.5, 7.5 Hz, 2H), 1.29 (t, J = 15.5, 8.0, 7.5 Hz, 3H). 13CNMR (126 MHz, CDCl3): δ 186.8, 175.5, 
152.7, 144.9, 142.3, 137.4, 136.3, 136.0, 135.3, 133.9, 133.1, 129.3, 127.8, 41.4, 29.4, 28.9, 15.6.  HRMS 
(ESI) calcd for C16H16O2 [M+H]+: 211.1124; found 211.1152. 
H2N
O
 
MO-10-NH2: yield: 77%.  Rf = 0.44 (1:1 EtOAc: Hexanes).  Mp = 131.0-132.2.  IR (KBr): ν: 3388, 3254, 
3242, 3233, 3206, 3176, 3152, 3147, 3118, 2960, 1606, 1512, 1453, 1433, 1410, 1343, 1273, 1240, 1180, 
1113, 915, 833, 757, 707, 584.  1HNMR (500 MHz, CD2Cl2): δ 7.52 (dd, J = 11.0, 1.5, 1.0 Hz, 1H), 7.41 (d, J 
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= 8.0 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.16 (td, J = 21.5, 11.5, 11.5, 1.5, 1.5, 1.0 Hz, 1H), 6.95 (dd, J = 10.5, 
0.5, 0.5 Hz, 1H), 6.80 (t, J = 20.5, 10.0, 10.5 Hz, 1H), 6.16 (s, 2H), 2.74 (q, J = 23.0, 8.0, 7.5, 7.5 Hz, 2H), 
1.32 (t, J = 15.0, 7.5, 7.5 Hz, 3H).  13CNMR (126 MHz, CD2Cl2): δ 174.6, 157.9, 143.6, 142.2, 140.2, 138.4, 
135.1, 129.6, 127.4, 123.0, 112.3, 28.8, 15.6.  HRMS (ESI) calcd for C15H15NO [M+H]+: 226.1236; found 
226.1262. 
HO
O
 
MO-10-OH: yield: 65%.  Rf = 0.47 (1:1 EtOAc: Hexanes).  Mp = 60.7-61.9.  IR (KBr): ν: 3168, 3022, 2964, 
2929, 2872, 1615, 1595, 1549, 1474, 1418, 1380, 1365, 1276, 1247, 914, 835, 751.  1HNMR (500 MHz, 
CD2Cl2): δ 7.63 (d, J = 10.5 Hz, 1H), 7.49-7.34 (m, 6H), 7.13 (t, J = 20.5, 10.5, 10.0 Hz, 1H), 2.77 (q, J = 23.0, 
7.5, 8.0, 7.5 Hz, 2H), 1.34 (t, J = 15.5, 7.5, 8.0 Hz, 3H).  13CNMR (126 MHz, CD2Cl2): δ 171.6, 170.3, 144.7, 
140.6, 139.1, 137.6, 136.6, 129.4, 127.8, 121.5, 28.8, 15.5.  HRMS (ESI) calcd for C15H14O2 [M+H]+: 
227.1072; found 227.1103. 
O
 
MO-9-H: yield: 97%.  Rf = 0.47 (25% EtOAc in Hexanes).  Mp = N/A.  IR (KBr): ν: 3024, 2956, 2929, 2869, 
2856, 1630, 1582, 1508, 1463, 1382, 1259, 1230, 1183, 902, 830, 781, 687, 558.  1HNMR (500 MHz, 
CDCl3): δ 7.43 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 12.0 Hz, 1H), 
7.03 (t, J = 19.9, 7.8, 12.1 Hz, 1H), 6.94 (t, J = 19.6, 10.6, 9.0 Hz, 1H), 6.85 (t, J = 19.4, 8.6, 10.8 Hz, 1H), 
2.63 (t, J = 15.5, 7.6, 7.9 Hz, 2H), 1.62 (p, J = 30.4, 7.4, 7.7, 7.5, 7.8 Hz, 2H), 1.38 (h, J = 37.0, 7.4, 7.4, 7.4, 
7.4, 7.4 Hz, 2H), 0.94 (t, J = 14.7, 7.4, 7.3 Hz, 3H).  13CNMR (126 MHz, CDCl3): δ 186.6, 152.4, 143.4, 
142.1, 137.5, 136.3, 135.3, 133.9, 133.1, 129.3, 128.3, 35.6, 33.7, 22.6, 14.2.  HRMS (ESI) calcd for 
C18H20O2 [M+H]+: 239.1437; found: 239.1498. 
H2N
O
 
MO-9-NH2: yield: 88%.  Rf = 0.50 (1:1 EtOAc: Hexanes).  Mp = 133.7-135.0.  IR (KBr): ν: 3398, 3240, 3232, 
3200, 3140, 3124, 3118, 2954, 2925, 1607, 1520, 1507, 1433, 1335, 1266, 1239, 916, 759, 706, 573.  
1HNMR (500 MHz, CD2Cl2): δ 7.51 (d, J = 9.6 Hz, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 7.9 Hz, 2H), 7.06 
(t, J = 20.0, 10.0, 10.0 Hz, 1H), 6.84 (d, J = 10.0 Hz, 1H), 6.74 (t, J = 19.6, 9.8, 9.8 Hz, 1H), 6.25 (s, 2H), 2.66 
(t, J = 15.4, 7.4, 8.0 Hz, 2H), 1.65 (p, J = 30.4, 7.4, 7.7, 6.8, 8.5 Hz, 2H), 1.41 (h, J = 36.9, 7.3, 7.4, 7.4, 7.5, 
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7.4 Hz, 2H), 0.96 (t, J = 14.7, 7.4, 7.3 Hz, 3H).  13CNMR (126 MHz, CD2Cl2): δ 174.0, 158.1, 141.8, 141.6, 
139.7, 138.4, 135.1, 129.2, 127.8, 122.6, 112.8, 35.3, 33.4, 22.3, 13.8. HRMS (ESI) calcd for C17H19NO 
[M+H]+: 254.1545; found: 254.1526. 
HO
O
 
MO-9-OH: yield: 87%.  Rf = 0.37 (1:1 EtOAc: Hexanes).  Mp = N/A.  IR (KBr): ν: 2957, 2928, 2856, 1613, 
1595, 1549, 1474, 1466, 1455, 1419, 1376, 1363, 1291, 1276, 1246, 1182, 730.  1HNMR (400 MHz, 
CD2Cl2): δ 7.60 (d, J = 10.1 Hz, 1H), 7.43-7.37 (m, 4H), 7.27 (d, J = 8.1 Hz, 2H), 7.11-7.06 (m, 1H), 2.70 (t, J 
= 15.5, 7.5, 8.0 Hz, 2H), 1.70 (p, J = 30.4, 7.2, 7.8, 7.6, 7.8 Hz, 2H), 1.40 (h, J = 36.9, 7.3, 7.4, 7.5, 7.4, 7.3 
Hz, 2H), 1.00 (t, J = 14.6, 7.3, 7.3 Hz, 3H).  13CNMR (101 MHz, CD2Cl2): δ 172.0, 170.7, 143.8, 141.0, 139.6, 
137.9, 137.0, 129.8, 128.7, 127.9, 121.9, 35.9, 34.3, 23.0, 14.3.  HRMS (ESI) calcd for C17H18O2 [M+H]+: 
255.1385; found: 255.1390. 
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SG-TMS-OMe 
 
 
358 
 
SG-TMS-OH 
 
 
359 
 
EF-1-OMe 
 
 
360 
 
EF-1-OH 
 
 
361 
 
EF-2-OH 
 
 
362 
 
EF-3-OMe 
 
 
363 
 
EF-3-OH 
 
 
364 
 
EF-4-OMe 
 
 
365 
 
EF-4-OH 
 
 
366 
 
Am-NO2-OMe 
 
 
367 
 
Am-NO2-OH 
 
 
368 
 
Am-NHBoc-OMe 
 
 
369 
 
Am-NH2-OH 
 
 
370 
 
Am-Piv-OH 
 
 
371 
 
Am-P5-OH 
 
 
372 
 
HC-1-OMe 
 
 
373 
 
HC-1-OH 
 
 
374 
 
HC-2-OMe 
 
 
375 
 
HC-2-OH 
 
 
376 
 
HC-3-OMe 
 
 
377 
 
BA-pCN-OMe 
 
 
378 
 
BA-pCN-OH 
 
 
379 
 
BA-pOH-OH 
 
 
380 
 
MO-DMe-OMe 
 
 
381 
 
MO-DMe-OH 
 
 
382 
 
MO-3-OH 
 
 
383 
 
HC-4-OMe 
 
 
384 
 
Am-Boc-H 
 
 
385 
 
Am-Boc-NH2 
 
 
 
 
 
 
 
 
 
386 
 
HC-5-H 
 
 
387 
 
HC-5-NH2 
 
 
388 
 
HC-5-OH 
 
 
389 
 
HC-6-H 
 
 
390 
 
HC-6-NH2 
 
 
391 
 
HC-6-OH 
 
 
392 
 
HC-7-H 
 
 
393 
 
HC-7-NH2 
 
 
394 
 
HC-7-OH 
 
 
395 
 
MO-pF-H 
 
 
396 
 
MO-pF-NH2 
 
 
397 
 
MO-pF-OH 
 
 
398 
 
HC-8-H 
 
 
399 
 
HC-8-NH2 
 
 
400 
 
HC-9-H 
 
 
401 
 
HC-9-NH2 
 
 
402 
 
Am-DMe-H 
 
 
403 
 
Am-DMe-NH2 
 
 
404 
 
HC-10-H 
 
 
405 
 
HC-10-NH2 
 
 
406 
 
HC-10-OH 
 
 
407 
 
MO-pSMe-H 
 
 
408 
 
MO-pSMe-NH2 
 
 
409 
 
MO-pSMe-OH 
 
 
410 
 
HC-11-H 
 
 
411 
 
HC-12-H 
 
 
412 
 
HC-12-NH2 
 
 
413 
 
HC-12-OH 
 
 
 
 
 
 
 
 
 
414 
 
MO-11-H 
 
 
415 
 
MO-11-NH2 
 
 
416 
 
MO-11-OH 
 
 
417 
 
MO-NHOH-PH 
 
 
418 
 
MO-SH-PH 
 
 
419 
 
HC-9-OMe 
 
 
420 
 
HC-13-H 
 
 
421 
 
HC-13-NH2 
 
 
422 
 
SG-PH-OMe 
 
 
423 
 
SG-PH-OH 
 
 
424 
 
EF-5-H 
 
 
425 
 
HC-12-OMe 
 
 
426 
 
Am-Ac-OH 
 
 
427 
 
MO-Am-PH 
 
 
428 
 
MO-OTs-PH 
 
 
429 
 
MO-SMe-PH 
 
 
430 
 
SG-EtOH-OMe 
 
 
431 
 
SG-iPr-OMe 
 
 
432 
 
Appendix B: Biological Data 
 
Compound % Inhibition Standard Deviation
Tenovin-6 21.18 0.32
Salermide 16.84 0.28
MO-1-OH 13.89 0.49
MO-10-OH 33.53 0.17
MO-OH-Nap 30.53 0.31
BA-pBr-OH 34.18 0.38
HC-1-OH 25.92 0.52
MO-OH-DM 38.81 7.56
MO-OH-PH 29.71 0.57
MO-7-OH 36.14 0.83
BA-SM-OH 43.74 0.55
BA-TM-OH 20.77 0.37
EF-3-OH 33.87 0.54
BA-PH-OH 26.60 4.06
MO-2-OH 10.40 0.41
Am-NO2-OH 18.93 1.26
EF-2-OH 22.86 0.81
MO-9-OH -1.94 1.68
BA-P7-OH -0.82 2.30
EF-1-OH 3.61 0.27
Am-NH2-OH 32.02 0.39
HKT 21.07 1.93
TDA 61.86 0.47
HC-2-OH 13.71 0.97
BA-pOH-OH 23.23 0.37
BA-pCN-OH 2.67 1.05
Am-Piv-OH 15.38 1.35
BA-HC2-OH 24.35 0.70
SG-TMS-OH 6.03 4.02
Trans-resveratrol -30.23 1.23
Sirt 1 Inhibition Assay
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Compound % Inhibition Standard Deviation
Tenovin-6 65.99 0.85
MO-1-OH -0.05 3.52
MO-10-OH 13.00 1.72
MO-OH-Nap 16.71 0.49
BA-pBr-OH 16.78 0.78
BA-Nap-OH 13.18 3.71
HC-1-OH 12.59 2.97
MO-OH-DM 5.69 2.55
MO-OH-PH 11.98 0.30
MO-7-OH 13.52 3.45
BA-SM-OH 57.48 0.79
BA-TM-OH 25.71 2.12
EF-3-OH 9.16 1.30
BA-PH-OH 18.37 2.56
MO-2-OH 15.25 2.88
Vorinostat 0.09 2.12
EF-2-OH 16.46 0.75
MO-9-OH 5.38 3.13
BA-P7-OH 10.94 5.33
EF-1-OH 4.64 1.15
Am-NH2-OH 22.08 0.60
HKT 5.37 2.80
TDA 92.09 0.54
HC-2-OH 15.55 1.60
BA-pOH-OH 86.36 0.71
BA-pCN-OH 12.96 4.19
Am-Piv-OH 49.12 1.71
BA-HC2-OH 34.46 0.65
SG-TMS-OH 17.12 0.64
Trans-Resveratrol 48.11 1.12
Sirt 2 Inhibition Assay
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Compound
Ba/F3 GC 
insertion
Ba/F3 88i point 
mutation
CH12
MO-OH-Nap 0.75 0.73 N/A
MO-OH-SM 1.01 0.93 N/A
MO-OH-DM 2.22 1.95 N/A
MO-OH-TM 3.51 3.32 N/A
MO-OH-PH 3.12 3.03 N/A
MO-1-OH 0.68 0.69 N/A
MO-2-OH 1.98 1.93 N/A
MO-7-OH 1.55 1.96 N/A
MO-10-OH 1.31 1.79 N/A
MO-9-OH 2.18 2.44 N/A
BA-P7-OH 0.29 0.46 1.84
BA-P8-OH 0.31 0.42 4.77
BA-pBr-OH 0.61 0.92 0.95
BA-Phe-OH 0.88 1.39 1.21
BA-Nap-OH 0.59 0.75 1.21
BA-SM-OH 0.8 1.13 1.27
BA-DM-OH 1.2 1.51 1.26
BA-TM-OH 1.12 1.54 1.27
EF-1-OH 0.31 0.60 2.09
EF-2-OH 0.41 0.60 1.83
EF-3-OH 0.68 0.54 2.11
HC-1-OH 0.12 0.23 >10
Am-pNH3-OH 0.32 0.31 2.35
Am-pNO2-OH 0.45 0.56 1.78
SAHA 0.16 0.35 0.68
Murine Malignant Hematologic Cell GI50 (µM)
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Cancer Causing Genes Associated with Molt-4 Cells 
Gene mutation type Nap HC-1 fold 
DICER1 missense 10.44427 10.44036 10.44232 
PAX8 missense 10.44427 10.44036 10.44232 
EGFR   5.754676 12.84959 9.302133 
HDAC9 missense 6.85147 6.856138 6.853804 
TERT missense 6.85147 6.856138 6.853804 
CD79A silent 5.208295 7.012781 6.110538 
CAMTA1 missense 6.82705 4.17405 5.50055 
TSC1 missense 4.101206 6.417841 5.259524 
EGFR   2.573569 7.426981 5.000275 
NRG1 missense 4.834759 4.832946 4.833853 
BCL11B missense 5.347897 4.206537 4.777217 
EGFR deletion/frameshift 3.214596 6.057353 4.635975 
PRDM16 deletion/frameshift 2.284347 5.718419 4.001383 
DNMT3A deletion/frameshift 2.515569 5.301685 3.908627 
BCAR3 missense 4.316066 2.998645 3.657356 
PRDM16   2.221528 5.087109 3.654318 
AZU1 silent 3.746343 3.548604 3.647474 
NCOA2 missense 3.710341 3.429571 3.569956 
ACVR1B missense 4.755257 1.859933 3.307595 
ATP2B3 unknown 2.14665 4.198014 3.172332 
FARP2 silent 3.548126 2.575947 3.062037 
HDAC7 missense 3.624204 2.23759 2.930897 
KDM5A missense 3.32002 2.47566 2.89784 
PAX8   2.618842 2.850439 2.734641 
PTPRB silent 3.859757 1.581139 2.720448 
TRAF7 missense 2.702256 2.704097 2.703177 
LRIG3 silent 2.638993 2.670182 2.654587 
ABL1 silent 2.971888 2.276293 2.624091 
MUC1 insertion/frameshift 2.52445 2.718775 2.621612 
TERT   2.616448 2.618231 2.61734 
SF3B1 missense 2.711639 2.307232 2.509435 
CREBBP missense 1.964166 2.754203 2.359185 
WHSC1 silent 2.578107 2.066212 2.322159 
ATM missense 2.585416 1.94967 2.267543 
BRCA2 silent 2.232649 2.296938 2.264794 
RARA   2.194239 2.28886 2.24155 
HRAS missense 2.908662 1.570436 2.239549 
PMS2 unknown 2.391718 2.020761 2.20624 
HNF1A missense 2.059261 2.291288 2.175275 
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RARA missense 2.265969 2.069964 2.167966 
TELO2 silent 1.807135 2.46387 2.135503 
ARHGEF12 missense 1.626647 2.520454 2.07355 
FLT3 missense 2.221848 1.911432 2.06664 
PIK3R1   2.114824 1.977994 2.046409 
PPFIBP1   2.478702 1.569657 2.02418 
NRG1   1.821143 2.190962 2.006053 
MLL3 silent 1.511369 2.427236 1.969303 
PPFIBP1 missense 1.542991 2.345792 1.944392 
PHOX2B missense 1.597356 2.287348 1.942352 
FBXO11 missense 2.153459 1.663024 1.908242 
PIK3R1 deletion/frameshift 1.557145 1.811219 1.684182 
MEN1 missense 1.589059 1.748744 1.668901 
BCL6 missense 1.657084 1.554004 1.605544 
     
  
red = upregulation 
 
  
green = downregulation 
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Compound HepG2
MO-OH-Nap >500
MO-OH-SM >500
MO-OH-DM >500
MO-OH-TM >500
MO-OH-PH >500
MO-1-OH >500
Compound MCF-7
MO-1-OH >10 
MO-2-OH 5.00
MO-7-OH 3.43
MO-9-OH 6.21
MO-10-OH 5.64
EF-C-1-OH 8.57
EF-C-2-OH 4.58
EF-C-3-OH 5.97
BA-pBr-OH 8.67
BA-Phe-OH 7.43
BA-SM-OH 4.40
BA-DM-OH 7.82
BA-TM-OH N/A 
BA-Nap-OH 6.62
BA-P7-OH N/A 
BA-P8-OH 1.00
HC-1-OH >10 
Am-NH2-OH 6.84
Am-NO2-OH 4.82
Non-Hematologic 
Malignant Cell GI50 (µM)
439 
 
 
 
 
 
 
C
o
m
p
o
u
n
d
 
2
: 
B
A
-T
M
-O
H
C
o
m
p
o
u
n
d
 
1
: 
B
A
-p
B
r-
O
H
0
10203040506070809010
0
B
T2
0
B
T-
54
9
M
D
A
-M
B
-2
31
M
D
A
-M
B
-1
57
M
C
F
-7
T4
7D
M
D
A
-3
61
H
M
E
C
% Inhibition
A
ss
es
sm
en
t 
o
f 
g
ro
w
th
 in
h
ib
it
io
n
 o
f 
tr
o
p
o
lo
n
es
 in
 b
re
as
t 
ce
ll
 
li
n
es
 (1
0 
µ
M
, 7
2h
)
C
o
m
p
d
1
C
o
m
p
d
2
C
e
ll
 l
in
e
 K
e
y
T
N
B
C
•B
T
-2
0
•B
T
-5
4
9
•M
D
A
-M
B
-2
3
1
•M
D
A
-M
B
-1
5
7
E
R
+
 
•M
C
F
-7
•
T
4
7
D
•M
D
A
-M
B
-3
6
1
N
o
n
-t
u
m
o
ri
g
e
n
ic
•H
M
E
C
440 
 
MICs (µg/mL) of Tropolones against E. coli and K. pneumoniae 
 
MIC MIC MIC MIC
Tropolones MW E. coli 25922 K. p 10031 UCHC K.p1 UCHC K.p3
Unsubstituted
Tropolone 122.12 >40ug/mL >50ug/mL N/A N/A
Negative control
HKT-OMe 178.23 >50 >500 N/A N/A
a-Substitution (1st gen)
MO-OH-PH 198.22 20 25 40 20
MO-OH-SM 228.24 N/A 40 N/A N/A
MO-OH-DM 258.27 >40 100 N/A N/A
MO-OH-TM 288.29 >40 100 N/A N/A
MO-OH-Nap 248.28 40 100 N/A N/A
b-Substitution (1st gen)
HKT 164.2 25 31.25 20 20
b-sec 178.23 N/A N/A N/A N/A
b-tert 178.23 >50 125 N/A N/A
b-cyclopentyl 190.24 50 62.5 N/A N/A
b-Phe 198.22 25 31.25 N/A N/A
b-SM 228.24 >50 62.5 N/A N/A
Alkyl linker
MO-1-OH 232.32 >40 25 >40 >40
MO-7-OH 240.3 40 25 40 20
Alkyl tail
MO-2-OH 192.25 20/10 10 40 20
MO-3-OH 190.24 40 40 N/A N/A
MO-9-OH 254.32 40 50 N/A N/A
MO-10-OH 226.27 20 10 >40 40
MO-11-OH 254.32 >40 40 N/A N/A
MO-pSMe-OH 244.31 20 20 20 20
BA-P5-OH 266.33 >40 N/A N/A N/A
BA-P7-OH 296.4 N/A >40 N/A N/A
Aniline  derivatives
Am-NO2-OH 243.21 ~40 20/10 40 40
Am-NH2-OH 213.23 40 50 N/A N/A
Am-Piv-OH 297.35 >40 40 N/A N/A
Am-P5-OH 295.33 40 20 >40 >40
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MIC MIC MIC MIC
Tropolones MW E. coli 25922 K. p 10031 UCHC K.p1 UCHC K.p3
Biaryl
BA-pBr-OH 277.11 20 12.5 20 20
MO-pF-OH 216.21 40 40 N/A N/A
BA-pOH-OH 214.22 >40 40 N/A N/A
BA-pCN-OH 223.27 >40 >40 N/A N/A
BA-Ph-OH 274.31 20 12.5 >40 >40
BA-SM-OH 304.34 N/A >40 N/A N/A
BA-DM-OH 334.36 40 20 >40 >40
BA-TM-OH 364.39 N/A 40 N/A N/A
BA-NAP-OH 324.37 N/A >40 N/A N/A
BA-HC2-OH 264.28 20 20 40 40
Heterocycles
HC-1-OH 256.25 40 20 >40 40
HC-2-OH 188.18 20 10 20 20
HC-3-OH 199.21 >40 >40 N/A N/A
HC-5-OH 242.23 >40 N/A N/A N/A
HC-6-OH 201.22 40 > 20 40 N/A N/A
HC-7-OH 311.33 >40 N/A N/A N/A
HC-10-OH 288.3 >40 N/A N/A N/A
HC-12-OH 218.27 40 40 N/A N/A
Acetylene
SG-TMS-OH 294.42 N/A >40 N/A N/A
Carbonyls
EF-1-OH (p-aldehyde) 226.26 40 40 N/A N/A
EF-2-OH (acetyl) 240.25 40 10 >40 40
EF-3-OH (methylester) 256.25 40/20 20 >40 >40
EF-4-OH (o-aldehyde) 226.26 N/A 40 N/A N/A
Other
TDA 212.25 20 20 20 20
Zn-ditrop-PH 459.81 20 N/A N/A N/A
Piv-trop 206.24 N/A >40 N/A N/A
ENOblock 631.18 N/A 20 N/A N/A
Alternative chelators
MO-SMe-PH 228.31 N/A >40 N/A N/A
MO-NH2-PH 197.23 N/A >40 N/A N/A
MO-PivAm-PH 281.35 N/A >40 N/A N/A
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MIC MIC MIC MIC
Tropolones MW E. coli 25922 K. p 10031 UCHC K.p1 UCHC K.p3
Gamma substitution
gamma amine 137.14 N/A >40 N/A N/A
gamma Piv 221.25 >40 >40 N/A N/A
Amine intermediate
MO-NH2-Ph 197.23 >40 N/A N/A N/A
MO-NH2-SM 227.26 >40 N/A N/A N/A
MO-NH2-DM 257.28 >40 N/A N/A N/A
MO-NH2-TM 287.31 >40 N/A N/A N/A
MO-NH2-Nap 247.29 >40 >400 N/A N/A
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Tropolones MW 25922 BW25113 JW0451 NR698 EFFECT
a-Substitution (1st gen)
MO-OH-PH 198.22 20 20 20 20 NONE
MO-OH-SM 228.24 N/A >20 40 40/20 NONE
MO-OH-DMe 226.27 N/A 40 40 40 NONE
Natural Product
HKT 164.2 25 20 20 20 NONE
tropodithietic acid 212.25 20 40 40 40/20 ?
Alkyl linker
MO-1-OH 232.32 >40 >40 >40 >40 NONE
MO-7-OH 240.3 40 20 20 20 NONE
Alkyl tail
MO-2-OH 192.25 20/10 40 40 40 ?
MO-9-OH 254.32 40 40 40 20 LPS
MO-10-OH 226.27 20 40 40/20 40/20 ?
MO-11-OH 254.32 >40 40 40/20 5 LPS
MO-pSMe-OH 244.31 20 20 20 10 LPS
BA-P5-OH 266.33 >40 >20 >40 20/10 LPS
BA-P8-OH 308.41 N/A >20 >40 >40 NONE
Biaryl
BA-pBr-OH 277.11 20 20 20 10 LPS
MO-pF-OH 216.21 40 40 40 40 NONE
BA-pOH-OH 214.22 >40 >20 >40 40 LPS
BA-pCN-OH 223.27 >40 >40 >40 >40 NONE
BA-Ph-OH 274.31 20 >40 >40 >40 ?
BA-SM-OH 304.34 N/A >40 >40 20/10 LPS
BA-DM-OH 334.36 40 >40 20 10 EFFLUX AND LPS
BA-TM-OH 364.39 N/A >40 40 20 LPS
BA-NAP-OH 324.37 N/A >40 >40 40 LPS
BA-HC2-OH 264.28 20 20 20 20 NONE
Aniline  derivatives
Am-NO2-OH 243.21 40 20 20 20 NONE
Am-NH2-OH 213.23 40 >20 40/20 40/20 NONE
Am-Ac-OH 255.27 N/A >40 >40 >40 NONE
Am-Piv-OH 297.35 >40 >20 40 40 NONE
Am-P5-OH 295.33 40 40 40 40 NONE
MICs in E. coli and E. coli knockout models
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Tropolones MW 25922 BW25113 JW0451 NR698 EFFECT
Heterocycles
HC-1-OH 256.25 40 40 40 40 NONE
HC-2-OH 188.18 20 20 20 20 NONE
HC-3-OH 199.21 >40 >20 >40 >40 NONE
HC-5-OH 242.23 >40 >40 >40 >40 NONE
HC-6-OH 201.22 40/20 40 20 20 ?
HC-7-OH 311.33 >40 >20 >40 ~40 NONE
HC-10-OH 288.3 >40 >40 40/20 10/5 LPS
HC-12-OH 218.27 40 40/20 40 40 NONE
Acetylene
SG-TMS-OH 294.42 N/A >20 >40 5 LPS
SG-PH-OH 298.33 N/A >40 >40 20 LPS
Carbonyls
EF-1-OH (p-aldehyde) 226.26 40 40 40 40 NONE
EF-2-OH (acetyl) 240.25 40 20 20 20 NONE
EF-3-OH (methylester) 256.25 40 40 40 40 NONE
EF-4-OH (o-aldehyde) 226.26 N/A 40 40 40 NONE
Other
Chlorotrop 140.57 N/A >40 >40 >40 NONE
Piv-trop 206.24 40/20 40 >40 40 NONE
ENOblock 631.18 40/20 40 40 10 LPS
Alternative chelators
MO-SH-PH 214.28 N/A >40 >40 >200 NONE
MO-NH2-PH 197.23 >40 >40 >40 >200 NONE
MO-AM-PH 239.27 N/A >40 >40 >40 NONE
MO-OMe-PH 212.24 N/A >40 >40 >40 NONE
MO-NHOH-PH 213.23 N/A >40 >40 >40 NONE
MO-SMe-PH 228.31 N/A >40 >40 >40 NONE
MO-H-PH 182.22 N/A >40 >40 >40 NONE
MO-PivAm-PH 281.35 N/A >40 >40 20/10 LPS
MICs in E. coli and E. coli knockout models
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Evaluation of HKT and γ-Tropolone Inhibitory Activity on E.coli Enolase (at 20 µM 
concentration). 
Compound Structure % Activity % Inhibition 
HKT 
 
45% 55% 
γ-NH2 
 
81% 19% 
γ-Piv 
 
47% 53% 
γ-P5 
 
85% 15% 
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Salt Version of Tropolones and Its Effect on Enolase Activity. 
Compound Concentration % Activity % Inhibition 
HKT 10 μM 57% 43% 
Na-HKT 10 μM 63% 37% 
HKT-Arginate 10 μM 52% 48% 
 
Compound Concentration % Activity % Inhibition 
HC-1-OH 10 μM 71% 29% 
HC-1-Arginate 10 μM 63% 37% 
 
Compound Concentration % Activity % Inhibition 
MO-OH-PH 20 μM 67% 33% 
Zn-ditrop-PH 20 μM 56% 44% 
 
 
 
Effect of Chloride and Pivalate Group on the Inhibitory Activity of the Tropone. 
Compound Concentration % Activity % Inhibition 
Tropolone 10 µM 61% 39% 
Chlorotropone 10 µM 45% 55% 
Piv-tropone 10 µM 27% 73% 
 
 
Compound Concentration % Activity % Inhibition 
Tropolone 20 µM 38% 62% 
Chlorotropone 20 µM 34% 66% 
Piv-tropone 20 µM 17% 83% 
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Dose-dependent Responses of α and β Substituted Tropolones. 
BA-pBr-OH 
Concentration % Activity % Inhibition 
1 µM 86% 14% 
5 µM 61% 39% 
10 µM 49% 51% 
20 µM 29% 71% 
 
MO-2-OH 
Concentration % Activity % Inhibition 
1 µM 80% 20% 
5 µM 65% 35% 
10 µM 52% 48% 
20 µM 22% 78% 
 
HC-7-OH 
Concentration % Activity % Inhibition 
5 µM 78% 22% 
10 µM 63% 37% 
20 µM 46% 54% 
 
Tropolone 
Concentration % Activity % Inhibition 
1 µM 94% 6% 
5 µM 74% 26% 
10 µM 63% 37% 
15 µM 54% 46% 
20 µM 39% 61% 
 
Chlorotropone 
Concentration % Activity % Inhibition 
5 µM 80% 20% 
10 µM 45% 55% 
20 µM 34% 66% 
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Piv-trop 
Concentration % Activity % Inhibition 
1 µM 94% 6% 
5 µM 67% 33% 
10 µM 32% 68% 
15 µM 16% 84% 
20 µM 11% 89% 
 
HKT 
Concentration % Activity % Inhibition 
1 µM 89% 11% 
5 µM 78% 22% 
10 µM 53% 47% 
20 µM 45% 55% 
 
